There O O
is O O
a O O
single O O
methionine B-DNA B-DNA
codon I-DNA I-DNA
- I-DNA I-DNA
initiated I-DNA I-DNA
open I-DNA I-DNA
reading I-DNA I-DNA
frame I-DNA I-DNA
of O O
1 O O
, O O
458 O O
nt O O
in O O
frame O O
with O O
a O O
homeobox B-DNA B-DNA
and O O
a O O
CAX B-DNA B-DNA
repeat I-DNA I-DNA
, O O
and O O
the O O
open B-DNA B-DNA
reading I-DNA I-DNA
frame I-DNA I-DNA
is O O
predicted O O
to O O
encode O O
a O O
protein O O
of O O
51 O O
, O O
659 O O
daltons O O
. O O

When O O
the O O
homeodomain B-DNA O
from O O
HB24 B-DNA B-DNA
was O O
compared O O
to O O
known O O
mammalian O O
and O O
Drosophila O O
homeodomains O O
it O O
was O O
found O O
to O O
be O O
only O O
moderately O O
conserved O O
, O O
but O O
when O O
it O O
was O O
compared O O
to O O
a O O
highly O O
diverged O O
Drosophila B-DNA O
homeodomain I-DNA O
, O O
H2 O O
. O O
0 O O
, O O
it O O
was O O
found O O
to O O
be O O
80 O O
% O O
identical O O
. O O

The O O
HB24 O O
mRNA O O
was O O
absent O O
or O O
present O O
at O O
low O O
levels O O
in O O
normal O O
B O O
and O O
T O O
lymphocytes O O
; O O
however O O
, O O
with O O
the O O
appropriate O O
activation O O
signal O O
HB24 O B-DNA
mRNA O O
was O O
induced O O
within O O
several O O
hours O O
even O O
in O O
the O O
presence O O
of O O
cycloheximide O O
. O O

Characterization O O
of O O
HB24 B-DNA B-DNA
expression O O
in O O
lymphoid O O
and O O
select O O
developing O O
tissues O O
was O O
performed O O
by O O
in O O
situ O O
hybridization O O
. O O

Positive O O
hybridization O O
was O O
found O O
in O O
thymus O O
, O O
tonsil O O
, O O
bone O O
marrow O O
, O O
developing O O
vessels O O
, O O
and O O
in O O
fetal O O
brain O O
. O O

HB24 B-DNA B-DNA
is O O
likely O O
to O O
have O O
an O O
important O O
role O O
in O O
lymphocytes O O
as O O
well O O
as O O
in O O
certain O O
developing O O
tissues O O
. O O

Platelet O O
- O O
activating O O
factor O O
induces O O
phospholipid O O
turnover O O
, O O
calcium O O
flux O O
, O O
arachidonic O O
acid O O
liberation O O
, O O
eicosanoid O O
generation O O
, O O
and O O
oncogene B-DNA B-DNA
expression O O
in O O
a O O
human O O
B O O
cell O O
line O O
. O O

Platelet O O
- O O
activating O O
factor O O
is O O
a O O
potent O O
mediator O O
of O O
the O O
inflammatory O O
response O O
. O O

Studies O O
of O O
the O O
actions O O
of O O
platelet O O
- O O
activating O O
factor O O
have O O
centered O O
mainly O O
around O O
neutrophils O O
, O O
monocytes O O
, O O
and O O
platelets O O
. O O

In O O
this O O
report O O
we O O
begin O O
to O O
uncover O O
the O O
influence O O
of O O
platelet O O
- O O
activating O O
factor O O
on O O
B O O
lymphocytes O O
. O O

Employing O O
the O O
EBV O O
- O O
transformed O O
human O O
B O O
cell O O
line O O
SKW6 O O
. O O
4 O O
, O O
we O O
demonstrate O O
that O O
platelet O O
- O O
activating O O
factor O O
significantly O O
alters O O
membrane O O
phospholipid O O
metabolism O O
indicated O O
by O O
the O O
incorporation O O
of O O
32P O O
into O O
phosphatidylcholine O O
, O O
phosphatidylinositol O O
, O O
and O O
phosphatidic O O
acid O O
but O O
not O O
significantly O O
into O O
phosphatidylethanolamine O O
at O O
concentrations O O
ranging O O
from O O
10 O O
( O O
- O O
9 O O
) O O
to O O
10 O O
( O O
- O O
6 O O
) O O
M O O
. O O

The O O
inactive O O
precursor O O
, O O
lyso O O
- O O
platelet O O
- O O
activating O O
factor O O
, O O
at O O
a O O
concentration O O
as O O
high O O
as O O
10 O O
( O O
- O O
7 O O
) O O
M O O
had O O
no O O
effect O O
on O O
any O O
of O O
the O O
membrane O O
phospholipids O O
. O O

We O O
also O O
show O O
that O O
platelet O O
- O O
activating O O
factor O O
from O O
10 O O
( O O
- O O
12 O O
) O O
to O O
10 O O
( O O
- O O
6 O O
) O O
M O O
induced O O
rapid O O
and O O
significant O O
elevation O O
in O O
intracellular O O
calcium O O
levels O O
, O O
whereas O O
lyso O O
- O O
platelet O O
- O O
activating O O
factor O O
was O O
again O O
ineffective O O
. O O

We O O
further O O
demonstrate O O
the O O
impact O O
of O O
platelet O O
- O O
activating O O
factor O O
binding O O
to O O
B O O
cells O O
by O O
measuring O O
platelet O O
- O O
activating O O
factor O O
induced O O
arachidonic O O
acid O O
release O O
and O O
5 O O
- O O
hydroxyeicosatetraenoic O O
acid O O
production O O
. O O

Moreover O O
, O O
platelet O O
- O O
activating O O
factor O O
was O O
capable O O
of O O
inducing O O
transcription O O
of O O
the O O
nuclear B-DNA B-DNA
proto I-DNA I-DNA
- I-DNA I-DNA
oncogenes I-DNA I-DNA
c B-DNA I-DNA
- I-DNA I-DNA
fos I-DNA I-DNA
and O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
. O O

Finally O O
we O O
explored O O
the O O
possible O O
role O O
of O O
5 O O
- O O
hydroxyeicosatetraenoic O O
acid O O
as O O
a O O
regulator O O
of O O
arachidonic O O
acid O O
liberation O O
demonstrating O O
that O O
endogenous O O
5 O O
- O O
lipoxygenase O O
activity O O
modulates O O
platelet O O
- O O
activating O O
factor O O
induced O O
arachidonic O O
acid O O
release O O
perhaps O O
acting O O
at O O
the O O
level O O
of O O
phospholipase O O
A2 O O
. O O

In O O
summary O O
, O O
platelet O O
- O O
activating O O
factor O O
is O O
shown O O
here O O
to O O
have O O
a O O
direct O O
and O O
profound O O
effect O O
on O O
a O O
pure O O
B O O
cell O O
line O O
. O O

Positive O O
and O O
negative O O
regulation O O
of O O
immunoglobulin B-DNA B-DNA
gene I-DNA I-DNA
expression O O
by O O
a O O
novel O O
B B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
enhancer I-DNA I-DNA
element I-DNA I-DNA
. O O

A O O
new O O
B B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
enhancer I-DNA I-DNA
element I-DNA I-DNA
has O O
been O O
identified O O
3 O O
' O O
of O O
E4 O B-DNA
and O O
the O O
octamerlike O B-DNA
motifs O I-DNA
in O O
the O O
human B-DNA B-DNA
immunoglobulin I-DNA I-DNA
heavy I-DNA I-DNA
- I-DNA I-DNA
chain I-DNA I-DNA
gene I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

Tandem O O
copies O O
of O O
this O O
67 B-DNA B-DNA
- I-DNA I-DNA
bp I-DNA I-DNA
MnlI I-DNA I-DNA
- I-DNA I-DNA
AluI I-DNA I-DNA
fragment I-DNA I-DNA
, O O
when O O
fused O O
to O O
the O O
chloramphenicol B-DNA B-DNA
acetyltransferase I-DNA I-DNA
gene I-DNA I-DNA
driven O O
by O O
the O O
conalbumin B-DNA B-DNA
promoter I-DNA I-DNA
, O O
stimulated O O
transcription O O
in O O
B O O
cells O O
but O O
not O O
in O O
Jurkat O O
T O O
cells O O
or O O
HeLa O O
cells O O
. O O

Footprinting O O
analysis O O
revealed O O
that O O
the O O
identical O O
sequence O O
CCGAAACTGAAAAGG O O
, O O
designated O O
E6 B-DNA B-DNA
, O O
was O O
protected O O
by O O
nuclear O O
extracts O O
from O O
B O O
cells O O
, O O
T O O
cells O O
, O O
or O O
HeLa O O
cells O O
. O O

Gel O O
mobility O O
shift O O
assays O O
using O O
a O O
synthetic B-DNA O
E6 I-DNA B-DNA
motif I-DNA I-DNA
detected O O
a O O
B O O
- O O
cell O O
- O O
specific O O
complex O O
in O O
addition O O
to O O
a O O
ubiquitous O O
band O O
found O O
also O O
in O O
T O O
cells O O
and O O
HeLa O O
cells O O
. O O

In O O
agreement O O
with O O
the O O
results O O
of O O
gel O O
retardation O O
assays O O
, O O
tandem O O
copies O O
of O O
the O O
E6 B-DNA B-DNA
motif I-DNA I-DNA
stimulated O O
transcription O O
in O O
ARH77 O O
and O O
Raji O O
cells O O
but O O
not O O
in O O
Jurkat O O
or O O
HeLa O O
cells O O
. O O

Furthermore O O
, O O
a O O
mutant B-DNA B-DNA
E6 I-DNA I-DNA
motif I-DNA I-DNA
lost O O
both O O
in O O
vitro O O
binding O O
activity O O
and O O
in O O
vivo O O
enhancer O O
activity O O
. O O

In O O
striking O O
contrast O O
to O O
the O O
mouse B-DNA B-DNA
Ig I-DNA I-DNA
heavy I-DNA I-DNA
- I-DNA I-DNA
chain I-DNA I-DNA
enhancer I-DNA I-DNA
, O O
in O O
which O O
the O O
octamer B-DNA B-DNA
motif I-DNA I-DNA
acts O O
as O O
a O O
B B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
enhancer I-DNA I-DNA
element I-DNA I-DNA
, O O
the O O
human B-DNA B-DNA
enhancer I-DNA I-DNA
contains O O
an O O
octamerlike B-DNA O
sequence I-DNA O
with O O
one O O
base O O
substitution O O
which O O
bound O O
octamer O O
- O O
binding O O
proteins O O
with O O
only O O
very O O
low O O
affinity O O
and O O
showed O O
no O O
enhancer O O
activity O O
of O O
its O O
own O O
. O O

Interestingly O O
, O O
the O O
MnlI B-DNA B-DNA
- I-DNA I-DNA
AluI I-DNA I-DNA
fragment I-DNA I-DNA
could O O
suppress O O
the O O
basal O O
- O O
level O O
activity O O
of O O
the O O
conalbumin B-DNA B-DNA
promoter I-DNA I-DNA
in O O
both O O
Jurkat O O
and O O
HeLa O O
cells O O
. O O

Moreover O O
, O O
simian O B-DNA
virus O I-DNA
40 O I-DNA
enhancer O I-DNA
activity O O
was O O
blocked O O
by O O
the O O
MnlI B-DNA B-DNA
- I-DNA I-DNA
AluI I-DNA I-DNA
fragment I-DNA I-DNA
in O O
HeLa O O
cells O O
but O O
not O O
in O O
B O O
cells O O
. O O

Thus O O
, O O
the O O
novel O O
enhancer O B-DNA
element O I-DNA
identified O O
in O O
this O O
study O O
is O O
probably O O
a O O
target O O
site O O
for O O
both O O
positive O O
and O O
negative O O
factors O O
. O O

Charybdotoxin O O
- O O
sensitive O O
, O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
membrane O O
potential O O
changes O O
are O O
not O O
involved O O
in O O
human O O
T O O
or O O
B O O
cell O O
activation O O
and O O
proliferation O O
. O O

The O O
involvement O O
of O O
ion O O
channels O O
in O O
B O O
and O O
T O O
lymphocyte O O
activation O O
is O O
supported O O
by O O
many O O
reports O O
of O O
changes O O
in O O
ion O O
fluxes O O
and O O
membrane O O
potential O O
after O O
mitogen O O
binding O O
. O O

Human O O
T O O
and O O
B O O
lymphocytes O O
demonstrate O O
an O O
early O O
and O O
transient O O
hyperpolarization O O
after O O
ligand O O
binding O O
. O O

Inasmuch O O
as O O
the O O
change O O
in O O
membrane O O
potential O O
is O O
dependent O O
on O O
elevation O O
of O O
free O O
cytosolic O O
calcium O O
, O O
the O O
hyperpolarization O O
is O O
presumably O O
through O O
opening O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
stimulated O O
K O O
+ O O
channels O O
. O O

We O O
have O O
used O O
charybdotoxin O O
, O O
a O O
known O O
inhibitor O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
K O O
+ O O
channels O O
, O O
to O O
study O O
the O O
role O O
of O O
these O O
channels O O
in O O
lymphocyte O O
activation O O
and O O
mitogenesis O O
. O O

We O O
demonstrate O O
that O O
charybdotoxin O O
inhibits O O
the O O
ligand O O
- O O
induced O O
transient O O
membrane O O
hyperpolarization O O
in O O
B O O
and O O
T O O
cells O O
in O O
a O O
dose O O
- O O
dependent O O
fashion O O
, O O
without O O
affecting O O
changes O O
in O O
cytosolic O O
Ca2 O O
+ O O
. O O

However O O
, O O
blockade O O
of O O
the O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
activated O O
K O O
+ O O
channel O O
is O O
not O O
associated O O
with O O
changes O O
in O O
cell O O
- O O
cycle O O
gene O O
activation O O
, O O
IL O O
- O O
2 O O
production O O
, O O
IL O O
- O O
2R O O
expression O O
or O O
B O O
and O O
T O O
cell O O
mitogenesis O O
. O O

These O O
results O O
imply O O
that O O
membrane O O
potential O O
changes O O
secondary O O
to O O
the O O
ligand O O
- O O
dependent O O
opening O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
activated O O
K O O
+ O O
channels O O
are O O
not O O
involved O O
in O O
B O O
and O O
T O O
lymphocyte O O
activation O O
and O O
mitogenesis O O
. O O

Activity O O
of O O
the O O
kappa B-DNA B-DNA
B I-DNA I-DNA
enhancer I-DNA I-DNA
of O O
the O O
interleukin O O
- O O
2 O O
receptor O O
alpha O O
chain O O
in O O
somatic O O
cell O O
hybrids O O
is O O
accompanied O O
by O O
the O O
nuclear O O
localization O O
of O O
NF O O
- O O
kappa O O
B O O
. O O

The O O
two O O
nuclear O O
proteins O O
NF O O
- O O
kappa O O
B O O
( O O
consisting O O
of O O
subunits O O
p50 O O
an O O
dp65 O O
) O O
and O O
the O O
DNA O O
- O O
binding O O
subunit O O
of O O
NF O O
- O O
kappa O O
B O O
( O O
p50 O O
) O O
by O O
itself O O
, O O
also O O
called O O
KBF1 O O
, O O
are O O
constitutively O O
expressed O O
and O O
localized O O
in O O
the O O
nucleus O O
of O O
the O O
human O O
T O O
- O O
cell O O
line O O
IARC O O
301 O O
. O O
5 O O
. O O

In O O
order O O
to O O
define O O
the O O
roles O O
of O O
these O O
two O O
factors O O
, O O
which O O
bind O O
to O O
the O O
same O O
kappa B-DNA B-DNA
B I-DNA I-DNA
enhancers I-DNA I-DNA
, O O
in O O
transcription O O
activation O O
we O O
have O O
prepared O O
somatic O O
cell O O
hybrids O O
between O O
IARC O O
301 O O
. O O
5 O O
and O O
a O O
murine O O
myeloma O O
. O O

Most O O
hybrids O O
express O O
both O O
KBF1 O O
and O O
NF O O
- O O
kappa O O
B O O
in O O
their O O
nuclei O O
, O O
but O O
one O O
hybrid O O
expresses O O
only O O
KBF1 O O
. O O

The O O
kappa B-DNA B-DNA
B I-DNA I-DNA
enhancer I-DNA I-DNA
of O O
the O O
gene O O
encoding O O
the O O
interleukin O O
- O O
2 O O
( O O
IL O O
- O O
2 O O
) O O
receptor O O
alpha O O
chain O O
( O O
IL O O
- O O
2R O O
alpha O O
) O O
is O O
functional O O
only O O
in O O
the O O
hybrids O O
expressing O O
nuclear O O
NF O O
- O O
kappa O O
B O O
. O O

These O O
findings O O
show O O
that O O
nuclear O O
NF O O
- O O
kappa O O
B O O
is O O
necessary O O
to O O
activate O O
the O O
kappa B-DNA B-DNA
B I-DNA I-DNA
enhancer I-DNA I-DNA
, O O
while O O
KBF1 O O
by O O
itself O O
is O O
not O O
sufficient O O
. O O

We O O
propose O O
that O O
KBF1 O O
is O O
a O O
competitive O O
inhibitor O O
of O O
NF O O
- O O
kappa O O
B O O
and O O
discuss O O
how O O
these O O
factors O O
may O O
be O O
involved O O
in O O
the O O
transient O O
expression O O
of O O
IL O O
- O O
2 O O
and O O
IL O O
- O O
2 O O
alpha O O
genes O O
during O O
the O O
immune O O
response O O
. O O

T O O
- O O
helper O O
- O O
cell O O
determinants O O
in O O
protein O O
antigens O O
are O O
preferentially O O
located O O
in O O
cysteine O O
- O O
rich O O
antigen O O
segments O O
resistant O O
to O O
proteolytic O O
cleavage O O
by O O
cathepsin O O
B O O
, O O
L O O
, O O
and O O
D O O
. O O

We O O
report O O
on O O
a O O
computer O O
algorithm O O
capable O O
of O O
predicting O O
the O O
location O O
of O O
T O O
- O O
helper O O
- O O
cell O O
epitopes O O
in O O
protein O O
antigen O O
( O O
Ag O O
) O O
by O O
analysing O O
the O O
Ag O O
amino O O
acid O O
sequence O O
. O O

The O O
algorithm O O
was O O
constructed O O
with O O
the O O
aim O O
of O O
identifying O O
segments O O
in O O
Ag O O
which O O
are O O
resistant O O
to O O
proteolytic O O
degradation O O
by O O
the O O
enzymes O O
cathepsin O O
B O O
, O O
L O O
, O O
and O O
D O O
. O O

These O O
are O O
prominent O O
enzymes O O
in O O
the O O
endocytic O O
pathway O O
through O O
which O O
soluble O O
protein O O
Ag O O
enter O O
APC O O
, O O
and O O
resistant O O
segments O O
in O O
Ag O O
may O O
, O O
therefore O O
, O O
be O O
expected O O
to O O
contain O O
more O O
T O O
- O O
cell O O
determinants O O
than O O
susceptible O O
segments O O
. O O

From O O
information O O
available O O
in O O
the O O
literature O O
on O O
the O O
substrate O O
specificity O O
of O O
the O O
three O O
enzymes O O
, O O
it O O
is O O
clear O O
that O O
a O O
cysteine O O
is O O
not O O
accepted O O
in O O
any O O
of O O
the O O
S2 O O
, O O
S1 O O
, O O
S1 O O
' O O
, O O
and O O
S2 O O
' O O
subsites O O
of O O
cathepsin O O
B O O
and O O
L O O
, O O
and O O
not O O
in O O
the O O
S1 O O
and O O
S1 O O
' O O
subsites O O
of O O
cathepsin O O
D O O
. O O

Moreover O O
, O O
we O O
have O O
noticed O O
that O O
cysteine O O
- O O
containing O O
T O O
- O O
cell O O
determinants O O
in O O
a O O
number O O
of O O
protein O O
Ag O O
are O O
particularly O O
rich O O
in O O
the O O
amino O O
acids O O
alanine O O
, O O
glycine O O
, O O
lysine O O
, O O
leucine O O
, O O
serine O O
, O O
threonine O O
, O O
and O O
valine O O
. O O

By O O
searching O O
protein O O
Ag O O
for O O
clusters O O
of O O
amino O O
acids O O
containing O O
cysteine O O
and O O
two O O
of O O
the O O
other O O
amino O O
acids O O
we O O
were O O
able O O
to O O
predict O O
17 O O
out O O
of O O
23 O O
empirically O O
known O O
T O O
- O O
cell O O
determinants O O
in O O
the O O
Ag O O
with O O
a O O
relatively O O
low O O
number O O
of O O
false O O
( O O
positive O O
) O O
predictions O O
. O O

Furthermore O O
, O O
we O O
present O O
a O O
new O O
principle O O
for O O
searching O O
Ag O O
for O O
potential O O
amphipatic O O
alpha O O
- O O
helical O O
protein O O
segments O O
. O O

Such O O
segments O O
accord O O
well O O
with O O
empirically O O
known O O
T O O
- O O
cell O O
determinants O O
and O O
our O O
algorithm O O
produces O O
a O O
lower O O
number O O
of O O
false O O
positive O O
predictions O O
than O O
the O O
principle O O
based O O
on O O
discrete O O
Fourier O O
transformations O O
previously O O
described O O
. O O

Contribution O O
of O O
NF O O
- O O
kappa O O
B O O
and O O
Sp1 B-DNA O
binding I-DNA O
motifs I-DNA O
to O O
the O O
replicative O O
capacity O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
: O O
distinct O O
patterns O O
of O O
viral O O
growth O O
are O O
determined O O
by O O
T O O
- O O
cell O O
types O O
. O O

Starting O O
with O O
a O O
replication O O
- O O
incompetent O O
molecular O O
clone O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
, O O
lacking O O
all O O
the O O
NF O O
- O O
kappa O O
B O O
and O O
Sp1 O O
binding O O
sites O O
present O O
in O O
the O O
native B-DNA B-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
, O O
proviruses O O
containing O O
reconstructed B-DNA O
LTRs I-DNA B-DNA
with O O
individual O O
or O O
combinations O O
of O O
NF O O
- O O
kappa O O
B O O
and O O
Sp1 O O
elements O O
were O O
generated O O
and O O
evaluated O O
for O O
their O O
capacity O O
to O O
produce O O
virus O O
progeny O O
following O O
transfection O O
- O O
cocultivation O O
. O O

Virus O O
stocks O O
obtained O O
from O O
these O O
experiments O O
exhibited O O
a O O
continuum O O
of O O
replicative O O
capacities O O
in O O
different O O
human O O
T O O
- O O
cell O O
types O O
depending O O
on O O
which O O
element B-DNA O
( O O
s O O
) O O
was O O
present O O
in O O
the O O
LTR B-DNA B-DNA
. O O

For O O
example O O
, O O
in O O
experiments O O
involving O O
proviral O O
clones O O
with O O
LTRs B-DNA B-DNA
containing O O
one O O
or O O
two O O
NF B-DNA B-DNA
- I-DNA I-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
elements I-DNA I-DNA
( O O
and O O
no O O
Sp1 B-DNA B-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
) O O
, O O
a O O
hierarchy O O
of O O
cellular O O
permissivity O O
to O O
virus O O
replication O O
( O O
peripheral O O
blood O O
lymphocytes O O
= O O
MT4 O O
greater O O
than O O
H9 O O
greater O O
than O O
CEM O O
greater O O
than O O
Jurkat O O
) O O
was O O
observed O O
. O O

Of O O
note O O
was O O
the O O
associated O O
emergence O O
of O O
second B-DNA B-DNA
- I-DNA I-DNA
site I-DNA I-DNA
LTR I-DNA I-DNA
revertants O I-DNA
which O O
involved O O
an O O
alteration O O
of O O
the O O
TATA B-DNA B-DNA
box I-DNA I-DNA
. O O

These O O
results O O
suggest O O
that O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
1 I-DNA I-DNA
LTR I-DNA I-DNA
possesses O O
functional O O
redundancy O O
which O O
ensures O O
virus O O
replication O O
in O O
different O O
T O O
- O O
cell O O
types O O
and O O
is O O
capable O O
of O O
changing O O
depending O O
on O O
the O O
particular O O
combination O O
of O O
transcriptional O O
factors O O
present O O
. O O

Stimulation O O
of O O
interferon B-DNA B-DNA
beta I-DNA I-DNA
gene I-DNA I-DNA
transcription O O
in O O
vitro O O
by O O
purified O O
NF O O
- O O
kappa O O
B O O
and O O
a O O
novel O O
TH O O
protein O O
. O O

The O O
human B-DNA B-DNA
interferon I-DNA I-DNA
beta I-DNA I-DNA
( I-DNA I-DNA
IFN I-DNA I-DNA
- I-DNA I-DNA
beta I-DNA I-DNA
) I-DNA I-DNA
regulatory I-DNA I-DNA
element I-DNA I-DNA
consists O O
of O O
multiple O O
enhanson B-DNA B-DNA
domains I-DNA I-DNA
which O O
are O O
targets O O
for O O
transcription O O
factors O O
involved O O
in O O
inducible O O
expression O O
of O O
the O O
promoter B-DNA B-DNA
. O O

To O O
further O O
characterize O O
the O O
protein O O
- O O
DNA O O
interactions O O
mediating O O
IFN O O
- O O
beta O O
induction O O
, O O
positive B-DNA O
regulatory I-DNA O
domain I-DNA O
( I-DNA O
PRD I-DNA O
) I-DNA O
II I-DNA O
binding O O
proteins O O
were O O
purified O O
from O O
phorbol O O
ester O O
induced O O
Jurkat O O
T O O
- O O
cells O O
and O O
from O O
IFN O O
primed O O
, O O
cycloheximide O O
/ O O
polyinosinic O O
- O O
polycytidylic O O
acid O O
treated O O
HeLa O O
S3 O O
cells O O
. O O

From O O
HeLa O O
cells O O
, O O
two O O
major O O
proteins O O
of O O
52 O O
and O O
45 O O
kilodaltons O O
( O O
kD O O
) O O
copurified O O
with O O
DNA O O
binding O O
activity O O
, O O
whereas O O
from O O
T O O
- O O
cells O O
, O O
four O O
proteins O O
- O O
- O O
a O O
major O O
protein O O
of O O
52 O O
kD O O
and O O
three O O
minor O O
proteins O O
of O O
82 O O
, O O
67 O O
, O O
and O O
43 O O
- O O
47 O O
kD O O
- O O
- O O
were O O
purified O O
. O O

Also O O
, O O
an O O
induction O O
specific O O
DNA O O
binding O O
protein O O
was O O
purified O O
from O O
HeLa O O
cells O O
that O O
interacted O O
with O O
the O O
( O B-DNA
AAGTGA O I-DNA
) O I-DNA
4 O I-DNA
tetrahexamer B-DNA I-DNA
sequence I-DNA I-DNA
and O O
the O O
PRDI B-DNA B-DNA
domain I-DNA I-DNA
. O O

This O O
protein O O
is O O
immunologically O O
distinct O O
from O O
IRF O O
- O O
1 O O
/ O O
ISGF2 O O
. O O

Uninduced O O
or O O
Sendai O O
virus O O
induced O O
HeLa O O
extracts O O
were O O
used O O
to O O
examine O O
transcription O O
in O O
vitro O O
using O O
a O O
series O O
of O O
IFN B-DNA B-DNA
beta I-DNA I-DNA
promoter I-DNA I-DNA
deletions I-DNA I-DNA
. O O

Deletions O O
upstream O O
of O O
the O O
PRDII B-DNA B-DNA
element I-DNA I-DNA
increased O O
transcription O O
in O O
the O O
uninduced O O
extract O O
, O O
indicating O O
predominantly O O
negative O O
regulation O O
of O O
the O O
promoter B-DNA B-DNA
. O O

A O O
2 O O
- O O
4 O O
- O O
fold O O
increase O O
in O O
IFN B-DNA B-DNA
- I-DNA I-DNA
beta I-DNA I-DNA
promoter I-DNA I-DNA
transcription O O
was O O
observed O O
in O O
Sendai O O
virus O O
induced O O
extracts O O
, O O
and O O
deletion O O
of O O
PRDI B-DNA O
and O O
PRDII B-DNA O
elements I-DNA O
decreased O O
this O O
induced O O
level O O
of O O
transcription O O
. O O

When O O
purified O O
PRDII O O
and O O
tetrahexamer O O
binding O O
proteins O O
were O O
added O O
to O O
the O O
induced O O
extract O O
, O O
a O O
4 O O
- O O
fold O O
increase O O
in O O
transcription O O
was O O
observed O O
. O O

These O O
experiments O O
demonstrate O O
that O O
it O O
is O O
possible O O
to O O
modulate O O
IFN O O
- O O
beta O O
transcription O O
in O O
vitro O O
but O O
indicate O O
that O O
additional O O
proteins O O
may O O
be O O
required O O
to O O
fully O O
activate O O
IFN O O
- O O
beta O O
transcription O O
. O O

The O O
rhombotin B-DNA B-DNA
family I-DNA I-DNA
of O I-DNA
cysteine B-DNA I-DNA
- I-DNA I-DNA
rich I-DNA I-DNA
LIM I-DNA I-DNA
- I-DNA I-DNA
domain I-DNA I-DNA
oncogenes I-DNA I-DNA
: O O
distinct O O
members O O
are O O
involved O O
in O O
T B-DNA O
- I-DNA O
cell I-DNA O
translocations I-DNA O
to O O
human O B-DNA
chromosomes O I-DNA
11p15 O B-DNA
and O O
11p13 O B-DNA
. O O

A O O
chromosomal O O
translocation O O
in O O
a O O
T O O
- O O
cell O O
leukemia O O
involving O O
the O O
short B-DNA O
arm I-DNA O
of O O
human B-DNA B-DNA
chromosome I-DNA I-DNA
11 I-DNA I-DNA
at O O
band B-DNA B-DNA
11p15 I-DNA I-DNA
disrupts O O
the O O
rhombotin B-DNA B-DNA
gene I-DNA I-DNA
. O O

This O O
gene O O
encodes O O
a O O
protein O O
with O O
duplicated O O
cysteine O O
- O O
rich O O
regions O O
called O O
LIM O O
domains O O
, O O
which O O
show O O
homology O O
to O O
zinc O O
- O O
binding O O
proteins O O
and O O
to O O
iron O O
- O O
sulfur O O
centers O O
of O O
ferredoxins O O
. O O

Two O O
homologues O O
of O O
the O O
rhombotin B-DNA B-DNA
gene I-DNA I-DNA
have O O
now O O
been O O
isolated O O
. O O

One O O
of O O
these O O
, O O
designated O O
Rhom B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
, O O
is O O
located O O
on O O
human B-DNA B-DNA
chromosome I-DNA I-DNA
11 I-DNA I-DNA
at O O
band B-DNA B-DNA
11p13 I-DNA I-DNA
, O O
where O O
a O O
cluster O O
of O O
T B-DNA O
- I-DNA O
cell I-DNA O
leukemia I-DNA O
- I-DNA O
specific I-DNA O
translocations I-DNA O
occur O O
; O O
all O O
translocation O B-DNA
breakpoints O I-DNA
at O O
11p13 B-DNA B-DNA
are O O
upstream O O
of O O
the O O
Rhom B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
gene I-DNA I-DNA
. O O

Human O O
and O O
mouse O O
Rhom O O
- O O
2 O O
are O O
highly O O
conserved O O
and O O
, O O
like O O
rhombotin B-DNA O
, O O
encode O O
two O O
tandem B-DNA O
cysteine I-DNA O
- I-DNA O
rich I-DNA O
LIM I-DNA O
domains I-DNA O
. O O

Rhom B-DNA O
- I-DNA O
2 I-DNA O
mRNA O O
is O O
expressed O O
in O O
early O O
mouse O O
development O O
in O O
central O O
nervous O O
system O O
, O O
lung O O
, O O
kidney O O
, O O
liver O O
, O O
and O O
spleen O O
but O O
only O O
very O O
low O O
levels O O
occur O O
in O O
thymus O O
. O O

The O O
other O O
gene O O
, O O
designated O O
Rhom B-DNA B-DNA
- I-DNA I-DNA
3 I-DNA I-DNA
, O O
is O O
not O O
on O O
chromosome O B-DNA
11 O I-DNA
but O O
also O O
retains O O
homology O O
to O O
the O O
LIM B-DNA B-DNA
domain I-DNA I-DNA
of O O
rhombotin B-DNA O
. O O

Since O O
the O O
Rhom B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
gene I-DNA I-DNA
is O O
such O O
a O O
common O O
site O O
of O O
chromosomal O O
damage O O
in O O
T O O
- O O
cell O O
tumors O O
, O O
the O O
consistency O O
of O O
translocations O O
near O O
the O O
rhombotin B-DNA B-DNA
gene I-DNA I-DNA
was O O
further O O
examined O O
. O O

A O O
second O O
translocation O O
adjacent O O
to O O
rhombotin B-DNA O
was O O
found O O
and O O
at O O
the O O
same O O
position O O
as O O
in O O
the O O
previous O O
example O O
. O O

Therefore O O
, O O
chromosome B-DNA B-DNA
bands I-DNA I-DNA
11p15 I-DNA B-DNA
( O O
rhombotin B-DNA B-DNA
) O O
and O O
11p13 B-DNA B-DNA
( O O
Rhom B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
) O O
are O O
consistent O O
sites O O
of O O
chromosome O B-DNA
translocation O I-DNA
in O O
T O O
- O O
cell O O
leukemia O O
, O O
with O O
the O O
11p15 B-DNA B-DNA
target I-DNA I-DNA
more O O
rarely O O
involved O O
. O O

The O O
results O O
define O O
the O O
rhombotin B-DNA B-DNA
gene O I-DNA
family O I-DNA
as O O
a O O
class O O
of O O
T B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
oncogenes I-DNA I-DNA
with O O
duplicated O O
cysteine O O
- O O
rich O O
LIM O O
domains O O
. O O

NF O O
- O O
kappa O O
B O O
activation O O
by O O
tumor O O
necrosis O O
factor O O
alpha O O
in O O
the O O
Jurkat O O
T O O
cell O O
line O O
is O O
independent O O
of O O
protein O O
kinase O O
A O O
, O O
protein O O
kinase O O
C O O
, O O
and O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
regulated O O
kinases O O
. O O

NF O O
- O O
kappa O O
B O O
is O O
a O O
DNA O O
- O O
binding O O
regulatory O O
factor O O
able O O
to O O
control O O
transcription O O
of O O
a O O
number O O
of O O
genes O O
, O O
including O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
( I-DNA I-DNA
HIV I-DNA I-DNA
) I-DNA I-DNA
genes I-DNA I-DNA
. O O

In O O
T O O
cells O O
, O O
NF O O
- O O
kappa O O
B O O
is O O
activated O O
upon O O
cellular O O
treatment O O
by O O
phorbol O O
esters O O
and O O
the O O
cytokine O O
tumor O O
necrosis O O
factor O O
alpha O O
( O O
TNF O O
alpha O O
) O O
. O O

In O O
the O O
present O O
work O O
, O O
we O O
investigated O O
the O O
molecular O O
events O O
leading O O
to O O
NF O O
- O O
kappa O O
B O O
activation O O
by O O
TNF O O
alpha O O
in O O
a O O
human O O
T O O
cell O O
line O O
( O O
Jurkat O O
) O O
and O O
its O O
subclone O O
JCT6 O O
, O O
which O O
presents O O
a O O
deficiency O O
in O O
the O O
PKA O O
transduction O O
pathway O O
. O O

We O O
found O O
that O O
in O O
both O O
cell O O
lines O O
, O O
both O O
phorbol O O
ester O O
and O O
TNF O O
alpha O O
were O O
able O O
to O O
activate O O
NF O O
- O O
kappa O O
B O O
. O O

Phorbol O O
activation O O
was O O
positively O O
modulated O O
by O O
Ca2 O O
+ O O
influx O O
while O O
TNF O O
alpha O O
activation O O
was O O
not O O
. O O

Furthermore O O
, O O
while O O
PMA O O
activation O O
was O O
inhibited O O
by O O
the O O
PKC O O
inhibitor O O
staurosporin O O
, O O
the O O
TNF O O
alpha O O
effect O O
was O O
unchanged O O
. O O

TNF O O
alpha O O
did O O
not O O
activate O O
cAMP O O
production O O
and O O
its O O
signal O O
was O O
not O O
modulated O O
by O O
cAMP O O
activators O O
. O O

Moreover O O
, O O
cAMP O O
activators O O
did O O
not O O
activate O O
NF O O
- O O
kappa O O
B O O
in O O
Jurkat O O
cells O O
. O O

Thus O O
, O O
TNF O O
alpha O O
- O O
induced O O
NF O O
- O O
kappa O O
B O O
activation O O
was O O
found O O
to O O
be O O
mediated O O
by O O
none O O
of O O
the O O
major O O
signal O O
- O O
mediating O O
kinases O O
such O O
as O O
protein O O
kinase O O
C O O
( O O
PKC O O
) O O
, O O
protein O O
kinase O O
A O O
, O O
or O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
regulated O O
kinases O O
. O O

Furthermore O O
, O O
we O O
found O O
that O O
cytoplasmic O O
acidification O O
facilitated O O
NF O O
- O O
kappa O O
B O O
activation O O
by O O
both O O
TNF O O
alpha O O
and O O
PKC O O
, O O
by O O
a O O
mechanism O O
that O O
increases O O
NF O O
- O O
kappa O O
B O O
/ O O
I O O
kappa O O
B O O
dissociation O O
without O O
affecting O O
the O O
NF O O
- O O
kappa O O
B O O
translocation O O
step O O
. O O

The O O
functional O O
domains O O
of O O
the O O
murine B-DNA B-DNA
Thy I-DNA I-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
. O O

The O O
Thy B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
resembles O O
a O O
" B-DNA B-DNA
housekeeping I-DNA I-DNA
" I-DNA I-DNA
promoter I-DNA I-DNA
in O O
that O O
it O O
is O O
located O O
within O O
a O O
methylation B-DNA B-DNA
- I-DNA I-DNA
free I-DNA I-DNA
island I-DNA I-DNA
, O O
lacks O O
a O O
canonical B-DNA O
TATA I-DNA B-DNA
box I-DNA I-DNA
, O O
and O O
displays O O
heterogeneity O O
in O O
the O O
5 O O
' O O
- O O
end O O
termini O O
of O O
the O O
mRNA O O
. O O

Using O O
transgenic O O
mice O O
, O O
we O O
show O O
that O O
this O O
promoter B-DNA O
does O O
not O O
confer O O
any O O
tissue O O
specificity O O
and O O
is O O
active O O
only O O
in O O
a O O
position O O
- O O
dependent O O
manner O O
. O O

It O O
can O O
only O O
be O O
activated O O
in O O
a O O
tissue O O
- O O
specific O O
manner O O
by O O
elements O O
that O O
lie O O
downstream O O
of O O
the O O
initiation B-DNA B-DNA
site I-DNA I-DNA
. O O

We O O
have O O
analyzed O O
the O O
functional O O
domains O O
of O O
the O O
minimal B-DNA B-DNA
Thy I-DNA I-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
promoter I-DNA I-DNA
and O O
show O O
that O O
the O O
dominant B-DNA B-DNA
promoter I-DNA I-DNA
elements I-DNA I-DNA
consist O O
of O O
multiple B-DNA B-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
for O O
the O O
transcription O O
factor O O
Sp1 O O
, O O
an O O
inverted O B-DNA
CCAAT B-DNA I-DNA
box I-DNA I-DNA
, O O
and O O
sequences O O
proximal O O
to O O
the O O
transcription B-DNA B-DNA
start I-DNA I-DNA
site I-DNA I-DNA
. O O

DNase O O
I O O
and O O
gel O O
mobility O O
shift O O
assays O O
show O O
the O O
binding O O
of O O
a O O
number O O
of O O
nuclear O O
factors O O
to O O
these O O
elements B-DNA O
, O O
including O O
Sp1 O O
and O O
CP1 O O
. O O

Our O O
results O O
show O O
that O O
the O O
structure O O
of O O
this O O
promoter B-DNA O
only O O
permits O O
productive O O
interactions O O
of O O
the O O
two O O
transcription O O
factors O O
Sp1 O O
and O O
CP1 O O
with O O
the O O
basal O O
transcription O O
machinery O O
in O O
the O O
presence O O
of O O
enhancer B-DNA B-DNA
sequences I-DNA I-DNA
. O O

Nuclear O O
factor O O
kappa O O
B O O
activates O O
proenkephalin O O
transcription O O
in O O
T O O
lymphocytes O O
. O O

Upon O O
activation O O
, O O
T O O
lymphocytes O O
accumulate O O
high O O
levels O O
of O O
the O O
neuropeptide O O
enkephalin O O
which O O
correlate O O
with O O
high O O
levels O O
of O O
proenkephalin O O
mRNA O O
in O O
the O O
cells O O
. O O

Here O O
we O O
investigated O O
the O O
transcriptional O O
basis O O
for O O
these O O
changes O O
. O O

The O O
proenkephalin O B-DNA
promoter O I-DNA
contains O O
a O O
sequence O O
GGGGACGTCCCC O O
, O O
named O O
B2 B-DNA O
, O O
which O O
is O O
similar O O
to O O
the O O
kappa B-DNA B-DNA
B I-DNA I-DNA
sequence I-DNA I-DNA
GGGGACTTTCC O O
, O O
the O O
binding O B-DNA
site O I-DNA
of O O
the O O
transcription O O
factor O O
nuclear O O
factor O O
( O O
NF O O
) O O
- O O
kappa O O
B O O
. O O

Activation O O
of O O
T O O
lymphocytes O O
induces O O
an O O
NF O O
- O O
kappa O O
B O O
- O O
like O O
binding O O
activity O O
to O O
the O O
B2 B-DNA B-DNA
site O I-DNA
, O O
concomitant O O
with O O
activation O O
of O O
the O O
proenkephalin B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Mutations O O
at O O
the O O
B2 B-DNA B-DNA
site O I-DNA
abolish O O
this O O
transcriptional O O
activation O O
. O O

The O O
purified O O
homodimer O O
( O O
two O O
p50s O O
) O O
of O O
the O O
DNA O O
- O O
binding O O
subunit O O
of O O
NF O O
- O O
kappa O O
B O O
binds O O
the O O
B2 B-DNA B-DNA
site O I-DNA
of O O
proenkephalin O O
relatively O O
better O O
than O O
does O O
the O O
heterotetramer O O
( O O
two O O
p65s O O
plus O O
two O O
p50s O O
) O O
form O O
of O O
the O O
factor O O
. O O

Thus O O
, O O
it O O
appears O O
that O O
the O O
T O O
- O O
cell O O
- O O
specific O O
activation O O
of O O
the O O
proenkephalin B-DNA B-DNA
promoter I-DNA I-DNA
is O O
mediated O O
by O O
NF O O
- O O
kappa O O
B O O
. O O

However O O
, O O
as O O
NF O O
- O O
kappa O O
B O O
is O O
ubiquitous O O
and O O
the O O
transcriptional O O
activation O O
through O O
the O O
B2 B-DNA B-DNA
site O I-DNA
is O O
T O O
cell O O
specific O O
, O O
yet O O
another O O
T O O
- O O
cell O O
- O O
specific O O
factor O O
which O O
synergizes O O
with O O
NF O O
- O O
kappa O O
B O O
should O O
be O O
considered O O
. O O

Induction O O
of O O
NF O O
- O O
KB O O
during O O
monocyte O O
differentiation O O
by O O
HIV O O
type O O
1 O O
infection O O
. O O

The O O
production O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV O O
- O O
1 O O
) O O
progeny O O
was O O
followed O O
in O O
the O O
U937 O O
promonocytic O O
cell O O
line O O
after O O
stimulation O O
either O O
with O O
retinoic O O
acid O O
or O O
PMA O O
, O O
and O O
in O O
purified O O
human O O
monocytes O O
and O O
macrophages O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
and O O
Southwestern O O
blotting O O
experiments O O
were O O
used O O
to O O
detect O O
the O O
binding O O
of O O
cellular O O
transactivation O O
factor O O
NF O O
- O O
KB O O
to O O
the O O
double B-DNA B-DNA
repeat I-DNA I-DNA
- I-DNA I-DNA
KB I-DNA I-DNA
enhancer I-DNA I-DNA
sequence I-DNA I-DNA
located O O
in O O
the O O
long B-DNA B-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
. O O

PMA O O
treatment O O
, O O
and O O
not O O
retinoic O O
acid O O
treatment O O
of O O
the O O
U937 O O
cells O O
acts O O
in O O
inducing O O
NF O O
- O O
KB O O
expression O O
in O O
the O O
nuclei O O
. O O

In O O
nuclear O O
extracts O O
from O O
monocytes O O
or O O
macrophages O O
, O O
induction O O
of O O
NF O O
- O O
KB O O
occurred O O
only O O
if O O
the O O
cells O O
were O O
previously O O
infected O O
with O O
HIV O O
- O O
1 O O
. O O

When O O
U937 O O
cells O O
were O O
infected O O
with O O
HIV O O
- O O
1 O O
, O O
no O O
induction O O
of O O
NF O O
- O O
KB O O
factor O O
was O O
detected O O
, O O
whereas O O
high O O
level O O
of O O
progeny O O
virions O O
was O O
produced O O
, O O
suggesting O O
that O O
this O O
factor O O
was O O
not O O
required O O
for O O
viral O O
replication O O
. O O

These O O
results O O
indicate O O
that O O
in O O
monocytic O O
cell O O
lineage O O
, O O
HIV O O
- O O
1 O O
could O O
mimic O O
some O O
differentiation O O
/ O O
activation O O
stimuli O O
allowing O O
nuclear O O
NF O O
- O O
KB O O
expression O O
. O O

Disruption O O
of O O
the O O
human B-DNA B-DNA
SCL I-DNA I-DNA
locus I-DNA I-DNA
by O O
" O O
illegitimate O O
" O O
V O O
- O O
( O O
D O O
) O O
- O O
J O O
recombinase O O
activity O O
. O O

A O O
fusion B-DNA B-DNA
complementary I-DNA I-DNA
DNA I-DNA I-DNA
in O O
the O O
T O O
cell O O
line O O
HSB O O
- O O
2 O O
elucidates O O
a O O
provocative O O
mechanism O O
for O O
the O O
disruption O O
of O O
the O O
putative O O
hematopoietic O O
transcription O O
factor O O
SCL O O
. O O

The O O
fusion B-DNA B-DNA
cDNA I-DNA I-DNA
results O O
from O O
an O O
interstitial O O
deletion O O
between O O
a O O
previously O O
unknown B-DNA O
locus I-DNA B-DNA
, O O
SIL B-DNA B-DNA
( O O
SCL B-DNA B-DNA
interrupting I-DNA I-DNA
locus I-DNA I-DNA
) O O
, O O
and O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
untranslated I-DNA I-DNA
region I-DNA I-DNA
of O O
SCL O B-DNA
. O O

Similar O O
to O O
1 O O
; O O
14 O O
translocations O O
, O O
this O O
deletion O O
disrupts O O
the O O
SCL B-DNA B-DNA
5 I-DNA I-DNA
' I-DNA I-DNA
regulatory I-DNA I-DNA
region I-DNA I-DNA
. O O

This O O
event O O
is O O
probably O O
mediated O O
by O O
V O O
- O O
( O O
D O O
) O O
- O O
J O O
recombinase O O
activity O O
, O O
although O O
neither O O
locus O O
is O O
an O O
immunoglobulin O O
or O O
a O O
T O O
cell O O
receptor O O
. O O

Two O O
other O O
T O O
cell O O
lines O O
, O O
CEM O O
and O O
RPMI O O
8402 O O
, O O
have O O
essentially O O
identical O O
deletions O O
. O O

Thus O O
, O O
in O O
lymphocytes O O
, O O
growth B-DNA B-DNA
- I-DNA I-DNA
affecting I-DNA I-DNA
genes I-DNA I-DNA
other O O
than O O
immune O O
receptors O O
risk O O
rearrangements O O
. O O

Thyroid O O
hormone O O
receptors O O
form O O
distinct O O
nuclear O O
protein O O
- O O
dependent O O
and O O
independent O O
complexes O O
with O O
a O O
thyroid B-DNA B-DNA
hormone I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
. O O

We O O
have O O
examined O O
the O O
binding O O
of O O
nuclear O O
proteins O O
and O O
recombinant O O
thyroid O O
hormone O O
receptors O O
( O O
TRs O O
) O O
to O O
the O O
palindromic B-DNA B-DNA
thyroid I-DNA I-DNA
hormone I-DNA I-DNA
responsive I-DNA I-DNA
element I-DNA I-DNA
AGGTCATGACCT O B-DNA
( O O
TREp B-DNA B-DNA
) O O
using O O
a O O
gel O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

Four O O
specific O O
protein O O
- O O
DNA O O
complexes O O
were O O
detected O O
after O O
incubation O O
of O O
nuclear O O
extracts O O
( O O
NE O O
) O O
from O O
T3 O O
- O O
responsive O O
pituitary O O
( O O
GH3 O O
) O O
cells O O
with O O
a O O
TREp B-DNA B-DNA
- I-DNA I-DNA
containing I-DNA I-DNA
DNA I-DNA I-DNA
fragment I-DNA I-DNA
. O O

This O O
was O O
compared O O
with O O
the O O
TREp B-DNA B-DNA
binding O O
of O O
reticulocyte O O
lysate O O
- O O
synthesized O O
TRs O O
. O O

TR O O
alpha O O
1 O O
and O O
TR O O
beta O O
2 O O
each O O
formed O O
a O O
single O O
major O O
TR O O
: O O
TREp B-DNA O
complex O O
which O O
comigrated O O
with O O
the O O
least O O
retarded O O
complex O O
formed O O
by O O
GH3 O O
NE O O
, O O
while O O
TR O O
beta O O
1 O O
formed O O
multiple O O
complexes O O
suggesting O O
that O O
it O O
can O O
bind O O
to O O
TREp B-DNA B-DNA
as O O
an O O
oligomer O O
. O O

Interestingly O O
, O O
coincubation O O
of O O
35S O O
- O O
TR O O
alpha O O
1 O O
, O O
GH3 O O
NE O O
, O O
and O O
unlabeled O O
TREp B-DNA O
resulted O O
in O O
not O O
only O O
the O O
35S O O
- O O
TR O O
: O O
TREp B-DNA B-DNA
complex O O
, O O
but O O
in O O
two O O
additional O O
more O O
greatly O O
retarded O O
complexes O O
containing O O
35S O O
- O O
TR O O
alpha O O
1 O O
and O O
comigrating O O
with O O
those O O
formed O O
by O O
GH3 O O
extract O O
alone O O
. O O

Incubation O O
of O O
each O O
of O O
the O O
TRs O O
with O O
NE O O
from O O
COS O O
- O O
7 O O
cells O O
, O O
which O O
do O O
not O O
possess O O
sufficient O O
endogenous O O
TRs O O
to O O
mediate O O
T3 O O
- O O
responses O O
, O O
resulted O O
in O O
formation O O
of O O
a O O
new O O
, O O
more O O
greatly O O
shifted O O
complex O O
. O O

A O O
similar O O
, O O
heat O O
labile O O
activity O O
which O O
altered O O
mobility O O
of O O
the O O
TR O B-DNA
: O O
TRE O B-DNA
complex O O
was O O
also O O
present O O
in O O
NE O O
from O O
T3 O O
- O O
unresponsive O O
JEG O O
- O O
3 O O
cells O O
. O O

At O O
high O O
concentration O O
of O O
NE O O
, O O
all O O
of O O
the O O
TR O O
bound O O
to O O
TREp B-DNA B-DNA
was O O
more O O
greatly O O
retarded O O
than O O
in O O
the O O
absence O O
of O O
NE O O
. O O

Truncation O O
of O O
TR O O
alpha O O
1 O O
at O O
amino O O
acid O O
210 O O
prevented O O
additional O O
complex O O
formation O O
in O O
the O O
presence O O
of O O
NE O O
without O O
affecting O O
DNA O O
binding O O
, O O
suggesting O O
that O O
the O O
carboxyl O O
- O O
terminus O O
of O O
the O O
TRs O O
is O O
essential O O
for O O
interaction O O
with O O
nuclear O O
proteins O O
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O
. O O

Cell O O
- O O
specific O O
differences O O
in O O
activation O O
of O O
NF B-DNA B-DNA
- I-DNA I-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
regulatory I-DNA I-DNA
elements I-DNA I-DNA
of O O
human O O
immunodeficiency O O
virus O O
and O O
beta O O
interferon O O
promoters O O
by O O
tumor O O
necrosis O O
factor O O
. O O

Three O O
aspects O O
of O O
the O O
involvement O O
of O O
tumor O O
necrosis O O
factor O O
in O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
pathogenesis O O
were O O
examined O O
. O O

Tumor O O
necrosis O O
factor O O
alpha O O
( O O
TNF O O
- O O
alpha O O
) O O
mRNA O O
production O O
was O O
analyzed O O
by O O
polymerase O O
chain O O
reaction O O
amplification O O
in O O
monocytic O O
U937 O O
cells O O
and O O
in O O
a O O
chronically O O
HIV O O
infected O O
U937 O O
cell O O
line O O
( O O
U9 O O
- O O
IIIB O O
) O O
. O O

TNF O O
- O O
alpha O O
RNA O O
was O O
undetectable O O
in O O
U937 O O
cells O O
, O O
whereas O O
a O O
low O O
constitutive O O
level O O
was O O
detected O O
in O O
U9 O O
- O O
IIIB O O
cells O O
. O O

Paramyxovirus O O
infection O O
induced O O
a O O
5 O O
- O O
to O O
10 O O
- O O
fold O O
increase O O
in O O
the O O
steady O O
- O O
state O O
level O O
of O O
TNF O O
- O O
alpha O O
RNA O O
in O O
U9 O O
- O O
IIIB O O
cells O O
compared O O
with O O
U937 O O
cells O O
, O O
suggesting O O
that O O
HIV O O
- O O
infected O O
monocytic O O
cells O O
produced O O
higher O O
levels O O
of O O
TNF O O
- O O
alpha O O
than O O
did O O
normal O O
cells O O
after O O
a O O
secondary O O
virus O O
infection O O
. O O

The O O
effects O O
of O O
TNF O O
- O O
alpha O O
on O O
gene O O
expression O O
were O O
examined O O
by O O
transient O O
expression O O
assays O O
using O O
reporter B-DNA B-DNA
chloramphenicol I-DNA I-DNA
acetyltransferase I-DNA I-DNA
plasmids I-DNA I-DNA
linked O O
to O O
regulatory B-DNA B-DNA
elements I-DNA I-DNA
from O O
the O O
HIV B-DNA B-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
and O O
the O O
beta B-DNA B-DNA
interferon I-DNA I-DNA
promoter I-DNA I-DNA
. O O

In O O
U937 O O
and O O
Jurkat O O
T O O
lymphoid O O
cells O O
, O O
the O O
inducibility O O
of O O
the O O
different O O
hybrid B-DNA B-DNA
promoters I-DNA I-DNA
by O O
TNF O O
- O O
alpha O O
or O O
phorbol O O
ester O O
varied O O
in O O
a O O
cell O O
type O O
- O O
and O O
promoter O O
context O O
- O O
specific O O
manner O O
; O O
the O O
levels O O
of O O
gene O O
activity O O
of O O
NF B-DNA B-DNA
- I-DNA I-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
- I-DNA I-DNA
containing I-DNA I-DNA
plasmids I-DNA I-DNA
correlated O O
directly O O
with O O
induction O O
of O O
NF O O
- O O
kappa O O
B O O
DNA O O
- O O
binding O O
activity O O
. O O

Although O O
the O O
intact O O
beta B-DNA B-DNA
interferon I-DNA I-DNA
promoter I-DNA I-DNA
was O O
only O O
weakly O O
stimulated O O
by O O
phorbol O O
ester O O
or O O
TNF O O
- O O
alpha O O
, O O
multimers O O
of O O
the O O
PRDII B-DNA O
NF I-DNA O
- I-DNA O
kappa I-DNA O
B I-DNA O
- I-DNA O
binding I-DNA O
domain I-DNA O
were O O
inducible O O
by O O
both O O
agents O O
. O O

TNF O O
- O O
alpha O O
was O O
able O O
to O O
increase O O
expression O O
of O O
the O O
HIV B-DNA B-DNA
LTR I-DNA I-DNA
in O O
T O O
cells O O
, O O
but O O
in O O
monocytic O O
cells O O
, O O
TNF O O
- O O
alpha O O
did O O
not O O
induce O O
the O O
HIV B-DNA B-DNA
LTR I-DNA I-DNA
above O O
a O O
constitutive O O
level O O
of O O
activity O O
. O O

This O O
level O O
of O O
NF O O
- O O
kappa O O
B O O
- O O
independent O O
activity O O
appears O O
to O O
be O O
sufficient O O
for O O
virus O O
multiplication O O
, O O
since O O
TNF O O
- O O
alpha O O
treatment O O
had O O
no O O
effect O O
on O O
the O O
kinetics O O
of O O
de O O
novo O O
HIV O O
type O O
1 O O
( O O
HIV O O
- O O
1 O O
) O O
infection O O
and O O
viral O O
RNA O O
production O O
in O O
U937 O O
cells O O
. O O

However O O
, O O
in O O
Jurkat O O
cells O O
, O O
TNF O O
- O O
alpha O O
dramatically O O
enhanced O O
the O O
spread O O
of O O
HIV O O
- O O
1 O O
through O O
the O O
cell O O
population O O
and O O
increased O O
viral O O
RNA O O
synthesis O O
, O O
indicating O O
that O O
in O O
T O O
cells O O
HIV O O
- O O
1 O O
multiplication O O
was O O
stimulated O O
by O O
TNF O O
- O O
alpha O O
treatment O O
. O O

Functional O O
analysis O O
of O O
cis B-DNA B-DNA
- I-DNA I-DNA
linked I-DNA I-DNA
regulatory I-DNA I-DNA
sequences I-DNA I-DNA
in O O
the O O
HLA B-DNA B-DNA
DRA I-DNA I-DNA
promoter I-DNA I-DNA
by O O
transcription O O
in O O
vitro O O
. O O

Two O O
consensus O B-DNA
sequences O I-DNA
, O O
called O O
X O B-DNA
and O O
Y O O
boxes O O
, O O
capable O O
of O O
binding O O
nuclear O O
proteins O O
and O O
regulating O O
expression O O
in O O
B O O
cells O O
have O O
been O O
defined O O
within O O
the O O
immediate O B-DNA
upstream O I-DNA
region O I-DNA
of O O
major B-DNA B-DNA
histocompatibility I-DNA I-DNA
complex I-DNA I-DNA
( I-DNA I-DNA
MHC I-DNA I-DNA
) I-DNA I-DNA
class I-DNA I-DNA
II I-DNA I-DNA
promoters I-DNA I-DNA
. O O

Unlike O O
other O O
class B-DNA B-DNA
II I-DNA I-DNA
promoters I-DNA I-DNA
, O O
the O O
HLA B-DNA B-DNA
- I-DNA I-DNA
DR I-DNA I-DNA
alpha I-DNA I-DNA
( I-DNA I-DNA
DRA I-DNA I-DNA
) I-DNA I-DNA
promoter I-DNA I-DNA
also O O
contains O O
one O O
element O O
identical O O
to O O
the O O
" B-DNA O
octamer I-DNA B-DNA
" I-DNA I-DNA
motif I-DNA I-DNA
of O O
immunoglobulin B-DNA B-DNA
variable I-DNA I-DNA
region I-DNA I-DNA
promoters I-DNA I-DNA
that O O
is O O
responsible O O
for O O
B O O
cell O O
- O O
specific O O
transcription O O
. O O

This O O
" O O
octamer B-DNA B-DNA
" O O
in O O
the O O
context O O
of O O
DRA O B-DNA
appears O O
capable O O
of O O
binding O O
both O O
the O O
ubiquitous O O
( O O
OTF O O
- O O
1 O O
) O O
and O O
lymphoid O O
- O O
specific O O
( O O
OTF O O
- O O
2 O O
) O O
" O O
octamer O O
" O O
binding O O
proteins O O
, O O
but O O
at O O
least O O
one O O
other O O
distinct O O
" O O
octamer O O
" O O
complex O O
was O O
found O O
. O O

In O O
order O O
to O O
characterize O O
the O O
function O O
of O O
cis B-DNA B-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
elements I-DNA I-DNA
, O O
we O O
have O O
developed O O
an O O
in O O
vitro O O
system O O
in O O
which O O
a O O
DRA B-DNA B-DNA
promoter I-DNA I-DNA
construct I-DNA I-DNA
is O O
transcribed O O
more O O
efficiently O O
in O O
extracts O O
from O O
B O O
cells O O
than O O
in O O
extracts O O
from O O
class O O
II O O
- O O
negative O O
HeLa O O
cells O O
. O O

5 O B-DNA
' O I-DNA
deletion O I-DNA
constructs O I-DNA
which O O
lacked O O
the O O
Y B-DNA B-DNA
box I-DNA I-DNA
, O O
but O O
retained O O
the O O
" B-DNA O
octamer I-DNA B-DNA
" I-DNA I-DNA
motif I-DNA I-DNA
and O O
TATA B-DNA B-DNA
box I-DNA I-DNA
were O O
completely O O
inactive O O
, O O
and O O
internal O O
deletion O O
of O O
the O O
Y B-DNA B-DNA
box I-DNA I-DNA
reduced O O
transcription O O
by O O
95 O O
% O O
. O O

Using O O
supercoiled O O
, O O
but O O
not O O
linear O O
templates O O
, O O
we O O
observed O O
differences O O
in O O
transcription O O
efficiencies O O
from O O
templates O O
lacking O O
or O O
disrupting O O
the O O
X B-DNA B-DNA
consensus I-DNA I-DNA
element I-DNA I-DNA
that O O
reflect O O
effects O O
of O O
random O O
replacement O O
of O O
X B-DNA B-DNA
box I-DNA I-DNA
sequences I-DNA I-DNA
in O O
transient O O
expression O O
assays O O
. O O

Demonstration O O
of O O
the O O
complete O O
dependence O O
on O O
the O O
Y B-DNA B-DNA
box I-DNA I-DNA
in O O
this O O
system O O
suggests O O
that O O
, O O
despite O O
its O O
demonstrated O O
importance O O
in O O
the O O
DRA B-DNA B-DNA
promoter I-DNA I-DNA
, O O
the O O
DRA B-DNA B-DNA
" I-DNA I-DNA
octamer I-DNA I-DNA
" I-DNA O
does O O
not O O
utilize O O
OTF O O
- O O
2 O O
in O O
a O O
manner O O
analogous O O
to O O
immunoglobulin B-DNA B-DNA
promoters I-DNA I-DNA
in O O
B O O
cells O O
. O O

Lipopolysaccharide O O
is O O
a O O
potent O O
monocyte O O
/ O O
macrophage O O
- O O
specific O O
stimulator O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
expression O O
. O O

Lipopolysaccharide O O
( O O
LPS O O
) O O
potently O O
stimulates O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
1 I-DNA I-DNA
- I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( I-DNA O
HIV I-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
- I-DNA I-DNA
LTR I-DNA I-DNA
) I-DNA I-DNA
CAT I-DNA I-DNA
constructs I-DNA I-DNA
transfected O O
into O O
monocyte O O
/ O O
macrophage O O
- O O
like O O
cell O O
lines O O
but O O
not O O
a O O
T O O
cell O O
line O O
. O O

This O O
effect O O
appears O O
to O O
be O O
mediated O O
through O O
the O O
induction O O
of O O
nuclear O O
factor O O
kappa O O
B O O
( O O
NF O O
- O O
kappa O O
B O O
) O O
. O O

Electrophoretic O O
mobility O O
shift O O
assays O O
demonstrate O O
that O O
LPS O O
induces O O
a O O
DNA O O
binding O O
activity O O
indistinguishable O O
from O O
NF O O
- O O
kappa O O
B O O
in O O
U937 O O
and O O
THP O O
- O O
1 O O
cells O O
. O O

LPS O O
is O O
also O O
shown O O
to O O
dramatically O O
increase O O
HIV O O
- O O
1 O O
production O O
from O O
a O O
chronically O O
infected O O
monocyte O O
/ O O
macrophage O O
- O O
like O O
cloned O O
cell O O
line O O
, O O
U1 O O
, O O
which O O
produces O O
very O O
low O O
levels O O
of O O
HIV O O
- O O
1 O O
at O O
baseline O O
. O O

The O O
stimulation O O
of O O
viral O O
production O O
from O O
this O O
cell O O
line O O
occurs O O
only O O
if O O
these O O
cells O O
are O O
treated O O
with O O
granulocyte O O
/ O O
macrophage O O
colony O O
- O O
stimulating O O
factor O O
( O O
GM O O
- O O
CSF O O
) O O
before O O
treatment O O
with O O
LPS O O
. O O

This O O
stimulation O O
of O O
HIV O O
- O O
1 O O
production O O
is O O
correlated O O
with O O
an O O
increase O O
in O O
the O O
level O O
of O O
HIV O O
- O O
1 O O
RNA O O
and O O
and O O
activation O O
of O O
NF O O
- O O
kappa O O
B O O
. O O

LPS O O
is O O
not O O
able O O
to O O
induce O O
HIV O O
- O O
1 O O
production O O
in O O
a O O
cloned O O
T O O
cell O O
line O O
. O O

The O O
effect O O
of O O
LPS O O
on O O
HIV O O
- O O
1 O O
replication O O
occurs O O
at O O
picogram O O
per O O
milliliter O O
concentrations O O
and O O
may O O
be O O
clinically O O
significant O O
in O O
understanding O O
the O O
variability O O
of O O
the O O
natural O O
history O O
of O O
HIV O O
- O O
1 O O
infection O O
. O O

Steroid O O
dose O O
sparing O O
: O O
pharmacodynamic O O
responses O O
to O O
single O O
versus O O
divided O O
doses O O
of O O
methylprednisolone O O
in O O
man O O
. O O

Inhibitory O O
drug O O
interactions O O
affecting O O
the O O
metabolism O O
of O O
methylprednisolone O O
( O O
MP O O
) O O
may O O
produce O O
either O O
steroid O O
sparing O O
or O O
adverse O O
effects O O
partly O O
by O O
increasing O O
the O O
exposure O O
time O O
to O O
the O O
steroid O O
. O O

This O O
phenomenon O O
can O O
be O O
mimicked O O
by O O
administering O O
MP O O
in O O
divided O O
doses O O
. O O

Two O O
types O O
of O O
responses O O
were O O
compared O O
after O O
a O O
single O O
MP O O
dose O O
( O O
40 O O
mg O O
bolus O O
) O O
and O O
a O O
divided O O
regimen O O
( O O
20 O O
mg O O
bolus O O
and O O
a O O
5 O O
mg O O
bolus O O
8 O O
hours O O
later O O
) O O
in O O
six O O
healthy O O
male O O
volunteers O O
. O O

The O O
suppression O O
of O O
basophils O O
measured O O
as O O
whole O O
blood O O
histamine O O
and O O
plasma O O
cortisol O O
concentrations O O
was O O
assessed O O
during O O
32 O O
hours O O
. O O

The O O
37 O O
. O O
5 O O
% O O
reduction O O
in O O
dose O O
produced O O
a O O
23 O O
% O O
overall O O
decreased O O
blood O O
histamine O O
response O O
. O O

A O O
pharmacodynamic O O
model O O
for O O
basophil O O
cell O O
distribution O O
to O O
and O O
from O O
an O O
extravascular O O
compartment O O
describes O O
the O O
effects O O
of O O
MP O O
after O O
both O O
regimens O O
. O O

A O O
slower O O
initial O O
decline O O
in O O
blood O O
histamine O O
after O O
the O O
divided O O
regimen O O
may O O
be O O
related O O
to O O
incomplete O O
suppression O O
of O O
basophil O O
cell O O
return O O
to O O
blood O O
. O O

The O O
50 O O
% O O
inhibitory O O
concentrations O O
of O O
MP O O
of O O
about O O
5 O O
ng O O
/ O O
ml O O
were O O
similar O O
for O O
both O O
regimens O O
. O O

The O O
decline O O
and O O
return O O
of O O
cortisol O O
concentrations O O
were O O
similar O O
between O O
MP O O
treatments O O
with O O
suppression O O
continuing O O
for O O
24 O O
hours O O
. O O

The O O
50 O O
% O O
inhibitory O O
concentrations O O
of O O
MP O O
values O O
for O O
adrenal O O
suppression O O
were O O
about O O
1 O O
ng O O
/ O O
ml O O
. O O

Pharmacodynamic O O
modeling O O
is O O
useful O O
in O O
quantitating O O
corticosteroid O O
responses O O
and O O
generally O O
predicted O O
the O O
" O O
dose O O
- O O
sparing O O
" O O
effects O O
that O O
were O O
achieved O O
by O O
prolonging O O
MP O O
plasma O O
concentrations O O
. O O

This O O
study O O
supports O O
previous O O
clinical O O
observations O O
that O O
patients O O
may O O
require O O
morning O O
through O O
evening O O
exposure O O
to O O
MP O O
to O O
optimize O O
efficacy O O
while O O
adrenal O O
suppression O O
is O O
being O O
minimized O O
. O O

1 O O
, O O
25 O O
( O O
OH O O
) O O
2D2 O O
production O O
by O O
T O O
lymphocytes O O
and O O
alveolar O O
macrophages O O
recovered O O
by O O
lavage O O
from O O
normocalcemic O O
patients O O
with O O
tuberculosis O O
. O O

To O O
compare O O
extra O O
- O O
renal O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
production O O
in O O
different O O
types O O
of O O
granulomatous O O
disease O O
, O O
and O O
to O O
identify O O
the O O
cell O O
types O O
responsible O O
, O O
we O O
have O O
evaluated O O
the O O
conversion O O
of O O
25 O O
( O O
OH O O
) O O
D3 O O
in O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
by O O
uncultured O O
cells O O
recovered O O
by O O
bronchoalveolar O O
lavage O O
and O O
blood O O
mononuclear O O
cells O O
from O O
normocalcemic O O
patients O O
with O O
sarcoidosis O O
and O O
tuberculosis O O
. O O

1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
was O O
produced O O
both O O
by O O
lavage O O
cells O O
( O O
12 O O
/ O O
12 O O
tuberculosis O O
patients O O
, O O
2 O O
/ O O
6 O O
sarcoidosis O O
patients O O
) O O
and O O
blood O O
mononuclear O O
cells O O
( O O
3 O O
/ O O
5 O O
tuberculosis O O
patients O O
, O O
0 O O
/ O O
3 O O
sarcoidosis O O
patients O O
) O O
from O O
patients O O
but O O
not O O
controls O O
, O O
but O O
significantly O O
greater O O
amounts O O
were O O
produced O O
by O O
lavage O O
cells O O
from O O
tuberculosis O O
patients O O
than O O
those O O
of O O
sarcoidosis O O
patients O O
( O O
P O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O

1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
production O O
by O O
lavage O O
cells O O
from O O
tuberculosis O O
patients O O
correlated O O
with O O
the O O
number O O
of O O
CD8 O O
+ O O
T O O
lymphocytes O O
present O O
but O O
not O O
other O O
cell O O
types O O
. O O

T O O
lymphocytes O O
appeared O O
to O O
be O O
an O O
important O O
source O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
production O O
, O O
since O O
purified O O
T O O
lymphocytes O O
from O O
all O O
patients O O
with O O
tuberculosis O O
produced O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
, O O
and O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
production O O
by O O
these O O
cells O O
correlated O O
closely O O
with O O
that O O
produced O O
by O O
unseparated O O
lavage O O
cells O O
. O O

Because O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
can O O
improve O O
the O O
capacity O O
of O O
macrophages O O
to O O
kill O O
mycobacteria O O
, O O
our O O
results O O
support O O
the O O
conclusion O O
that O O
macrophage O O
- O O
lymphocyte O O
interactions O O
, O O
mediated O O
at O O
least O O
in O O
part O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
, O O
may O O
be O O
an O O
important O O
component O O
of O O
a O O
successful O O
antituberculous O O
immune O O
response O O
. O O

Megakaryocytic O O
and O O
erythrocytic O O
lineages O O
share O O
specific O O
transcription O O
factors O O
. O O

Erythroid B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
genes I-DNA I-DNA
contain O O
binding O B-DNA
sites O I-DNA
for O O
NF O O
- O O
E1 O O
( O O
also O O
called O O
GF O O
- O O
1 O O
and O O
Eryf O O
- O O
1 O O
; O O
refs O O
1 O O
- O O
3 O O
respectively O O
) O O
, O O
the O O
principal O O
DNA O O
- O O
binding O O
protein O O
of O O
the O O
erythrocytic O O
lineage O O
. O O

NF O O
- O O
E1 O O
expression O O
seems O O
to O O
be O O
restricted O O
to O O
the O O
erythrocytic O O
lineage O O
. O O

A O O
closely O O
related O O
( O O
if O O
not O O
identical O O
) O O
protein O O
is O O
found O O
in O O
both O O
a O O
human O O
megakaryocytic O O
cell O O
line O O
and O O
purified O O
human O O
megakaryocytes O O
; O O
it O O
binds O O
to O O
promoter B-DNA B-DNA
regions I-DNA I-DNA
of O O
two O O
megakaryocytic B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
genes I-DNA I-DNA
. O O

The O O
binding O O
sites O O
and O O
partial O O
proteolysis O O
profile O O
of O O
this O O
protein O O
are O O
indistinguishable O O
from O O
those O O
of O O
the O O
erythroid O O
protein O O
; O O
also O O
, O O
NF O O
- O O
E1 O O
messenger O O
RNA O O
is O O
the O O
same O O
size O O
in O O
both O O
the O O
megakaryocytic O O
and O O
erythroid O O
cell O O
lines O O
. O O

Furthermore O O
, O O
point O O
mutations O O
that O O
abolish O O
binding O O
of O O
NF O O
- O O
E1 O O
result O O
in O O
a O O
70 O O
% O O
decrease O O
in O O
the O O
transcriptional O O
activity O O
of O O
a O O
megakaryocytic B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
promoter I-DNA I-DNA
. O O

We O O
also O O
find O O
that O O
NF O O
- O O
E2 O O
, O O
another O O
trans O O
- O O
acting O O
factor O O
of O O
the O O
erythrocytic O O
lineage O O
, O O
is O O
present O O
in O O
megakaryocytes O O
. O O

Transcriptional O O
effects O O
in O O
both O O
lineages O O
might O O
then O O
be O O
mediated O O
in O O
part O O
by O O
the O O
same O O
specific O O
trans O O
- O O
acting O O
factors O O
. O O

Our O O
data O O
strengthen O O
the O O
idea O O
of O O
a O O
close O O
association O O
between O O
the O O
erythrocytic O O
and O O
the O O
megakaryocytic O O
lineages O O
and O O
could O O
also O O
explain O O
the O O
expression O O
of O O
markers O O
specific O O
to O O
the O O
erythrocytic O O
and O O
megakaryocytic O O
lineages O O
in O O
most O O
erythroblastic O O
and O O
megakaryoblastic O O
permanent O O
cell O O
lines O O
. O O

Transcriptional O O
down O O
- O O
regulation O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
myc I-DNA I-DNA
expression O O
by O O
protein O O
synthesis O O
- O O
dependent O O
and O O
- O O
independent O O
pathways O O
in O O
a O O
human O O
T O O
lymphoblastic O O
tumor O O
cell O O
line O O
. O O

We O O
show O O
that O O
in O O
the O O
human O O
T O O
lymphoblastic O O
tumor O O
cell O O
line O O
Molt4 O O
c B-DNA O
- I-DNA O
myc I-DNA O
mRNA O O
and O O
protein O O
expression O O
is O O
down O O
- O O
regulated O O
after O O
exposure O O
to O O
dimethyl O O
sulfoxide O O
, O O
to O O
phorbol O O
myristate O O
acetate O O
, O O
or O O
to O O
the O O
calcium O O
ionophore O O
A23187 O O
, O O
which O O
raises O O
the O O
intracellular O O
calcium O O
concentration O O
. O O

A O O
block O O
to O O
RNA O O
elongation O O
is O O
largely O O
responsible O O
for O O
decreased O O
c B-DNA B-DNA
- I-DNA I-DNA
myc I-DNA I-DNA
transcription O O
. O O

Although O O
negative O O
regulation O O
by O O
dimethyl O O
sulfoxide O O
takes O O
place O O
even O O
when O O
protein O O
synthesis O O
is O O
inhibited O O
by O O
cycloheximide O O
, O O
the O O
phorbol O O
myristate O O
acetate O O
effect O O
is O O
blocked O O
to O O
some O O
extent O O
only O O
by O O
cycloheximide O O
. O O

The O O
calcium O O
ionophore O O
- O O
induced O O
c B-DNA B-DNA
- I-DNA I-DNA
myc I-DNA I-DNA
suppression O O
, O O
however O O
, O O
strictly O O
requires O O
de O O
novo O O
protein O O
synthesis O O
. O O

Therefore O O
, O O
two O O
different O O
negative O O
regulatory O O
pathways O O
are O O
involved O O
in O O
c B-DNA B-DNA
- I-DNA I-DNA
myc I-DNA I-DNA
regulation O O
: O O
one O O
which O O
is O O
independent O O
and O O
one O O
which O O
depends O O
on O O
de O O
novo O O
protein O O
synthesis O O
. O O

The O O
latter O O
one O O
appears O O
to O O
be O O
mediated O O
by O O
a O O
rapidly O O
calcium O O
- O O
dependent O O
induced O O
gene O O
product O O
. O O

Oestrogen O O
receptor O O
( O O
ER O O
) O O
analysis O O
in O O
B O O
- O O
cell O O
chronic O O
lymphocytic O O
leukemia O O
: O O
correlation O O
of O O
biochemical O O
and O O
immunocytochemical O O
methods O O
. O O

Oestrogen O O
receptors O O
( O O
ER O O
) O O
are O O
present O O
in O O
neoplastic O O
lymphoid O O
cells O O
and O O
have O O
been O O
considered O O
a O O
physiological O O
marker O O
of O O
growth O O
rate O O
or O O
differentiation O O
. O O

Tamoxifen O O
, O O
an O O
oestrogen O O
antagonist O O
, O O
has O O
been O O
given O O
in O O
some O O
patients O O
with O O
CLL O O
and O O
Hodgkin O O
' O O
s O O
disease O O
, O O
with O O
dramatic O O
response O O
in O O
single O O
cases O O
. O O

Until O O
now O O
, O O
ER O O
status O O
has O O
been O O
assessed O O
using O O
a O O
steroid O O
binding O O
assay O O
( O O
SBA O O
) O O
which O O
has O O
many O O
inherent O O
problems O O
. O O

Recently O O
, O O
the O O
development O O
of O O
monoclonal O O
antibodies O O
directed O O
against O O
ER O O
has O O
been O O
applied O O
to O O
the O O
study O O
of O O
breast O O
carcinomas O O
and O O
results O O
obtained O O
show O O
good O O
correlation O O
with O O
the O O
quantitative O O
SBA O O
. O O

We O O
studied O O
49 O O
cases O O
of O O
B O O
- O O
cell O O
chronic O O
lymphocytic O O
leukemia O O
( O O
CLL O O
) O O
using O O
immunostaining O O
of O O
cytospin O O
preparations O O
. O O

In O O
30 O O
of O O
these O O
cases O O
ER O O
enzyme O O
immunoassay O O
( O O
ER O O
- O O
EIA O O
) O O
was O O
also O O
performed O O
. O O

Cultured O O
MCF O O
- O O
7 O O
cells O O
, O O
derived O O
from O O
a O O
pleural O O
effusion O O
of O O
a O O
breast O O
cancer O O
patient O O
, O O
known O O
to O O
contain O O
high O O
levels O O
of O O
ER O O
were O O
used O O
as O O
a O O
positive O O
control O O
( O O
40 O O
- O O
48 O O
% O O
ER O O
positive O O
cells O O
by O O
immunocytochemistry O O
; O O
200 O O
fmol O O
/ O O
mg O O
protein O O
by O O
EIA O O
) O O
. O O

All O O
of O O
the O O
CLL O O
cases O O
except O O
two O O
( O O
96 O O
% O O
) O O
were O O
negative O O
for O O
ER O O
( O O
less O O
than O O
1 O O
% O O
staining O O
; O O
less O O
than O O
4 O O
fmol O O
/ O O
mg O O
protein O O
) O O
. O O

The O O
two O O
positive O O
cases O O
expressed O O
granular O O
ER O O
staining O O
over O O
the O O
nucleus O O
( O O
9 O O
. O O
2 O O
and O O
12 O O
. O O
1 O O
% O O
positive O O
cells O O
) O O
and O O
were O O
positive O O
by O O
EIA O O
and O O
SBA O O
. O O

It O O
is O O
concluded O O
that O O
( O O
i O O
) O O
patients O O
with O O
CLL O O
rarely O O
express O O
ER O O
and O O
( O O
ii O O
) O O
immunocytochemical O O
staining O O
of O O
cytospin O O
preparations O O
is O O
a O O
valid O O
technique O O
for O O
the O O
measurement O O
of O O
ER O O
. O O

It O O
is O O
of O O
interest O O
that O O
one O O
of O O
the O O
positive O O
cases O O
was O O
diagnosed O O
as O O
CLL O O
with O O
Richter O O
' O O
s O O
transformation O O
confirming O O
earlier O O
findings O O
. O O

Type O O
- O O
II O O
estrogen O O
binding O O
sites O O
in O O
a O O
lymphoblastoid O O
cell O O
line O O
and O O
growth O O
- O O
inhibitory O O
effect O O
of O O
estrogen O O
, O O
anti O O
- O O
estrogen O O
and O O
bioflavonoids O O
. O O

Type O B-DNA
- O I-DNA
II O I-DNA
estrogen O I-DNA
- O I-DNA
binding O I-DNA
sites O I-DNA
( O O
type O B-DNA
- O I-DNA
II O I-DNA
EBS O I-DNA
) O O
have O O
been O O
demonstrated O O
in O O
the O O
human O O
lymphoblastoid O O
cell O O
line O O
IM O O
- O O
9 O O
using O O
a O O
whole O O
- O O
cell O O
assay O O
with O O
( O O
6 O O
, O O
7 O O
- O O
3H O O
) O O
estradiol O O
( O O
3H O O
- O O
E2 O O
) O O
as O O
tracer O O
. O O

Competition O O
analysis O O
showed O O
that O O
the O O
anti O O
- O O
estrogen O O
tamoxifen O O
and O O
the O O
flavonoids O O
quercetin O O
and O O
rutin O O
competed O O
for O O
( O O
3H O O
) O O
- O O
E2 O O
binding O O
to O O
type O O
- O O
II O O
EBS O O
. O O

Growth O O
experiments O O
demonstrated O O
that O O
diethylstilbestrol O O
( O O
DES O O
) O O
tamoxifen O O
( O O
TAM O O
) O O
, O O
quercetin O O
and O O
rutin O O
exerted O O
a O O
reversible O O
dose O O
- O O
dependent O O
inhibition O O
of O O
cell O O
proliferation O O
in O O
the O O
range O O
of O O
concentrations O O
between O O
10 O O
nM O O
and O O
10 O O
microM O O
. O O

The O O
relative O O
binding O O
affinity O O
of O O
quercetin O O
, O O
rutin O O
, O O
DES O O
and O O
TAM O O
for O O
type O O
- O O
II O O
EBS O O
correlated O O
well O O
with O O
their O O
potency O O
as O O
cell O O
growth O O
inhibitors O O
. O O

Moreover O O
, O O
hesperidin O O
, O O
a O O
flavonoid O O
which O O
does O O
not O O
bind O O
to O O
type O O
- O O
II O O
EBS O O
, O O
was O O
ineffective O O
in O O
inhibiting O O
cell O O
growth O O
. O O

Cell O O
- O O
cycle O O
analysis O O
showed O O
that O O
the O O
growth O O
- O O
inhibitory O O
effect O O
of O O
DES O O
, O O
TAM O O
or O O
quercetin O O
was O O
due O O
to O O
a O O
blocking O O
effect O O
in O O
the O O
G0 O O
- O O
G1 O O
phases O O
. O O

Our O O
results O O
suggest O O
that O O
high O O
estrogen O O
and O O
anti O O
- O O
estrogen O O
concentrations O O
and O O
flavonoids O O
may O O
regulate O O
IM O O
- O O
9 O O
cell O O
growth O O
through O O
a O O
common O O
mechanism O O
involving O O
a O O
binding O O
interaction O O
with O O
type O O
- O O
II O O
EBS O O
. O O

[ O O
Glucocorticoid O O
receptors O O
in O O
peripheral O O
blood O O
lymphocytes O O
of O O
patients O O
with O O
bronchial O O
asthma O O
] O O
. O O

Quantitation O O
of O O
glucocorticoid O O
receptors O O
( O O
GCR O O
) O O
and O O
the O O
study O O
of O O
their O O
affinity O O
for O O
glucocorticosteroids O O
( O O
GCS O O
) O O
were O O
made O O
in O O
peripheral O O
blood O O
lymphocytes O O
of O O
bronchial O O
asthma O O
( O O
BA O O
) O O
patients O O
in O O
consideration O O
of O O
GCR O O
treatment O O
and O O
serum O O
levels O O
of O O
endogenous O O
cortisol O O
. O O

It O O
is O O
stated O O
that O O
GCR O O
of O O
healthy O O
controls O O
and O O
GCS O O
- O O
untreated O O
patients O O
outnumbered O O
those O O
of O O
cortisol O O
- O O
dependent O O
BA O O
patients O O
on O O
hormone O O
therapy O O
. O O

Following O O
discontinuation O O
of O O
glucocorticoid O O
drugs O O
GCR O O
count O O
in O O
cortisol O O
- O O
dependent O O
BA O O
tends O O
to O O
rise O O
. O O

Endogenous O O
cortisol O O
has O O
no O O
effect O O
on O O
GCR O O
level O O
estimated O O
by O O
3H O O
- O O
triamcinolone O O
acetonide O O
. O O

Two O O
glucocorticoid O B-DNA
binding O I-DNA
sites O I-DNA
on O O
the O O
human O O
glucocorticoid O O
receptor O O
. O O

Glucocorticoids O O
are O O
known O O
to O O
have O O
a O O
lytic O O
effect O O
in O O
leukemic O O
cells O O
via O O
interactions O O
with O O
the O O
glucocorticoid O O
receptor O O
( O O
GR O O
) O O
. O O

Cortisol O O
and O O
various O O
synthetic O O
glucocorticoids O O
bind O O
to O O
the O O
GR O O
with O O
one O O
- O O
site O O
kinetics O O
. O O

Cortivazol O O
( O O
CVZ O O
) O O
is O O
a O O
unique O O
, O O
high O O
potency O O
synthetic O O
glucocorticoid O O
, O O
which O O
has O O
a O O
phenylpyrazol O O
fused O O
to O O
the O O
A O O
- O O
ring O O
of O O
the O O
steroid O O
nucleus O O
and O O
displays O O
binding O O
consistent O O
with O O
two O O
or O O
more O O
sites O O
in O O
the O O
cytosol O O
from O O
CEM O O
C7 O O
cells O O
( O O
a O O
human O O
acute O O
lymphoblastic O O
T O O
- O O
cell O O
line O O
) O O
. O O

It O O
has O O
previously O O
been O O
shown O O
that O O
the O O
lower O O
affinity O O
class O O
of O O
sites O O
are O O
similar O O
in O O
affinity O O
and O O
site O O
molarity O O
to O O
those O O
recognized O O
by O O
dexamethasone O O
. O O

The O O
higher O O
affinity O O
sites O O
bind O O
CVZ O O
with O O
20 O O
- O O
to O O
50 O O
- O O
fold O O
greater O O
affinity O O
, O O
consistent O O
with O O
CVZ O O
' O O
s O O
enhanced O O
biological O O
effects O O
. O O

In O O
mutant O O
leukemic O O
cells O O
resistant O O
to O O
the O O
lytic O O
effects O O
of O O
dexamethasone O O
, O O
CVZ O O
both O O
lyses O O
the O O
cells O O
and O O
recognizes O O
a O O
single O O
class O O
of O O
sites O O
similar O O
to O O
the O O
high O O
affinity O O
site O O
in O O
CEM O O
C7 O O
cells O O
. O O

We O O
have O O
carried O O
out O O
experiments O O
to O O
define O O
the O O
nature O O
of O O
the O O
higher O O
affinity O O
CVZ O B-DNA
binding O I-DNA
site O I-DNA
. O O

We O O
now O O
show O O
that O O
: O O
1 O O
) O O
CVZ O O
has O O
more O O
than O O
one O O
binding O O
site O O
in O O
a O O
second O O
, O O
independent O O
, O O
B O O
- O O
cell O O
line O O
, O O
IM O O
- O O
9 O O
; O O
2 O O
) O O
the O O
antiglucocorticoid O O
RU O O
38486 O O
is O O
able O O
to O O
block O O
both O O
CVZ O O
' O O
s O O
higher O O
and O O
lower O O
affinity O O
sites O O
; O O
3 O O
) O O
all O O
of O O
CVZ O O
' O O
s O O
binding O O
sites O O
are O O
on O O
a O O
protein O O
immunologically O O
indistinguishable O O
from O O
the O O
human O O
GR O O
; O O
and O O
4 O O
) O O
freshly O O
isolated O O
clones O O
of O O
CVZ O O
- O O
resistant O O
cells O O
have O O
lost O O
all O O
binding O B-DNA
sites O I-DNA
for O O
CVZ O O
. O O

These O O
data O O
indicate O O
that O O
CVZ O O
is O O
recognizing O O
two O O
glucocorticoid O B-DNA
binding O I-DNA
sites O I-DNA
on O O
the O O
human O O
GR O O
or O O
a O O
protein O O
very O O
similar O O
to O O
it O O
. O O

Retroviral O O
mediated O O
transfer O O
and O O
expression O O
of O O
exogenous B-DNA B-DNA
genes I-DNA I-DNA
in O O
primary O O
lymphoid O O
cells O O
: O O
assaying O O
for O O
a O O
viral O O
transactivator O O
activity O O
in O O
normal O O
and O O
malignant O O
cells O O
. O O

In O O
this O O
report O O
we O O
describe O O
the O O
use O O
of O O
recombinant O O
retroviruses O O
to O O
characterize O O
the O O
activity O O
of O O
an O O
exogenous B-DNA B-DNA
promoter I-DNA I-DNA
in O O
primary O O
cells O O
obtained O O
from O O
patients O O
with O O
lymphoproliferative O O
disorders O O
. O O

The O O
infection O O
of O O
a O O
variety O O
of O O
cultured O O
and O O
primary O O
lymphoid O O
cells O O
with O O
a O O
recombinant O O
retrovirus O O
containing O O
a O O
histone B-DNA B-DNA
promoter I-DNA I-DNA
- I-DNA I-DNA
driven I-DNA I-DNA
beta I-DNA I-DNA
- I-DNA I-DNA
galactosidase I-DNA I-DNA
gene I-DNA I-DNA
is O O
shown O O
to O O
result O O
in O O
the O O
expression O O
of O O
beta O O
- O O
galactosidase O O
in O O
50 O O
% O O
to O O
100 O O
% O O
of O O
the O O
cells O O
. O O

A O O
similar O O
infection O O
with O O
a O O
recombinant O O
retrovirus O O
containing O O
the O O
beta B-DNA B-DNA
- I-DNA I-DNA
galactosidase I-DNA I-DNA
gene I-DNA I-DNA
with O O
an O O
adenovirus B-DNA B-DNA
E2 I-DNA I-DNA
promoter I-DNA I-DNA
, O O
results O O
in O O
beta O O
- O O
galactosidase O O
activity O O
in O O
a O O
limited O O
number O O
of O O
cultured O O
and O O
primary O O
cells O O
. O O

Since O O
the O O
adenovirus B-DNA B-DNA
E2 I-DNA I-DNA
promoter I-DNA I-DNA
has O O
been O O
well O O
characterized O O
and O O
is O O
known O O
to O O
be O O
regulated O O
by O O
transactivators O O
encoded O O
by O O
many O O
viruses O O
, O O
the O O
activity O O
of O O
this O O
promoter O O
in O O
specific O O
cell O O
types O O
is O O
discussed O O
in O O
reference O O
to O O
both O O
the O O
biology O O
of O O
the O O
cell O O
and O O
the O O
possible O O
presence O O
of O O
as O O
yet O O
undetected O O
viral O O
gene O O
products O O
. O O

[ O O
The O O
effect O O
of O O
24 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
( O O
dioxyvit O O
) O O
on O O
Ca O O
metabolism O O
and O O
immune O O
status O O
during O O
chronic O O
kidney O O
failure O O
] O O
. O O

Active O O
metabolite O O
of O O
vitamin O O
D3 O O
, O O
24R O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
( O O
dioxyvit O O
) O O
was O O
used O O
at O O
a O O
daily O O
dose O O
of O O
100 O O
micrograms O O
in O O
treatment O O
of O O
children O O
affected O O
with O O
tubulointerstitial O O
disease O O
of O O
kidney O O
and O O
with O O
chronic O O
glomerulonephritis O O
under O O
conditions O O
of O O
kidney O O
insufficiency O O
. O O

The O O
drug O O
exhibited O O
distinct O O
normalizing O O
effect O O
on O O
patterns O O
of O O
calcium O O
metabolism O O
: O O
increase O O
of O O
total O O
and O O
ionized O O
Ca2 O O
+ O O
and O O
of O O
25 O O
- O O
OHD O O
, O O
decrease O O
in O O
concentration O O
of O O
parath O O
hormone O O
and O O
osteocalcine O O
in O O
blood O O
serum O O
as O O
well O O
as O O
on O O
immunological O O
parameters O O
: O O
restoration O O
of O O
decreased O O
content O O
of O O
T O O
- O O
and O O
0 O O
- O O
lymphocytes O O
. O O

Concentration O O
of O O
receptors O O
of O O
hormonal O O
form O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
was O O
found O O
to O O
be O O
minimal O O
in O O
lymphocytes O O
under O O
conditions O O
of O O
chronic O O
kidney O O
insufficiency O O
, O O
while O O
their O O
expression O O
, O O
after O O
the O O
dioxyvit O O
action O O
, O O
was O O
detected O O
only O O
in O O
patients O O
with O O
glomerulonephritis O O
. O O

Specific O O
calcitropic O O
effect O O
of O O
dioxyvit O O
with O O
simultaneous O O
correction O O
of O O
vitamin O O
D O O
deficiency O O
were O O
apparently O O
responsible O O
for O O
high O O
efficacy O O
of O O
the O O
drug O O
in O O
treatment O O
of O O
calcium O O
metabolism O O
and O O
immunity O O
impairments O O
in O O
children O O
with O O
renal O O
deteriorations O O
at O O
the O O
step O O
of O O
chronic O O
kidney O O
insufficiency O O
. O O

[ O O
The O O
role O O
of O O
glucocorticoid O O
receptors O O
and O O
HLA O O
antigens O O
in O O
the O O
pathogenesis O O
of O O
Cushing O O
' O O
s O O
syndrome O O
] O O
. O O

Lymphocytic O O
levels O O
of O O
glucocorticoid O O
receptors O O
were O O
evaluated O O
in O O
114 O O
patients O O
suffering O O
from O O
Icenko O O
- O O
Cushing O O
' O O
s O O
syndrome O O
. O O

Incidence O O
of O O
HLA O O
antigens O O
was O O
determined O O
in O O
94 O O
of O O
them O O
. O O

A O O
significant O O
rise O O
of O O
A10 O O
and O O
B27 O O
antigen O O
incidence O O
compared O O
to O O
that O O
in O O
normal O O
subjects O O
allows O O
these O O
antigens O O
to O O
be O O
considered O O
genetic O O
markers O O
of O O
Icenko O O
- O O
Cushing O O
' O O
s O O
syndrome O O
. O O

The O O
levels O O
of O O
glucocorticoid O O
receptors O O
in O O
lymphocytes O O
of O O
the O O
patients O O
are O O
lower O O
than O O
in O O
normal O O
subjects O O
both O O
in O O
the O O
active O O
stage O O
of O O
the O O
disease O O
and O O
following O O
bilateral O O
total O O
adrenalectomy O O
. O O

The O O
patients O O
carrying O O
B27 O O
antigen O O
had O O
lymphocytic O O
receptor O O
concentrations O O
under O O
the O O
levels O O
of O O
such O O
in O O
patients O O
free O O
of O O
the O O
antigen O O
carriage O O
. O O

Antigen O O
B27 O O
seems O O
to O O
be O O
a O O
cause O O
of O O
lower O O
levels O O
of O O
glucocorticoid O O
receptors O O
in O O
blood O O
lymphocytes O O
. O O

Effects O O
of O O
1 O O
alpha O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
on O O
the O O
human O O
chronic O O
myelogenous O O
leukemia O O
cell O O
line O O
RWLeu O O
- O O
4 O O
. O O

The O O
effects O O
of O O
1 O O
alpha O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
( O O
VD3 O O
) O O
on O O
proliferation O O
, O O
differentiation O O
, O O
and O O
macromolecular O O
synthesis O O
in O O
the O O
new O O
Philadelphia O O
chromosome O O
- O O
positive O O
chronic O O
myelogenous O O
leukemia O O
cell O O
line O O
, O O
RWLeu O O
- O O
4 O O
, O O
were O O
investigated O O
. O O

Binding O O
of O O
[ O O
3H O O
] O O
VD3 O O
was O O
saturable O O
, O O
with O O
approximately O O
2000 O O
- O O
3000 O O
sites O O
/ O O
cell O O
, O O
and O O
half O O
- O O
maximal O O
binding O O
occurring O O
at O O
0 O O
. O O
21 O O
- O O
0 O O
. O O
33 O O
nM O O
. O O

Treatment O O
of O O
RWLeu O O
- O O
4 O O
cells O O
with O O
VD3 O O
induced O O
24R O O
- O O
hydroxylase O O
activity O O
, O O
a O O
marker O O
of O O
vitamin O O
D3 O O
responsiveness O O
in O O
many O O
tissues O O
. O O

Exposure O O
of O O
RWLeu O O
- O O
4 O O
cells O O
to O O
VD3 O O
also O O
inhibited O O
proliferation O O
and O O
DNA O O
synthesis O O
with O O
a O O
50 O O
% O O
effective O O
dose O O
of O O
3 O O
. O O
5 O O
- O O
10 O O
nM O O
within O O
72 O O
h O O
; O O
in O O
addition O O
, O O
protein O O
and O O
RNA O O
synthesis O O
were O O
inhibited O O
by O O
VD3 O O
treatment O O
. O O

Exposure O O
of O O
RWLeu O O
- O O
4 O O
cells O O
to O O
5 O O
nM O O
VD3 O O
for O O
72 O O
h O O
caused O O
50 O O
% O O
of O O
the O O
cells O O
to O O
differentiate O O
into O O
macrophage O O
/ O O
monocyte O O
type O O
cells O O
as O O
judged O O
by O O
nitroblue O O
tetrazolium O O
staining O O
and O O
adherence O O
to O O
plastic O O
. O O

Progressive O O
expression O O
of O O
cell O O
surface O O
maturation O O
- O O
specific O O
antigens O O
of O O
the O O
monocyte O O
/ O O
macrophage O O
lineage O O
was O O
induced O O
by O O
treatment O O
of O O
RWLeu O O
- O O
4 O O
cells O O
with O O
VD3 O O
for O O
24 O O
to O O
72 O O
h O O
at O O
doses O O
that O O
inhibited O O
cellular O O
proliferation O O
. O O

c O O
- O O
myc O O
RNA O O
, O O
which O O
is O O
constitutively O O
expressed O O
in O O
RWLeu O O
- O O
4 O O
cells O O
, O O
increased O O
after O O
0 O O
. O O
5 O O
h O O
of O O
treatment O O
with O O
50 O O
nM O O
VD3 O O
and O O
then O O
rapidly O O
decreased O O
to O O
barely O O
detectable O O
levels O O
after O O
4 O O
h O O
of O O
treatment O O
. O O

Finally O O
, O O
the O O
in O O
vitro O O
tyrosine O O
kinase O O
activity O O
associated O O
with O O
the O O
p210bcr B-DNA B-DNA
- I-DNA I-DNA
abl I-DNA I-DNA
oncogene I-DNA I-DNA
product O O
was O O
decreased O O
approximately O O
50 O O
% O O
by O O
VD3 O O
treatment O O
. O O

Because O O
of O O
the O O
presence O O
of O O
a O O
functional O O
receptor O O
- O O
effector O O
system O O
for O O
VD3 O O
and O O
multiple O O
biological O O
responses O O
to O O
the O O
hormone O O
, O O
these O O
cells O O
provide O O
a O O
unique O O
model O O
system O O
with O O
which O O
to O O
probe O O
the O O
specific O O
effects O O
of O O
VD3 O O
on O O
cell O O
growth O O
and O O
differentiation O O
in O O
chronic O O
myelogenous O O
leukemia O O
. O O

A O O
new O O
member O O
of O O
the O O
leucine O O
zipper O O
class O O
of O O
proteins O O
that O O
binds O O
to O O
the O O
HLA B-DNA B-DNA
DR I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Several O O
mutants O O
derived O O
from O O
transformed O O
human O O
B O O
cell O O
lines O O
are O O
defective O O
in O O
expressing O O
major B-DNA B-DNA
histocompatibility I-DNA I-DNA
complex I-DNA I-DNA
( I-DNA I-DNA
MHC I-DNA I-DNA
) I-DNA I-DNA
class I-DNA I-DNA
II I-DNA I-DNA
genes I-DNA I-DNA
. O O

The O O
failure O O
to O O
express O O
a O O
class B-DNA B-DNA
II I-DNA I-DNA
gene I-DNA I-DNA
in O O
at O O
least O O
one O O
such O O
mutant O O
line O O
has O O
been O O
mapped O O
to O O
the O O
MHC B-DNA B-DNA
class I-DNA I-DNA
II I-DNA I-DNA
X I-DNA I-DNA
box I-DNA I-DNA
, O O
a O O
conserved B-DNA B-DNA
transcriptional I-DNA I-DNA
element I-DNA I-DNA
in O O
the O O
promoter B-DNA B-DNA
region I-DNA I-DNA
. O O

A O O
complementary B-DNA B-DNA
DNA I-DNA I-DNA
encoding O O
a O O
DNA O O
- O O
binding O O
protein O O
( O O
human O O
X O O
box O O
binding O O
protein O O
, O O
hXBP O O
- O O
1 O O
) O O
whose O O
target O O
is O O
the O O
human B-DNA B-DNA
DR I-DNA I-DNA
alpha I-DNA I-DNA
X I-DNA I-DNA
box I-DNA I-DNA
and O O
the O O
3 B-DNA B-DNA
' I-DNA I-DNA
flanking I-DNA I-DNA
region I-DNA I-DNA
has O O
now O O
been O O
cloned O O
. O O

This O O
complementary B-DNA B-DNA
DNA I-DNA I-DNA
encoded O O
a O O
protein O O
with O O
structural O O
similarities O O
to O O
the O O
c O O
- O O
jun O O
proto O O
- O O
oncogene O O
product O O
, O O
and O O
its O O
target O O
sequence O O
was O O
closely O O
related O O
to O O
the O O
palindromic B-DNA B-DNA
target I-DNA I-DNA
sequence I-DNA I-DNA
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
. O O

Mutation O O
of O O
the O O
hXBP B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
DNA I-DNA I-DNA
target I-DNA I-DNA
sequence I-DNA I-DNA
decreased O O
DR B-DNA B-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
activity O O
in O O
vivo O O
. O O

These O O
studies O O
suggest O O
that O O
the O O
hXBP O O
- O O
1 O O
protein O O
acts O O
as O O
a O O
transcription O O
factor O O
in O O
B O O
cells O O
. O O

Pseudohypoaldosteronism O O
in O O
eight O O
families O O
: O O
different O O
forms O O
of O O
inheritance O O
are O O
evidence O O
for O O
various O O
genetic O O
defects O O
. O O

Pseudohypoaldosteronism O O
is O O
a O O
rare O O
hereditary O O
disorder O O
presenting O O
in O O
early O O
infancy O O
with O O
renal O O
salt O O
loss O O
leading O O
to O O
hyponatremia O O
and O O
hyperkalemia O O
despite O O
high O O
levels O O
of O O
plasma O O
aldosterone O O
. O O

The O O
patients O O
are O O
insensitive O O
to O O
mineralocorticoids O O
; O O
however O O
, O O
sodium O O
supplementation O O
is O O
able O O
to O O
correct O O
electrolyte O O
abnormalities O O
. O O

Absent O O
or O O
greatly O O
diminished O O
type O O
I O O
aldosterone O O
receptors O O
in O O
peripheral O O
mononuclear O O
leucocytes O O
have O O
been O O
recently O O
demonstrated O O
and O O
explain O O
the O O
lack O O
of O O
response O O
to O O
mineralocorticoids O O
. O O

We O O
have O O
studied O O
the O O
mode O O
of O O
inheritance O O
in O O
eight O O
families O O
with O O
a O O
total O O
of O O
nine O O
patients O O
. O O

There O O
was O O
evidence O O
for O O
an O O
autosomal O O
recessive O O
form O O
of O O
inheritance O O
in O O
four O O
families O O
, O O
while O O
the O O
other O O
four O O
families O O
appeared O O
to O O
have O O
an O O
autosomal O O
dominant O O
mode O O
of O O
transmission O O
. O O

In O O
three O O
families O O
the O O
autosomal O O
recessive O O
form O O
was O O
characterized O O
by O O
normal O O
receptor O O
as O O
well O O
as O O
hormone O O
data O O
in O O
both O O
parents O O
, O O
while O O
in O O
one O O
family O O
receptor O O
levels O O
in O O
both O O
parents O O
were O O
greatly O O
reduced O O
, O O
but O O
hormone O O
levels O O
were O O
normal O O
. O O

In O O
the O O
four O O
families O O
with O O
an O O
autosomal O O
dominant O O
mode O O
of O O
transmission O O
there O O
was O O
always O O
one O O
parent O O
with O O
reduced O O
receptor O O
binding O O
in O O
peripheral O O
mononuclear O O
leucocytes O O
and O O
elevated O O
serum O O
hormone O O
levels O O
. O O

These O O
parents O O
were O O
entirely O O
asymptomatic O O
. O O

In O O
an O O
extended O O
family O O
we O O
were O O
able O O
to O O
study O O
an O O
aunt O O
and O O
her O O
newborn O O
daughter O O
, O O
who O O
were O O
both O O
also O O
biochemically O O
affected O O
but O O
clinically O O
asymptomatic O O
. O O

It O O
, O O
therefore O O
, O O
appears O O
that O O
this O O
dual O O
pattern O O
of O O
genetic O O
transmission O O
may O O
indicate O O
differing O O
genetic O O
defects O O
which O O
cause O O
the O O
same O O
clinical O O
picture O O
of O O
pseudohypoaldosteronism O O
. O O

Perceived O O
social O O
support O O
and O O
tumor O O
estrogen O O
/ O O
progesterone O O
receptor O O
status O O
as O O
predictors O O
of O O
natural O O
killer O O
cell O O
activity O O
in O O
breast O O
cancer O O
patients O O
. O O

This O O
report O O
is O O
concerned O O
with O O
the O O
prediction O O
of O O
natural O O
killer O O
( O O
NK O O
) O O
cell O O
activity O O
in O O
61 O O
Stage O O
I O O
and O O
II O O
breast O O
cancer O O
patients O O
, O O
between O O
the O O
ages O O
of O O
25 O O
and O O
70 O O
, O O
who O O
were O O
accrued O O
to O O
this O O
project O O
. O O

All O O
baseline O O
interview O O
and O O
testing O O
data O O
were O O
obtained O O
either O O
just O O
before O O
patients O O
were O O
discharged O O
from O O
the O O
hospital O O
, O O
or O O
at O O
their O O
first O O
outpatient O O
visit O O
, O O
within O O
two O O
weeks O O
of O O
discharge O O
. O O

A O O
major O O
interest O O
of O O
this O O
project O O
is O O
the O O
predictive O O
value O O
of O O
perceived O O
social O O
support O O
, O O
as O O
a O O
potential O O
" O O
stress O O
" O O
buffer O O
, O O
related O O
to O O
NK O O
activity O O
. O O

In O O
the O O
main O O
model O O
reported O O
here O O
, O O
we O O
found O O
that O O
a O O
significant O O
amount O O
of O O
NK O O
activity O O
variance O O
could O O
be O O
explained O O
by O O
five O O
variables O O
. O O

Higher O O
NK O O
activity O O
could O O
be O O
predicted O O
by O O
the O O
perception O O
of O O
high O O
quality O O
emotional O O
support O O
from O O
a O O
spouse O O
or O O
intimate O O
other O O
, O O
perceived O O
social O O
support O O
from O O
the O O
patient O O
' O O
s O O
physician O O
, O O
estrogen O O
receptor O O
- O O
negative O O
tumor O O
status O O
, O O
having O O
an O O
excisional O O
biopsy O O
as O O
surgical O O
treatment O O
, O O
and O O
actively O O
seeking O O
social O O
support O O
as O O
a O O
major O O
coping O O
strategy O O
( O O
R2 O O
= O O
0 O O
. O O
33 O O
, O O
F O O
( O O
5 O O
, O O
55 O O
) O O
= O O
5 O O
. O O
5 O O
, O O
p O O
less O O
than O O
0 O O
. O O
0004 O O
) O O
. O O

Findings O O
are O O
discussed O O
in O O
terms O O
of O O
host O O
interaction O O
with O O
tumor O O
endocrine O O
status O O
, O O
and O O
the O O
role O O
that O O
social O O
support O O
might O O
play O O
in O O
modulating O O
such O O
activity O O
. O O

[ O O
Estrogen O O
receptor O O
content O O
of O O
peripheral O O
blood O O
lymphocytes O O
in O O
patients O O
with O O
systemic O O
lupus O O
erythematosus O O
] O O
. O O

ER O O
content O O
in O O
lymphocytes O O
of O O
peripheral O O
blood O O
from O O
27 O O
SLE O O
patients O O
and O O
20 O O
healthy O O
controls O O
were O O
determined O O
by O O
dextran O O
- O O
coated O O
charcoal O O
assay O O
. O O

ER O O
content O O
in O O
lymphocytes O O
of O O
each O O
sample O O
was O O
expressed O O
by O O
both O O
fmol O O
/ O O
mg O O
of O O
lymphocyte O O
cytosolic O O
protein O O
and O O
fmol O O
/ O O
micrograms O O
of O O
lymphocyte B-DNA B-DNA
DNA I-DNA I-DNA
. O O

The O O
results O O
showed O O
that O O
there O O
was O O
no O O
significant O O
difference O O
between O O
the O O
ER O O
content O O
of O O
lymphocytes O O
from O O
the O O
controls O O
and O O
that O O
from O O
patients O O
with O O
SLE O O
. O O

But O O
the O O
logarithmic O O
mean O O
of O O
ER O O
content O O
in O O
lymphocytes O O
, O O
expressed O O
by O O
fmol O O
/ O O
mg O O
of O O
cytosolic O O
protein O O
, O O
in O O
14 O O
patients O O
with O O
active O O
SLE O O
( O O
0 O O
. O O
9356 O O
+ O O
/ O O
- O O
0 O O
. O O
31 O O
) O O
was O O
significantly O O
higher O O
than O O
that O O
in O O
13 O O
patients O O
with O O
inactive O O
SLE O O
( O O
0 O O
. O O
2979 O O
+ O O
/ O O
- O O
0 O O
. O O
23 O O
, O O
P O O
less O O
than O O
0 O O
. O O
001 O O
) O O
and O O
in O O
the O O
controls O O
( O O
0 O O
. O O
6204 O O
+ O O
/ O O
- O O
0 O O
. O O
52 O O
, O O
P O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O

The O O
normal O O
upper O O
limit O O
of O O
ER O O
content O O
in O O
lymphocytes O O
, O O
expressed O O
by O O
fmol O O
/ O O
micrograms O O
of O O
DNA O O
, O O
was O O
0 O O
. O O
136 O O
. O O

The O O
elevated O O
rate O O
of O O
ER O O
content O O
in O O
lymphocytes O O
in O O
14 O O
active O O
SLE O O
( O O
92 O O
. O O
9 O O
% O O
) O O
was O O
also O O
higher O O
than O O
that O O
in O O
quieiescent O O
patients O O
( O O
23 O O
. O O
1 O O
% O O
, O O
P O O
less O O
than O O
0 O O
. O O
001 O O
) O O
and O O
in O O
the O O
controls O O
( O O
10 O O
% O O
, O O
P O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O

Moreover O O
, O O
the O O
elevated O O
level O O
of O O
ER O O
content O O
was O O
found O O
to O O
be O O
related O O
to O O
the O O
positive O O
antidsDNA O O
antibody O O
and O O
hypocomplementemia O O
. O O

An O O
in O O
vitro O O
globin B-DNA O
gene I-DNA O
switching O O
model O O
based O O
on O O
differentiated O O
embryonic O O
stem O O
cells O O
. O O

We O O
used O O
mouse O O
embryonic O O
stem O O
( O O
ES O O
) O O
cells O O
to O O
study O O
globin B-DNA B-DNA
gene I-DNA I-DNA
expression O O
and O O
switching O O
in O O
vitro O O
. O O

We O O
show O O
that O O
ES O O
- O O
derived O O
embryoid O O
bodies O O
express O O
the O O
full O O
complement O O
of O O
mouse B-DNA B-DNA
embryonic I-DNA I-DNA
globin I-DNA I-DNA
genes I-DNA I-DNA
in O O
the O O
correct O O
temporal O O
order O O
and O O
that O O
on O O
further O O
differentiation O O
, O O
a O O
switch O O
occurs O O
to O O
the O O
fetal B-DNA B-DNA
/ I-DNA I-DNA
adult I-DNA I-DNA
genes I-DNA I-DNA
. O O

In O O
addition O O
, O O
the O O
erythroid O O
- O O
specific O O
transcription O O
factor O O
NF O O
- O O
E1 O O
was O O
shown O O
to O O
be O O
expressed O O
coordinately O O
with O O
that O O
of O O
globin O O
in O O
embryoid O O
bodies O O
. O O

We O O
conclude O O
from O O
these O O
experiments O O
that O O
the O O
ES O O
cell O O
system O O
provides O O
a O O
good O O
model O O
to O O
study O O
hematopoietic O O
development O O
. O O

When O O
the O O
human O O
epsilon O O
- O O
or O O
beta O O
- O O
globin O O
genes O O
driven O O
by O O
the O O
dominant B-DNA B-DNA
control I-DNA I-DNA
region I-DNA I-DNA
( O O
DCR B-DNA B-DNA
) O O
are O O
introduced O O
into O O
this O O
system O O
, O O
the O O
human B-DNA B-DNA
epsilon I-DNA I-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
gene I-DNA I-DNA
, O O
in O O
contrast O O
to O O
the O O
beta B-DNA B-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
gene I-DNA I-DNA
, O O
is O O
not O O
deregulated O O
by O O
the O O
presence O O
of O O
the O O
DCR B-DNA B-DNA
and O O
is O O
expressed O O
strictly O O
as O O
an O O
embryonic B-DNA B-DNA
gene I-DNA I-DNA
. O O

We O O
conclude O O
from O O
this O O
that O O
the O O
epsilon B-DNA B-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
gene I-DNA I-DNA
is O O
not O O
regulated O O
by O O
competition O O
with O O
other O O
genes O O
in O O
the O O
human B-DNA B-DNA
beta I-DNA I-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
locus I-DNA I-DNA
. O O

Cloning O O
of O O
a O O
mitogen B-DNA B-DNA
- I-DNA I-DNA
inducible I-DNA I-DNA
gene I-DNA I-DNA
encoding O O
a O O
kappa O O
B O O
DNA O O
- O O
binding O O
protein O O
with O O
homology O O
to O O
the O O
rel B-DNA B-DNA
oncogene I-DNA I-DNA
and O O
to O O
cell B-DNA B-DNA
- I-DNA I-DNA
cycle I-DNA I-DNA
motifs I-DNA I-DNA
. O O

We O O
have O O
cloned O O
and O O
characterized O O
a O O
mitogen B-DNA B-DNA
- I-DNA I-DNA
inducible I-DNA I-DNA
gene I-DNA I-DNA
isolated O O
from O O
human O O
T O O
cells O O
that O O
predicts O O
a O O
protein O O
of O O
968 O O
amino O O
acids O O
. O O

The O O
amino O O
- O O
terminal O O
domain O O
has O O
regions O O
homologous O O
to O O
the O O
oncogene B-DNA B-DNA
rel I-DNA I-DNA
and O O
to O O
the O O
developmentally O O
important O O
gene O O
dorsal B-DNA O
of O O
Drosophila O B-DNA
. O O

The O O
carboxy O O
- O O
terminal O O
domain O O
contains O O
repeat O O
structures O O
found O O
in O O
a O O
variety O O
of O O
proteins O O
that O O
are O O
involved O O
in O O
cell O O
- O O
cycle O O
control O O
of O O
yeast O O
and O O
in O O
tissue O O
differentiation O O
in O O
Drosophila O O
and O O
Ceanorhabditis O O
elegans O O
, O O
as O O
well O O
as O O
in O O
the O O
putative B-DNA B-DNA
human I-DNA I-DNA
oncogene I-DNA I-DNA
bcl I-DNA I-DNA
- I-DNA I-DNA
3 I-DNA I-DNA
and O O
in O O
the O O
ankyrin O O
protein O O
. O O

A O O
truncated O O
form O O
of O O
the O O
product O O
of O O
this O O
gene O O
translated O O
in O O
vitro O O
is O O
a O O
DNA O O
- O O
binding O O
protein O O
which O O
interacts O O
specifically O O
with O O
the O O
kappa B-DNA B-DNA
B I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
found O O
in O O
many O O
inducible B-DNA B-DNA
genes I-DNA I-DNA
, O O
including O O
the O O
enhancer O O
in O O
human O O
immunodeficiency O O
virus O O
. O O

This O O
gene O O
is O O
yet O O
another O O
in O O
a O O
growing O O
list O O
of O O
important O O
regulatory O O
molecules O O
whose O O
expression O O
is O O
transcriptionally O O
induced O O
upon O O
cellular O O
activation O O
. O O

Extrarenal O O
receptor O O
- O O
effector O O
- O O
mechanisms O O
for O O
aldosterone O O
: O O
the O O
sequence O O
of O O
effects O O
on O O
the O O
cellular O O
electrolyte O O
transport O O
in O O
human O O
lymphocytes O O
and O O
their O O
implications O O
for O O
disorders O O
of O O
the O O
water O O
and O O
electrolyte O O
balances O O
. O O

High O O
affinity O O
aldosterone O O
binding O O
sites O O
have O O
not O O
only O O
been O O
described O O
in O O
the O O
classic O O
target O O
tissues O O
such O O
as O O
the O O
renal O O
tubules O O
, O O
but O O
also O O
in O O
non O O
- O O
classic O O
target O O
tissues O O
such O O
as O O
the O O
hippocampus O O
, O O
mammary O O
gland O O
, O O
endothelial O O
cells O O
and O O
, O O
recently O O
, O O
human O O
mononuclear O O
leukocytes O O
. O O

An O O
in O O
vitro O O
effect O O
of O O
aldosterone O O
on O O
intracellular O O
sodium O O
, O O
potassium O O
and O O
calcium O O
concentrations O O
and O O
cell O O
volume O O
was O O
shown O O
in O O
human O O
mononuclear O O
leukocytes O O
. O O

In O O
the O O
absence O O
of O O
aldosterone O O
, O O
the O O
intracellular O O
Na O O
+ O O
, O O
K O O
+ O O
and O O
Ca2 O O
+ O O
concentrations O O
and O O
the O O
cell O O
volume O O
decreased O O
significantly O O
, O O
but O O
remained O O
constant O O
when O O
aldosterone O O
( O O
1 O O
. O O
4 O O
nmol O O
/ O O
l O O
) O O
was O O
added O O
to O O
the O O
incubation O O
medium O O
. O O

These O O
effects O O
of O O
aldosterone O O
were O O
blocked O O
by O O
the O O
aldosterone O O
antagonist O O
canrenone O O
( O O
140 O O
nmol O O
/ O O
l O O
) O O
. O O

The O O
sodium O O
/ O O
proton O O
exchanger O O
of O O
the O O
cell O O
membrane O O
could O O
be O O
identified O O
as O O
the O O
primary O O
target O O
of O O
the O O
aldosterone O O
action O O
, O O
possibly O O
non O O
- O O
genomically O O
mediated O O
through O O
membrane O O
receptors O O
. O O

The O O
clinical O O
significance O O
of O O
this O O
model O O
was O O
underlined O O
by O O
the O O
demonstration O O
of O O
absent O O
or O O
a O O
decreased O O
number O O
of O O
mineralocorticoid O O
receptors O O
and O O
the O O
lack O O
of O O
electrolyte O O
response O O
to O O
aldosterone O O
in O O
human O O
mononuclear O O
leukocytes O O
of O O
patients O O
with O O
pseudohypoaldosteronism O O
and O O
aldosteronism O O
. O O

Additionally O O
, O O
an O O
abnormal O O
effector O O
mechanism O O
could O O
be O O
demonstrated O O
in O O
human O O
mononuclear O O
leukocytes O O
from O O
essential O O
hypertensives O O
. O O

These O O
studies O O
are O O
the O O
first O O
to O O
demonstrate O O
the O O
significance O O
of O O
extrarenal O O
, O O
nonepithelial O O
mineralocorticoid O O
receptors O O
and O O
the O O
related O O
effector O O
mechanism O O
in O O
different O O
disorders O O
of O O
the O O
water O O
and O O
electrolyte O O
balance O O
in O O
man O O
. O O

Immunohistochemical O O
study O O
of O O
steroid O O
hormones O O
and O O
an O O
estrogen O O
binding O O
assay O O
in O O
malignant O O
soft O O
tissue O O
tumors O O
. O O

Immunohistochemically O O
, O O
the O O
immunoreaction O O
against O O
5 O O
steroid O O
hormone O O
anti O O
- O O
sera O O
( O O
estradiol O O
, O O
estriol O O
, O O
cortisol O O
, O O
progesterone O O
and O O
testosterone O O
) O O
was O O
examined O O
in O O
39 O O
cases O O
with O O
the O O
malignant O O
soft O O
tissue O O
tumors O O
( O O
fibrosarcoma O O
: O O
8 O O
, O O
malignant O O
fibrous O O
histiocytoma O O
: O O
6 O O
, O O
rhabdomyosarcoma O O
: O O
10 O O
, O O
leiomyosarcoma O O
: O O
10 O O
, O O
liposarcoma O O
: O O
5 O O
) O O
. O O

Seventeen O O
cases O O
revealed O O
distinct O O
immunostaining O O
against O O
at O O
least O O
1 O O
of O O
the O O
5 O O
steroid O O
hormones O O
. O O

Immunostained O O
tumor O O
cells O O
were O O
more O O
frequently O O
distributed O O
in O O
the O O
area O O
where O O
tumor O O
cell O O
infiltration O O
was O O
more O O
invasive O O
. O O

The O O
majority O O
of O O
the O O
positive O O
cases O O
occurred O O
in O O
female O O
cases O O
. O O

Furthermore O O
, O O
the O O
existence O O
of O O
estrogen O O
receptor O O
( O O
estrogen O O
binding O O
activity O O
) O O
was O O
examined O O
histochemically O O
in O O
39 O O
cases O O
and O O
it O O
was O O
detected O O
in O O
8 O O
. O O

We O O
concluded O O
that O O
steroid O O
hormones O O
might O O
be O O
closely O O
related O O
to O O
tumor O O
cell O O
infiltration O O
of O O
some O O
malignant O O
soft O O
tissue O O
tumors O O
. O O

Involvement O O
of O O
cyclic O O
AMP O O
- O O
dependent O O
protein O O
kinases O O
in O O
the O O
signal O O
transduction O O
pathway O O
for O O
interleukin O O
- O O
1 O O
. O O

Expression O O
of O O
a O O
highly O O
specific O O
protein O O
inhibitor O O
for O O
cyclic O O
AMP O O
- O O
dependent O O
protein O O
kinases O O
in O O
interleukin O O
- O O
1 O O
( O O
IL O O
- O O
1 O O
) O O
- O O
responsive O O
cells O O
blocked O O
IL B-DNA O
- I-DNA O
1 I-DNA O
- I-DNA O
induced I-DNA O
gene I-DNA O
transcription O O
that O O
was O O
driven O O
by O O
the O O
kappa B-DNA B-DNA
immunoglobulin I-DNA I-DNA
enhancer I-DNA I-DNA
or O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
. O O

This O O
inhibitor O O
did O O
not O O
affect O O
protein O O
kinase O O
C O O
- O O
mediated O O
gene O O
transcription O O
, O O
suggesting O O
that O O
cyclic O O
AMP O O
- O O
dependent O O
protein O O
kinases O O
are O O
involved O O
in O O
the O O
signal O O
transduction O O
pathway O O
for O O
IL O O
- O O
1 O O
in O O
a O O
number O O
of O O
responsive O O
cell O O
types O O
. O O

The O O
Epstein B-DNA B-DNA
- I-DNA I-DNA
Barr I-DNA I-DNA
virus I-DNA I-DNA
( I-DNA I-DNA
EBV I-DNA I-DNA
) I-DNA I-DNA
ORI1yt I-DNA I-DNA
enhancer I-DNA I-DNA
is O O
not O O
B O O
- O O
cell O O
specific O O
and O O
does O O
not O O
respond O O
synergistically O O
to O O
the O O
EBV O O
transcription O O
factors O O
R O O
and O O
Z O O
. O O

The O O
Epstein B-DNA B-DNA
- I-DNA I-DNA
Barr I-DNA I-DNA
virus I-DNA I-DNA
DR I-DNA I-DNA
promoter I-DNA I-DNA
is O O
located O O
upstream O O
of O O
the O O
PstI B-DNA B-DNA
repeats I-DNA I-DNA
, O O
and O O
in O O
addition O O
to O O
the O O
TATA B-DNA B-DNA
box I-DNA I-DNA
, O O
it O O
contains O O
an O O
upstream B-DNA B-DNA
region I-DNA I-DNA
( O O
positions O O
- O B-DNA
69 O I-DNA
to O I-DNA
- O I-DNA
220 O I-DNA
) O O
responsive O O
to O O
EB1 O O
( O O
Z O O
) O O
( O O
the O O
BZLF1 O O
- O O
encoded O O
transcription O O
factor O O
) O O
and O O
an O O
enhancer B-DNA O
with O O
two O O
functionally O O
distinct O O
domains O O
, O O
A B-DNA O
and O O
B B-DNA O
. O O

Domain B-DNA O
B I-DNA O
has O O
been O O
described O O
as O O
a O O
B B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
EB1 I-DNA I-DNA
- I-DNA I-DNA
responsive I-DNA I-DNA
element I-DNA I-DNA
( O O
P O O
. O O
M O O
. O O
Lieberman O O
, O O
J O O
. O O
M O O
. O O
Hardwick O O
, O O
and O O
S O O
. O O
D O O
. O O
Hayward O O
, O O
J O O
. O O
Virol O O
. O O
63 O O
: O O
3040 O O
- O O
3050 O O
, O O
1989 O O
) O O
activated O O
synergistically O O
by O O
EB1 O O
and O O
R O O
, O O
an O O
EBV O O
early O O
product O O
encoded O O
by O O
the O O
open B-DNA B-DNA
reading I-DNA I-DNA
frame I-DNA I-DNA
BRLF1 I-DNA I-DNA
( O O
M O O
. O O
A O O
. O O
Cox O O
, O O
J O O
. O O
Leahy O O
, O O
and O O
J O O
. O O
M O O
. O O
Hardwick O O
, O O
J O O
. O O
Virol O O
. O O
64 O O
: O O
313 O O
- O O
321 O O
, O O
1990 O O
) O O
. O O

We O O
show O O
here O O
that O O
domain B-DNA O
B I-DNA O
is O O
an O O
R B-DNA B-DNA
- I-DNA I-DNA
responsive I-DNA I-DNA
element I-DNA I-DNA
in O O
HeLa O O
cells O O
and O O
is O O
therefore O O
not O O
an O O
EB1 B-DNA B-DNA
- I-DNA I-DNA
responsive I-DNA I-DNA
B I-DNA I-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
element I-DNA I-DNA
. O O

However O O
, O O
there O O
is O O
an O O
EB1 B-DNA B-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
( O O
ZRE B-DNA B-DNA
- I-DNA I-DNA
B I-DNA I-DNA
) O O
located O O
within O O
the O O
R B-DNA B-DNA
- I-DNA I-DNA
responsive I-DNA I-DNA
enhancer I-DNA I-DNA
region I-DNA I-DNA
. O O

ZRE B-DNA B-DNA
- I-DNA I-DNA
B I-DNA I-DNA
can O O
be O O
deleted O O
without O O
affecting O O
the O O
R O B-DNA
- O I-DNA
dependent O I-DNA
enhancer O I-DNA
activity O O
. O O

Moreover O O
, O O
there O O
is O O
no O O
cooperation O O
or O O
synergy O O
between O O
R O O
and O O
EB1 O O
when O O
activating O O
the O O
B B-DNA B-DNA
domain I-DNA I-DNA
( O O
ZRE B-DNA B-DNA
- I-DNA I-DNA
B I-DNA I-DNA
plus O O
the O O
R B-DNA B-DNA
- I-DNA I-DNA
responsive I-DNA I-DNA
element I-DNA I-DNA
) O O
positioned O O
as O O
an O O
enhancer B-DNA B-DNA
. O O

ZRE B-DNA B-DNA
- I-DNA I-DNA
B I-DNA I-DNA
is O O
therefore O O
not O O
part O O
of O O
the O O
R B-DNA B-DNA
- I-DNA I-DNA
inducible I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

We O O
have O O
tested O O
several O O
subregions O O
of O O
the O O
DR B-DNA B-DNA
enhancer I-DNA I-DNA
B B-DNA B-DNA
domain I-DNA I-DNA
, O O
either O O
alone O O
or O O
in O O
combination O O
, O O
for O O
their O O
capacity O O
to O O
transmit O O
the O O
R O O
- O O
activating O O
signal O O
to O O
the O O
rabbit B-DNA B-DNA
beta I-DNA I-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
promoter I-DNA I-DNA
. O O

We O O
found O O
that O O
the O O
R B-DNA B-DNA
- I-DNA I-DNA
responsive I-DNA I-DNA
element I-DNA I-DNA
is O O
composed O O
of O O
four O O
protoenhancers B-DNA O
that O O
span O O
the O O
whole O O
B B-DNA O
domain I-DNA O
. O O

These O O
protoenhancers B-DNA O
alone O O
are O O
weakly O O
or O O
not O O
responsive O O
to O O
R O O
. O O

One O O
of O O
the O O
protoenhancers B-DNA O
contains O O
the O O
overlapping B-DNA B-DNA
palindromes I-DNA I-DNA
5 O I-DNA
' O I-DNA
- O I-DNA
TTGTCCcgtGGACAAaTGTCC O I-DNA
- O I-DNA
3 O I-DNA
' O I-DNA
. O O

However O O
, O O
one O O
palindrome B-DNA B-DNA
, O O
either O O
alone O O
or O O
duplicated O O
, O O
or O O
the O O
overlapping B-DNA B-DNA
palindromes I-DNA I-DNA
did O O
not O O
respond O O
to O O
R O O
. O O

Nuclear O O
3 O O
, O O
5 O O
, O O
3 O O
' O O
- O O
triiodothyronine O O
receptors O O
( O O
T3R O O
) O O
of O O
circulating O O
human O O
lymphocytes O O
in O O
hyper O O
- O O
and O O
hypothyroidism O O
and O O
nonthyroidal O O
diseases O O
. O O

The O O
clinical O O
implications O O
of O O
nuclear O O
T3R O O
alterations O O
of O O
circulating O O
lymphocytes O O
in O O
hyperthyroidism O O
, O O
hypothyroidism O O
and O O
nonthyroidal O O
diseases O O
were O O
investigated O O
. O O

Nuclear O O
T3R O O
in O O
lymphocytes O O
was O O
determined O O
by O O
radio O O
- O O
ligand O O
binding O O
analysis O O
. O O

The O O
results O O
showed O O
that O O
in O O
hyper O O
- O O
and O O
hypothyroid O O
patients O O
the O O
nuclear O O
affinity O O
( O O
Ka O O
) O O
for O O
T3 O O
was O O
similar O O
to O O
that O O
of O O
normal O O
subjects O O
. O O

In O O
hyperthyroidism O O
nuclear O O
T3 O O
maximal O O
binding O O
capacity O O
( O O
MBC O O
) O O
was O O
unaltered O O
, O O
whereas O O
in O O
hypothyroidism O O
the O O
MBC O O
was O O
significantly O O
increased O O
. O O

In O O
the O O
patients O O
with O O
diabetes O O
mellitus O O
, O O
chronic O O
renal O O
failure O O
and O O
hepatic O O
cirrhosis O O
, O O
the O O
nuclear O O
T3R O O
MBC O O
of O O
lymphocytes O O
was O O
about O O
1 O O
. O O
5 O O
- O O
1 O O
. O O
6 O O
times O O
of O O
the O O
normal O O
controls O O
. O O

It O O
was O O
concluded O O
that O O
there O O
existed O O
hormonal O O
regulation O O
of O O
nuclear O O
T3R O O
, O O
and O O
up O O
- O O
regulation O O
was O O
seen O O
in O O
hypothyroidism O O
and O O
low O O
T3 O O
syndrome O O
. O O

Lymphocyte O O
cell O O
lines O O
from O O
vitamin O O
D O O
- O O
dependent O O
rickets O O
type O O
II O O
show O O
functional O O
defects O O
in O O
the O O
1 O O
alpha O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
receptor O O
. O O

Lymphocyte O O
cell O O
lines O O
were O O
established O O
from O O
five O O
patients O O
with O O
vitamin O O
D O O
- O O
dependent O O
rickets O O
, O O
type O O
II O O
( O O
VDDR O O
- O O
II O O
) O O
. O O

These O O
lines O O
were O O
established O O
by O O
infection O O
with O O
human O O
T O O
- O O
lymphotrophic O O
virus O O
type O O
I O O
( O O
HTLV O O
- O O
I O O
) O O
. O O

Binding O O
of O O
[ O O
3H O O
] O O
1 O O
alpha O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
( O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
) O O
to O O
its O O
receptor O O
in O O
these O O
cell O O
lines O O
was O O
compared O O
to O O
binding O O
studies O O
using O O
a O O
T O O
- O O
lymphocyte O O
cell O O
line O O
( O O
S O O
- O O
LB1 O O
) O O
from O O
a O O
normal O O
individual O O
. O O

The O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
receptor O O
of O O
S O O
- O O
LB1 O O
was O O
comparable O O
to O O
the O O
well O O
- O O
characterized O O
chick O O
intestinal O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
receptor O O
in O O
terms O O
of O O
its O O
ligand O O
binding O O
affinity O O
and O O
capacity O O
, O O
its O O
mobility O O
on O O
5 O O
- O O
20 O O
% O O
sucrose O O
gradients O O
, O O
and O O
its O O
adsorption O O
to O O
and O O
elution O O
properties O O
from O O
DNA O O
- O O
cellulose O O
. O O

Three O O
cell O O
lines O O
established O O
from O O
patients O O
with O O
VDDR O O
- O O
II O O
( O O
Rh O O
- O O
VDR O O
, O O
Sh O O
- O O
VDR O O
, O O
and O O
Ab O O
- O O
VDR O O
) O O
showed O O
no O O
specific O O
binding O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
to O O
a O O
receptor O O
and O O
treatment O O
of O O
the O O
cultured O O
cells O O
with O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
did O O
not O O
stimulate O O
production O O
of O O
24 O O
, O O
25 O O
- O O
dihydroxy O O
- O O
vitamin O O
D3 O O
( O O
24 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
) O O
, O O
a O O
response O O
which O O
is O O
diagnostic O O
of O O
the O O
presence O O
of O O
a O O
functional O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
receptor O O
. O O

In O O
a O O
fourth O O
cell O O
line O O
, O O
A1 O O
- O O
VDR O O
, O O
the O O
receptor O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
had O O
a O O
low O O
binding O O
capacity O O
and O O
25 O O
( O O
OH O O
) O O
D3 O O
- O O
24 O O
- O O
hydroxylase O O
activity O O
was O O
not O O
detectable O O
. O O

Induction O O
of O O
24 O O
, O O
25 O O
- O O
( O O
OH O O
) O O
2D3 O O
synthesis O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
was O O
observed O O
in O O
the O O
fifth O O
cell O O
line O O
, O O
designated O O
Ro O O
- O O
VDR O O
, O O
although O O
the O O
sensitivity O O
to O O
hormone O O
treatment O O
was O O
lower O O
than O O
in O O
the O O
control O O
cell O O
line O O
from O O
a O O
normal O O
donor O O
. O O

The O O
capacity O O
of O O
the O O
receptor O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
was O O
low O O
in O O
Ro O O
- O O
VDR O O
. O O

In O O
all O O
cell O O
lines O O
where O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
binding O O
to O O
a O O
receptor O O
was O O
detectable O O
, O O
the O O
receptor O O
had O O
the O O
typical O O
sedimentation O O
coefficient O O
of O O
3 O O
. O O
7 O O
S O O
on O O
sucrose O O
density O O
gradient O O
analysis O O
. O O

Binding O O
and O O
elution O O
properties O O
to O O
DNA O O
- O O
cellulose O O
, O O
however O O
, O O
differed O O
from O O
normal O O
in O O
both O O
Ro O O
- O O
VDR O O
and O O
A1 O O
- O O
VDR O O
cells O O
where O O
elution O O
from O O
DNA O O
- O O
cellulose O O
occurred O O
at O O
a O O
lower O O
salt O O
concentration O O
than O O
is O O
typical O O
of O O
the O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
receptor O O
. O O

While O O
Ro O O
- O O
VDR O O
cells O O
showed O O
typical O O
nuclear O O
localization O O
of O O
the O O
unoccupied O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
receptor O O
, O O
neither O O
the O O
unoccupied O O
nor O O
the O O
occupied O O
receptor O O
from O O
A1 O O
- O O
VDR O O
cells O O
was O O
completely O O
localized O O
in O O
the O O
nucleus O O
. O O

In O O
a O O
series O O
of O O
functional O O
studies O O
we O O
found O O
that O O
modulation O O
of O O
the O O
level O O
of O O
the O O
mRNAs O O
coding O O
for O O
both O O
the O O
c B-DNA B-DNA
- I-DNA I-DNA
myc I-DNA I-DNA
oncogene I-DNA I-DNA
and O O
the O O
growth O O
factor O O
known O O
as O O
granulocyte O O
- O O
monocyte O O
colony O O
stimulating O O
activity O O
by O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
correlated O O
with O O
the O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
receptor O O
status O O
of O O
these O O
cells O O
. O O

Use O O
of O O
these O O
cell O O
lines O O
will O O
facilitate O O
further O O
study O O
of O O
the O O
molecular O O
defect O O
( O O
s O O
) O O
in O O
the O O
receptor O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
in O O
vitamin O O
D O O
- O O
dependent O O
rickets O O
type O O
II O O
and O O
will O O
allow O O
a O O
correlation O O
with O O
impairment O O
of O O
cellular O O
functions O O
. O O

Transcriptional O O
and O O
post O O
- O O
transcriptional O O
regulation O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
expression O O
during O O
monocytic O O
differentiation O O
of O O
human O O
myeloid O O
leukemic O O
cells O O
. O O

AP O O
- O O
1 O O
, O O
the O O
polypeptide O O
product O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
, O O
recognizes O O
and O O
binds O O
to O O
specific B-DNA B-DNA
DNA I-DNA I-DNA
sequences I-DNA I-DNA
and O O
stimulates O O
transcription O O
of O O
genes B-DNA O
responsive O O
to O O
certain O O
growth O O
factors O O
and O O
phorbol O O
esters O O
such O O
as O O
12 O O
- O O
O O O
- O O
tetradecanoylphorbol O O
- O O
13 O O
- O O
acetate O O
( O O
TPA O O
) O O
. O O

We O O
studied O O
the O O
effects O O
of O O
TPA O O
on O O
the O O
regulation O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
gene O I-DNA
expression O O
in O O
HL O O
- O O
60 O O
cells O O
during O O
monocytic O O
differentiation O O
. O O

Low O O
levels O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
transcripts O O
were O O
detectable O O
in O O
untreated O O
HL O O
- O O
60 O O
leukemic O O
cells O O
, O O
increased O O
significantly O O
by O O
6 O O
h O O
, O O
and O O
reached O O
near O O
maximal O O
levels O O
by O O
24 O O
h O O
of O O
exposure O O
to O O
32 O O
nM O O
TPA O O
. O O

Similar O O
kinetics O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
induction O O
by O O
TPA O O
were O O
observed O O
in O O
human O O
U O O
- O O
937 O O
and O O
THP O O
- O O
1 O O
monocytic O O
leukemia O O
cells O O
. O O

Similar O O
findings O O
were O O
obtained O O
with O O
bryostatin O O
1 O O
( O O
10 O O
nM O O
) O O
, O O
another O O
activator O O
of O O
protein O O
kinase O O
C O O
and O O
inducer O O
of O O
monocytic O O
differentiation O O
. O O

Furthermore O O
, O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
( O O
0 O O
. O O
5 O O
microM O O
) O O
, O O
a O O
structurally O O
distinct O O
agent O O
which O O
also O O
induces O O
HL O O
- O O
60 O O
monocytic O O
differentiation O O
, O O
increased O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
expression O O
. O O

TPA O O
treatment O O
of O O
HL O O
- O O
60 O O
cells O O
in O O
the O O
presence O O
of O O
cycloheximide O O
was O O
associated O O
with O O
superinduction O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
transcripts O O
. O O

Run O O
- O O
on O O
analysis O O
demonstrated O O
detectable O O
levels O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
gene O I-DNA
transcription O O
in O O
untreated O O
HL O O
- O O
60 O O
cells O O
, O O
and O O
that O O
exposure O O
to O O
TPA O O
increases O O
this O O
rate O O
3 O O
. O O
3 O O
- O O
fold O O
. O O

Treatment O O
of O O
HL O O
- O O
60 O O
cells O O
with O O
both O O
TPA O O
and O O
cycloheximide O O
had O O
no O O
effect O O
on O O
the O O
rates O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
transcription O O
. O O

The O O
half O O
- O O
life O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
RNA O O
as O O
determined O O
by O O
treating O O
HL O O
- O O
60 O O
cells O O
with O O
TPA O O
and O O
actinomycin O O
D O O
was O O
30 O O
min O O
. O O

In O O
contrast O O
, O O
the O O
half O O
- O O
life O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
RNA O O
in O O
TPA O O
- O O
treated O O
HL O O
- O O
60 O O
cells O O
exposed O O
to O O
cycloheximide O O
and O O
actinomycin O O
D O O
was O O
greater O O
than O O
2 O O
h O O
. O O

These O O
findings O O
suggested O O
that O O
the O O
increase O O
in O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
RNA O O
observed O O
during O O
TPA O O
- O O
induced O O
monocytic O O
differentiation O O
is O O
mediated O O
by O O
both O O
transcriptional O O
and O O
post O O
- O O
transcriptional O O
mechanisms O O
. O O

[ O O
Hormonal O O
interactions O O
and O O
glucocorticoid O O
receptors O O
in O O
patients O O
with O O
the O O
nephrotic O O
syndrome O O
] O O
. O O

As O O
many O O
as O O
27 O O
children O O
aged O O
6 O O
to O O
15 O O
years O O
with O O
morphologically O O
verified O O
nephropathies O O
were O O
examined O O
. O O

Four O O
variants O O
of O O
changes O O
in O O
the O O
thyroid O O
status O O
, O O
characteristic O O
of O O
children O O
with O O
different O O
variants O O
of O O
nephrotic O O
syndrome O O
were O O
distinguished O O
: O O
1 O O
) O O
biochemical O O
signs O O
of O O
primary O O
hypothyroidism O O
, O O
2 O O
) O O
biochemical O O
signs O O
of O O
secondary O O
hypothyroidism O O
, O O
3 O O
) O O
low O O
content O O
of O O
T3 O O
, O O
4 O O
) O O
dysfunction O O
of O O
the O O
hypophyseal O O
and O O
thyroid O O
system O O
. O O

It O O
is O O
shown O O
that O O
the O O
low O O
level O O
of O O
steroid O O
receptors O O
, O O
thyroid O O
hormones O O
that O O
the O O
low O O
level O O
of O O
steroid O O
receptors O O
, O O
thyroid O O
hormones O O
( O O
T3 O O
and O O
T4 O O
) O O
and O O
cortisol O O
is O O
typical O O
of O O
children O O
with O O
the O O
signs O O
of O O
renal O O
dysplasia O O
. O O

It O O
is O O
assumed O O
that O O
superaddition O O
under O O
such O O
conditions O O
of O O
immune O O
glomerulopathy O O
( O O
glomerulonephritis O O
and O O
nephrotic O O
syndrome O O
) O O
gives O O
rise O O
to O O
the O O
resistance O O
to O O
the O O
treatment O O
with O O
glucocorticoids O O
. O O

Lymphoid O O
specific O O
gene O O
expression O O
of O O
the O O
adenovirus B-DNA B-DNA
early I-DNA I-DNA
region I-DNA I-DNA
3 I-DNA I-DNA
promoter I-DNA I-DNA
is O O
mediated O O
by O O
NF B-DNA B-DNA
- I-DNA I-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
binding I-DNA I-DNA
motifs I-DNA I-DNA
. O O

A O O
primary O O
site O O
of O O
infection O O
by O O
human O O
adenoviruses O O
is O O
lymphoid O O
cells O O
. O O

However O O
, O O
analysis O O
of O O
the O O
viral B-DNA B-DNA
control I-DNA I-DNA
elements I-DNA I-DNA
and O O
the O O
cellular O O
factors O O
that O O
regulate O O
adenoviral O O
gene O O
expression O O
in O O
lymphocytes O O
has O O
not O O
been O O
reported O O
. O O

The O O
adenovirus B-DNA B-DNA
early I-DNA I-DNA
region I-DNA I-DNA
3 I-DNA I-DNA
( O O
ES B-DNA O
) O O
gene O O
products O O
are O O
involved O O
in O O
the O O
maintenance O O
of O O
viral O O
persistence O O
by O O
complexing O O
with O O
the O O
class O O
I O O
MHC O O
antigens O O
, O O
thus O O
preventing O O
their O O
cell O O
surface O O
expression O O
with O O
a O O
resultant O O
decrease O O
in O O
host O O
immunologic O O
destruction O O
. O O

To O O
determine O O
whether O O
different O O
cellular O O
factors O O
were O O
involved O O
in O O
E3 O O
regulation O O
in O O
lymphocytes O O
as O O
compared O O
with O O
HeLa O O
cells O O
, O O
both O O
DNA O O
binding O O
and O O
transfection O O
analysis O O
with O O
the O O
E3 B-DNA B-DNA
promoter I-DNA I-DNA
in O O
both O O
cell O O
types O O
were O O
performed O O
. O O

These O O
studies O O
detected O O
two O O
novel B-DNA O
domains I-DNA O
referred O O
to O O
as O O
L1 B-DNA B-DNA
and O O
L2 B-DNA B-DNA
with O O
a O O
variety O O
of O O
lymphoid O O
but O O
not O O
HeLa O O
extracts O O
. O O

Each O O
of O O
these O O
domains O O
possessed O O
strong O O
homology O O
to O O
motifs O O
previously O O
found O O
to O O
bind O O
the O O
cellular O O
factor O O
NF O O
- O O
kappa O O
B O O
. O O

Transfections O O
of O O
E3 B-DNA B-DNA
constructs I-DNA I-DNA
linked O O
to O O
the O O
chloramphenicol B-DNA B-DNA
acetyltransferase I-DNA I-DNA
gene I-DNA I-DNA
revealed O O
that O O
mutagenesis O O
of O O
the O O
distal B-DNA B-DNA
NF I-DNA I-DNA
- I-DNA I-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
motif I-DNA I-DNA
( O O
L2 B-DNA B-DNA
) O O
had O O
minimal O O
effects O O
on O O
promoter O O
expression O O
in O O
HeLa O O
cells O O
, O O
but O O
resulted O O
in O O
dramatic O O
decreases O O
in O O
expression O O
by O O
lymphoid O O
cells O O
. O O

In O O
contrast O O
, O O
mutagenesis O O
of O O
proximal B-DNA B-DNA
NF I-DNA I-DNA
- I-DNA I-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
motif I-DNA I-DNA
( O O
L1 B-DNA B-DNA
) O O
had O O
minimal O O
effects O O
on O O
gene O O
expression O O
in O O
both O O
HeLa O O
cells O O
and O O
lymphoid O O
cells O O
but O O
resulted O O
in O O
a O O
small O O
, O O
but O O
reproducible O O
, O O
increase O O
in O O
gene O O
expression O O
in O O
lymphoid O O
cells O O
when O O
coupled O O
to O O
the O O
L2 B-DNA O
mutation O O
. O O

Reversing O O
the O O
position O O
and O O
subsequent O O
mutagenesis O O
of O O
the O O
L1 B-DNA O
and O O
L2 B-DNA O
domains I-DNA O
indicated O O
that O O
the O O
primary B-DNA O
sequence I-DNA O
of O O
these O O
motifs O O
rather O O
than O O
their O O
position O O
in O O
the O O
E3 B-DNA B-DNA
promoter I-DNA I-DNA
was O O
critical O O
for O O
regulating O O
gene O O
expression O O
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O
. O O

Characterization O O
of O O
defensin O O
resistance O O
phenotypes O O
associated O O
with O O
mutations O O
in O O
the O O
phoP B-DNA O
virulence I-DNA O
regulon I-DNA O
of O O
Salmonella O O
typhimurium O O
. O O

The O O
defensin O O
sensitivities O O
of O O
Salmonella O O
typhimurium O O
strains O O
with O O
mutations O O
in O O
the O O
phoP B-DNA O
/ I-DNA O
phoQ I-DNA O
two I-DNA O
- I-DNA O
component I-DNA O
virulence I-DNA O
regulon I-DNA O
were O O
tested O O
by O O
using O O
purified O O
defensins O O
NP O O
- O O
1 O O
and O O
NP O O
- O O
2 O O
. O O

Strains O O
with O O
mutations O O
in O O
either O O
gene O O
of O O
the O O
regulatory B-DNA O
pair I-DNA O
( O O
phoP B-DNA O
[ O O
transcriptional B-DNA O
activator I-DNA O
] O O
or O O
phoQ B-DNA O
[ O O
membrane O O
sensor O O
kinase O O
] O O
) O O
had O O
increased O O
sensitivities O O
to O O
defensin O O
. O O

The O O
predicted O O
periplasmic O O
domain O O
of O O
the O O
PhoQ O O
protein O O
contained O O
a O O
markedly O O
anionic O O
domain O O
that O O
could O O
interact O O
with O O
cationic O O
proteins O O
and O O
that O O
could O O
be O O
responsible O O
for O O
resistance O O
to O O
defensin O O
. O O

Because O O
insertion O O
mutations O O
in O O
phoP B-DNA O
are O O
polar O O
on O O
phoQ B-DNA O
, O O
we O O
constructed O O
strains O O
that O O
expressed O O
the O O
PhoQ O O
protein O O
in O O
the O O
absence O O
of O O
PhoP O O
to O O
test O O
whether O O
resistance O O
to O O
defensin O O
requires O O
only O O
the O O
phoQ B-DNA O
gene O O
product O O
. O O

We O O
found O O
that O O
resistance O O
to O O
defensin O O
requires O O
the O O
function O O
of O O
both O O
components O O
of O O
this O O
regulatory O O
system O O
, O O
because O O
strains O O
expressing O O
PhoQ O O
without O O
PhoP O O
were O O
still O O
markedly O O
sensitive O O
to O O
defensins O O
. O O

This O O
implied O O
that O O
a O O
pag B-DNA O
( O O
phoP B-DNA B-DNA
- I-DNA I-DNA
activated I-DNA I-DNA
gene I-DNA I-DNA
) O O
product O O
is O O
responsible O O
for O O
defensin O O
resistance O O
. O O

We O O
also O O
tested O O
for O O
the O O
ability O O
of O O
defensins O O
NP O O
- O O
1 O O
, O O
NP O O
- O O
5 O O
, O O
and O O
HNP O O
- O O
1 O O
to O O
activate O O
pag B-DNA O
expression O O
and O O
found O O
that O O
these O O
peptides O O
have O O
no O O
effect O O
. O O

Defensin O O
resistance O O
is O O
not O O
the O O
only O O
virulence O O
characteristic O O
controlled O O
by O O
the O O
PhoP O O
- O O
PhoQ O O
regulon O O
because O O
mutations O O
in O O
pagC B-DNA O
, O O
as O O
well O O
as O O
ones O O
in O O
the O O
phoP B-DNA B-DNA
locus I-DNA I-DNA
that O O
resulted O O
in O O
constitutive O O
pag B-DNA O
activation O O
( O O
phenotype O O
PhoPc O O
) O O
, O O
had O O
no O O
effect O O
on O O
defensin O O
resistance O O
, O O
even O O
though O O
they O O
rendered O O
the O O
organism O O
avirulent O O
and O O
deficient O O
in O O
survival O O
within O O
macrophages O O
. O O

The O O
virulence O O
defect O O
conferred O O
by O O
mutations O O
in O O
the O O
phoP B-DNA O
- B-DNA O
phoQ I-DNA O
two O O
- O O
component O O
regulatory O O
system O O
is O O
not O O
completely O O
explained O O
by O O
alterations O O
in O O
resistance O O
to O O
cationic O O
proteins O O
and O O
involves O O
the O O
control O O
of O O
other O O
proteins O O
necessary O O
for O O
S O O
. O O
typhimurium O O
survival O O
within O O
macrophages O O
. O O

Stimulation O O
of O O
a O O
human O O
T O O
- O O
cell O O
clone O O
with O O
anti O O
- O O
CD3 O O
or O O
tumor O O
necrosis O O
factor O O
induces O O
NF O O
- O O
kappa O O
B O O
translocation O O
but O O
not O O
human O B-DNA
immunodeficiency O I-DNA
virus O I-DNA
1 O I-DNA
enhancer O I-DNA
- O O
dependent O O
transcription O O
. O O

The O O
expression O O
of O O
transiently O B-DNA
transfected O I-DNA
expression O I-DNA
vectors O I-DNA
under O O
the O O
control O O
of O O
the O O
long B-DNA B-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
or O O
its O O
enhancer B-DNA B-DNA
sequence I-DNA I-DNA
and O O
the O O
translocation O O
of O O
the O O
HIV O O
enhancer O O
- O O
binding O O
protein O O
NF O O
- O O
kappa O O
B O O
were O O
analyzed O O
in O O
two O O
human O O
T O O
- O O
cell O O
clones O O
stimulated O O
through O O
their O O
T O O
- O O
cell O O
receptor O O
complex O O
or O O
by O O
tumor O O
necrosis O O
factor O O
or O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
. O O

We O O
found O O
a O O
dissociation O O
of O O
NF O O
- O O
kappa O O
B O O
translocation O O
from O O
transactivation O O
of O O
either O O
the O O
HIV B-DNA B-DNA
LTR I-DNA I-DNA
or O O
the O O
HIV B-DNA B-DNA
enhancer I-DNA I-DNA
. O O

Interleukin O O
2 O O
induced O O
proliferation O O
but O O
not O O
NF O O
- O O
kappa O O
B O O
translocation O O
or O O
LTR B-DNA B-DNA
transactivation O O
. O O

Phorbol O O
ester O O
or O O
specific O O
antigen O O
recognition O O
induced O O
HIV B-DNA B-DNA
LTR I-DNA I-DNA
transactivation O O
, O O
whereas O O
stimulation O O
with O O
tumor O O
necrosis O O
factor O O
or O O
antibody O O
to O O
CD3 O O
did O O
not O O
. O O

The O O
two O O
latter O O
signals O O
were O O
nevertheless O O
able O O
to O O
induce O O
NF O O
- O O
kappa O O
B O O
translocation O O
with O O
a O O
pattern O O
in O O
the O O
band O O
- O O
shift O O
assay O O
indistinguishable O O
from O O
that O O
observed O O
using O O
phorbol O O
ester O O
. O O

Our O O
finding O O
that O O
induction O O
of O O
NF O O
- O O
kappa O O
B O O
by O O
tumor O O
necrosis O O
factor O O
or O O
antibody O O
to O O
CD3 O O
is O O
not O O
sufficient O O
to O O
induce O O
HIV B-DNA B-DNA
enhancer I-DNA I-DNA
- O O
dependent O O
transcription O O
in O O
cloned O O
T O O
cells O O
contrasts O O
with O O
results O O
obtained O O
in O O
most O O
lymphoblastoid O O
T O O
- O O
cell O O
lines O O
and O O
indicates O O
that O O
normal O O
T O O
lymphocytes O O
differ O O
from O O
tumoral O O
T O O
cells O O
in O O
terms O O
of O O
requirements O O
for O O
HIV B-DNA B-DNA
LTR I-DNA I-DNA
activation O O
. O O

Furthermore O O
, O O
our O O
results O O
suggest O O
that O O
events O O
linked O O
to O O
T O O
- O O
cell O O
activation O O
, O O
in O O
addition O O
to O O
NF O O
- O O
kappa O O
B O O
translocation O O
per O O
se O O
, O O
induce O O
functional O O
interactions O O
of O O
the O O
NF O O
- O O
kappa O O
B O O
complex O O
with O O
the O O
HIV B-DNA B-DNA
enhancer I-DNA I-DNA
. O O

Decreased O O
concentration O O
of O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
receptors O O
in O O
peripheral O O
mononuclear O O
cells O O
of O O
patients O O
with O O
X O O
- O O
linked O O
hypophosphatemic O O
rickets O O
: O O
effect O O
of O O
phosphate O O
supplementation O O
. O O

Abnormal O O
renal O O
tubular O O
phosphate O O
transport O O
is O O
considered O O
to O O
be O O
the O O
primary O O
defect O O
in O O
X O O
- O O
linked O O
hypophosphatemic O O
rickets O O
( O O
XLH O O
) O O
. O O

However O O
, O O
the O O
resistance O O
to O O
vitamin O O
D O O
treatment O O
in O O
XLH O O
cannot O O
be O O
explained O O
by O O
hypophosphatemia O O
alone O O
. O O

Since O O
most O O
of O O
the O O
actions O O
of O O
vitamin O O
D O O
are O O
mediated O O
by O O
its O O
receptors O O
( O O
VDR O O
) O O
, O O
abnormalities O O
of O O
VDR O O
have O O
been O O
postulated O O
in O O
XLH O O
. O O

In O O
order O O
to O O
investigate O O
this O O
possibility O O
, O O
we O O
measured O O
the O O
concentration O O
of O O
VDR O O
in O O
PHA O O
- O O
activated O O
peripheral O O
mononuclear O O
cells O O
from O O
10 O O
XLH O O
patients O O
. O O

Patients O O
without O O
phosphate O O
supplementation O O
showed O O
significantly O O
lower O O
concentration O O
( O O
21 O O
. O O
7 O O
+ O O
/ O O
- O O
5 O O
. O O
1 O O
fmol O O
/ O O
mg O O
protein O O
, O O
mean O O
+ O O
/ O O
- O O
SEM O O
) O O
compared O O
to O O
the O O
normal O O
controls O O
( O O
60 O O
. O O
7 O O
+ O O
/ O O
- O O
4 O O
. O O
0 O O
) O O
. O O

On O O
the O O
contrary O O
, O O
there O O
was O O
no O O
significant O O
difference O O
between O O
the O O
phosphate O O
- O O
supplemented O O
patients O O
( O O
58 O O
. O O
3 O O
+ O O
/ O O
- O O
2 O O
. O O
7 O O
) O O
and O O
controls O O
. O O

There O O
was O O
a O O
significant O O
positive O O
correlation O O
between O O
VDR O O
concentration O O
and O O
serum O O
phosphate O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

In O O
two O O
patients O O
, O O
VDR O O
was O O
increased O O
after O O
daily O O
phosphate O O
supplementation O O
was O O
started O O
. O O

These O O
results O O
indicate O O
that O O
a O O
decreased O O
concentration O O
of O O
VDR O O
secondary O O
to O O
persistent O O
hypophosphatemia O O
is O O
one O O
of O O
the O O
causes O O
of O O
vitamin O O
D O O
resistance O O
in O O
XLH O O
. O O

Two O O
distinct O O
forms O O
of O O
active O O
transcription O O
factor O O
CREB O O
( O O
cAMP O O
response O O
element O O
binding O O
protein O O
) O O
. O O

Mammalian O O
cells O O
express O O
two O O
distinct O O
forms O O
of O O
transcription O O
factor O O
CREB O O
( O O
cAMP O O
response O O
element O O
binding O O
protein O O
) O O
that O O
are O O
apparently O O
the O O
products O O
of O O
alternative O O
splicing O O
of O O
the O O
CREB O B-DNA
gene O I-DNA
transcript O O
. O O

The O O
two O O
proteins O O
differ O O
by O O
a O O
14 O O
- O O
amino O O
acid O O
serine O O
- O O
rich O O
insertion O O
present O O
in O O
one O O
of O O
the O O
CREB O O
isoforms O O
. O O

We O O
show O O
that O O
both O O
CREB O O
isoforms O O
are O O
expressed O O
in O O
many O O
cell O O
types O O
and O O
mammalian O O
species O O
. O O

Both O O
encode O O
proteins O O
that O O
bind O O
specifically O O
to O O
a O O
cAMP B-DNA B-DNA
response I-DNA I-DNA
element I-DNA I-DNA
in I-DNA O
vitro I-DNA O
. O O

As O O
expected O O
for O O
proteins O O
of O O
this O O
class O O
, O O
the O O
CREB O O
proteins O O
bind O O
DNA O O
as O O
dimers O O
. O O

Both O O
proteins O O
impart O O
cAMP O O
- O O
regulated O O
transcriptional O O
activity O O
to O O
a O O
heterologous B-DNA O
DNA I-DNA O
- I-DNA O
binding I-DNA O
domain I-DNA O
, O O
showing O O
that O O
cAMP O O
directly O O
modulates O O
the O O
transcriptional O O
stimulatory O O
activity O O
of O O
CREB O O
. O O

The O O
presence O O
of O O
multiple O O
CREB O O
isoforms O O
with O O
identical O O
DNA O O
- O O
binding O O
specificities O O
but O O
differences O O
in O O
the O O
presumed O O
regulatory O O
domain O O
raises O O
the O O
possibility O O
that O O
CREB O O
proteins O O
may O O
be O O
able O O
to O O
integrate O O
distinct O O
regulatory O O
signals O O
at O O
the O O
level O O
of O O
gene O O
transcription O O
. O O

Human O O
immunodeficiency O O
virus O O
vpr O O
product O O
is O O
a O O
virion O O
- O O
associated O O
regulatory O O
protein O O
. O O

The O O
vpr O O
product O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV O O
- O O
1 O O
) O O
acts O O
in O O
trans O O
to O O
accelerate O O
virus O O
replication O O
and O O
cytopathic O O
effect O O
in O O
T O O
cells O O
. O O

Here O O
it O O
is O O
shown O O
that O O
the O O
HIV O O
- O O
1 O O
viral O O
particle O O
contains O O
multiple O O
copies O O
of O O
the O O
vpr O O
protein O O
. O O

The O O
vpr O O
product O O
is O O
the O O
first O O
regulatory O O
protein O O
of O O
HIV O O
- O O
1 O O
to O O
be O O
found O O
in O O
the O O
virus O O
particle O O
. O O

This O O
observation O O
raises O O
the O O
possibility O O
that O O
vpr B-DNA O
acts O O
to O O
facilitate O O
the O O
early O O
steps O O
of O O
infection O O
before O O
de O O
novo O O
viral O O
protein O O
synthesis O O
occurs O O
. O O

A O O
novel O O
B O O
- O O
cell O O
lineage O O
- O O
specific O O
transcription O O
factor O O
present O O
at O O
early O O
but O O
not O O
late O O
stages O O
of O O
differentiation O O
. O O

A O O
novel O O
B O O
- O O
cell O O
- O O
specific O O
transcription O O
factor O O
, O O
BSAP O O
, O O
was O O
identified O O
as O O
a O O
mammalian O O
homolog O O
of O O
the O O
sea O O
urchin O O
protein O O
TSAP O O
, O O
which O O
interacts O O
with O O
the O O
promoters B-DNA B-DNA
of O O
four O O
tissue O O
- O O
specific O O
late O O
histone O O
H2A O O
- O O
2 O O
and O O
H2B O O
- O O
2 O O
genes O O
. O O

As O O
shown O O
by O O
mobility O O
- O O
shift O O
, O O
methylation O O
interference O O
, O O
and O O
mutational O O
analyses O O
, O O
the O O
mammalian O O
protein O O
BSAP O O
recognizes O O
all O O
four O O
sea B-DNA O
urchin I-DNA O
binding I-DNA O
sites I-DNA O
in O O
a O O
manner O O
indistinguishable O O
from O O
TSAP O O
; O O
however O O
, O O
the O O
two O O
proteins O O
differ O O
in O O
molecular O O
weight O O
. O O

BSAP O O
is O O
exclusively O O
restricted O O
to O O
the O O
B O O
- O O
cell O O
lineage O O
of O O
lymphoid O O
differentiation O O
. O O

Its O O
expression O O
appears O O
to O O
be O O
activated O O
during O O
pro O O
- O O
B O O
- O O
cell O O
development O O
, O O
is O O
abundant O O
at O O
the O O
pre O O
- O O
B O O
- O O
and O O
mature O O
B O O
- O O
cell O O
stages O O
, O O
but O O
is O O
absent O O
in O O
terminally O O
differentiated O O
plasma O O
cells O O
. O O

Moreover O O
, O O
BSAP O O
is O O
clearly O O
a O O
B O O
- O O
cell O O
- O O
specific O O
transcription O O
factor O O
, O O
as O O
a O O
wild B-DNA O
- I-DNA O
type I-DNA O
but O O
not O O
a O O
mutant B-DNA B-DNA
TSAP I-DNA I-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
of O O
the O O
sea O O
urchin O O
functions O O
only O O
in O O
transfected O O
B O O
cells O O
as O O
an O O
upstream B-DNA B-DNA
promoter I-DNA I-DNA
element I-DNA I-DNA
. O O

Competition O O
experiments O O
did O O
not O O
reveal O O
any O O
high B-DNA B-DNA
- I-DNA I-DNA
affinity I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
for O O
BSAP O O
in O O
known O O
regulatory B-DNA B-DNA
regions I-DNA I-DNA
of O O
immunoglobulin O O
and O O
class O B-DNA
II O I-DNA
major O I-DNA
histocompatibility O I-DNA
( O I-DNA
MHC O I-DNA
) O I-DNA
genes O I-DNA
, O O
suggesting O O
that O O
BSAP O O
is O O
a O O
regulator O O
of O O
a O O
different O O
set O O
of O O
B B-DNA B-DNA
- I-DNA I-DNA
lymphoid I-DNA I-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
genes I-DNA I-DNA
. O O

Octamer O O
transcription O O
factors O O
and O O
the O O
cell B-DNA O
type I-DNA O
- I-DNA O
specificity I-DNA O
of I-DNA O
immunoglobulin I-DNA O
gene I-DNA O
expression O O
. O O

Antibodies O O
are O O
produced O O
exclusively O O
in O O
B O O
lymphocytes O O
. O O

The O O
expression O O
of O O
the O O
antibody B-DNA B-DNA
- I-DNA I-DNA
encoding I-DNA I-DNA
genes I-DNA I-DNA
, O O
the O O
immunoglobulin B-DNA B-DNA
( I-DNA I-DNA
Ig I-DNA I-DNA
) I-DNA I-DNA
genes I-DNA I-DNA
, O O
is O O
also O O
restricted O O
to O O
B O O
cells O O
. O O

The O O
octamer B-DNA B-DNA
sequence I-DNA I-DNA
ATGCAAAT O O
is O O
present O O
in O O
the O O
promoter B-DNA B-DNA
and O O
the O O
enhancer B-DNA B-DNA
of O O
Ig B-DNA B-DNA
genes I-DNA I-DNA
, O O
and O O
plays O O
an O O
important O O
role O O
in O O
its O O
tissue O O
- O O
specific O O
expression O O
. O O

This O O
sequence B-DNA O
motif I-DNA O
is O O
a O O
binding O B-DNA
site O I-DNA
for O O
nuclear O O
proteins O O
, O O
the O O
so O O
- O O
called O O
octamer O O
transcription O O
factors O O
( O O
Oct O O
or O O
OTF O O
factors O O
) O O
. O O

The O O
Oct O O
- O O
1 O O
protein O O
is O O
present O O
in O O
all O O
cell O O
types O O
analyzed O O
so O O
far O O
, O O
whereas O O
Oct O O
- O O
2A O O
and O O
Oct O O
- O O
2B O O
are O O
found O O
mainly O O
in O O
B O O
lymphocytes O O
. O O

All O O
three O O
proteins O O
show O O
the O O
same O O
sequence O O
specificity O O
and O O
binding O O
affinity O O
. O O

It O O
appears O O
that O O
the O O
B O O
cell O O
- O O
specific O O
expression O O
of O O
Ig B-DNA B-DNA
genes I-DNA I-DNA
is O O
mediated O O
at O O
least O O
in O O
part O O
by O O
cell O O
type O O
- O O
specific O O
Oct O O
factors O O
, O O
and O O
that O O
there O O
are O O
both O O
quantitative O O
and O O
qualitative O O
differences O O
between O O
Oct O O
- O O
1 O O
and O O
Oct O O
- O O
2 O O
factors O O
. O O

Recently O O
, O O
a O O
number O O
of O O
other O O
octamer O O
factor O O
variants O O
were O O
identified O O
. O O

Many O O
of O O
these O O
may O O
be O O
created O O
by O O
alternative O O
splicing O O
of O O
a O O
primary O O
transcript O O
of O O
one O O
Oct O B-DNA
factor O I-DNA
gene O I-DNA
and O O
may O O
serve O O
a O O
specific O O
function O O
in O O
the O O
fine O O
tuning O O
of O O
gene O O
expression O O
. O O

A O O
factor O O
known O O
to O O
bind O O
to O O
endogenous B-DNA B-DNA
Ig I-DNA I-DNA
heavy I-DNA I-DNA
chain I-DNA I-DNA
enhancer I-DNA I-DNA
only O O
in O O
lymphocytes O O
is O O
a O O
ubiquitously O O
active O O
transcription O O
factor O O
. O O

The O O
transcriptional B-DNA B-DNA
enhancer I-DNA I-DNA
located O O
in O O
the O O
first O B-DNA
intron O I-DNA
of O O
the O O
immunoglobulin B-DNA B-DNA
heavy I-DNA I-DNA
chain I-DNA I-DNA
constant I-DNA I-DNA
region I-DNA I-DNA
is O O
a O O
major O O
determinant O O
of O O
B O O
- O O
cell O O
- O O
specific O O
expression O O
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
. O O

Like O O
other O O
enhancers B-DNA B-DNA
, O O
the O O
Ig B-DNA B-DNA
heavy I-DNA I-DNA
chain I-DNA I-DNA
enhancer I-DNA I-DNA
contains O O
several O O
short O B-DNA
sequence B-DNA I-DNA
motifs I-DNA I-DNA
that O O
bind O O
specific O O
transcription O O
factors O O
. O O

Each O O
binding B-DNA B-DNA
site I-DNA I-DNA
contributes O O
to O O
the O O
overall O O
activity O O
of O O
the O O
enhancer B-DNA O
, O O
however O O
no O O
single O O
element O O
seems O O
absolutely O O
required O O
for O O
activity O O
. O O

For O O
a O O
better O O
understanding O O
of O O
the O O
Ig B-DNA O
heavy I-DNA O
chain I-DNA O
enhancer I-DNA O
components I-DNA O
, O O
we O O
have O O
cloned O O
and O O
analyzed O O
individual O B-DNA
sequence B-DNA I-DNA
elements I-DNA I-DNA
. O O

We O O
find O O
that O O
the O O
factor O O
that O O
binds O O
to O O
the O O
E3 B-DNA B-DNA
enhancer I-DNA I-DNA
motif I-DNA I-DNA
, O O
CATGTGGC O O
, O O
is O O
a O O
ubiquitous O O
transcription O O
factor O O
. O O

It O O
is O O
present O O
in O O
an O O
active O O
form O O
in O O
both O O
B O O
cells O O
and O O
non O O
- O O
B O O
cells O O
, O O
where O O
it O O
can O O
mediate O O
transcriptional O O
activation O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

However O O
, O O
despite O O
its O O
ability O O
to O O
activate O O
transcription O O
of O O
a O O
transfected B-DNA O
reporter I-DNA B-DNA
gene I-DNA I-DNA
, O O
the O O
factor O O
is O O
apparently O O
unable O O
to O O
bind O O
to O O
the O O
endogenous B-DNA O
Ig I-DNA B-DNA
heavy I-DNA I-DNA
chain I-DNA I-DNA
enhancer I-DNA I-DNA
in O O
non O O
- O O
lymphoid O O
cells O O
: O O
In O O
previous O O
experiments O O
by O O
others O O
, O O
the O O
characteristic O O
in O O
vivo O O
footprint O O
of O O
this O O
factor O O
, O O
designated O O
NF O O
- O O
muE3 O O
, O O
was O O
detected O O
in O O
B O O
cells O O
but O O
not O O
in O O
non O O
- O O
B O O
cells O O
. O O

From O O
this O O
and O O
other O O
findings O O
the O O
picture O O
emerges O O
that O O
there O O
are O O
at O O
least O O
three O O
categories O O
of O O
factors O O
which O O
mediate O O
cell O O
- O O
type O O
- O O
specific O O
transcription O O
in O O
B O O
lymphocytes O O
: O O
( O O
a O O
) O O
cell O O
- O O
specific O O
factors O O
such O O
as O O
Oct O O
- O O
2A O O
and O O
Oct O O
- O O
2B O O
that O O
are O O
not O O
expressed O O
in O O
most O O
other O O
cell O O
types O O
: O O
( O O
b O O
) O O
ubiquitous O O
factors O O
such O O
as O O
NF O O
- O O
kappa O O
B O O
that O O
are O O
constitutively O O
active O O
in O O
B O O
cells O O
but O O
are O O
sequestered O O
in O O
an O O
inactive O O
form O O
in O O
other O O
cells O O
; O O
( O O
c O O
) O O
ubiquitously O O
active O O
factors O O
, O O
exemplified O O
by O O
the O O
one O O
binding O O
to O O
the O O
E3 B-DNA B-DNA
sequence I-DNA I-DNA
motif I-DNA I-DNA
. O O

This O O
factor O O
is O O
present O O
in O O
an O O
active O O
form O O
in O O
a O O
variety O O
of O O
cell O O
types O O
but O O
is O O
apparently O O
unable O O
to O O
bind O O
to O O
the O O
endogenous B-DNA O
Ig I-DNA B-DNA
heavy I-DNA I-DNA
chain I-DNA I-DNA
enhancer I-DNA I-DNA
in O O
non O O
- O O
B O O
cells O O
, O O
perhaps O O
due O O
to O O
a O O
non O B-DNA
- O I-DNA
permissive O I-DNA
chromatin B-DNA I-DNA
structure O I-DNA
of O O
the O O
Ig B-DNA B-DNA
heavy I-DNA I-DNA
chain I-DNA I-DNA
locus I-DNA I-DNA
. O O

[ O O
Endocrine O O
status O O
changes O O
in O O
children O O
with O O
bronchial O O
asthma O O
] O O
. O O

A O O
study O O
was O O
made O O
of O O
adrenocortical O O
function O O
by O O
measuring O O
blood O O
plasma O O
cortisol O O
concentration O O
and O O
amount O O
of O O
glucocorticoid O O
receptors O O
in O O
lymphocytes O O
as O O
well O O
as O O
thyroid O O
function O O
by O O
measuring O O
blood O O
plasma O O
triidothyronine O O
and O O
thyroxine O O
concentration O O
in O O
58 O O
bronchial O O
asthma O O
children O O
aged O O
1 O O
to O O
14 O O
years O O
. O O

The O O
authors O O
revealed O O
alterations O O
in O O
the O O
functional O O
activity O O
of O O
the O O
indicated O O
endocrine O O
glands O O
depending O O
on O O
the O O
intensity O O
of O O
bronchial O O
patency O O
disorders O O
and O O
the O O
nature O O
of O O
the O O
therapeutic O O
measures O O
carried O O
out O O
. O O

TAR B-DNA B-DNA
independent O O
activation O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
in O O
phorbol O O
ester O O
stimulated O O
T O O
lymphocytes O O
. O O

Multiple B-DNA O
regulatory I-DNA B-DNA
elements I-DNA I-DNA
in O O
the O O
human O B-DNA
immunodeficiency O I-DNA
virus O I-DNA
long B-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
HIV B-DNA B-DNA
LTR I-DNA I-DNA
) O O
are O O
required O O
for O O
activation O O
of O O
HIV O B-DNA
gene O I-DNA
expression O O
. O O

Previous O O
transfection O O
studies O O
of O O
HIV B-DNA B-DNA
LTR I-DNA I-DNA
constructs I-DNA I-DNA
linked O O
to O O
the O O
chloramphenicol B-DNA B-DNA
acetyltransferase I-DNA I-DNA
gene I-DNA I-DNA
indicated O O
that O O
multiple O O
regulatory B-DNA B-DNA
regions I-DNA I-DNA
including O O
the O O
enhancer B-DNA B-DNA
, O O
SP1 B-DNA B-DNA
, O O
TATA B-DNA O
and O O
TAR B-DNA B-DNA
regions I-DNA I-DNA
were O O
important O O
for O O
HIV O B-DNA
gene O I-DNA
expression O O
. O O

To O O
characterize O O
these O O
regulatory B-DNA B-DNA
elements I-DNA I-DNA
further O O
, O O
mutations O O
in O O
these O O
regions O O
were O O
inserted O O
into O O
both O O
the O O
5 O B-DNA
' O I-DNA
and O I-DNA
3 O I-DNA
' O I-DNA
HIV B-DNA I-DNA
LTRs I-DNA I-DNA
and O O
infectious O O
proviral O O
constructs O O
were O O
assembled O O
. O O

These O O
constructs O O
were O O
transfected O O
into O O
either O O
HeLa O O
cells O O
, O O
Jurkat O O
cells O O
or O O
U937 O O
cells O O
in O O
both O O
the O O
presence O O
and O O
absence O O
of O O
phorbol O O
esters O O
which O O
have O O
previously O O
been O O
demonstrated O O
to O O
activate O O
HIV O O
gene O O
expression O O
. O O

Viral O O
gene O O
expression O O
was O O
assayed O O
by O O
the O O
level O O
of O O
p24 O O
gag O O
protein O O
released O O
from O O
cultures O O
transfected O O
with O O
the O O
proviral O B-DNA
constructs O I-DNA
. O O

Results O O
in O O
all O O
cell O O
lines O O
indicated O O
that O O
mutations O O
of O O
the O O
SP1 B-DNA B-DNA
, O O
TATA B-DNA O
and O O
the O O
TAR B-DNA B-DNA
loop I-DNA O
and O O
stem B-DNA O
secondary I-DNA O
structure I-DNA O
resulted O O
in O O
marked O O
decreases O O
in O O
gene O O
expression O O
while O O
mutations O O
of O O
the O O
enhancer B-DNA B-DNA
motif I-DNA I-DNA
or O O
TAR B-DNA B-DNA
primary I-DNA I-DNA
sequence I-DNA I-DNA
resulted O O
in O O
only O O
slight O O
decreases O O
. O O

However O O
, O O
viruses O O
containing O O
mutations O O
in O O
either O O
the O O
TAR B-DNA B-DNA
loop I-DNA I-DNA
sequences I-DNA I-DNA
or O O
stem B-DNA B-DNA
secondary I-DNA I-DNA
structure I-DNA I-DNA
which O O
were O O
very O O
defective O O
for O O
gene O O
expression O O
in O O
untreated O O
Jurkat O O
cells O O
, O O
gave O O
nearly O O
wild O O
- O O
type O O
levels O O
of O O
gene O O
expression O O
in O O
phorbol O O
ester O O
- O O
treated O O
Jurkat O O
cells O O
but O O
not O O
in O O
phorbol O O
ester O O
- O O
treated O O
HeLa O O
or O O
U937 O O
cells O O
. O O

High O O
level O O
gene O O
expression O O
of O O
these O O
TAR B-DNA B-DNA
mutant I-DNA I-DNA
constructs I-DNA I-DNA
in O O
phorbol O O
ester O O
- O O
treated O O
Jurkat O O
cells O O
was O O
eliminated O O
by O O
second O O
site O O
mutations O O
in O O
the O O
enhancer B-DNA B-DNA
region I-DNA I-DNA
or O O
by O O
disruption O O
of O O
the O O
tat B-DNA B-DNA
gene I-DNA I-DNA
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O
. O O

A O O
case O O
of O O
hypersensitivity O O
to O O
thyroid O O
hormones O O
with O O
normally O O
functioning O O
thyroid O O
gland O O
and O O
increased O O
nuclear O O
triiodothyronine O O
receptors O O
. O O

A O O
52 O O
- O O
year O O
- O O
old O O
male O O
presented O O
himself O O
with O O
tachycardia O O
crises O O
which O O
appeared O O
first O O
during O O
childhood O O
, O O
increased O O
in O O
frequency O O
without O O
goiter O O
or O O
exophthalmos O O
. O O

Cardiac O O
and O O
adrenergic O O
diseases O O
were O O
excluded O O
. O O

The O O
thyroid O O
function O O
was O O
normal O O
regarding O O
T4 O O
, O O
free O O
T4 O O
and O O
T3 O O
, O O
TBG O O
, O O
radioiodine O O
uptake O O
, O O
TSH O O
and O O
T3 O O
suppressibility O O
; O O
however O O
the O O
TSH O O
response O O
to O O
TRH O O
was O O
decreased O O
. O O

The O O
lymphocyte O O
nuclear O O
T3 O O
receptor O O
was O O
found O O
with O O
an O O
affinity O O
close O O
to O O
that O O
of O O
normal O O
volunteers O O
( O O
Ka O O
: O O
1 O O
. O O
42 O O
x O O
10 O O
( O O
10 O O
) O O
M O O
- O O
1 O O
vs O O
1 O O
. O O
95 O O
+ O O
/ O O
- O O
0 O O
. O O
35 O O
x O O
10 O O
( O O
10 O O
) O O
M O O
- O O
1 O O
) O O
and O O
a O O
binding O O
capacity O O
markedly O O
increased O O
( O O
9 O O
. O O
9 O O
vs O O
3 O O
. O O
7 O O
+ O O
/ O O
- O O
0 O O
. O O
4 O O
fmol O O
T3 O O
/ O O
100 O O
micrograms O O
DNA O O
) O O
. O O

Pindolol O O
was O O
inefficient O O
on O O
the O O
dysrhythmia O O
which O O
disappeared O O
with O O
carbimazole O O
and O O
relapsed O O
after O O
withdrawal O O
of O O
the O O
antithyroid O O
drug O O
. O O

Under O O
carbimazole O O
, O O
the O O
plasma O O
T4 O O
markedly O O
decreased O O
( O O
27 O O
. O O
7 O O
+ O O
/ O O
- O O
3 O O
. O O
6 O O
nmol O O
/ O O
l O O
) O O
but O O
the O O
patient O O
remained O O
euthyroid O O
. O O

The O O
clinical O O
course O O
and O O
the O O
laboratory O O
data O O
suggest O O
that O O
the O O
tachycardia O O
crises O O
are O O
the O O
consequence O O
of O O
a O O
hypersensitivity O O
of O O
the O O
heart O O
to O O
thyroid O O
hormones O O
, O O
associated O O
with O O
an O O
increased O O
number O O
of O O
T3 O O
nuclear O O
receptor O O
sites O O
in O O
lymphocytes O O
. O O

Induction O O
of O O
immediate B-DNA B-DNA
early I-DNA I-DNA
response I-DNA I-DNA
genes I-DNA I-DNA
by O O
macrophage O O
colony O O
- O O
stimulating O O
factor O O
in O O
normal O O
human O O
monocytes O O
. O O

A O O
group O O
of O O
coordinately O O
induced O O
protooncogenes B-DNA B-DNA
, O O
cytoskeletal O B-DNA
, O O
and O O
extracellular O O
matrix O O
genes O O
have O O
been O O
termed O O
immediate B-DNA B-DNA
early I-DNA I-DNA
response I-DNA I-DNA
genes I-DNA I-DNA
, O O
and O O
their O O
induction O O
has O O
been O O
associated O O
with O O
growth O O
factor O O
- O O
stimulated O O
cell O O
proliferation O O
. O O

We O O
have O O
investigated O O
the O O
induction O O
of O O
these O O
genes O O
by O O
macrophage O O
- O O
CSF O O
( O O
M O O
- O O
CSF O O
) O O
in O O
human O O
monocytes O O
that O O
do O O
not O O
proliferate O O
in O O
response O O
to O O
M O O
- O O
CSF O O
but O O
require O O
the O O
factor O O
for O O
optimal O O
cell O O
differentiation O O
. O O

Normal O O
human O O
monocytes O O
were O O
isolated O O
, O O
carefully O O
washed O O
, O O
and O O
incubated O O
for O O
36 O O
to O O
48 O O
h O O
in O O
fetal O O
bovine O O
serum O O
- O O
containing O O
medium O O
. O O

At O O
the O O
end O O
of O O
this O O
incubation O O
the O O
resting O O
cells O O
were O O
stimulated O O
with O O
M O O
- O O
CSF O O
, O O
and O O
RNA O O
was O O
isolated O O
for O O
analysis O O
by O O
Northern O O
blotting O O
. O O

RNA O O
from O O
control O O
resting O O
cells O O
contained O O
low O O
to O O
undetectable O O
levels O O
of O O
c O O
- O O
jun O O
, O O
fibronectin O O
receptor O O
, O O
and O O
actin O O
mRNA O O
. O O

Within O O
15 O O
to O O
30 O O
min O O
of O O
addition O O
of O O
M O O
- O O
CSF O O
, O O
however O O
, O O
there O O
was O O
a O O
dramatic O O
coordinate O O
induction O O
of O O
these O O
genes O O
. O O

The O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
gene I-DNA I-DNA
expression O O
was O O
very O O
transient O O
and O O
was O O
not O O
detectable O O
by O O
60 O O
min O O
after O O
M O O
- O O
CSF O O
addition O O
. O O

In O O
contrast O O
, O O
the O O
expression O O
of O O
actin O O
and O O
fibronectin O O
receptor O O
mRNA O O
was O O
more O O
sustained O O
, O O
and O O
the O O
expression O O
of O O
these O O
genes O O
remained O O
elevated O O
at O O
24 O O
to O O
48 O O
h O O
after O O
M O O
- O O
CSF O O
addition O O
. O O

We O O
also O O
observed O O
the O O
induction O O
of O O
the O O
myelomonocytic B-DNA B-DNA
specific I-DNA I-DNA
tyrosine I-DNA I-DNA
kinase I-DNA I-DNA
hck I-DNA I-DNA
gene I-DNA I-DNA
simultaneously O O
with O O
the O O
other O O
immediate B-DNA B-DNA
early I-DNA I-DNA
response I-DNA I-DNA
genes I-DNA I-DNA
. O O

The O O
protein O O
synthesis O O
inhibitor O O
cycloheximide O O
did O O
not O O
block O O
the O O
induction O O
of O O
any O O
of O O
these O O
genes O O
, O O
and O O
in O O
fact O O
, O O
super O O
- O O
induced O O
the O O
expression O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
and O O
hck B-DNA B-DNA
. O O

Nuclear O O
run O O
on O O
transcription O O
of O O
the O O
c B-DNA O
- I-DNA O
jun I-DNA O
, O O
hck B-DNA O
, O O
and O O
actin B-DNA O
genes I-DNA O
. O O

Therefore O O
, O O
in O O
normal O O
human O O
monocytes O O
M O O
- O O
CSF O O
induces O O
immediate B-DNA B-DNA
early I-DNA I-DNA
response I-DNA I-DNA
genes I-DNA I-DNA
without O O
inducing O O
cell O O
proliferation O O
. O O

These O O
genes O O
may O O
then O O
play O O
a O O
role O O
in O O
altering O O
the O O
physiologic O O
status O O
of O O
the O O
cells O O
in O O
response O O
to O O
CSF O O
. O O

Inducible O O
nuclear O O
factor O O
binding O O
to O O
the O O
kappa B-DNA B-DNA
B I-DNA I-DNA
elements I-DNA I-DNA
of O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
enhancer I-DNA I-DNA
in O O
T O O
cells O O
can O O
be O O
blocked O O
by O O
cyclosporin O O
A O O
in O O
a O O
signal O O
- O O
dependent O O
manner O O
. O O

Cyclosporin O O
A O O
( O O
CsA O O
) O O
is O O
thought O O
to O O
exert O O
its O O
immunosuppressive O O
effects O O
by O O
inhibiting O O
the O O
expression O O
of O O
a O O
distinct O O
set O O
of O O
lymphokine B-DNA B-DNA
genes I-DNA I-DNA
which O O
are O O
induced O O
upon O O
T O O
- O O
cell O O
activation O O
, O O
among O O
them O O
the O O
gene O O
coding O O
for O O
interleukin O O
- O O
2 O O
. O O

In O O
addition O O
, O O
the O O
activation O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
is O O
partially O O
suppressed O O
. O O

To O O
better O O
understand O O
the O O
molecular O O
mechanisms O O
underlying O O
suppression O O
by O O
CsA O O
, O O
we O O
have O O
investigated O O
the O O
effects O O
of O O
this O O
drug O O
on O O
transcription O O
factors O O
in O O
T O O
cells O O
. O O

Here O O
we O O
report O O
that O O
the O O
formation O O
of O O
two O O
distinct O O
mitogen O O
- O O
inducible O O
DNA O O
- O O
binding O O
complexes O O
, O O
the O O
kappa O O
B O O
complex O O
within O O
the O O
HIV B-DNA B-DNA
enhancer I-DNA I-DNA
and O O
the O O
NFAT O O
- O O
1 O O
complex O O
within O O
the O O
interleukin B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
enhancer I-DNA I-DNA
, O O
is O O
inhibited O O
in O O
the O O
presence O O
of O O
CsA O O
. O O

The O O
kappa O O
B O O
- O O
binding O O
activity O O
with O O
the O O
HIV B-DNA B-DNA
enhancer I-DNA I-DNA
is O O
inhibited O O
only O O
if O O
it O O
is O O
activated O O
via O O
the O O
mitogen O O
phytohemagglutinin O O
whereas O O
phorbol O O
myristate O O
acetate O O
- O O
mediated O O
activation O O
is O O
completely O O
insensitive O O
to O O
the O O
drug O O
. O O

This O O
suggests O O
a O O
model O O
in O O
which O O
functionally O O
indistinguishable O O
kappa O O
B O O
complexes O O
can O O
be O O
activated O O
via O O
two O O
separate O O
pathways O O
of O O
signal O O
transduction O O
distinguishable O O
by O O
CsA O O
. O O

Purification O O
of O O
TCF O O
- O O
1 O O
alpha O O
, O O
a O O
T O O
- O O
cell O O
- O O
specific O O
transcription O O
factor O O
that O O
activates O O
the O O
T B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
receptor I-DNA I-DNA
C I-DNA I-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
enhancer I-DNA I-DNA
in O O
a O O
context O O
- O O
dependent O O
manner O O
. O O

The O O
differentiation O O
of O O
T O O
cells O O
into O O
functionally O O
diverse O O
subpopulations O O
is O O
controlled O O
in O O
part O O
, O O
by O O
transcriptional O O
activation O O
and O O
silencing O O
; O O
however O O
, O O
little O O
is O O
known O O
in O O
detail O O
about O O
the O O
proteins O O
that O O
influence O O
this O O
developmental O O
process O O
. O O

We O O
have O O
purified O O
a O O
new O O
T O O
- O O
cell O O
- O O
specific O O
factor O O
, O O
TCF O O
- O O
1 O O
alpha O O
, O O
that O O
is O O
implicated O O
in O O
the O O
activation O O
of O O
genes O O
encoding O O
a O O
major O O
component O O
of O O
the O O
human O O
T O O
- O O
cell O O
receptor O O
( O O
TCR O O
) O O
. O O

TCF O O
- O O
1 O O
alpha O O
, O O
originally O O
identified O O
and O O
purified O O
through O O
its O O
binding O O
sites O O
on O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
promoter I-DNA I-DNA
, O O
was O O
found O O
to O O
bind O O
to O O
the O O
TCR B-DNA B-DNA
alpha I-DNA I-DNA
enhancer I-DNA I-DNA
and O O
to O O
promoters B-DNA B-DNA
for O O
several O O
genes B-DNA O
expressed O O
at O O
significantly O O
earlier O O
stages O O
of O O
T O O
- O O
cell O O
development O O
than O O
the O O
TCR B-DNA B-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
( O O
e O O
. O O
g O O
. O O
, O O
p56lck B-DNA B-DNA
and O O
CD3 B-DNA B-DNA
delta I-DNA I-DNA
) O O
. O O

Sequences O O
related O O
to O O
the O O
TCF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
alpha I-DNA I-DNA
binding I-DNA I-DNA
motif I-DNA I-DNA
( O O
5 O O
' O O
- O O
GGCACCCTTTGA O O
- O O
3 O O
' O O
) O O
are O O
also O O
found O O
in O O
the O O
human B-DNA B-DNA
TCR I-DNA I-DNA
delta I-DNA I-DNA
( O O
and O O
possibly O O
TCR B-DNA B-DNA
beta I-DNA I-DNA
) O I-DNA
enhancers B-DNA I-DNA
. O O

Southwestern O O
and O O
gel O O
renaturation O O
experiments O O
with O O
the O O
use O O
of O O
purified O O
protein O O
fractions O O
revealed O O
that O O
TCF O O
- O O
1 O O
alpha O O
activity O O
is O O
derived O O
from O O
a O O
family O O
of O O
57 O O
- O O
to O O
53 O O
- O O
kD O O
proteins O O
that O O
are O O
abundantly O O
expressed O O
in O O
mature O O
and O O
immature O O
T O O
- O O
cell O O
lines O O
( O O
Jurkat O O
, O O
CCRF O O
- O O
CEM O O
) O O
and O O
not O O
in O O
mature O O
B O O
cells O O
( O O
JY O O
, O O
Namalwa O O
) O O
or O O
nonlymphoid O O
( O O
HeLa O O
) O O
cell O O
lines O O
. O O

A O O
small O O
95 O B-DNA
- O I-DNA
bp O I-DNA
fragment O I-DNA
of O O
the O O
TCR B-DNA B-DNA
alpha I-DNA I-DNA
control I-DNA I-DNA
region I-DNA I-DNA
that O O
contains O O
the O O
TCF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
alpha I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
juxtaposed O O
between O O
a O O
cAMP B-DNA B-DNA
- I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
( O O
the O O
CRE B-DNA B-DNA
or O O
T B-DNA B-DNA
alpha I-DNA I-DNA
1 I-DNA I-DNA
motif I-DNA I-DNA
) O O
and O O
the O O
binding B-DNA B-DNA
site I-DNA I-DNA
for O O
a O O
distinct O O
lymphoid O O
- O O
specific O O
protein O O
( O O
TCF O O
- O O
2 O O
alpha O O
) O O
behaved O O
as O O
a O O
potent O O
T B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
enhancer I-DNA I-DNA
in O O
vivo O O
. O O

Tandem O O
copies O O
of O O
this O O
enhancer O B-DNA
functioned O O
synergistically O O
in O O
mature O O
( O O
Jurkat O O
) O O
T O O
- O O
cell O O
lines O O
as O O
well O O
as O O
resting O O
and O O
activated O O
immature O O
( O O
CCRF O O
- O O
CEM O O
) O O
T O O
- O O
cell O O
lines O O
. O O

Mutation O O
of O O
the O O
TCF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
alpha I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
diminished O O
enhancer O O
activity O O
and O O
disrupted O O
the O O
synergism O O
observed O O
in O O
vivo O O
between O O
tandem B-DNA B-DNA
enhancer I-DNA I-DNA
repeats I-DNA I-DNA
. O O

The O O
TCF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
alpha I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
was O O
also O O
required O O
for O O
TCR O B-DNA
alpha O I-DNA
enhancer O I-DNA
activity O O
in O O
transcriptionally O O
active O O
extracts O O
from O O
Jurkat O O
but O O
not O O
HeLa O O
cells O O
, O O
confirming O O
that O O
TCF O O
- O O
1 O O
alpha O O
is O O
a O O
T O O
- O O
cell O O
- O O
specific O O
transcription O O
factor O O
. O O

Curiously O O
, O O
the O O
TCF O B-DNA
- O I-DNA
1 O I-DNA
alpha O I-DNA
binding O I-DNA
element O I-DNA
was O O
inactive O O
in O O
vivo O O
when O O
removed O O
from O O
its O O
neighboring O O
elements O O
on O O
the O O
TCR B-DNA B-DNA
alpha I-DNA I-DNA
enhancer I-DNA I-DNA
and O O
positioned O O
in O O
one O O
or O O
more O O
copies O O
upstream O O
of O O
a O O
heterologous B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Thus O O
, O O
the O O
transcriptional O O
activity O O
of O O
TCF O O
- O O
1 O O
alpha O O
appears O O
to O O
depend O O
on O O
the O O
TCF O O
- O O
2 O O
alpha O O
and O O
T O O
alpha O O
1 O O
( O O
CREB O O
) O O
transcription O O
factors O O
and O O
the O O
context O O
of O O
its O O
binding O B-DNA
site O I-DNA
within O O
the O O
TCR B-DNA B-DNA
alpha I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

Tandem B-DNA O
AP I-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
within O O
the O O
human B-DNA B-DNA
beta I-DNA I-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
dominant I-DNA I-DNA
control I-DNA I-DNA
region I-DNA I-DNA
function O O
as O O
an O O
inducible B-DNA B-DNA
enhancer I-DNA I-DNA
in O O
erythroid O O
cells O O
. O O

A O O
powerful O O
enhancer O O
has O O
been O O
mapped O O
to O O
an O O
18 B-DNA B-DNA
- I-DNA I-DNA
bp I-DNA I-DNA
DNA I-DNA I-DNA
segment I-DNA I-DNA
located O O
11 O O
kb O O
5 O O
' O O
to O O
the O O
human B-DNA B-DNA
epsilon I-DNA I-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
gene I-DNA I-DNA
within O O
the O O
dominant B-DNA O
control I-DNA O
or O O
locus B-DNA B-DNA
- I-DNA I-DNA
activating I-DNA I-DNA
region I-DNA I-DNA
. O O

This O O
enhancer B-DNA O
is O O
inducible O O
in O O
K562 O O
human O O
erythroleukemia O O
cells O O
, O O
increasing O O
linked O O
gamma B-DNA B-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
promoter I-DNA I-DNA
/ O I-DNA
luciferase O I-DNA
gene O I-DNA
expression O O
to O O
170 O O
- O O
fold O O
over O O
an O O
enhancerless B-DNA B-DNA
construct I-DNA I-DNA
. O O

The O O
enhancer B-DNA B-DNA
consists O O
of O O
tandem B-DNA O
AP I-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
, O O
phased O O
10 O B-DNA
bp O I-DNA
apart O I-DNA
, O O
which O O
are O O
both O O
required O O
for O O
full O O
activity O O
. O O

DNA O O
- O O
protein O O
binding O O
assays O O
with O O
nuclear O O
extracts O O
from O O
induced O O
cells O O
demonstrate O O
a O O
high O O
molecular O O
weight O O
complex O O
on O O
the O O
enhancer B-DNA B-DNA
. O O

The O O
formation O O
of O O
this O O
complex O O
also O O
requires O O
both O O
AP B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
sites I-DNA I-DNA
and O O
correlates O O
with O O
maximal O O
enhancer B-DNA O
activity O O
. O O

Induction O O
of O O
the O O
enhancer B-DNA B-DNA
may O O
have O O
a O O
role O O
in O O
the O O
increase O O
in O O
globin B-DNA B-DNA
gene I-DNA I-DNA
transcription O O
that O O
characterizes O O
erythroid O O
maturation O O
. O O

Enhancer O O
activity O O
appears O O
to O O
be O O
mediated O O
by O O
the O O
binding O O
of O O
a O O
complex O O
of O O
proteins O O
from O O
the O O
jun B-DNA O
and I-DNA O
fos I-DNA O
families I-DNA O
to O O
tandem B-DNA B-DNA
AP I-DNA I-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
consensus I-DNA I-DNA
sequences I-DNA I-DNA
. O O

Identification O O
of O O
a O O
novel O O
factor O O
that O O
interacts O O
with O O
an O O
immunoglobulin B-DNA B-DNA
heavy I-DNA I-DNA
- I-DNA I-DNA
chain I-DNA I-DNA
promoter I-DNA I-DNA
and O O
stimulates O O
transcription O O
in O O
conjunction O O
with O O
the O O
lymphoid O O
cell O O
- O O
specific O O
factor O O
OTF2 O O
. O O

The O O
tissue O O
- O O
specific O O
expression O O
of O O
the O O
MOPC B-DNA B-DNA
141 I-DNA I-DNA
immunoglobulin I-DNA I-DNA
heavy I-DNA I-DNA
- I-DNA I-DNA
chain I-DNA I-DNA
gene I-DNA I-DNA
was O O
studied O O
by O O
using O O
in O O
vitro O O
transcription O O
. O O

B O O
- O O
cell O O
- O O
specific O O
transcription O O
of O O
this O O
gene O O
was O O
dependent O O
on O O
the O O
octamer B-DNA B-DNA
element I-DNA I-DNA
5 O O
' O O
- O O
ATGCAAAG O O
- O O
3 O O
' O O
, O O
located O O
in O O
the O O
upstream B-DNA B-DNA
region I-DNA I-DNA
of O O
this O O
promoter B-DNA B-DNA
and O O
in O O
the O O
promoters B-DNA B-DNA
of O O
all O O
other O O
immunoglobulin O O
heavy O O
- O O
and O O
light O O
- O O
chain O O
genes O O
. O O

The O O
interaction O O
of O O
purified O O
octamer O O
transcription O O
factors O O
1 O O
and O O
2 O O
( O O
OTF1 O O
and O O
OTF2 O O
) O O
with O O
the O O
MOPC B-DNA B-DNA
141 I-DNA I-DNA
promoter I-DNA I-DNA
was O O
studied O O
by O O
using O O
electrophoretic O O
mobility O O
shift O O
assays O O
and O O
DNase O O
I O O
footprinting O O
. O O

Purified O O
OTF1 O O
from O O
HeLa O O
cells O O
and O O
OTF1 O O
and O O
OTF2 O O
from O O
B O O
cells O O
bound O O
to O O
identical O O
sequences O O
within O O
the O O
heavy B-DNA B-DNA
- I-DNA I-DNA
chain I-DNA I-DNA
promoter I-DNA I-DNA
. O O

The O O
OTF O O
interactions O O
we O O
observed O O
extended O O
over O O
the O O
heptamer B-DNA B-DNA
element I-DNA I-DNA
5 O O
' O O
- O O
CTCAGGA O O
- O O
3 O O
' O O
, O O
and O O
it O O
seems O O
likely O O
that O O
the O O
binding O O
of O O
the O O
purified O O
factors O O
involves O O
cooperation O O
between O O
octamer O B-DNA
and O O
heptamer O B-DNA
sites O I-DNA
in O O
this O O
promoter B-DNA B-DNA
. O O

In O O
addition O O
to O O
these O O
elements O O
, O O
we O O
identified O O
a O O
second O O
regulatory B-DNA B-DNA
element I-DNA I-DNA
, O O
the O O
N B-DNA B-DNA
element I-DNA I-DNA
with O O
the O O
sequence O O
5 O O
' O O
- O O
GGAACCTCCCCC O O
- O O
3 O O
' O O
. O O

The O O
N B-DNA B-DNA
element I-DNA I-DNA
could O O
independently O O
mediate O O
low O O
levels O O
of O O
transcription O O
in O O
both O O
B O O
- O O
cell O O
and O O
HeLa O O
- O O
cell O O
extracts O O
, O O
and O O
, O O
in O O
conjunction O O
with O O
the O O
octamer B-DNA B-DNA
element I-DNA I-DNA
, O O
it O O
can O O
promote O O
high O O
levels O O
of O O
transcription O O
in O O
B O O
- O O
cell O O
extracts O O
. O O

The O O
N B-DNA B-DNA
element I-DNA I-DNA
bound O O
a O O
transcription O O
factor O O
, O O
NTF O O
, O O
that O O
is O O
ubiquitous O O
in O O
cell O O
- O O
type O O
distribution O O
, O O
and O O
NTF O O
was O O
distinct O O
from O O
any O O
of O O
the O O
previously O O
described O O
proteins O O
that O O
bind O O
to O O
similar O O
sequences O O
. O O

Based O O
on O O
these O O
results O O
, O O
we O O
propose O O
that O O
NTF O O
and O O
OTF2 O O
interactions O O
( O O
both O O
with O O
their O O
cognate B-DNA B-DNA
DNA I-DNA I-DNA
elements I-DNA I-DNA
and O O
possibly O O
at O O
the O O
protein O O
- O O
protein O O
level O O
) O O
may O O
be O O
critical O O
to O O
B O O
- O O
cell O O
- O O
specific O O
expression O O
and O O
that O O
these O O
interactions O O
provide O O
additional O O
pathways O O
for O O
regulating O O
gene O O
expression O O
. O O

NF O O
- O O
kappa O O
B O O
as O O
inducible O O
transcriptional O O
activator O O
of O O
the O O
granulocyte B-DNA B-DNA
- I-DNA I-DNA
macrophage I-DNA I-DNA
colony I-DNA I-DNA
- I-DNA I-DNA
stimulating I-DNA I-DNA
factor I-DNA I-DNA
gene I-DNA I-DNA
. O O

The O O
expression O O
of O O
the O O
gene O O
encoding O O
the O O
granulocyte O O
- O O
macrophage O O
colony O O
- O O
stimulating O O
factor O O
( O O
GM O O
- O O
CSF O O
) O O
is O O
induced O O
upon O O
activation O O
of O O
T O O
cells O O
with O O
phytohemagglutinin O O
and O O
active O O
phorbolester O O
and O O
upon O O
expression O O
of O O
tax1 O O
, O O
a O O
transactivating O O
protein O O
of O O
the O O
human O O
T O O
- O O
cell O O
leukemia O O
virus O O
type O O
I O O
. O O

The O O
same O O
agents O O
induce O O
transcription O O
from O O
the O O
interleukin O O
- O O
2 O O
receptor O O
alpha O O
- O O
chain O O
and O O
interleukin O O
- O O
2 O O
genes O O
, O O
depending O O
on O O
promoter B-DNA B-DNA
elements I-DNA I-DNA
that O O
bind O O
the O O
inducible O O
transcription O O
factor O O
NF O O
- O O
kappa O O
B O O
( O O
or O O
an O O
NF O O
- O O
kappa O O
B O O
- O O
like O O
factor O O
) O O
. O O

We O O
therefore O O
tested O O
the O O
possibility O O
that O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
gene I-DNA I-DNA
is O O
also O O
regulated O O
by O O
a O O
cognate O O
motif O O
for O O
the O O
NF O O
- O O
kappa O O
B O O
transcription O O
factor O O
. O O

A O O
recent O O
functional O O
analysis O O
by O O
Miyatake O O
et O O
al O O
. O O
( O O
S O O
. O O
Miyatake O O
, O O
M O O
. O O
Seiki O O
, O O
M O O
. O O
Yoshida O O
, O O
and O O
K O O
. O O
Arai O O
, O O
Mol O O
. O O
Cell O O
. O O
Biol O O
. O O
8 O O
: O O
5581 O O
- O O
5587 O O
, O O
1988 O O
) O O
described O O
a O O
short B-DNA B-DNA
promoter I-DNA I-DNA
region I-DNA I-DNA
in O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
gene I-DNA I-DNA
that O O
conferred O O
strong O O
inducibility O O
by O O
T O O
- O O
cell O O
- O O
activating O O
signals O O
and O O
tax1 O O
, O O
but O O
no O O
NF B-DNA B-DNA
- I-DNA I-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
motifs I-DNA I-DNA
were O O
identified O O
. O O

Using O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
we O O
showed O O
binding O O
of O O
purified O O
human O O
NF O O
- O O
kappa O O
B O O
and O O
of O O
the O O
NF O O
- O O
kappa O O
B O O
activated O O
in O O
Jurkat O O
T O O
cells O O
to O O
an O O
oligonucleotide O O
comprising O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
promoter I-DNA I-DNA
element I-DNA I-DNA
responsible O O
for O O
mediating O O
responsiveness O O
to O O
T O O
- O O
cell O O
- O O
activating O O
signals O O
and O O
tax1 O O
. O O

As O O
shown O O
by O O
a O O
methylation O O
interference O O
analysis O O
and O O
oligonucleotide O O
competition O O
experiments O O
, O O
purified O O
NF O O
- O O
kappa O O
B O O
binds O O
at O O
positions B-DNA O
- I-DNA B-DNA
82 I-DNA I-DNA
to I-DNA I-DNA
- I-DNA I-DNA
91 I-DNA I-DNA
( O O
GGGAACTACC O O
) O O
of O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
promoter I-DNA I-DNA
sequence O I-DNA
with O O
an O O
affinity O O
similar O O
to O O
that O O
with O O
which O O
it O O
binds O O
to O O
the O O
biologically B-DNA O
functional I-DNA O
kappa I-DNA B-DNA
B I-DNA I-DNA
motif I-DNA I-DNA
in O O
the O O
beta B-DNA B-DNA
interferon I-DNA I-DNA
promoter I-DNA I-DNA
( O O
GGGAAATTCC O O
) O O
. O O

Two O O
kappa B-DNA B-DNA
B I-DNA I-DNA
- I-DNA I-DNA
like I-DNA I-DNA
motifs I-DNA I-DNA
at O O
positions B-DNA O
- I-DNA B-DNA
98 I-DNA I-DNA
to I-DNA I-DNA
- I-DNA I-DNA
108 I-DNA I-DNA
of O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
promoter I-DNA I-DNA
were O O
also O O
recognized O O
but O O
with O O
much O O
lower O O
affinities O O
. O O

Our O O
data O O
provide O O
strong O O
evidence O O
that O O
the O O
expression O O
of O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
gene I-DNA I-DNA
following O O
T O O
- O O
cell O O
activation O O
is O O
controlled O O
by O O
binding O O
of O O
the O O
NF O O
- O O
kappa O O
B O O
transcription O O
factor O O
to O O
a O O
high B-DNA B-DNA
- I-DNA I-DNA
affinity I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
in O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Effects O O
of O O
mitogenic O O
agents O O
upon O O
glucocorticoid O O
action O O
in O O
human O O
tonsillar O O
T O O
- O O
lymphocytes O O
. O O

The O O
treatment O O
of O O
human O O
tonsillar O O
T O O
- O O
lymphocytes O O
with O O
4 O O
- O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
( O O
PMA O O
) O O
, O O
resulted O O
in O O
about O O
two O O
fold O O
increase O O
in O O
glucocorticoid O O
receptor O O
( O O
GR O O
) O O
number O O
, O O
without O O
any O O
significant O O
change O O
in O O
the O O
receptor O O
affinity O O
. O O

This O O
increase O O
disappeared O O
in O O
the O O
presence O O
of O O
cycloheximide O O
. O O

Alone O O
, O O
PMA O O
and O O
calcium O O
ionophore O O
A23187 O O
did O O
not O O
affect O O
, O O
but O O
together O O
stimulated O O
, O O
like O O
phytohaemagglutinin O O
( O O
PHA O O
) O O
, O O
leucine O O
and O O
, O O
in O O
particular O O
, O O
thymidine O O
incorporation O O
. O O

PMA O O
enhanced O O
slightly O O
the O O
stimulatory O O
effect O O
of O O
PHA O O
. O O

Alone O O
, O O
these O O
agents O O
failed O O
to O O
alter O O
the O O
suppressive O O
effect O O
of O O
dexamethasone O O
on O O
thymidine O O
and O O
leucine O O
incorporation O O
; O O
however O O
, O O
PMA O O
- O O
A23187 O O
and O O
PMA O O
- O O
PHA O O
combinations O O
appeared O O
to O O
antagonize O O
the O O
suppression O O
by O O
dexamethasone O O
. O O

To O O
be O O
or O O
not O O
to O O
be O O
a O O
responder O O
in O O
T O O
- O O
cell O O
responses O O
: O O
ubiquitous O O
oligopeptides O O
in O O
all O O
proteins O O
. O O

Amino O O
acid O O
sequences O O
of O O
all O O
proteins O O
are O O
essays O O
written O O
in O O
the O O
same O O
language O O
. O O

Accordingly O O
, O O
the O O
same O O
set O O
of O O
words O O
and O O
phrases O O
( O O
oligopeptides O O
) O O
appear O O
in O O
totally O O
unrelated O O
proteins O O
. O O

The O O
reason O O
that O O
only O O
certain O O
individuals O O
of O O
particular O O
major O O
histocompatibility O O
complex O O
( O O
MHC O O
) O O
haplotypes O O
can O O
mount O O
T O O
- O O
cell O O
responses O O
against O O
a O O
given O O
antigen O O
of O O
pathogens O O
is O O
found O O
in O O
the O O
fact O O
that O O
T O O
- O O
cell O O
receptors O O
are O O
designed O O
to O O
recognize O O
18 O O
- O O
20 O O
residue O O
- O O
long O O
peptide O O
fragments O O
sandwiched O O
between O O
two O O
alpha O O
- O O
helices O O
of O O
class O O
I O O
or O O
class O O
II O O
MHC O O
molecules O O
. O O

At O O
this O O
range O O
of O O
peptide O O
lengths O O
, O O
most O O
would O O
appear O O
as O O
self O O
, O O
while O O
nonselfness O O
of O O
the O O
remainders O O
are O O
destined O O
to O O
be O O
quite O O
ambiguous O O
, O O
hence O O
creating O O
responders O O
and O O
nonresponders O O
. O O

Two O O
distinct O O
signal O O
transmission O O
pathways O O
in O O
T O O
lymphocytes O O
are O O
inhibited O O
by O O
complexes O O
formed O O
between O O
an O O
immunophilin O O
and O O
either O O
FK506 O O
or O O
rapamycin O O
. O O

Proliferation O O
and O O
immunologic O O
function O O
of O O
T O O
lymphocytes O O
are O O
initiated O O
by O O
signals O O
from O O
the O O
antigen O O
receptor O O
that O O
are O O
inhibited O O
by O O
the O O
immunosuppressant O O
FK506 O O
but O O
not O O
by O O
its O O
structural O O
analog O O
, O O
rapamycin O O
. O O

On O O
the O O
other O O
hand O O
, O O
interleukin O O
2 O O
( O O
IL O O
- O O
2 O O
) O O
- O O
induced O O
signals O O
are O O
blocked O O
by O O
rapamycin O O
but O O
not O O
by O O
FK506 O O
. O O

Remarkably O O
, O O
these O O
two O O
drugs O O
inhibit O O
each O O
other O O
' O O
s O O
actions O O
, O O
raising O O
the O O
possibility O O
that O O
both O O
act O O
by O O
means O O
of O O
a O O
common O O
immunophilin O O
( O O
immunosuppressant O O
binding O O
protein O O
) O O
. O O

We O O
find O O
that O O
the O O
dissociation O O
constant O O
of O O
rapamycin O O
to O O
the O O
FK506 O O
binding O O
protein O O
FKBP O O
( O O
Kd O O
= O O
0 O O
. O O
2 O O
nM O O
) O O
is O O
close O O
to O O
the O O
dissociation O O
constant O O
of O O
FK506 O O
to O O
FKBP O O
( O O
Kd O O
= O O
0 O O
. O O
4 O O
nM O O
) O O
and O O
to O O
their O O
effective O O
biologic O O
inhibitory O O
concentrations O O
. O O

However O O
, O O
an O O
excess O O
of O O
rapamycin O O
is O O
needed O O
to O O
revert O O
FK506 O O
- O O
mediated O O
inhibition O O
of O O
IL O O
- O O
2 O O
production O O
, O O
apoptosis O O
, O O
and O O
transcriptional O O
activation O O
of O O
NF O O
- O O
AT O O
, O O
a O O
T O O
- O O
cell O O
- O O
specific O O
transcription O O
factor O O
necessary O O
for O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
gene I-DNA I-DNA
activation O O
. O O

Similarly O O
, O O
an O O
excess O O
of O O
FK506 O O
is O O
needed O O
to O O
revert O O
rapamycin O O
- O O
mediated O O
inhibition O O
of O O
IL O O
- O O
2 O O
- O O
induced O O
proliferation O O
. O O

The O O
drug O O
concentrations O O
required O O
for O O
antagonism O O
may O O
be O O
explained O O
by O O
the O O
relative O O
affinity O O
of O O
the O O
drugs O O
to O O
, O O
and O O
by O O
the O O
abundance O O
of O O
, O O
the O O
immunophilin O O
FKBP O O
. O O

FKBP O O
has O O
been O O
shown O O
to O O
catalyze O O
the O O
interconversion O O
of O O
the O O
cis O O
- O O
and O O
trans O O
- O O
rotamers O O
of O O
the O O
peptidyl O O
- O O
prolyl O O
amide O O
bond O O
of O O
peptide O O
substrates O O
; O O
here O O
we O O
show O O
that O O
rapamycin O O
, O O
like O O
FK506 O O
, O O
is O O
a O O
potent O O
inhibitor O O
of O O
the O O
rotamase O O
activity O O
of O O
FKBP O O
( O O
Ki O O
= O O
0 O O
. O O
2 O O
nM O O
) O O
. O O

Neither O O
FKBP O O
binding O O
nor O O
inhibition O O
of O O
rotamase O O
activity O O
of O O
FKBP O O
alone O O
is O O
sufficient O O
to O O
explain O O
the O O
biologic O O
actions O O
of O O
these O O
drugs O O
. O O

Rather O O
, O O
these O O
findings O O
suggest O O
that O O
immunophilin O O
bound O O
to O O
FK506 O O
interferes O O
with O O
antigen O O
receptor O O
- O O
induced O O
signals O O
, O O
while O O
rapamycin O O
bound O O
to O O
the O O
immunophilin O O
interferes O O
with O O
IL O O
- O O
2 O O
- O O
induced O O
signals O O
. O O

Adherence O O
- O O
dependent O O
increase O O
in O O
human O O
monocyte O O
PDGF O O
( O O
B O O
) O O
mRNA O O
is O O
associated O O
with O O
increases O O
in O O
c O B-DNA
- O I-DNA
fos O I-DNA
, O O
c O O
- O O
jun O O
, O O
and O O
EGR2 O B-DNA
mRNA O O
. O O

Adherence O O
is O O
an O O
important O O
initial O O
step O O
in O O
the O O
transition O O
of O O
a O O
circulating O O
monocyte O O
to O O
a O O
tissue O O
macrophage O O
. O O

This O O
differentiation O O
is O O
accompanied O O
by O O
an O O
augmented O O
capacity O O
to O O
generate O O
growth O O
factors O O
. O O

We O O
hypothesized O O
that O O
adherence O O
itself O O
might O O
be O O
an O O
important O O
trigger O O
for O O
a O O
sequence O O
of O O
gene O O
activation O O
culminating O O
in O O
cells O O
with O O
increased O O
mRNA O O
encoding O O
profibrotic O O
growth O O
factors O O
such O O
as O O
platelet O O
- O O
derived O O
growth O O
factor O O
B O O
subunit O O
( O O
PDGF O O
[ O O
B O O
] O O
) O O
and O O
transforming O O
growth O O
factor O O
- O O
beta O O
( O O
TGF O O
- O O
beta O O
) O O
. O O

After O O
in O O
vitro O O
adherence O O
, O O
human O O
monocytes O O
had O O
a O O
biphasic O O
increase O O
in O O
PDGF O O
( O O
B O O
) O O
mRNA O O
with O O
peaks O O
at O O
6 O O
h O O
and O O
13 O O
d O O
. O O

No O O
increase O O
in O O
TGF O O
- O O
beta O O
mRNA O O
was O O
observed O O
. O O

The O O
6 O O
- O O
h O O
increase O O
in O O
PDGF O O
( O O
B O O
) O O
mRNA O O
was O O
adherence O O
dependent O O
, O O
and O O
in O O
addition O O
, O O
was O O
abrogated O O
when O O
the O O
cytoskeletal O O
integrity O O
was O O
compromised O O
by O O
cytochalasin O O
D O O
. O O

The O O
6 O O
- O O
h O O
increase O O
in O O
PDGF O O
( O O
B O O
) O O
mRNA O O
was O O
unaltered O O
by O O
adherence O O
in O O
the O O
presence O O
of O O
the O O
monocyte O O
stimulus O O
lipopolysaccharide O O
. O O

Adherence O O
to O O
either O O
fibronectin O O
or O O
collagen O O
- O O
coated O O
plastic O O
had O O
little O O
consistent O O
effect O O
on O O
PDGF O O
( O O
B O O
) O O
mRNA O O
accumulation O O
. O O

The O O
increased O O
PDGF O O
( O O
B O O
) O O
mRNA O O
observed O O
in O O
adherent O O
monocytes O O
was O O
accompanied O O
by O O
increases O O
in O O
mRNAs O O
of O O
the O O
early B-DNA B-DNA
growth I-DNA I-DNA
response I-DNA I-DNA
genes I-DNA I-DNA
c B-DNA B-DNA
- I-DNA I-DNA
fos I-DNA I-DNA
( O O
maximal O O
at O O
20 O O
min O O
) O O
, O O
c O B-DNA
- O I-DNA
jun O I-DNA
, O O
and O O
EGR2 O B-DNA
( O O
maximal O O
at O O
6 O O
- O O
24 O O
h O O
) O O
. O O

The O O
increase O O
in O O
c O B-DNA
- O I-DNA
jun O I-DNA
and O O
EGR2 O O
, O O
but O O
not O O
c B-DNA O
- I-DNA O
fos I-DNA O
, O O
mRNA O O
was O O
also O O
abrogated O O
by O O
cytochalasin O O
D O O
. O O

These O O
observations O O
suggest O O
that O O
adherence O O
results O O
in O O
increases O O
of O O
c O O
- O O
fos O O
, O O
c O O
- O O
jun O O
, O O
EGR2 O O
, O O
and O O
PDGF O O
( O O
B O O
) O O
mRNA O O
. O O

In O O
addition O O
, O O
the O O
increases O O
in O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
, O O
EGR2 B-DNA B-DNA
, O O
and O O
PDGF O O
( O O
B O O
) O O
may O O
depend O O
on O O
cytoskeletal O O
rearrangement O O
. O O

Modulation O O
of O O
these O O
events O O
at O O
the O O
time O O
of O O
adherence O O
offers O O
a O O
mechanism O O
by O O
which O O
differential O O
priming O O
of O O
the O O
cells O O
may O O
be O O
accomplished O O
. O O

Single O O
cell O O
assay O O
of O O
a O O
transcription O O
factor O O
reveals O O
a O O
threshold O O
in O O
transcription O O
activated O O
by O O
signals O O
emanating O O
from O O
the O O
T O O
- O O
cell O O
antigen O O
receptor O O
. O O

Stimulation O O
of O O
T O O
lymphocytes O O
through O O
their O O
antigen O O
receptor O O
leads O O
to O O
the O O
appearance O O
of O O
several O O
transcription O O
factors O O
, O O
including O O
NF O O
- O O
AT O O
and O O
NF O O
- O O
kappa O O
B O O
, O O
which O O
are O O
involved O O
in O O
regulating O O
genes O O
required O O
for O O
immunologic O O
activation O O
. O O

To O O
investigate O O
the O O
activity O O
of O O
a O O
single O O
transcription O O
factor O O
in O O
individual O O
viable O O
cells O O
, O O
we O O
have O O
applied O O
an O O
assay O O
that O O
uses O O
the O O
fluorescence O O
- O O
activated O O
cell O O
sorter O O
to O O
quantitate O O
beta O O
- O O
galactosidase O O
( O O
beta O O
- O O
gal O O
) O O
. O O

We O O
have O O
analyzed O O
the O O
distribution O O
of O O
NF O O
- O O
AT O O
transcriptional O O
activity O O
among O O
T O O
cells O O
undergoing O O
activation O O
by O O
using O O
a O O
construct O O
in O O
which O O
three O O
tandem O O
copies O O
of O O
the O O
NF B-DNA B-DNA
- I-DNA I-DNA
AT I-DNA I-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
directs O O
transcription O O
of O O
the O O
lacZ B-DNA B-DNA
gene I-DNA I-DNA
. O O

Unexpectedly O O
, O O
stimulation O O
of O O
cloned O O
stably O O
transfected O O
Jurkat O O
T O O
cells O O
leads O O
to O O
a O O
bimodal O O
pattern O O
of O O
beta O B-DNA
- O I-DNA
gal O I-DNA
expression O O
in O O
which O O
some O O
cells O O
express O O
no O O
beta O O
- O O
gal O O
and O O
others O O
express O O
high O O
levels O O
. O O

This O O
expression O O
pattern O O
cannot O O
be O O
accounted O O
for O O
by O O
cell O O
- O O
cycle O O
position O O
or O O
heritable O O
variation O O
. O O

Further O O
results O O
, O O
in O O
which O O
beta O O
- O O
gal O O
activity O O
is O O
correlated O O
with O O
NF O O
- O O
AT O O
- O O
binding O O
activity O O
, O O
indicate O O
that O O
the O O
concentration O O
of O O
NF O O
- O O
AT O O
must O O
exceed O O
a O O
critical O O
threshold O O
before O O
transcription O O
initiates O O
. O O

This O O
threshold O O
likely O O
reflects O O
the O O
NF O O
- O O
AT O O
concentration O O
- O O
dependent O O
assembly O O
of O O
transcription O O
complexes O O
at O O
the O O
promoter B-DNA B-DNA
. O O

Similar O O
constructs O O
controlled O O
by O O
NF O O
- O O
kappa O O
B O O
or O O
the O O
entire O O
interleukin B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
enhancer I-DNA I-DNA
show O O
bimodal O O
expression O O
patterns O O
during O O
induction O O
, O O
suggesting O O
that O O
thresholds O O
set O O
by O O
the O O
concentration O O
of O O
transcription O O
factors O O
may O O
be O O
a O O
common O O
property O O
of O O
inducible B-DNA B-DNA
genes I-DNA I-DNA
. O O

The O O
Epstein B-DNA B-DNA
- I-DNA I-DNA
Barr I-DNA I-DNA
virus I-DNA I-DNA
( I-DNA I-DNA
EBV I-DNA I-DNA
) I-DNA I-DNA
BMRF1 I-DNA I-DNA
promoter I-DNA I-DNA
for O O
early O O
antigen O O
( O O
EA O O
- O O
D O O
) O O
is O O
regulated O O
by O O
the O O
EBV O O
transactivators O O
, O O
BRLF1 O O
and O O
BZLF1 O O
, O O
in O O
a O O
cell O O
- O O
specific O O
manner O O
. O O

The O O
Epstein O O
- O O
Barr O O
virus O O
early O O
antigen O O
diffuse O O
component O O
( O O
EA O O
- O O
D O O
) O O
is O O
essential O O
for O O
Epstein O O
- O O
Barr O O
virus B-DNA O
DNA I-DNA O
polymerase O O
activity O O
, O O
and O O
its O O
activity O O
is O O
suppressed O O
during O O
latent O O
infection O O
. O O

We O O
investigated O O
the O O
regulation O O
of O O
the O O
promoter B-DNA B-DNA
( O O
BMRF1 B-DNA B-DNA
) O O
for O O
this O O
early O O
gene O O
by O O
studying O O
its O O
responsiveness O O
in O O
vitro O O
to O O
two O O
immediate O O
- O O
early O O
viral O O
transactivators O O
, O O
BZLF1 O O
( O O
Z O O
) O O
and O O
BRLF1 O O
( O O
R O O
) O O
, O O
focusing O O
on O O
the O O
differences O O
in O O
response O O
in O O
lymphoid O O
cells O O
and O O
epithelial O O
cells O O
. O O

In O O
lymphoid O O
cells O O
, O O
Z O O
or O O
R O O
alone O O
produced O O
only O O
small O O
increases O O
in O O
EA B-DNA B-DNA
- I-DNA I-DNA
D I-DNA I-DNA
promoter I-DNA I-DNA
activity O O
, O O
whereas O O
both O O
transactivators O O
together O O
produced O O
a O O
large O O
stimulatory O O
effect O O
. O O

In O O
epithelial O O
cells O O
, O O
the O O
Z O O
transactivator O O
alone O O
produced O O
maximal O O
stimulation O O
of O O
the O O
EA B-DNA B-DNA
- I-DNA I-DNA
D I-DNA I-DNA
promoter I-DNA I-DNA
; O O
the O O
effect O O
of O O
R O O
and O O
Z O O
together O O
was O O
no O O
greater O O
than O O
that O O
of O O
Z O O
alone O O
. O O

Deletional O O
analysis O O
and O O
site O O
- O O
directed O O
mutagenesis O O
of O O
the O O
EA B-DNA B-DNA
- I-DNA I-DNA
D I-DNA I-DNA
promoter I-DNA I-DNA
demonstrated O O
that O O
in O O
epithelial O O
cells O O
the O O
potential O O
AP B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
plays O O
an O O
essential O O
role O O
in O O
Z O O
responsiveness O O
, O O
although O O
sequences O O
further O O
upstream O O
are O O
also O O
important O O
. O O

In O O
lymphoid O O
cells O O
, O O
only O O
the O O
upstream B-DNA B-DNA
sequences I-DNA I-DNA
are O O
required O O
for O O
transactivation O O
by O O
the O O
Z O O
/ O O
R O O
combination O O
, O O
and O O
the O O
AP O B-DNA
- O I-DNA
1 O I-DNA
site O I-DNA
is O O
dispensable O O
. O O

These O O
data O O
suggest O O
that O O
EA B-DNA B-DNA
- I-DNA I-DNA
D I-DNA I-DNA
( I-DNA I-DNA
BMRF1 I-DNA I-DNA
) I-DNA I-DNA
promoter I-DNA I-DNA
regulation O O
by O O
Z O O
and O O
R O O
is O O
cell O O
type O O
specific O O
and O O
appears O O
to O O
involve O O
different O O
mechanisms O O
in O O
each O O
cell O O
type O O
. O O

Complementary B-DNA O
DNA I-DNA O
encoding O O
the O O
human O O
T O O
- O O
cell O O
FK506 O O
- O O
binding O O
protein O O
, O O
a O O
peptidylprolyl O O
cis O O
- O O
trans O O
isomerase O O
distinct O O
from O O
cyclophilin O O
. O O

The O O
recently O O
discovered O O
macrolide O O
FK506 O O
has O O
been O O
demonstrated O O
to O O
have O O
potent O O
immunosuppressive O O
activity O O
at O O
concentrations O O
100 O O
- O O
fold O O
lower O O
than O O
cyclosporin O O
A O O
, O O
a O O
cyclic O O
undecapeptide O O
that O O
is O O
used O O
to O O
prevent O O
rejection O O
after O O
transplantation O O
of O O
bone O O
marrow O O
and O O
organs O O
, O O
such O O
as O O
kidney O O
, O O
heart O O
, O O
and O O
liver O O
. O O

After O O
the O O
recent O O
discovery O O
that O O
the O O
cyclosporin O O
A O O
- O O
binding O O
protein O O
cyclophilin O O
is O O
identical O O
to O O
peptidylprolyl O O
cis O O
- O O
trans O O
isomerase O O
, O O
a O O
cellular O O
binding O O
protein O O
for O O
FK506 O O
was O O
found O O
to O O
be O O
distinct O O
from O O
cyclophilin O O
but O O
to O O
have O O
the O O
same O O
enzymatic O O
activity O O
. O O

In O O
this O O
study O O
, O O
we O O
isolated O O
a O O
cDNA B-DNA B-DNA
coding O O
for O O
FK506 O O
- O O
binding O O
protein O O
( O O
FKBP O O
) O O
from O O
human O O
peripheral O O
blood O O
T O O
cells O O
by O O
using O O
mixed O O
20 O O
- O O
mer O O
oligonucleotide O O
probes O O
synthesized O O
on O O
the O O
basis O O
of O O
the O O
sequence O O
, O O
Glu O O
- O O
Asp O O
- O O
Gly O O
- O O
Lys O O
- O O
Lys O O
- O O
Phe O O
- O O
Asp O O
, O O
reported O O
for O O
bovine O O
FKBP O O
. O O

The O O
DNA O O
isolated O O
contained O O
an O O
open O B-DNA
reading O I-DNA
frame O I-DNA
encoding O O
108 O O
amino O O
acid O O
residues O O
. O O

The O O
first O O
40 O O
residues O O
of O O
the O O
deduced O O
amino O O
acid O O
sequence O O
were O O
identical O O
to O O
those O O
of O O
the O O
reported O O
amino O O
- O O
terminal O O
sequence O O
of O O
bovine O O
FKBP O O
, O O
indicating O O
that O O
the O O
DNA O B-DNA
sequence O I-DNA
isolated O O
represents O O
the O O
gene O O
coding O O
for O O
FKBP O O
. O O

Computer O O
- O O
assisted O O
analysis O O
of O O
the O O
deduced O O
amino O O
acid O O
sequence O O
indicates O O
that O O
FKBP O O
exhibits O O
no O O
internal O O
homology O O
and O O
does O O
not O O
have O O
significant O O
sequence O O
similarity O O
to O O
any O O
other O O
amino O O
acid O O
sequences O O
of O O
known O O
proteins O O
, O O
including O O
cyclophilin O O
. O O

This O O
result O O
suggests O O
that O O
two O O
catalytically O O
similar O O
proteins O O
, O O
cyclophilin O O
and O O
FKBP O O
, O O
evolved O O
independently O O
. O O

In O O
Northern O O
blot O O
analysis O O
, O O
mRNA O O
species O O
of O O
approximately O O
1 O O
. O O
8 O O
kilobases O O
that O O
hybridized O O
with O O
human B-DNA B-DNA
FKBP I-DNA I-DNA
cDNA I-DNA I-DNA
were O O
detected O O
in O O
poly O O
( O O
A O O
) O O
+ O O
RNAs O O
from O O
brain O O
, O O
lung O O
, O O
liver O O
, O O
and O O
placental O O
cells O O
and O O
leukocytes O O
. O O

Induction O O
of O O
Jurkat O O
leukemic O O
T O O
cells O O
with O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
and O O
ionomycin O O
did O O
not O O
affect O O
the O O
level O O
of O O
FKBP O O
mRNA O O
. O O

Southern O O
blot O O
analysis O O
of O O
human B-DNA B-DNA
genomic I-DNA I-DNA
DNA I-DNA I-DNA
digested O O
with O O
different O O
restriction O O
enzymes O O
suggests O O
the O O
existence O O
of O O
only O O
a O O
few O O
copies O O
of O O
the O O
DNA O B-DNA
sequence O I-DNA
encoding O O
FKBP O O
. O O

This O O
is O O
in O O
contrast O O
to O O
the O O
result O O
that O O
as O O
many O O
as O O
20 O O
copies O O
of O O
the O O
cyclophilin B-DNA B-DNA
gene I-DNA I-DNA
and O O
possible O O
pseudogenes O B-DNA
may O O
be O O
present O O
in O O
the O O
mammalian B-DNA B-DNA
genome I-DNA I-DNA
. O O

Involvement O O
of O O
a O O
second O O
lymphoid B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
enhancer I-DNA I-DNA
element I-DNA I-DNA
in O O
the O O
regulation O O
of O O
immunoglobulin B-DNA B-DNA
heavy I-DNA I-DNA
- I-DNA I-DNA
chain I-DNA I-DNA
gene I-DNA I-DNA
expression O O
. O O

To O O
determine O O
whether O O
enhancer B-DNA B-DNA
elements I-DNA I-DNA
in O O
addition O O
to O O
the O O
highly O B-DNA
conserved O I-DNA
octamer B-DNA I-DNA
( I-DNA I-DNA
OCTA I-DNA I-DNA
) I-DNA I-DNA
- I-DNA I-DNA
nucleotide I-DNA I-DNA
motif I-DNA I-DNA
are O O
important O O
for O O
lymphoid O O
- O O
specific O O
expression O O
of O O
the O O
immunoglobulin B-DNA B-DNA
heavy I-DNA I-DNA
- I-DNA I-DNA
chain I-DNA I-DNA
( I-DNA I-DNA
IgH I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
, O O
we O O
have O O
investigated O O
the O O
effect O O
of O O
mutating O O
the O O
binding B-DNA B-DNA
site I-DNA I-DNA
for O O
a O O
putative O O
additional O O
lymphoid O O
- O O
specific O O
transcription O O
factor O O
, O O
designated O O
NF O B-DNA
- O I-DNA
microB O I-DNA
, O O
in O O
the O O
murine B-DNA B-DNA
IgH I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

We O O
demonstrate O O
that O O
the O O
NF B-DNA B-DNA
- I-DNA I-DNA
microB I-DNA I-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
plays O O
a O O
critical O O
role O O
in O O
the O O
IgH B-DNA B-DNA
enhancer I-DNA I-DNA
, O O
because O O
mutation O O
of O O
the O O
microB O B-DNA
DNA O I-DNA
motif O I-DNA
decreased O O
transcriptional O O
activity O O
of O O
the O O
IgH B-DNA B-DNA
enhancer I-DNA I-DNA
in O O
cells O O
of O O
the O O
B O O
- O O
cell O O
lineage O O
but O O
not O O
in O O
nonlymphoid O O
cells O O
. O O

This O O
effect O O
was O O
comparable O O
to O O
or O O
even O O
stronger O O
than O O
the O O
effect O O
of O O
a O O
mutation O O
in O O
the O O
OCTA B-DNA B-DNA
site I-DNA I-DNA
. O O

Moreover O O
, O O
combined O O
mutation O O
of O O
both O O
microB B-DNA O
and O O
OCTA B-DNA O
sites I-DNA O
further O O
reduced O O
enhancer O O
activity O O
in O O
lymphoid O O
cells O O
. O O

Interestingly O O
, O O
alteration O O
of O O
either O O
the O O
microB B-DNA B-DNA
or O O
E3 B-DNA B-DNA
site I-DNA I-DNA
in O O
a O O
70 B-DNA B-DNA
- I-DNA I-DNA
base I-DNA I-DNA
- I-DNA I-DNA
pair I-DNA I-DNA
fragment I-DNA I-DNA
of O O
the O O
IgH B-DNA B-DNA
enhancer I-DNA I-DNA
that O O
lacks O O
the O O
binding O B-DNA
site O I-DNA
for O O
OCTA O O
abolished O O
enhancer O O
activity O O
in O O
lymphoid O O
cells O O
completely O O
. O O

Nevertheless O O
, O O
a O O
multimer O O
of O O
the O O
microB B-DNA B-DNA
motif I-DNA I-DNA
alone O O
showed O O
no O O
enhancer O O
activity O O
. O O

DNase O O
footprinting O O
analysis O O
corroborated O O
the O O
functional O O
data O O
showing O O
that O O
a O O
lymphoid O O
- O O
specific O O
protein O O
binds O O
to O O
the O O
microB B-DNA B-DNA
DNA I-DNA I-DNA
motif I-DNA I-DNA
. O O

Our O O
results O O
suggest O O
that O O
the O O
microB B-DNA B-DNA
element I-DNA I-DNA
is O O
a O O
new O O
crucial O O
element O O
important O O
for O O
lymphoid O O
- O O
specific O O
expression O O
of O O
the O O
IgH O B-DNA
gene O I-DNA
but O O
that O O
interaction O O
with O O
another O O
enhancer B-DNA B-DNA
element I-DNA I-DNA
is O O
essential O O
for O O
its O O
activity O O
. O O

Stimulation O O
of O O
the O O
human O B-DNA
immunodeficiency O I-DNA
virus O I-DNA
type O I-DNA
2 O I-DNA
( O I-DNA
HIV O I-DNA
- O I-DNA
2 O I-DNA
) O I-DNA
gene O I-DNA
expression O O
by O O
the O O
cytomegalovirus O O
and O O
HIV B-DNA O
- I-DNA O
2 I-DNA O
transactivator I-DNA O
gene I-DNA O
. O O

Human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
often O O
causes O O
latent O O
infection O O
. O O

Transactivation O O
by O O
some O O
DNA O O
viruses O O
has O O
been O O
implicated O O
in O O
inducing O O
HIV O O
- O O
1 O O
replication O O
and O O
pathogenesis O O
. O O

The O O
transactivator B-DNA B-DNA
( I-DNA I-DNA
IE I-DNA I-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
of O O
the O O
human O O
cytomegalovirus O O
( O O
CMV O O
) O O
can O O
enhance O O
HIV O O
- O O
2 O O
as O O
well O O
as O O
HIV O O
- O O
1 O O
gene O O
expression O O
in O O
vitro O O
. O O

This O O
inducer O O
can O O
act O O
in O O
concert O O
with O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
tat I-DNA I-DNA
gene I-DNA I-DNA
and O O
T O O
- O O
cell O O
activation O O
in O O
enhancing O O
gene O O
expression O O
in O O
human O O
CD4 O O
+ O O
lymphocytes O O
. O O

While O O
the O O
HIV O O
- O O
2 O O
and O O
HIV B-DNA O
- I-DNA O
1 I-DNA O
tat I-DNA O
genes I-DNA O
and O O
T O O
- O O
cell O O
activators O O
apparently O O
employ O O
independent O O
modes O O
of O O
action O O
, O O
the O O
CMV B-DNA O
transactivator I-DNA O
in O O
combination O O
with O O
the O O
HIV B-DNA O
- I-DNA O
2 I-DNA O
tat I-DNA O
or O O
T O O
- O O
cell O O
activators O O
may O O
employ O O
a O O
gene O O
activation O O
pathway O O
with O O
some O O
common O O
and O O
some O O
distinct O O
components O O
. O O

Both O O
HIV O O
- O O
2 O O
and O O
CMV B-DNA O
transactivators I-DNA O
enhance O O
HIV O O
- O O
2 O O
gene O O
expression O O
by O O
transcriptional O O
activation O O
involving O O
transcript O O
initiation O O
as O O
well O O
as O O
elongation O O
, O O
with O O
CMV B-DNA O
transactivator I-DNA O
affecting O O
elongation O O
more O O
than O O
the O O
initiation O O
. O O

A O O
significant O O
proportion O O
of O O
transcripts O O
appear O O
to O O
terminate O O
prematurely O O
in O O
the O O
absence O O
of O O
transactivators O O
. O O

Deletion O O
mutation O O
analysis O O
of O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
suggests O O
that O O
the O O
element O O
that O O
responds O O
to O O
CMV O O
transactivation O O
in O O
human O O
CD4 O O
+ O O
lymphocytes O O
is O O
either O O
a O O
diffuse O O
one O O
or O O
located O O
downstream O O
of O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
enhancer I-DNA I-DNA
element I-DNA I-DNA
. O O

Quantitative O O
immunohistochemical O O
analysis O O
of O O
mononuclear O O
infiltrates O O
in O O
breast O O
carcinomas O O
- O O
- O O
correlation O O
with O O
tumour O O
differentiation O O
. O O

Inflammatory O O
infiltrates O O
were O O
analysed O O
in O O
tissue O O
sections O O
of O O
76 O O
breast O O
carcinomas O O
by O O
counting O O
the O O
percentage O O
of O O
macrophages O O
, O O
IgA O O
+ O O
and O O
IgG O O
+ O O
plasma O O
cells O O
, O O
T O O
cells O O
with O O
their O O
subpopulations O O
, O O
and O O
natural O O
killer O O
cells O O
, O O
and O O
by O O
measuring O O
postcapillary O O
venules O O
( O O
PCVs O O
, O O
found O O
in O O
12 O O
cases O O
) O O
within O O
the O O
infiltrates O O
. O O

These O O
parameters O O
were O O
correlated O O
with O O
nuclear O O
grade O O
and O O
biochemically O O
determined O O
hormone O O
receptor O O
status O O
, O O
known O O
markers O O
of O O
tumour O O
differentiation O O
. O O

A O O
direct O O
correlation O O
was O O
found O O
between O O
the O O
extent O O
of O O
inflammation O O
and O O
nuclear O O
grade O O
( O O
P O O
less O O
than O O
0 O O
. O O
0001 O O
) O O
, O O
and O O
an O O
inverse O O
correlation O O
between O O
inflammation O O
and O O
oestrogen O O
receptor O O
( O O
OR O O
) O O
positivity O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
as O O
well O O
as O O
inflammation O O
and O O
progesterone O O
receptor O O
( O O
PR O O
) O O
positivity O O
( O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

The O O
percentage O O
of O O
the O O
OKT8 O O
+ O O
suppressor O O
/ O O
cytotoxic O O
T O O
cells O O
increased O O
when O O
the O O
inflammation O O
expanded O O
from O O
scanty O O
to O O
moderate O O
( O O
P O O
less O O
than O O
0 O O
. O O
02 O O
) O O
. O O

The O O
diameter O O
of O O
the O O
PCVs O O
also O O
increased O O
with O O
increasing O O
inflammatory O O
infiltrate O O
( O O
P O O
less O O
than O O
0 O O
. O O
02 O O
) O O
. O O

In O O
addition O O
, O O
a O O
direct O O
correlation O O
exists O O
between O O
the O O
diameter O O
of O O
the O O
PCVs O O
and O O
both O O
the O O
percentage O O
of O O
the O O
OKT8 O O
+ O O
T O O
cells O O
( O O
P O O
less O O
than O O
0 O O
. O O
04 O O
) O O
and O O
the O O
Leu O O
- O O
7 O O
+ O O
natural O O
killer O O
cells O O
( O O
P O O
less O O
than O O
0 O O
. O O
03 O O
) O O
. O O

Reactivity O O
of O O
lymphocytes O O
to O O
a O O
progesterone O O
receptor O O
- O O
specific O O
monoclonal O O
antibody O O
. O O

In O O
this O O
study O O
we O O
present O O
evidence O O
for O O
reactivity O O
of O O
pregnancy O O
lymphocytes O O
, O O
but O O
not O O
nonpregnancy O O
lymphocytes O O
, O O
with O O
the O O
progesterone O O
receptor O O
- O O
specific O O
monoclonal O O
antibody O O
mPRI O O
. O O

Using O O
an O O
avidin O O
- O O
biotin O O
peroxidase O O
detection O O
system O O
, O O
we O O
found O O
a O O
nuclear O O
staining O O
in O O
14 O O
. O O
6 O O
+ O O
/ O O
- O O
3 O O
. O O
7 O O
% O O
( O O
mean O O
+ O O
/ O O
- O O
SEM O O
, O O
N O O
= O O
27 O O
) O O
of O O
pregnancy O O
lymphocytes O O
, O O
while O O
only O O
0 O O
. O O
47 O O
+ O O
/ O O
- O O
0 O O
. O O
33 O O
% O O
( O O
mean O O
+ O O
/ O O
- O O
SEM O O
, O O
N O O
= O O
15 O O
) O O
of O O
nonpregnancy O O
lymphocytes O O
reacted O O
with O O
the O O
antibody O O
. O O

To O O
characterize O O
the O O
receptor O O
- O O
bearing O O
subset O O
, O O
CD8 O O
+ O O
and O O
CD4 O O
+ O O
cells O O
were O O
depleted O O
by O O
complement O O
- O O
dependent O O
lysis O O
. O O

Depletion O O
of O O
CD8 O O
+ O O
cells O O
was O O
accompanied O O
by O O
62 O O
+ O O
/ O O
- O O
18 O O
% O O
loss O O
of O O
progesterone O O
receptor O O
- O O
bearing O O
cells O O
, O O
while O O
depletion O O
of O O
CD4 O O
+ O O
cells O O
resulted O O
in O O
a O O
twofold O O
increase O O
in O O
the O O
number O O
of O O
positively O O
staining O O
lymphocytes O O
. O O

In O O
nonpregnancy O O
lymphocytes O O
a O O
3 O O
- O O
day O O
PHA O O
treatment O O
, O O
as O O
well O O
as O O
allogeneic O O
stimulation O O
, O O
resulted O O
in O O
a O O
significant O O
increase O O
in O O
the O O
number O O
of O O
receptor O O
- O O
containing O O
cells O O
. O O

These O O
results O O
suggest O O
that O O
pregnancy O O
, O O
but O O
not O O
nonpregnancy O O
, O O
lymphocytes O O
contain O O
progesterone O O
binding O O
structures O O
, O O
and O O
that O O
these O O
are O O
inducible O O
by O O
mitogenic O O
or O O
alloantigenic O O
stimuli O O
. O O

Activation O O
of O O
human O O
CD4 O O
T O O
lymphocytes O O
. O O

Interaction O O
of O O
fibronectin O O
with O O
VLA O O
- O O
5 O O
receptor O O
on O O
CD4 O O
cells O O
induces O O
the O O
AP O O
- O O
1 O O
transcription O O
factor O O
. O O

Fibronectin O O
synergized O O
with O O
anti O O
- O O
CD3 O O
antibody O O
to O O
promote O O
CD4 O O
cell O O
proliferation O O
in O O
a O O
serum O O
- O O
free O O
culture O O
system O O
whereas O O
no O O
proliferation O O
was O O
observed O O
when O O
CD4 O O
cells O O
were O O
cultured O O
with O O
anti O O
- O O
CD3 O O
alone O O
or O O
fibronectin O O
alone O O
. O O

In O O
addition O O
, O O
anti O O
- O O
CD29 O O
( O O
integrin O O
beta O O
1 O O
) O O
as O O
well O O
as O O
anti O O
- O O
VLA O O
- O O
5 O O
( O O
human O O
fibronectin O O
receptor O O
) O O
antibodies O O
blocked O O
this O O
CD4 O O
cell O O
activation O O
in O O
this O O
system O O
. O O

Although O O
anti O O
- O O
CD3 O O
alone O O
or O O
fibronectin O O
alone O O
cannot O O
induce O O
IL O O
- O O
2 O O
message O O
by O O
CD4 O O
cells O O
, O O
the O O
combination O O
of O O
anti O O
- O O
CD3 O O
plus O O
fibronectin O O
induced O O
IL O O
- O O
2 O O
message O O
by O O
CD4 O O
cells O O
. O O

In O O
an O O
analysis O O
of O O
the O O
molecular O O
mechanism O O
by O O
which O O
IL O O
- O O
2 O O
message O O
was O O
generated O O
, O O
we O O
showed O O
that O O
a O O
fibronectin O O
- O O
VLA O O
- O O
5 O O
fibronectin O O
receptor O O
interaction O O
may O O
contribute O O
an O O
independent O O
signal O O
distinct O O
from O O
the O O
CD3 O O
pathway O O
of O O
activation O O
by O O
the O O
induction O O
of O O
an O O
AP O O
- O O
1 O O
transcriptional O O
factor O O
. O O

Thus O O
the O O
VLA O O
- O O
5 O O
fibronectin O O
receptor O O
on O O
CD4 O O
cells O O
can O O
play O O
a O O
complementary O O
role O O
in O O
CD3 O O
- O O
TCR O O
- O O
mediated O O
signal O O
transduction O O
through O O
its O O
interaction O O
with O O
fibronectin O O
. O O

Glucocorticoid O O
receptors O O
on O O
mononuclear O O
leukocytes O O
in O O
Alzheimer O O
' O O
s O O
disease O O
. O O

Several O O
lines O O
of O O
evidence O O
suggest O O
disturbances O O
of O O
the O O
hypothalamic O O
- O O
pituitary O O
- O O
adrenal O O
( O O
HPA O O
) O O
system O O
in O O
Alzheimer O O
' O O
s O O
disease O O
( O O
AD O O
) O O
. O O

In O O
an O O
exploration O O
of O O
the O O
potential O O
role O O
of O O
the O O
glucocorticoid O O
receptor O O
( O O
GR O O
) O O
in O O
AD O O
, O O
GR O O
density O O
and O O
affinity O O
were O O
assessed O O
on O O
mononuclear O O
leukocytes O O
of O O
12 O O
AD O O
patients O O
and O O
12 O O
healthy O O
controls O O
. O O

GR O O
binding O O
characteristics O O
did O O
not O O
differ O O
between O O
patients O O
and O O
controls O O
or O O
between O O
patients O O
subdivided O O
according O O
to O O
diagnosis O O
or O O
associated O O
clinical O O
features O O
. O O

These O O
data O O
suggest O O
that O O
the O O
abnormalities O O
of O O
the O O
HPA O O
system O O
in O O
AD O O
are O O
not O O
related O O
to O O
a O O
GR O O
deficiency O O
. O O

Oncogene O O
amplification O O
correlates O O
with O O
dense O O
lymphocyte O O
infiltration O O
in O O
human O O
breast O O
cancers O O
: O O
a O O
role O O
for O O
hematopoietic O O
growth O O
factor O O
release O O
by O O
tumor O O
cells O O
? O O
. O O

One O O
hundred O O
six O O
primary O O
breast O O
cancer O O
samples O O
were O O
analysed O O
for O O
c O O
- O O
erbB2 O O
, O O
int O O
- O O
2 O O
, O O
and O O
c O O
- O O
myc O O
gene O O
amplification O O
. O O

Surgically O O
confirmed O O
nodal O O
involvement O O
was O O
observed O O
in O O
42 O O
% O O
. O O

Level O O
of O O
gene O O
amplification O O
was O O
studied O O
by O O
Southern O O
and O O
/ O O
or O O
slot O O
blot O O
techniques O O
. O O

Amplified O O
c B-DNA B-DNA
- I-DNA I-DNA
erbB2 I-DNA I-DNA
gene I-DNA I-DNA
sequences I-DNA I-DNA
were O O
present O O
in O O
21 O O
. O O
5 O O
% O O
of O O
all O O
samples O O
. O O

Int B-DNA O
- I-DNA O
2 I-DNA O
was O O
amplified O O
in O O
13 O O
. O O
1 O O
% O O
and O O
c B-DNA B-DNA
- I-DNA I-DNA
myc I-DNA I-DNA
was O O
amplified O O
in O O
10 O O
. O O
3 O O
% O O
. O O

In O O
a O O
non O O
- O O
parametric O O
test O O
( O O
Kruskal O O
- O O
Wallis O O
) O O
a O O
strong O O
negative O O
association O O
was O O
found O O
between O O
high O O
levels O O
of O O
c B-DNA O
- I-DNA O
erbB2 I-DNA O
amplification O O
and O O
absence O O
of O O
estrogen O O
receptor O O
( O O
ER O O
) O O
( O O
P O O
= O O
. O O
0009 O O
) O O
or O O
progesterone O O
receptor O O
( O O
PR O O
) O O
( O O
P O O
= O O
. O O
011 O O
) O O
expression O O
. O O

No O O
correlations O O
were O O
found O O
between O O
all O O
or O O
high O O
levels O O
of O O
amplification O O
of O O
each O O
oncogene O B-DNA
separately O O
or O O
combined O O
with O O
T O O
, O O
N O O
, O O
grade O O
, O O
multifocality O O
of O O
tumor O O
, O O
or O O
associated O O
carcinoma O O
in O O
situ O O
. O O

There O O
was O O
a O O
trend O O
approaching O O
statistical O O
significance O O
for O O
patients O O
with O O
c B-DNA O
- I-DNA O
erbB2 I-DNA O
amplifications O O
to O O
have O O
positive O O
lymph O O
nodes O O
at O O
surgery O O
( O O
P O O
= O O
0 O O
. O O
09 O O
) O O
. O O

A O O
somewhat O O
surprising O O
finding O O
however O O
was O O
a O O
very O O
strong O O
association O O
between O O
oncogene B-DNA B-DNA
amplification O O
and O O
dense O O
lymphocyte O O
infiltration O O
of O O
the O O
tumor O O
( O O
P O O
= O O
. O O
05 O O
) O O
. O O
This O O
correlation O O
is O O
even O O
stronger O O
when O O
only O O
high O O
levels O O
of O O
amplification O O
are O O
considered O O
, O O
either O O
for O O
each O O
oncogene O B-DNA
separately O O
( O O
P O O
= O O
. O O
0048 O O
) O O
or O O
in O O
combination O O
( O O
P O O
= O O
. O O
0007 O O
) O O
. O O

We O O
propose O O
that O O
malignant O O
cell O O
cytokine O O
production O O
may O O
help O O
explain O O
this O O
observation O O
. O O

Suppression O O
of O O
signals O O
required O O
for O O
activation O O
of O O
transcription O O
factor O O
NF O O
- O O
kappa O O
B O O
in O O
cells O O
constitutively O O
expressing O O
the O O
HTLV O O
- O O
I O O
Tax O O
protein O O
. O O

Transient O O
short O O
- O O
term O O
expression O O
of O O
the O O
Tax O O
protein O O
of O O
human O O
T O O
- O O
cell O O
leukemia O O
virus O O
type O O
- O O
I O O
( O O
HTLV O O
- O O
I O O
) O O
leads O O
to O O
activation O O
of O O
the O O
pleiotropic O O
transcription O O
factor O O
NF O O
- O O
kappa O O
B O O
. O O

Consistent O O
with O O
findings O O
obtained O O
with O O
transient O O
expression O O
assays O O
, O O
we O O
observed O O
marked O O
accumulation O O
of O O
the O O
transcription O O
factor O O
NF O O
- O O
kappa O O
B O O
in O O
the O O
nucleus O O
of O O
Namalwa O O
B O O
lymphoid O O
cells O O
, O O
which O O
constitutively O O
express O O
Tax O O
. O O

In O O
contrast O O
, O O
NF O O
- O O
kappa O O
B O O
activity O O
was O O
not O O
detected O O
in O O
the O O
nucleus O O
following O O
long O O
- O O
term O O
expression O O
of O O
Tax O O
in O O
Jurkat O O
T O O
lymphocytes O O
. O O

The O O
ability O O
of O O
both O O
mitogens O O
and O O
cytokines O O
to O O
activate O O
NF O O
- O O
kappa O O
B O O
was O O
also O O
blocked O O
in O O
Jurkat O O
cells O O
constitutively O O
expressing O O
Tax O O
. O O

However O O
, O O
the O O
activation O O
of O O
other O O
mitogen O O
- O O
inducible O O
transcription O O
factors O O
, O O
such O O
as O O
Fos O O
and O O
Jun O O
, O O
was O O
unaffected O O
. O O

Thus O O
, O O
depending O O
on O O
the O O
cellular O O
environment O O
, O O
the O O
short O O
- O O
and O O
long O O
- O O
term O O
effects O O
of O O
Tax O O
expression O O
can O O
be O O
quite O O
different O O
. O O

Consequently O O
, O O
one O O
function O O
of O O
Tax O O
in O O
cells O O
infected O O
with O O
HTLV O O
- O O
I O O
might O O
involve O O
cell O O
- O O
type O O
- O O
specific O O
suppression O O
, O O
as O O
opposed O O
to O O
activation O O
, O O
of O O
distinct O O
signal O O
pathways O O
. O O

The O O
cells O O
lines O O
described O O
here O O
should O O
be O O
useful O O
for O O
the O O
delineation O O
of O O
signaling O O
pathways O O
utilized O O
in O O
the O O
selective O O
regulation O O
of O O
gene O O
expression O O
. O O

Interferon O O
- O O
gamma O O
and O O
the O O
sexual O O
dimorphism O O
of O O
autoimmunity O O
. O O

The O O
sexual O O
difference O O
in O O
the O O
incidence O O
of O O
autoimmune O O
diseases O O
has O O
remained O O
an O O
enigma O O
for O O
many O O
years O O
. O O

In O O
the O O
examination O O
of O O
the O O
induction O O
of O O
autoimmunity O O
in O O
transgenic O O
mice O O
, O O
evidence O O
has O O
been O O
obtained O O
further O O
implicating O O
the O O
lymphokine O O
interferon O O
- O O
gamma O O
in O O
the O O
etiology O O
of O O
autoimmunity O O
. O O

Sex O O
steroid O O
regulation O O
of O O
the O O
production O O
of O O
this O O
molecule O O
, O O
as O O
well O O
as O O
other O O
cytokines O O
, O O
may O O
help O O
explain O O
the O O
gender O O
- O O
specific O O
differences O O
in O O
the O O
immune O O
system O O
, O O
including O O
autoimmunity O O
. O O

Cloning O O
of O O
a O O
transcriptionally O O
active O O
human O O
TATA O O
binding O O
factor O O
. O O

Transcription O O
factor O O
IID O O
( O O
TFIID O O
) O O
binds O O
to O O
the O O
TATA B-DNA B-DNA
box I-DNA I-DNA
promoter I-DNA I-DNA
element I-DNA I-DNA
and O O
regulates O O
the O O
expression O O
of O O
most O O
eukaryotic B-DNA B-DNA
genes I-DNA I-DNA
transcribed O O
by O O
RNA O O
polymerase O O
II O O
. O O

Complementary B-DNA B-DNA
DNA I-DNA I-DNA
( O O
cDNA B-DNA B-DNA
) O O
encoding O O
a O O
human O O
TFIID O O
protein O O
has O O
been O O
cloned O O
. O O

The O O
human O O
TFIID O O
polypeptide O O
has O O
339 O O
amino O O
acids O O
and O O
a O O
molecular O O
size O O
of O O
37 O O
, O O
745 O O
daltons O O
. O O

The O O
carboxyl O O
- O O
terminal O O
181 O O
amino O O
acids O O
of O O
the O O
human O O
TFIID O O
protein O O
shares O O
80 O O
% O O
identity O O
with O O
the O O
TFIID O O
protein O O
from O O
Saccharomyces O O
cerevisiae O O
. O O

The O O
amino O O
terminus O O
contains O O
an O O
unusual O O
repeat O O
of O O
38 O O
consecutive O O
glutamine O O
residues O O
and O O
an O O
X O O
- O O
Thr O O
- O O
Pro O O
repeat O O
. O O

Expression O O
of O O
DNA B-DNA O
in O O
reticulocyte O O
lysates O O
or O O
in O O
Escherichia O O
coli O O
yielded O O
a O O
protein O O
that O O
was O O
competent O O
for O O
both O O
DNA O O
binding O O
and O O
transcription O O
activation O O
. O O

A O O
novel O O
T O O
- O O
cell O O
trans O O
- O O
activator O O
that O O
recognizes O O
a O O
phorbol B-DNA B-DNA
ester I-DNA I-DNA
- I-DNA I-DNA
inducible I-DNA I-DNA
element I-DNA I-DNA
of O O
the O O
interleukin B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
promoter I-DNA I-DNA
. O O

The O O
interleukin B-DNA B-DNA
2 I-DNA I-DNA
( I-DNA I-DNA
IL I-DNA I-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
is O O
recognized O O
by O O
several O O
cell O O
- O O
type O O
- O O
specific O O
and O O
ubiquitous O O
transcriptional O O
regulators O O
that O O
integrate O O
information O O
transmitted O O
by O O
various O O
signaling O O
systems O O
leading O O
to O O
IL O O
- O O
2 O O
production O O
and O O
T O O
- O O
cell O O
activation O O
. O O

Using O O
a O O
combination O O
of O O
transfection O O
, O O
protein O O
- O O
DNA O O
binding O O
, O O
and O O
in O O
vitro O O
transcription O O
methods O O
, O O
we O O
have O O
discovered O O
the O O
novel O O
T O O
- O O
cell O O
- O O
specific O O
transcriptional O O
activator O O
TCF O O
- O O
1 O O
( O O
for O O
T O O
- O O
Cell O O
Factor O O
- O O
1 O O
) O O
, O O
which O O
recognizes O O
a O O
T B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
( O O
TCE B-DNA B-DNA
) O O
located O O
within O O
the O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Although O O
the O O
TCE B-DNA B-DNA
is O O
similar O O
in O O
sequence O O
to O O
a O O
consensus B-DNA B-DNA
NF I-DNA I-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
site I-DNA I-DNA
, O O
several O O
criteria O O
indicate O O
that O O
TCF O O
- O O
1 O O
is O O
distinct O O
from O O
NF O O
kappa O O
B O O
. O O

However O O
, O O
like O O
NF O O
kappa O O
B O O
, O O
TCF O O
- O O
1 O O
activity O O
is O O
induced O O
by O O
phorbol O O
esters O O
and O O
other O O
T O O
- O O
cell O O
activators O O
. O O

Risk O O
factors O O
for O O
breast O O
recurrence O O
in O O
premenopausal O O
and O O
postmenopausal O O
patients O O
with O O
ductal O O
cancers O O
treated O O
by O O
conservation O O
therapy O O
. O O

Risk O O
factors O O
for O O
local O O
failure O O
were O O
evaluated O O
for O O
496 O O
clinical O O
Stage O O
I O O
- O O
II O O
patients O O
with O O
infiltrating O O
ductal O O
carcinomas O O
( O O
median O O
follow O O
- O O
up O O
, O O
71 O O
months O O
) O O
treated O O
by O O
conservative O O
surgery O O
and O O
radiotherapy O O
. O O

Monofactorial O O
analysis O O
identified O O
the O O
following O O
factors O O
to O O
be O O
correlated O O
with O O
increased O O
risk O O
: O O
moderate O O
/ O O
marked O O
mononuclear O O
cell O O
reaction O O
( O O
MCR O O
) O O
, O O
high O O
histologic O O
grade O O
( O O
G O O
) O O
, O O
extensive O O
intraductal O O
component O O
( O O
EIC O O
) O O
, O O
tumor O O
necrosis O O
, O O
macroscopic O O
multiplicity O O
, O O
estrogen O O
receptor O O
negativity O O
, O O
anatomic O O
tumor O O
size O O
, O O
age O O
younger O O
than O O
40 O O
years O O
, O O
and O O
vascular O O
invasion O O
. O O

Only O O
MCR O O
, O O
G O O
, O O
and O O
EIC O O
proved O O
significant O O
in O O
Cox O O
multivariate O O
analysis O O
. O O

These O O
risk O O
factors O O
were O O
highly O O
age O O
dependent O O
, O O
with O O
EIC O O
markedly O O
more O O
prevalent O O
in O O
women O O
younger O O
than O O
50 O O
, O O
MCR O O
and O O
G O O
in O O
women O O
younger O O
than O O
40 O O
. O O

Separate O O
Cox O O
analysis O O
for O O
premenopausal O O
patients O O
showed O O
that O O
MCR O O
/ O O
EIC O O
determined O O
risk O O
independent O O
of O O
resection O O
margins O O
: O O
tumors O O
with O O
MCR O O
had O O
a O O
28 O O
% O O
, O O
and O O
with O O
EIC O O
a O O
22 O O
% O O
probability O O
of O O
recurring O O
locally O O
by O O
5 O O
years O O
. O O

Premenopausal O O
patients O O
with O O
neither O O
risk O O
factor O O
had O O
a O O
very O O
low O O
failure O O
rate O O
( O O
2 O O
. O O
6 O O
% O O
at O O
5 O O
years O O
) O O
, O O
regardless O O
of O O
age O O
. O O

For O O
postmenopausal O O
patients O O
risk O O
of O O
breast O O
recurrence O O
was O O
determined O O
both O O
by O O
adequacy O O
of O O
resection O O
margins O O
and O O
grade O O
, O O
with O O
a O O
high O O
local O O
failure O O
rate O O
for O O
patients O O
having O O
G3 O O
tumors O O
with O O
positive O O
or O O
indeterminate O O
margins O O
( O O
31 O O
% O O
at O O
5 O O
years O O
) O O
. O O

The O O
authors O O
conclude O O
that O O
the O O
microscopic O O
examination O O
is O O
the O O
only O O
useful O O
tool O O
for O O
assessing O O
the O O
risk O O
of O O
local O O
failure O O
, O O
which O O
is O O
quite O O
low O O
for O O
the O O
majority O O
of O O
patients O O
treated O O
with O O
breast O O
conservation O O
. O O

High O O
- O O
risk O O
patients O O
can O O
be O O
recognized O O
morphologically O O
. O O

The O O
age O O
dependence O O
of O O
morphologic O O
risk O O
factors O O
appears O O
to O O
explain O O
the O O
high O O
local O O
failure O O
rate O O
seen O O
in O O
patients O O
younger O O
than O O
40 O O
. O O

Tax O O
- O O
independent O O
binding O O
of O O
multiple O O
cellular O O
factors O O
to O O
Tax B-DNA B-DNA
- I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
DNA I-DNA I-DNA
of O O
HTLV O O
- O O
I O O
. O O

The O O
human B-DNA B-DNA
T I-DNA I-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
leukemia I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
I I-DNA I-DNA
( I-DNA I-DNA
HTLV I-DNA I-DNA
- I-DNA I-DNA
I I-DNA I-DNA
) I-DNA I-DNA
promoter I-DNA I-DNA
contains O O
three O O
copies O O
of O O
imperfect O O
repeats O O
of O O
a O O
21 O B-DNA
- O I-DNA
base O I-DNA
pair O I-DNA
sequence O I-DNA
designated O O
here O O
as O O
TRE B-DNA B-DNA
( O O
Tax B-DNA B-DNA
- I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
) O O
that O O
is O O
responsive O O
to O O
the O O
virally O O
encoded O O
transactivator O O
protein O O
Tax O O
. O O

We O O
have O O
identified O O
and O O
separated O O
four O O
nuclear O O
proteins O O
from O O
C81 O O
- O O
66 O O
- O O
45 O O
cells O O
, O O
an O O
HTLV O O
- O O
I O O
immortalized O O
Tax O O
- O O
expressing O O
human O O
T O O
- O O
lymphocyte O O
line O O
( O O
Salahuddin O O
et O O
al O O
. O O
, O O
1983 O O
) O O
, O O
that O O
interact O O
with O O
the O O
TRE B-DNA B-DNA
- I-DNA I-DNA
DNA I-DNA I-DNA
, O O
none O O
of O O
which O O
are O O
identical O O
with O O
the O O
Tax O O
- O O
protein O O
. O O

The O O
proteins O O
identified O O
have O O
molecular O O
weights O O
of O O
about O O
32 O O
, O O
36 O O
to O O
42 O O
, O O
50 O O
and O O
110 O O
kD O O
. O O

Four O O
different O O
methods O O
were O O
used O O
to O O
identify O O
the O O
proteins O O
. O O

First O O
, O O
from O O
different O O
cell O O
lines O O
three O O
or O O
all O O
four O O
of O O
the O O
nuclear O O
proteins O O
were O O
specifically O O
cross O O
- O O
linked O O
by O O
UV O O
irradiation O O
to O O
the O O
radioactively O O
labeled O O
TRE B-DNA B-DNA
- I-DNA I-DNA
DNA I-DNA I-DNA
fragment I-DNA I-DNA
. O O

Second O O
, O O
TRE B-DNA B-DNA
- O O
DNA O O
binding O O
proteins O O
sedimented O O
through O O
a O O
glycerol O O
density O O
gradient O O
at O O
rates O O
corresponding O O
to O O
proteins O O
of O O
native O O
molecular O O
weights O O
of O O
35 O O
to O O
50 O O
kD O O
and O O
110 O O
kD O O
. O O

Third O O
, O O
only O O
the O O
50 O O
kD O O
protein O O
was O O
retained O O
on O O
a O O
biotinylated O O
DNA O O
- O O
streptavidin O O
matrix O O
when O O
the O O
DNA O B-DNA
fragment O I-DNA
contained O O
the O O
TRE B-DNA B-DNA
- I-DNA I-DNA
DNA I-DNA I-DNA
. O O

Fourth O O
, O O
extensive O O
purification O O
by O O
several O O
cycles O O
of O O
TRE B-DNA B-DNA
- O O
DNA O O
affinity O O
chromatography O O
resulted O O
in O O
the O O
32 O O
, O O
36 O O
to O O
42 O O
and O O
110 O O
kD O O
proteins O O
and O O
to O O
less O O
extent O O
the O O
50 O O
kD O O
factor O O
. O O

Two O O
abundant O O
proteins O O
of O O
75 O O
and O O
80 O O
kD O O
were O O
competed O O
out O O
by O O
poly O O
[ O O
d O O
( O O
I O O
- O O
C O O
) O O
] O O
in O O
all O O
reactions O O
. O O

The O O
cAMP B-DNA B-DNA
- I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
CRE B-DNA B-DNA
, O O
TGACGTCA O B-DNA
, O O
present O O
in O O
the O O
21 B-DNA B-DNA
base I-DNA I-DNA
- I-DNA I-DNA
pair I-DNA I-DNA
sequence I-DNA I-DNA
, O O
appears O O
to O O
be O O
essential O O
for O O
specific O O
protein O O
- O O
TRE B-DNA B-DNA
- O O
DNA O O
interactions O O
because O O
mutation O O
of O O
the O O
two O O
G O O
' O O
s O O
destroys O O
this O O
complex O O
. O O

This O O
result O O
suggests O O
that O O
the O O
cAMP O O
response O O
element O O
binding O O
protein O O
, O O
CREB O O
, O O
is O O
involved O O
in O O
the O O
protein O O
- O O
TRE B-DNA B-DNA
- O O
DNA O O
complex O O
and O O
in O O
mediating O O
the O O
Tax O O
response O O
. O O

Two O O
distinct O O
transcription O O
factors O O
that O O
bind O O
the O O
immunoglobulin B-DNA B-DNA
enhancer I-DNA I-DNA
microE5 B-DNA I-DNA
/ I-DNA I-DNA
kappa I-DNA I-DNA
2 I-DNA I-DNA
motif I-DNA I-DNA
. O O

Activity O O
of O O
the O O
immunoglobulin O O
heavy O O
and O O
kappa O O
light O O
chain O O
gene O O
enhancers O O
depends O O
on O O
a O O
complex O O
interplay O O
of O O
ubiquitous O O
and O O
developmentally O O
regulated O O
proteins O O
. O O

Two O O
complementary B-DNA B-DNA
DNAs I-DNA I-DNA
were O O
isolated O O
that O O
encode O O
proteins O O
, O O
denoted O O
ITF O O
- O O
1 O O
and O O
ITF O O
- O O
2 O O
, O O
that O O
are O O
expressed O O
in O O
a O O
variety O O
of O O
cell O O
types O O
and O O
bind O O
the O O
microE5 B-DNA B-DNA
/ I-DNA I-DNA
kappa I-DNA I-DNA
2 I-DNA I-DNA
motif I-DNA I-DNA
found O O
in O O
both O O
heavy O O
and O O
kappa O O
light O O
chain O O
enhancers O O
. O O

The O O
complementary B-DNA B-DNA
DNAs I-DNA I-DNA
are O O
the O O
products O O
of O O
distinct O O
genes O O
, O O
yet O O
both O O
ITF O O
- O O
1 O O
and O O
ITF O B-DNA
- O I-DNA
2 O I-DNA
are O O
structurally O O
and O O
functionally O O
similar O O
. O O

The O O
two O O
proteins O O
interact O O
with O O
one O O
another O O
through O O
their O O
putative O O
helix O O
- O O
loop O O
- O O
helix O O
motifs O O
and O O
each O O
possesses O O
a O O
distinct O O
domain O O
that O O
dictates O O
transcription O O
activation O O
. O O

Elevated O O
glucocorticoid O O
receptor O O
concentrations O O
before O O
and O O
after O O
glucocorticoid O O
therapy O O
in O O
peripheral O O
mononuclear O O
leukocytes O O
of O O
patients O O
with O O
atopic O O
dermatitis O O
. O O

The O O
number O O
and O O
affinity O O
of O O
glucocorticoid O B-DNA
binding O I-DNA
sites O I-DNA
in O O
peripheral O O
mononuclear O O
leukocytes O O
of O O
patients O O
with O O
atopic O O
dermatitis O O
( O O
AD O O
) O O
and O O
healthy O O
controls O O
were O O
determined O O
under O O
baseline O O
conditions O O
and O O
after O O
a O O
defined O O
oral O O
glucocorticoid O O
treatment O O
. O O

Patients O O
with O O
AD O O
( O O
n O O
= O O
15 O O
) O O
exhibited O O
significantly O O
more O O
glucocorticoid O O
receptors O O
( O O
GR O O
) O O
per O O
cell O O
than O O
the O O
control O O
group O O
( O O
n O O
= O O
22 O O
) O O
, O O
while O O
the O O
GR O O
affinity O O
did O O
not O O
differ O O
. O O

Methylprednisolone O O
treatment O O
resulted O O
in O O
a O O
significant O O
reduction O O
of O O
the O O
GR O O
sites O O
per O O
cell O O
in O O
the O O
steroid O O
- O O
treated O O
control O O
group O O
( O O
n O O
= O O
10 O O
) O O
in O O
contrast O O
to O O
the O O
patients O O
. O O

The O O
dissociation O O
constant O O
was O O
not O O
affected O O
by O O
methylprednisolone O O
treatment O O
in O O
either O O
group O O
. O O

In O O
view O O
of O O
the O O
therapeutic O O
efficiency O O
of O O
glucocorticoids O O
in O O
AD O O
and O O
findings O O
of O O
abnormal O O
cAMP O O
and O O
cAMP O O
- O O
phosphodiesterase O O
activity O O
, O O
the O O
elevated O O
GR O O
concentrations O O
in O O
AD O O
lend O O
support O O
to O O
the O O
hypothesis O O
of O O
a O O
compensatory O O
GR O O
upregulation O O
due O O
to O O
an O O
insufficient O O
action O O
of O O
endogenous O O
cortisol O O
or O O
to O O
altered O O
cAMP O O
- O O
induced O O
GR O O
expression O O
. O O

The O O
actions O O
of O O
cyclosporin O O
A O O
and O O
FK506 O O
suggest O O
a O O
novel O O
step O O
in O O
the O O
activation O O
of O O
T O O
lymphocytes O O
. O O

Cyclosporin O O
A O O
and O O
FK506 O O
are O O
immunosuppressive O O
compounds O O
that O O
have O O
similar O O
inhibitory O O
effects O O
on O O
the O O
expression O O
of O O
several O O
lymphokines O O
produced O O
by O O
T O O
lymphocytes O O
. O O

Despite O O
their O O
similar O O
effects O O
the O O
drugs O O
bind O O
to O O
two O O
different O O
cytosolic O O
protein O O
, O O
cyclophilin O O
and O O
FKBP O O
respectively O O
, O O
which O O
raises O O
the O O
possibility O O
that O O
they O O
have O O
different O O
modes O O
of O O
action O O
. O O

Using O O
constructs O O
in O O
which O O
mRNA O O
production O O
controlled O O
by O O
a O O
specific O O
transcription O O
factor O O
could O O
be O O
readily O O
measured O O
we O O
found O O
that O O
both O O
cyclosporin O O
A O O
and O O
FK506 O O
completely O O
inhibited O O
transcription O O
activated O O
by O O
NF O O
- O O
AT O O
, O O
NFIL2 O O
A O O
, O O
NFIL2 O O
B O O
and O O
partially O O
inhibited O O
transcription O O
activated O O
by O O
NF O O
kappa O O
B O O
. O O

Cyclosporin O O
A O O
and O O
FK506 O O
inhibited O O
only O O
transcriptional O O
activation O O
that O O
was O O
dependent O O
on O O
Ca2 O O
+ O O
mobilization O O
. O O

However O O
, O O
cyclosporin O O
A O O
and O O
FK506 O O
did O O
not O O
inhibit O O
Ca2 O O
+ O O
mobilization O O
dependent O O
expression O O
of O O
c O B-DNA
- O I-DNA
fos O I-DNA
mRNA O O
indicating O O
that O O
only O O
a O O
subset O O
of O O
signalling O O
pathways O O
regulated O O
by O O
Ca2 O O
+ O O
is O O
sensitive O O
to O O
these O O
drugs O O
. O O

Furthermore O O
, O O
we O O
did O O
not O O
observe O O
any O O
qualitative O O
differences O O
between O O
the O O
effect O O
of O O
cyclosporin O O
A O O
and O O
FK506 O O
on O O
six O O
different O O
transcription O O
factors O O
which O O
suggests O O
that O O
these O O
drugs O O
may O O
interfere O O
with O O
the O O
activity O O
of O O
a O O
novel O O
Ca2 O O
+ O O
dependent O O
step O O
that O O
regulates O O
several O O
transcription O O
factors O O
. O O

The O O
internal O B-DNA
methionine O I-DNA
codons O I-DNA
of O O
human B-DNA B-DNA
T I-DNA I-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
leukemia I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
II I-DNA I-DNA
rex I-DNA I-DNA
gene I-DNA I-DNA
are O O
not O O
required O O
for O O
p24rex O O
production O O
or O O
virus O O
replication O O
and O O
transformation O O
. O O

Human O O
T O O
- O O
cell O O
leukemia O O
virus O O
types O O
I O O
( O O
HTLV O O
- O O
I O O
) O O
and O O
II O O
( O O
HTLV O O
- O O
II O O
) O O
have O O
two O O
nonstructural B-DNA O
trans I-DNA B-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
regulatory I-DNA I-DNA
genes I-DNA I-DNA
, O O
tax B-DNA B-DNA
and O O
rex B-DNA B-DNA
, O O
located O O
in O O
the O O
3 B-DNA B-DNA
' I-DNA I-DNA
region I-DNA I-DNA
of O O
the O O
viral B-DNA B-DNA
genome I-DNA I-DNA
. O O

The O O
tax B-DNA O
gene O O
product O O
( O O
HTLV O O
- O O
I O O
p40tax B-DNA O
and O O
HTLV O O
- O O
II O O
p37tax B-DNA O
) O O
is O O
the O O
transcriptional O O
activator O O
of O O
the O O
viral B-DNA B-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
. O O

The O O
rex B-DNA B-DNA
gene I-DNA I-DNA
encodes O O
two O O
protein O O
products O O
, O O
p27rex O O
/ O O
p21rex O O
and O O
p26rex O O
/ O O
p24rex O O
in O O
HTLV O O
- O O
I O O
and O O
HTLV O O
- O O
II O O
, O O
respectively O O
. O O

Rex O O
acts O O
posttranscriptionally O O
to O O
facilitate O O
accumulation O O
of O O
full O O
- O O
length O O
gag O O
/ O O
pol O O
and O O
singly O O
spliced O O
env O O
mRNA O O
in O O
the O O
cytoplasm O O
of O O
HTLV O O
- O O
infected O O
cells O O
. O O

Previous O O
studies O O
showed O O
that O O
the O O
first O O
ATG O O
of O O
the O O
rex B-DNA B-DNA
gene I-DNA I-DNA
is O O
critical O O
for O O
Rex O O
production O O
and O O
function O O
. O O

The O O
importance O O
of O O
the O O
internal O O
ATGs O O
to O O
Rex O O
function O O
is O O
not O O
known O O
. O O

However O O
, O O
in O O
vitro O O
mutagenesis O O
of O O
the O O
HTLV O B-DNA
- O I-DNA
I O I-DNA
rex B-DNA I-DNA
gene I-DNA I-DNA
has O O
provided O O
indirect O O
evidence O O
which O O
suggests O O
that O O
p21rex O O
, O O
and O O
by O O
analogy O O
HTLV O O
- O O
II O O
p24rex O O
, O O
results O O
from O O
initiation O O
at O O
an O O
internal O B-DNA
AUG O I-DNA
of O O
the O O
tax B-DNA O
/ B-DNA O
rex I-DNA O
mRNA O O
. O O

By O O
using O O
an O O
infectious O O
molecular O O
clone O O
of O O
HTLV O O
- O O
II O O
, O O
we O O
investigated O O
the O O
importance O O
of O O
the O O
internal O O
ATGs O O
of O O
the O O
rex B-DNA B-DNA
gene I-DNA I-DNA
on O O
Rex O O
protein O O
production O O
and O O
function O O
. O O

Our O O
results O O
indicate O O
that O O
p24rex O O
of O O
HTLV O O
- O O
II O O
is O O
not O O
initiated O O
at O O
an O O
internal O O
AUG O B-DNA
and O O
that O O
the O O
internal O B-DNA
methionine O I-DNA
codons O I-DNA
are O O
not O O
crucial O O
to O O
the O O
function O O
of O O
the O O
rex B-DNA B-DNA
gene I-DNA I-DNA
and O O
, O O
ultimately O O
, O O
the O O
transforming O O
properties O O
of O O
the O O
virus O O
. O O

Astrocytes O O
and O O
glioblastoma O O
cells O O
express O O
novel O O
octamer O O
- O O
DNA O O
binding O O
proteins O O
distinct O O
from O O
the O O
ubiquitous O O
Oct O O
- O O
1 O O
and O O
B O O
cell O O
type O O
Oct O O
- O O
2 O O
proteins O O
. O O

The O O
' B-DNA B-DNA
octamer I-DNA I-DNA
' I-DNA I-DNA
sequence I-DNA I-DNA
, O O
ATGCAAAT O O
or O O
its O O
complement O O
ATTTGCAT O O
, O O
is O O
a O O
key O O
element O O
for O O
the O O
transcriptional O O
regulation O O
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
in O O
B O O
- O O
lymphocytes O O
as O O
well O O
as O O
a O O
number O O
of O O
housekeeping B-DNA B-DNA
genes I-DNA I-DNA
in O O
all O O
cell O O
types O O
. O O

In O O
lymphocytes O O
, O O
the O O
octamer O O
- O O
binding O O
protein O O
Oct O O
- O O
2A O O
and O O
variants O O
thereof O O
are O O
thought O O
to O O
contribute O O
to O O
the O O
B B-DNA O
- I-DNA O
cell I-DNA O
specific I-DNA O
gene I-DNA O
expression O O
, O O
while O O
the O O
ubiquitous O O
protein O O
Oct O O
- O O
1 O O
seems O O
to O O
control O O
general O O
octamer B-DNA B-DNA
site I-DNA I-DNA
- O O
dependent O O
transcription O O
. O O

Various O O
other O O
genes O O
, O O
for O O
example O O
interleukin O O
- O O
1 O O
and O O
MHC O B-DNA
class O I-DNA
II O I-DNA
genes O I-DNA
, O O
contain O O
an O O
octamer B-DNA B-DNA
sequence I-DNA I-DNA
in O O
the O O
promoter B-DNA B-DNA
and O O
are O O
expressed O O
in O O
cells O O
of O O
both O O
the O O
immune O O
and O O
nervous O O
systems O O
. O O

This O O
prompted O O
us O O
to O O
analyze O O
the O O
octamer O O
- O O
binding O O
proteins O O
in O O
the O O
latter O O
cells O O
. O O

Using O O
the O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
at O O
least O O
six O O
novel O O
octamer O O
binding O O
proteins O O
were O O
detected O O
in O O
nuclear O O
extracts O O
of O O
cultured O O
mouse O O
astrocytes O O
. O O

These O O
proteins O O
are O O
differentially O O
expressed O O
in O O
human O O
glioblastoma O O
and O O
neuroblastoma O O
cell O O
lines O O
. O O

The O O
nervous O O
system O O
- O O
derived O O
( O O
N O O
- O O
Oct O O
) O O
proteins O O
bound O O
to O O
the O O
octamer B-DNA B-DNA
DNA I-DNA I-DNA
sequence I-DNA I-DNA
in O O
a O O
manner O O
which O O
is O O
indistinguishable O O
from O O
the O O
Oct O O
- O O
1 O O
and O O
Oct O O
- O O
2A O O
proteins O O
. O O

The O O
relationship O O
of O O
the O O
N O O
- O O
Oct O O
proteins O O
to O O
Oct O O
- O O
1 O O
and O O
Oct O O
- O O
2A O O
was O O
analyzed O O
by O O
proteolytic O O
clipping O O
bandshift O O
assays O O
and O O
by O O
their O O
reactivity O O
towards O O
antisera O O
raised O O
against O O
recombinant O O
Oct O O
- O O
1 O O
and O O
Oct O O
- O O
2A O O
proteins O O
. O O

On O O
the O O
basis O O
of O O
these O O
assays O O
, O O
all O O
N O O
- O O
Oct O O
- O O
factors O O
were O O
found O O
to O O
be O O
distinct O O
from O O
the O O
ubiquitous O O
Oct O O
- O O
1 O O
and O O
the O O
lymphoid O O
- O O
specific O O
Oct O O
- O O
2A O O
proteins O O
. O O

In O O
melanoma O O
cells O O
that O O
contain O O
the O O
N O O
- O O
Oct O O
- O O
3 O O
factor O O
, O O
a O O
transfected O O
lymphocyte O B-DNA
- O I-DNA
specific O I-DNA
promoter O I-DNA
was O O
neither O O
activated O O
nor O O
was O O
it O O
repressed O O
upon O O
contransfection O O
with O O
an O O
Oct B-DNA B-DNA
- I-DNA I-DNA
2A I-DNA I-DNA
expression I-DNA I-DNA
vector I-DNA I-DNA
. O O

We O O
therefore O O
speculate O O
that O O
N O O
- O O
Oct O O
- O O
3 O O
and O O
other O O
N O O
- O O
Oct O O
factors O O
have O O
a O O
specific O O
role O O
in O O
gene O O
expression O O
in O O
cells O O
of O O
the O O
nervous O O
system O O
. O O

Detection O O
in O O
non O O
- O O
erythroid O O
cells O O
of O O
a O O
factor O O
with O O
the O O
binding O O
characteristics O O
of O O
the O O
erythroid O O
cell O O
transcription O O
factor O O
EF1 O O
. O O

The O O
erythroid O O
transcription O O
factor O O
erythroid O O
factor O O
- O O
1 O O
( O O
EF1 O O
) O O
plays O O
a O O
critical O O
role O O
in O O
the O O
transcription O O
of O O
erythroid B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
genes I-DNA I-DNA
. O O

Here O O
we O O
report O O
the O O
presence O O
of O O
a O O
factor O O
with O O
the O O
mobility O O
and O O
sequence O O
- O O
specific O O
DNA O O
- O O
binding O O
characteristics O O
of O O
EF1 O O
at O O
low O O
abundance O O
in O O
a O O
wide O O
variety O O
of O O
non O O
- O O
erythroid O O
cell O O
types O O
. O O

This O O
is O O
the O O
first O O
report O O
of O O
an O O
EF1 O O
- O O
like O O
activity O O
in O O
non O O
- O O
erythroid O O
cells O O
and O O
indicates O O
that O O
this O O
factor O O
may O O
play O O
a O O
role O O
in O O
the O O
regulation O O
of O O
genes B-DNA O
expressed O O
in O O
such O O
cells O O
. O O

Protein O O
kinase O O
inhibitor O O
H O O
- O O
7 O O
blocks O O
accumulation O O
of O O
unspliced O O
mRNA O O
of O O
human O O
T O O
- O O
cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV O O
- O O
I O O
) O O
. O O

Rex O O
, O O
the O O
post O O
- O O
transcriptional O O
regulator O O
of O O
human O O
T O O
- O O
cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV O O
- O O
I O O
) O O
, O O
is O O
known O O
to O O
induce O O
accumulation O O
of O O
the O O
unspliced O O
viral O O
gag O O
- O O
pol O O
mRNA O O
. O O

Rex O O
is O O
a O O
phosphoprotein O O
found O O
in O O
the O O
cell O O
nucleolus O O
, O O
whose O O
function O O
may O O
be O O
regulated O O
by O O
its O O
localization O O
and O O
phosphorylation O O
. O O

We O O
have O O
examined O O
the O O
role O O
of O O
phosphorylation O O
on O O
Rex O O
function O O
by O O
using O O
a O O
protein O O
kinase O O
inhibitor O O
, O O
H O O
- O O
7 O O
[ O O
1 O O
- O O
( O O
5 O O
- O O
isoquinolinyl O O
- O O
sulfonyl O O
) O O
- O O
2 O O
- O O
methylpiperazine O O
] O O
. O O

Treatment O O
of O O
an O O
HTLV O O
- O O
I O O
infected O O
human O O
T O O
- O O
cell O O
line O O
with O O
H O O
- O O
7 O O
blocked O O
specifically O O
accumulation O O
of O O
the O O
unspliced O O
gag O O
- O O
pol O O
mRNA O O
, O O
resulting O O
in O O
the O O
decreased O O
Gag O O
protein O O
synthesis O O
that O O
corresponds O O
with O O
the O O
decreased O O
in O O
vivo O O
phosphorylation O O
of O O
Rex O O
. O O

In O O
contrast O O
, O O
other O O
viral O O
and O O
cellular O O
products O O
have O O
not O O
been O O
influenced O O
by O O
the O O
level O O
of O O
H O O
- O O
7 O O
used O O
. O O

Therefore O O
, O O
the O O
phosphorylation O O
of O O
Rex O O
is O O
required O O
for O O
the O O
viral O O
RNA O O
partition O O
of O O
HTLV O O
- O O
I O O
. O O

Increased O O
glucocorticoid O O
responsiveness O O
of O O
CD4 O O
+ O O
T O O
- O O
cell O O
clonal O O
lines O O
grown O O
in O O
serum O O
- O O
free O O
media O O
. O O

CEM O O
- O O
C7 O O
, O O
a O O
human O O
leukemic O O
CD4 O O
+ O O
T O O
- O O
lymphocyte O O
cell O O
line O O
and O O
three O O
of O O
its O O
subclones O O
, O O
CEM O O
- O O
4R4 O O
, O O
CEM O O
- O O
3R43 O O
, O O
and O O
ICR O O
- O O
27 O O
, O O
previously O O
cultured O O
in O O
a O O
medium O O
supplemented O O
with O O
5 O O
to O O
10 O O
% O O
fetal O O
bovine O O
serum O O
, O O
have O O
been O O
adapted O O
to O O
serum O O
- O O
free O O
media O O
. O O

The O O
best O O
medium O O
of O O
those O O
tested O O
was O O
RPMI O O
1640 O O
supplemented O O
with O O
5 O O
micrograms O O
/ O O
ml O O
each O O
transferrin O O
and O O
insulin O O
+ O O
5 O O
ng O O
/ O O
ml O O
sodium O O
selenite O O
+ O O
/ O O
- O O
0 O O
. O O
1 O O
% O O
bovine O O
serum O O
albumin O O
. O O

While O O
growing O O
either O O
with O O
or O O
without O O
albumin O O
, O O
the O O
several O O
clonal O O
lines O O
of O O
CEM O O
cells O O
displayed O O
growth O O
similar O O
to O O
serum O O
- O O
supplemented O O
cultures O O
. O O

Cell O O
proliferation O O
of O O
CEM O O
- O O
C7 O O
cells O O
cultured O O
in O O
both O O
serum O O
- O O
free O O
media O O
has O O
been O O
sustained O O
for O O
3 O O
mo O O
. O O

with O O
culture O O
doubling O O
times O O
of O O
about O O
25 O O
h O O
for O O
both O O
serum O O
- O O
supplemented O O
and O O
serum O O
- O O
free O O
cultures O O
( O O
viability O O
greater O O
than O O
or O O
equal O O
to O O
90 O O
% O O
) O O
. O O

Cell O O
morphology O O
remained O O
essentially O O
the O O
same O O
in O O
serum O O
- O O
free O O
or O O
serum O O
containing O O
media O O
. O O

The O O
expression O O
of O O
CD4 O O
, O O
a O O
marker O O
for O O
T O O
- O O
derived O O
lymphoid O O
cells O O
, O O
was O O
not O O
significantly O O
different O O
in O O
serum O O
- O O
free O O
medium O O
. O O

When O O
grown O O
in O O
serum O O
- O O
free O O
medium O O
, O O
CEM O O
- O O
C7 O O
cells O O
exhibited O O
increased O O
steroid O O
responsiveness O O
as O O
evidenced O O
by O O
increased O O
glucocorticoid O O
receptor O O
binding O O
sites O O
, O O
increased O O
induction O O
of O O
glutamine O O
synthetase O O
, O O
and O O
cell O O
lysis O O
at O O
lower O O
concentrations O O
of O O
steroid O O
. O O

Receptor O O
mutant O O
subclones O O
of O O
CEM O O
- O O
C7 O O
, O O
which O O
are O O
proven O O
to O O
be O O
completely O O
unresponsive O O
to O O
micromolar O O
concentrations O O
of O O
dexamethasone O O
when O O
grown O O
in O O
serum O O
- O O
supplemented O O
medium O O
, O O
become O O
partially O O
sensitive O O
to O O
the O O
hormone O O
after O O
growth O O
in O O
defined O O
medium O O
. O O

The O O
increased O O
sensitivity O O
of O O
CEM O O
- O O
C7 O O
cells O O
and O O
its O O
subclones O O
to O O
dexamethasone O O
in O O
serum O O
- O O
free O O
medium O O
returned O O
to O O
previous O O
levels O O
when O O
these O O
cells O O
were O O
recultured O O
in O O
serum O O
- O O
containing O O
medium O O
. O O

Our O O
results O O
suggest O O
that O O
substances O O
in O O
serum O O
influence O O
steroid O O
effects O O
on O O
these O O
cells O O
and O O
that O O
the O O
molecular O O
details O O
of O O
glucocorticoid O O
hormone O O
action O O
may O O
be O O
pursued O O
more O O
precisely O O
in O O
a O O
clearly O O
defined O O
culture O O
medium O O
. O O

[ O O
Glucocorticoid O O
receptors O O
on O O
human O O
peripheral O O
mononuclear O O
and O O
polymorphonuclear O O
leucocytes O O
: O O
changes O O
in O O
patients O O
with O O
yang O O
- O O
deficiency O O
] O O
. O O

It O O
was O O
found O O
that O O
, O O
in O O
former O O
works O O
, O O
the O O
glucocorticoid O O
receptors O O
( O O
GCR O O
) O O
on O O
peripheral O O
mixed O O
leucocytes O O
in O O
patients O O
with O O
Yang O O
- O O
deficiency O O
were O O
decreased O O
. O O

In O O
this O O
work O O
, O O
the O O
mixed O O
leucocytes O O
were O O
further O O
separated O O
into O O
mononuclear O O
( O O
MNL O O
) O O
and O O
polymorphonuclear O O
( O O
PML O O
) O O
leucocytes O O
, O O
and O O
GCR O O
were O O
determined O O
in O O
each O O
part O O
of O O
leucocytes O O
. O O

GCR O O
on O O
MNL O O
and O O
PML O O
in O O
6 O O
Yang O O
deficient O O
patients O O
were O O
3473 O O
+ O O
/ O O
- O O
413 O O
and O O
4433 O O
+ O O
/ O O
- O O
651 O O
sites O O
/ O O
cell O O
respectively O O
, O O
statistically O O
significant O O
from O O
the O O
normal O O
control O O
group O O
( O O
4462 O O
+ O O
/ O O
- O O
962 O O
and O O
5622 O O
+ O O
/ O O
- O O
782 O O
sites O O
/ O O
cell O O
respectively O O
, O O
P O O
less O O
than O O
0 O O
. O O
05 O O
) O O
. O O

GCR O O
on O O
MNL O O
, O O
PML O O
and O O
mixed O O
leucocytes O O
in O O
5 O O
patients O O
were O O
determined O O
simultaneously O O
, O O
and O O
all O O
lowered O O
from O O
the O O
control O O
group O O
. O O

The O O
results O O
were O O
3369 O O
+ O O
/ O O
- O O
370 O O
, O O
4986 O O
+ O O
/ O O
- O O
419 O O
and O O
4524 O O
+ O O
/ O O
- O O
852 O O
sites O O
/ O O
cell O O
respectively O O
, O O
with O O
the O O
lowest O O
GCR O O
on O O
MNL O O
and O O
highest O O
on O O
PML O O
. O O

The O O
ubiquitous O O
octamer O O
- O O
binding O O
protein O O
( O O
s O O
) O O
is O O
sufficient O O
for O O
transcription O O
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
. O O

All O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
contain O O
a O O
conserved O O
octanucleotide B-DNA B-DNA
promoter I-DNA I-DNA
element I-DNA I-DNA
, O O
ATGCAAAT O B-DNA
, O O
which O O
has O O
been O O
shown O O
to O O
be O O
required O O
for O O
their O O
normal O O
B O O
- O O
cell O O
- O O
specific O O
transcription O O
. O O

Proteins O O
that O O
bind O O
this O O
octamer O B-DNA
have O O
been O O
purified O O
, O O
and O O
cDNAs B-DNA B-DNA
encoding O O
octamer O O
- O O
binding O O
proteins O O
have O O
been O O
cloned O O
. O O

Some O O
of O O
these O O
proteins O O
( O O
referred O O
to O O
as O O
OTF O O
- O O
2 O O
) O O
are O O
lymphoid O O
specific O O
, O O
whereas O O
at O O
least O O
one O O
other O O
, O O
and O O
possibly O O
more O O
( O O
referred O O
to O O
as O O
OTF O O
- O O
1 O O
) O O
, O O
is O O
found O O
ubiquitously O O
in O O
all O O
cell O O
types O O
. O O

The O O
exact O O
role O O
of O O
these O O
different O O
proteins O O
in O O
directing O O
the O O
tissue O O
- O O
specific O O
expression O O
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
is O O
unclear O O
. O O

We O O
have O O
identified O O
two O O
human O O
pre O O
- O O
B O O
- O O
cell O O
lines O O
that O O
contain O O
extremely O O
low O O
levels O O
of O O
OTF O O
- O O
2 O O
yet O O
still O O
express O O
high O O
levels O O
of O O
steady O O
- O O
state O O
immunoglobulin O O
heavy O O
- O O
chain O O
mRNA O O
in O O
vivo O O
and O O
efficiently O O
transcribe O O
an O O
immunoglobulin B-DNA B-DNA
gene I-DNA I-DNA
in O O
vitro O O
. O O

Addition O O
of O O
a O O
highly O O
enriched O O
preparation O O
of O O
OTF O O
- O O
1 O O
made O O
from O O
one O O
of O O
these O O
pre O O
- O O
B O O
cells O O
or O O
from O O
HeLa O O
cells O O
specifically O O
stimulated O O
in O O
vitro O O
transcription O O
of O O
an O O
immunoglobulin B-DNA B-DNA
gene I-DNA I-DNA
. O O

Furthermore O O
, O O
OFT O O
- O O
1 O O
appeared O O
to O O
have O O
approximately O O
the O O
same O O
transactivation O O
ability O O
as O O
OTF O O
- O O
2 O O
when O O
normalized O O
for O O
binding O O
activity O O
. O O

These O O
results O O
suggest O O
that O O
OTF O O
- O O
1 O O
, O O
without O O
OTF O O
- O O
2 O O
, O O
is O O
sufficient O O
for O O
transcription O O
of O O
immunoglobulin B-DNA B-DNA
genes I-DNA I-DNA
and O O
that O O
OTF O O
- O O
2 O O
alone O O
is O O
not O O
responsible O O
for O O
the O O
B O O
- O O
cell O O
- O O
specific O O
regulation O O
of O O
immunoglobulin B-DNA B-DNA
gene I-DNA I-DNA
expression O O
. O O

Effects O O
of O O
aldosterone O O
on O O
intralymphocytic O O
sodium O O
and O O
potassium O O
in O O
patients O O
with O O
essential O O
hypertension O O
. O O

In O O
vitro O O
binding O O
of O O
aldosterone O O
to O O
mineralocorticoid O O
receptors O O
on O O
human O O
mononuclear O O
leukocytes O O
( O O
HML O O
) O O
and O O
its O O
effects O O
on O O
the O O
intracellular O O
sodium O O
and O O
potassium O O
concentrations O O
of O O
HML O O
have O O
already O O
been O O
described O O
. O O

In O O
the O O
present O O
paper O O
this O O
easily O O
accessible O O
human O O
cell O O
model O O
was O O
investigated O O
in O O
13 O O
patients O O
with O O
essential O O
hypertension O O
. O O

In O O
only O O
four O O
patients O O
sodium O O
in O O
HML O O
without O O
incubation O O
was O O
elevated O O
compared O O
with O O
the O O
range O O
for O O
normal O O
persons O O
. O O

A O O
decrease O O
of O O
intracellular O O
sodium O O
or O O
potassium O O
occurred O O
during O O
incubation O O
without O O
aldosterone O O
( O O
P O O
less O O
than O O
0 O O
. O O
02 O O
) O O
. O O

The O O
addition O O
of O O
1 O O
. O O
4 O O
nM O O
aldosterone O O
did O O
not O O
prevent O O
this O O
loss O O
of O O
electrolytes O O
as O O
observed O O
in O O
normal O O
persons O O
. O O

Plasma O O
renin O O
activity O O
and O O
aldosterone O O
were O O
not O O
correlated O O
with O O
the O O
electrolyte O O
response O O
and O O
were O O
within O O
the O O
normal O O
limits O O
. O O

The O O
number O O
of O O
mineralocorticoid O O
receptors O O
/ O O
cell O O
were O O
within O O
or O O
close O O
to O O
the O O
normal O O
range O O
( O O
n O O
= O O
9 O O
) O O
. O O

The O O
independence O O
of O O
intracellular O O
electrolytes O O
from O O
aldosterone O O
despite O O
a O O
normal O O
number O O
of O O
mineralocorticoid O O
receptors O O
may O O
reflect O O
an O O
impairment O O
of O O
the O O
mineralocorticoid O O
effector O O
mechanism O O
in O O
the O O
HML O O
of O O
patients O O
with O O
essential O O
hypertension O O
. O O

[ O O
Differential O O
diagnostic O O
value O O
of O O
receptors O O
of O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
( O O
calcitriol O O
) O O
determination O O
in O O
lymphocytes O O
of O O
children O O
with O O
rickets O O
and O O
rickets O O
- O O
like O O
diseases O O
] O O
. O O

The O O
authors O O
provide O O
the O O
results O O
of O O
studying O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
( O O
calcitriol O O
) O O
in O O
lymphocytes O O
of O O
children O O
with O O
rickets O O
and O O
rickets O O
- O O
like O O
diseases O O
. O O

It O O
is O O
proposed O O
that O O
the O O
character O O
of O O
their O O
expression O O
under O O
the O O
influence O O
of O O
vitamin O O
D O O
may O O
be O O
used O O
with O O
differential O O
diagnostic O O
purposes O O
in O O
view O O
. O O

Regulation O O
of O O
gene O O
expression O O
with O O
double O O
- O O
stranded O O
phosphorothioate O O
oligonucleotides O O
. O O

Alteration O O
of O O
gene O O
transcription O O
by O O
inhibition O O
of O O
specific O O
transcriptional O O
regulatory O O
proteins O O
is O O
necessary O O
for O O
determining O O
how O O
these O O
factors O O
participate O O
in O O
cellular O O
differentiation O O
. O O

The O O
functions O O
of O O
these O O
proteins O O
can O O
be O O
antagonized O O
by O O
several O O
methods O O
, O O
each O O
with O O
specific O O
limitations O O
. O O

Inhibition O O
of O O
sequence O O
- O O
specific O O
DNA O O
- O O
binding O O
proteins O O
was O O
achieved O O
with O O
double O O
- O O
stranded O O
( O O
ds O O
) O O
phosphorothioate O O
oligonucleotides O O
that O O
contained O O
octamer O B-DNA
or O O
kappa O B-DNA
B O I-DNA
consensus O I-DNA
sequences O I-DNA
. O O

The O O
phosphorothioate O O
oligonucleotides O O
specifically O O
bound O O
either O O
octamer O O
transcription O O
factor O O
or O O
nuclear O O
factor O O
( O O
NF O O
) O O
- O O
kappa O O
B O O
. O O

The O O
modified O O
oligonucleotides O O
accumulated O O
in O O
cells O O
more O O
effectively O O
than O O
standard O O
ds O O
oligonucleotides O O
and O O
modulated O O
gene O O
expression O O
in O O
a O O
specific O O
manner O O
. O O

Octamer O O
- O O
dependent O O
activation O O
of O O
a O O
reporter B-DNA B-DNA
plasmid I-DNA I-DNA
or O O
NF O O
- O O
kappa O O
B O O
- O O
dependent O O
activation O O
of O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
( I-DNA I-DNA
HIV I-DNA I-DNA
) I-DNA I-DNA
enhancer I-DNA I-DNA
was O O
inhibited O O
when O O
the O O
appropriate O O
phosphorothioate O O
oligonucleotide O O
was O O
added O O
to O O
a O O
transiently O O
transfected O O
B O O
cell O O
line O O
. O O

Addition O O
of O O
phosphorothioate O O
oligonucleotides O O
that O O
contained O O
the O O
octamer B-DNA B-DNA
consensus I-DNA I-DNA
to O O
Jurkat O O
T O O
leukemia O O
cells O O
inhibited O O
interleukin O O
- O O
2 O O
( O O
IL O O
- O O
2 O O
) O O
secretion O O
to O O
a O O
degree O O
similar O O
to O O
that O O
observed O O
with O O
a O O
mutated B-DNA O
octamer I-DNA B-DNA
site I-DNA I-DNA
in O O
the O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

The O O
ds O O
phosphorothioate O O
oligonucleotides O O
probably O O
compete O O
for O O
binding O O
of O O
specific O O
transcription O O
factors O O
and O O
may O O
provide O O
anti O O
- O O
viral O O
, O O
immunosuppressive O O
, O O
or O O
other O O
therapeutic O O
effects O O
. O O

[ O O
Effect O O
of O O
the O O
regimen O O
of O O
kidney O O
- O O
tonifying O O
and O O
qi O O
- O O
invigorating O O
on O O
aging O O
changes O O
of O O
glucocorticoid O O
receptor O O
] O O
. O O

The O O
plasma O O
cortisol O O
concentration O O
and O O
the O O
sites O O
of O O
glucocorticoid O O
receptor O O
( O O
GCR O O
) O O
in O O
the O O
peripheral O O
lymphocytes O O
were O O
measured O O
in O O
32 O O
healthy O O
aged O O
persons O O
and O O
13 O O
young O O
adults O O
. O O

In O O
animal O O
experiment O O
, O O
GCR O O
of O O
spleen O O
lymphocytic O O
cell O O
was O O
also O O
measured O O
in O O
18 O O
aged O O
rats O O
and O O
9 O O
young O O
rats O O
. O O

The O O
results O O
showed O O
that O O
GCR O O
was O O
significantly O O
lower O O
in O O
the O O
aged O O
persons O O
or O O
rats O O
than O O
that O O
in O O
the O O
young O O
while O O
the O O
plasma O O
cortisol O O
level O O
didn O O
' O O
t O O
change O O
with O O
aging O O
. O O

So O O
we O O
think O O
that O O
GCR O O
is O O
more O O
sensitive O O
than O O
the O O
plasma O O
cortisol O O
level O O
to O O
reflect O O
the O O
aging O O
change O O
of O O
the O O
adrenal O O
cortex O O
function O O
. O O

After O O
the O O
treatment O O
with O O
the O O
regimen O O
of O O
Kidney O O
- O O
tonifying O O
and O O
Qi O O
- O O
invigorating O O
, O O
the O O
GCR O O
of O O
the O O
aged O O
persons O O
and O O
rats O O
was O O
enhanced O O
, O O
and O O
in O O
this O O
way O O
, O O
the O O
function O O
of O O
the O O
aged O O
adrenal O O
cortex O O
was O O
improved O O
. O O

Interferon O O
affects O O
nuclear O O
proteins O O
in O O
cells O O
of O O
clinically O O
sensitive O O
chronic O O
myelogenous O O
leukemia O O
patients O O
. O O

Cytoplasmic O O
protein O O
extracts O O
from O O
chronic O O
myelogenous O O
leukemia O O
( O O
CML O O
) O O
cells O O
contained O O
an O O
activity O O
that O O
altered O O
the O O
electrophoretic O O
mobility O O
of O O
complexes O O
formed O O
between O O
nuclear O O
proteins O O
and O O
the O O
transcriptional O B-DNA
enhancers O I-DNA
of O O
interferon O B-DNA
( O I-DNA
IFN O I-DNA
) O I-DNA
- O I-DNA
inducible O I-DNA
genes O I-DNA
. O O

Exposure O O
of O O
CML O O
cells O O
to O O
IFN O O
- O O
alpha O O
diminished O O
the O O
effect O O
of O O
the O O
CML O O
cytoplasmic O O
proteins O O
on O O
these O O
nuclear O O
protein O O
- O O
DNA O O
complexes O O
. O O

The O O
presence O O
of O O
clinical O O
responsiveness O O
to O O
IFN O O
- O O
alpha O O
correlated O O
with O O
the O O
sensitivity O O
to O O
the O O
IFN O O
- O O
induced O O
change O O
in O O
the O O
electrophoretic O O
mobility O O
of O O
nuclear O O
protein O O
- O O
DNA O O
complexes O O
. O O

These O O
data O O
suggest O O
that O O
the O O
action O O
of O O
IFN O O
- O O
alpha O O
in O O
CML O O
may O O
be O O
linked O O
to O O
a O O
pathway O O
that O O
can O O
result O O
in O O
posttranslational O O
modification O O
of O O
nuclear O O
proteins O O
. O O

Epstein O O
- O O
Barr O O
virus O O
nuclear O O
antigen O O
2 O O
transactivates O O
latent O O
membrane O O
protein O O
LMP1 O O
. O O

Several O O
lines O O
of O O
evidence O O
are O O
compatible O O
with O O
the O O
hypothesis O O
that O O
Epstein O O
- O O
Barr O O
virus O O
( O O
EBV O O
) O O
nuclear O O
antigen O O
2 O O
( O O
EBNA O O
- O O
2 O O
) O O
or O O
leader O O
protein O O
( O O
EBNA O O
- O O
LP O O
) O O
affects O O
expression O O
of O O
the O O
EBV O O
latent O O
infection O O
membrane O O
protein O O
LMP1 O O
. O O

We O O
now O O
demonstrate O O
the O O
following O O
. O O

( O O
i O O
) O O
Acute O O
transfection O O
and O O
expression O O
of O O
EBNA O O
- O O
2 O O
under O O
control O O
of O O
simian O O
virus O O
40 O O
or O O
Moloney O O
murine O O
leukemia O O
virus O O
promoters O O
resulted O O
in O O
increased O O
LMP1 O O
expression O O
in O O
P3HR O O
- O O
1 O O
- O O
infected O O
Burkitt O O
' O O
s O O
lymphoma O O
cells O O
and O O
the O O
P3HR O O
- O O
1 O O
or O O
Daudi O O
cell O O
line O O
. O O

( O O
ii O O
) O O
Transfection O O
and O O
expression O O
of O O
EBNA O O
- O O
LP O O
alone O O
had O O
no O O
effect O O
on O O
LMP1 O O
expression O O
and O O
did O O
not O O
act O O
synergistically O O
with O O
EBNA O O
- O O
2 O O
to O O
affect O O
LMP1 O O
expression O O
. O O

( O O
iii O O
) O O
LMP1 O O
expression O O
in O O
Daudi O O
and O O
P3HR O O
- O O
1 O O
- O O
infected O O
cells O O
was O O
controlled O O
at O O
the O O
mRNA O O
level O O
, O O
and O O
EBNA O O
- O O
2 O O
expression O O
in O O
Daudi O O
cells O O
increased O O
LMP1 O O
mRNA O O
. O O

( O O
iv O O
) O O
No O O
other O O
EBV B-DNA B-DNA
genes I-DNA I-DNA
were O O
required O O
for O O
EBNA O O
- O O
2 O O
transactivation O O
of O O
LMP1 O O
since O O
cotransfection O O
of O O
recombinant B-DNA B-DNA
EBNA I-DNA I-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
expression I-DNA I-DNA
vectors I-DNA I-DNA
and O O
genomic O B-DNA
LMP1 B-DNA I-DNA
DNA I-DNA I-DNA
fragments I-DNA I-DNA
enhanced O O
LMP1 O O
expression O O
in O O
the O O
EBV O O
- O O
negative O O
B O O
- O O
lymphoma O O
cell O O
lines O O
BJAB O O
, O O
Louckes O O
, O O
and O O
BL30 O O
. O O

( O O
v O O
) O O
An O O
EBNA B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
- I-DNA I-DNA
responsive I-DNA I-DNA
element I-DNA I-DNA
was O O
found O O
within O O
the O O
- B-DNA B-DNA
512 I-DNA I-DNA
to I-DNA I-DNA
+ I-DNA I-DNA
40 I-DNA I-DNA
LMP1 I-DNA I-DNA
DNA I-DNA I-DNA
since O O
this O O
DNA O O
linked O O
to O O
a O O
chloramphenicol B-DNA B-DNA
acetyltransferase I-DNA I-DNA
reporter I-DNA I-DNA
gene I-DNA I-DNA
was O O
transactivated O O
by O O
cotransfection O O
with O O
an O O
EBNA B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
expression I-DNA I-DNA
vector I-DNA I-DNA
. O O

( O O
vi O O
) O O
The O O
EBV O O
type O O
2 O O
EBNA O O
- O O
2 O O
transactivated O O
LMP1 O O
as O O
well O O
as O O
the O O
EBV O O
type O O
1 O O
EBNA O O
- O O
2 O O
. O O

( O O
vii O O
) O O
Two O O
deletions O O
within O O
the O O
EBNA O B-DNA
- O I-DNA
2 O I-DNA
gene O I-DNA
which O O
rendered O O
EBV O O
transformation O O
incompetent O O
did O O
not O O
transactivate O O
LMP1 O O
, O O
whereas O O
a O O
transformation B-DNA O
- I-DNA O
competent I-DNA O
EBNA I-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
deletion I-DNA I-DNA
mutant I-DNA I-DNA
did O O
transactivate O O
LMP1 O O
. O O

LMP1 O O
is O O
a O O
potent O O
effector O O
of O O
B O O
- O O
lymphocyte O O
activation O O
and O O
can O O
act O O
synergistically O O
with O O
EBNA O O
- O O
2 O O
to O O
induce O O
cellular O O
CD23 O O
gene O O
expression O O
. O O

Thus O O
, O O
EBNA O O
- O O
2 O O
transactivation O O
of O O
LMP1 O O
amplifies O O
the O O
biological O O
impact O O
of O O
EBNA O O
- O O
2 O O
and O O
underscores O O
its O O
central O O
role O O
in O O
EBV O O
- O O
induced O O
growth O O
transformation O O
. O O

The O O
expression O O
of O O
c B-DNA O
- I-DNA O
fos I-DNA O
, O O
c B-DNA O
- I-DNA O
jun I-DNA O
, O O
and O O
c B-DNA O
- I-DNA O
myc I-DNA O
genes I-DNA O
is O O
regulated O O
by O O
heat O O
shock O O
in O O
human O O
lymphoid O O
cells O O
. O O

The O O
effect O O
of O O
heat O O
shock O O
on O O
the O O
expression O O
of O O
the O O
nuclear B-DNA B-DNA
protooncogenes I-DNA I-DNA
c B-DNA I-DNA
- I-DNA I-DNA
fos I-DNA I-DNA
, O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
, O O
and O O
c B-DNA B-DNA
- I-DNA I-DNA
myc I-DNA I-DNA
was O O
studied O O
in O O
human O O
lymphoid O O
cells O O
. O O

Heat O O
shock O O
caused O O
an O O
increase O O
in O O
c O O
- O O
fos O O
and O O
c O O
- O O
jun O O
mRNA O O
levels O O
and O O
a O O
decrease O O
in O O
c B-DNA O
- I-DNA O
myc I-DNA O
mRNA O O
levels O O
in O O
pre O O
- O O
B O O
( O O
Hyon O O
) O O
and O O
T O O
( O O
DND O O
- O O
41 O O
) O O
cell O O
lines O O
as O O
well O O
as O O
in O O
freshly O O
isolated O O
normal O O
human O O
thymocytes O O
. O O

The O O
changes O O
in O O
the O O
mRNA O O
levels O O
of O O
these O O
protooncogenes B-DNA B-DNA
in O O
Hyon O O
cells O O
were O O
most O O
pronounced O O
at O O
42 O O
and O O
43 O O
degrees O O
C O O
; O O
kinetic O O
analysis O O
demonstrated O O
that O O
the O O
changes O O
could O O
be O O
detected O O
within O O
30 O O
min O O
of O O
heat O O
shock O O
. O O

Altered O O
transcription O O
of O O
c B-DNA O
- I-DNA O
fos I-DNA O
and O O
c B-DNA O
- I-DNA O
myc I-DNA O
genes I-DNA O
was O O
the O O
primary O O
effect O O
of O O
heat O O
shock O O
. O O

Secondarily O O
, O O
heat O O
shock O O
of O O
Hyon O O
cells O O
stabilized O O
the O O
c B-DNA O
- I-DNA O
myc I-DNA O
mRNA O O
level O O
by O O
increasing O O
its O O
half O O
- O O
life O O
from O O
24 O O
to O O
45 O O
min O O
. O O

The O O
overall O O
effect O O
of O O
heat O O
shock O O
on O O
c B-DNA O
- I-DNA O
myc I-DNA O
mRNA O O
level O O
, O O
however O O
, O O
was O O
a O O
marked O O
inhibition O O
of O O
its O O
transcription O O
. O O

These O O
results O O
demonstrate O O
that O O
the O O
transcription O O
of O O
nuclear B-DNA B-DNA
protooncogenes I-DNA I-DNA
is O O
regulated O O
by O O
heat O O
shock O O
indicating O O
a O O
role O O
for O O
nuclear B-DNA B-DNA
protooncogenes I-DNA I-DNA
in O O
the O O
stress O O
response O O
of O O
lymphoid O O
cells O O
. O O

Mapping O O
of O O
B O O
- O O
cell O O
epitopes O O
of O O
the O O
human O O
hepatitis O O
B O O
virus O O
X O O
protein O O
. O O

The O O
immune O O
response O O
to O O
the O O
X O O
protein O O
of O O
human O O
hepatitis O O
B O O
virus O O
( O O
HBV O O
) O O
was O O
studied O O
by O O
epitope O O
mapping O O
by O O
using O O
a O O
set O O
of O O
MS2 O O
- O O
HBx O O
fusion O O
proteins O O
and O O
synthetic O O
peptides O O
. O O

Antibodies O O
in O O
sera O O
of O O
patients O O
with O O
acute O O
and O O
chronic O O
HBV O O
infection O O
showed O O
a O O
multispecific O O
immune O O
response O O
. O O

Each O O
serum O O
contained O O
antibodies O O
to O O
a O O
different O O
set O O
of O O
epitopes O O
, O O
which O O
taken O O
together O O
cover O O
most O O
of O O
the O O
HBx O B-DNA
sequence O I-DNA
. O O

Some O O
of O O
the O O
epitopes O O
were O O
detectable O O
only O O
by O O
immunoblotting O O
with O O
fusion O O
proteins O O
; O O
others O O
were O O
detectable O O
only O O
by O O
an O O
enzyme O O
- O O
linked O O
immunosorbent O O
assay O O
( O O
ELISA O O
) O O
with O O
synthetic O O
peptides O O
. O O

The O O
carboxy O O
- O O
terminal O O
half O O
of O O
the O O
HBx O O
protein O O
was O O
preferentially O O
recognized O O
by O O
antibodies O O
from O O
patients O O
with O O
chronic O O
hepatitis O O
and O O
contained O O
a O O
short O O
immunodominant O O
antigenic O O
region O O
with O O
at O O
least O O
two O O
major O O
nonoverlapping O O
epitopes O O
. O O

Anti O O
- O O
HBx O O
antibody O O
titers O O
as O O
revealed O O
by O O
peptide O O
ELISAs O O
were O O
highest O O
and O O
most O O
frequent O O
in O O
patients O O
with O O
chronic O O
hepatitis O O
and O O
usually O O
low O O
in O O
acutely O O
infected O O
patients O O
and O O
asymptomatic O O
carriers O O
. O O

The O O
data O O
demonstrate O O
a O O
remarkable O O
qualitative O O
and O O
quantitative O O
heterogeneity O O
of O O
the O O
humoral O O
HBx O O
immune O O
response O O
which O O
can O O
be O O
monitored O O
by O O
HBx O O
- O O
specific O O
peptide O O
ELISAs O O
. O O

Such O O
tests O O
may O O
become O O
useful O O
diagnostic O O
tools O O
. O O

[ O O
The O O
inhibitory O O
effect O O
of O O
hydrocortisone O O
on O O
the O O
chemotactic O O
migration O O
of O O
human O O
leukocytes O O
] O O
. O O

Random O O
migration O O
( O O
RM O O
) O O
and O O
chemotactic O O
migration O O
( O O
ChtM O O
) O O
of O O
human O O
leukocytes O O
to O O
yeast O O
activated O O
serum O O
were O O
studied O O
with O O
the O O
modified O O
Boyden O O
chamber O O
method O O
. O O

Both O O
RM O O
and O O
ChtM O O
showed O O
circadian O O
rhythm O O
. O O

Leukocytes O O
migrated O O
most O O
rapidly O O
at O O
night O O
. O O

The O O
difference O O
between O O
the O O
peak O O
( O O
0 O O
: O O
00 O O
) O O
and O O
trough O O
values O O
( O O
8 O O
: O O
00 O O
) O O
of O O
RM O O
and O O
ChtM O O
was O O
significant O O
statistically O O
( O O
P O O
less O O
than O O
0 O O
. O O
01 O O
) O O
. O O

ChtM O O
was O O
inhibited O O
by O O
hydrocortisone O O
( O O
F O O
) O O
of O O
physiological O O
concentration O O
( O O
10 O O
( O O
- O O
9 O O
) O O
- O O
10 O O
( O O
- O O
7 O O
) O O
mol O O
/ O O
L O O
) O O
which O O
was O O
dose O O
- O O
dependent O O
and O O
completely O O
antagonized O O
by O O
the O O
competitive O O
antagonist O O
, O O
RU38486 O O
. O O

The O O
inhibitory O O
effect O O
was O O
much O O
more O O
evident O O
with O O
higher O O
dose O O
( O O
more O O
than O O
10 O O
( O O
- O O
5 O O
) O O
mol O O
/ O O
L O O
) O O
and O O
it O O
was O O
also O O
reversed O O
by O O
RU38486 O O
, O O
but O O
only O O
partially O O
. O O

It O O
is O O
suggested O O
that O O
glucocorticoids O O
( O O
GC O O
) O O
may O O
be O O
a O O
physiological O O
regulator O O
of O O
the O O
activity O O
of O O
leukocytes O O
and O O
its O O
inhibitory O O
action O O
on O O
ChtM O O
may O O
be O O
involved O O
in O O
antiinflammatory O O
mechanisms O O
of O O
GC O O
of O O
pharmacological O O
doses O O
. O O

The O O
action O O
of O O
physiological O O
and O O
pharmacological O O
concentration O O
of O O
GC O O
may O O
be O O
mediated O O
by O O
low O O
affinity O O
specific O O
binding O O
sites O O
of O O
glucocorticoid O O
receptors O O
. O O

Heterogeneity O O
of O O
antigen O O
molecules O O
recognized O O
by O O
anti O O
- O O
tax1 O O
monoclonal O O
antibody O O
Lt O O
- O O
4 O O
in O O
cell O O
lines O O
bearing O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
I O O
and O O
related O O
retroviruses O O
. O O

Using O O
a O O
monoclonal O O
antibody O O
, O O
Lt O O
- O O
4 O O
, O O
directed O O
against O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV O O
- O O
I O O
) O O
trans O O
- O O
activator O O
( O O
tax1 O O
) O O
antigen O O
, O O
we O O
examined O O
the O O
expression O O
of O O
tax1 O O
and O O
related O O
antigens O O
in O O
a O O
variety O O
of O O
T O O
cell O O
lines O O
bearing O O
HTLV O O
- O O
I O O
and O O
related O O
retroviruses O O
, O O
simian O O
T O O
cell O O
leukemia O O
virus O O
type O O
I O O
( O O
STLV O O
- O O
I O O
) O O
and O O
HTLV O O
- O O
II O O
, O O
by O O
immunofluorescence O O
and O O
immunoblot O O
assays O O
. O O

Lt O O
- O O
4 O O
reacted O O
with O O
all O O
HTLV O O
- O O
I O O
- O O
bearing O O
cell O O
lines O O
tested O O
and O O
five O O
out O O
of O O
eight O O
simian O O
cell O O
lines O O
bearing O O
STLV O O
- O O
I O O
, O O
but O O
not O O
with O O
an O O
HTLV O O
- O O
II O O
- O O
bearing O O
cell O O
line O O
. O O

Lt O O
- O O
4 O O
detected O O
40 O O
kd O O
tax1 O O
antigen O O
molecules O O
in O O
most O O
HTLV O O
- O O
I O O
- O O
bearing O O
cell O O
lines O O
except O O
one O O
cell O O
line O O
that O O
expressed O O
39 O O
kd O O
tax1 O O
antigen O O
. O O

In O O
the O O
STLV O O
- O O
I O O
- O O
bearing O O
T O O
cell O O
lines O O
, O O
tax1 O O
- O O
related O O
antigen O O
molecules O O
detected O O
by O O
Lt O O
- O O
4 O O
were O O
heterogeneous O O
, O O
having O O
molecular O O
weights O O
in O O
the O O
range O O
of O O
36 O O
- O O
41 O O
kd O O
. O O

Characterization O O
of O O
the O O
human B-DNA O
immunodeficiency I-DNA O
virus I-DNA O
type I-DNA O
1 I-DNA O
enhancer I-DNA O
- O O
binding O O
proteins O O
from O O
the O O
human O O
T O O
- O O
cell O O
line O O
Jurkat O O
. O O

The O O
transcription O O
of O O
the O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV O O
- O O
1 O O
) O O
is O O
under O O
the O O
control O O
of O O
cellular O O
proteins O O
that O O
bind O O
to O O
the O O
viral B-DNA B-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
. O O

Among O O
the O O
protein O B-DNA
- O I-DNA
binding O I-DNA
regions O I-DNA
of O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
LTR I-DNA I-DNA
is O O
the O O
transcription B-DNA B-DNA
- I-DNA I-DNA
enhancer I-DNA I-DNA
region I-DNA I-DNA
. O O

We O O
show O O
that O O
at O O
least O O
one O O
inducible O O
, O O
C1 O O
, O O
and O O
one O O
constitutive O O
, O O
C2 O O
, O O
protein O O
can O O
bind O O
to O O
the O O
HIV B-DNA B-DNA
enhancer I-DNA I-DNA
in O O
Jurkat O O
cells O O
. O O

The O O
two O O
proteins O O
differ O O
in O O
their O O
surface O O
charge O O
, O O
since O O
they O O
are O O
separable O O
by O O
anion O O
- O O
exchange O O
chromatography O O
. O O

Bivalent O O
cations O O
such O O
as O O
Mg2 O O
+ O O
and O O
Zn2 O O
+ O O
differentially O O
affect O O
their O O
binding O O
to O O
oligonucleotides O O
which O O
contain O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
enhancer I-DNA I-DNA
domain I-DNA I-DNA
. O O

Both O O
C1 O O
and O O
C2 O O
proteins O O
also O O
bind O O
to O O
a O O
similar O O
sequence O O
found O O
in O O
the O O
interleukin B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
- I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
- I-DNA I-DNA
subunit I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

The O O
inducible O O
C1 O O
protein O O
was O O
partially O O
purified O O
by O O
three O O
chromatographic O O
steps O O
and O O
characterized O O
by O O
u O O
. O O
v O O
. O O
cross O O
- O O
linking O O
as O O
a O O
47 O O
kDa O O
protein O O
. O O

Differences O O
in O O
transcriptional B-DNA B-DNA
enhancers I-DNA I-DNA
of O O
HIV O O
- O O
1 O O
and O O
HIV O O
- O O
2 O O
. O O

Response O O
to O O
T O O
cell O O
activation O O
signals O O
. O O

T O O
cell O O
activation O O
results O O
in O O
high O O
levels O O
of O O
HIV O O
replication O O
and O O
is O O
thought O O
to O O
be O O
one O O
mechanism O O
leading O O
to O O
the O O
conversion O O
from O O
latent O O
to O O
active O O
viral O O
infection O O
. O O

In O O
HIV O O
- O O
1 O O
, O O
the O O
sequences O O
that O O
respond O O
to O O
these O O
signaling O O
events O O
are O O
found O O
in O O
the O O
long B-DNA B-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
and O O
comprise O O
the O O
transcriptional B-DNA B-DNA
enhancer I-DNA I-DNA
, O O
which O O
contains O O
two O O
conserved B-DNA B-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
for O O
the O O
nuclear O O
factor O O
kappa O O
B O O
( O O
NF O O
kappa O O
B O O
) O O
. O O

The O O
corresponding O O
region O O
in O O
the O O
second O O
AIDS O O
retrovirus O O
, O O
HIV O O
- O O
2 O O
, O O
contains O O
a O O
conserved O O
and O O
a O O
divergent O O
NF B-DNA B-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
. O O

We O O
demonstrate O O
that O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
LTR I-DNA I-DNA
responds O O
better O O
than O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
LTR I-DNA I-DNA
to O O
T O O
cell O O
activation O O
signals O O
. O O

These O O
qualitative O O
differences O O
in O O
the O O
response O O
to O O
T O O
cell O O
activation O O
are O O
reproduced O O
not O O
only O O
when O O
HIV O O
- O O
1 O O
or O O
HIV O B-DNA
- O I-DNA
2 O I-DNA
enhancers O I-DNA
are O O
placed O O
upstream O O
of O O
a O O
heterologous B-DNA B-DNA
promoter I-DNA I-DNA
but O O
also O O
when O O
these O O
enhancers B-DNA B-DNA
are O O
switched O O
between O O
their O O
respective O O
LTR B-DNA B-DNA
. O O

In O O
electrophoretic O O
mobility O O
shift O O
assays O O
, O O
NF O O
kappa O O
B O O
binds O O
to O O
both O O
conserved O O
sites O O
in O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
transcriptional I-DNA I-DNA
enhancer I-DNA I-DNA
and O O
only O O
to O O
the O O
single O O
conserved O B-DNA
site O I-DNA
in O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
transcriptional I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

Instead O O
of O O
NF O O
kappa O O
B O O
, O O
the O O
activator O O
protein O O
3 O O
binds O O
to O O
the O O
divergent O O
site O O
in O O
HIV O O
- O O
2 O O
. O O

In O O
conclusion O O
, O O
HIV O O
- O O
1 O O
and O O
HIV O O
- O O
2 O O
are O O
differentially O O
regulated O O
by O O
T O O
cell O O
activation O O
signals O O
, O O
and O O
this O O
difference O O
may O O
account O O
for O O
the O O
longer O O
period O O
of O O
viral O O
latency O O
observed O O
with O O
HIV O O
- O O
2 O O
than O O
with O O
HIV O O
- O O
1 O O
infection O O
. O O

NF O O
- O O
X2 O O
that O O
binds O O
to O O
the O O
DRA B-DNA B-DNA
X2 I-DNA I-DNA
- I-DNA I-DNA
box I-DNA I-DNA
is O O
activator O O
protein O O
1 O O
. O O

Expression O O
cloning O O
of O O
c O O
- O O
Jun O O
. O O

Human O O
class O O
II O O
MHC O O
Ag O O
are O O
a O O
family O O
of O O
cell O O
surface O O
glycoproteins O O
. O O

Their O O
constitutive O O
expression O O
is O O
limited O O
to O O
B O O
lymphocytes O O
and O O
thymic O O
epithelial O O
cells O O
. O O

In O O
many O O
other O O
cells O O
their O O
expression O O
can O O
be O O
induced O O
by O O
IFN O O
- O O
gamma O O
. O O

Conserved O B-DNA
upstream O I-DNA
promoter O I-DNA
sequences O I-DNA
regulate O O
this O O
tissue O O
- O O
specific O O
expression O O
of O O
class B-DNA B-DNA
II I-DNA I-DNA
genes I-DNA I-DNA
. O O

In O O
the O O
DRA B-DNA B-DNA
promoter I-DNA I-DNA
, O O
one O O
of O O
these O O
cis B-DNA B-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
regulatory I-DNA I-DNA
motifs I-DNA I-DNA
is O O
the O O
X2 B-DNA B-DNA
- I-DNA I-DNA
box I-DNA I-DNA
to O O
which O O
nuclear O O
factor O O
X2 O O
( O O
NF O O
- O O
X2 O O
) O O
binds O O
. O O

Here O O
, O O
we O O
present O O
the O O
isolation O O
and O O
characterization O O
of O O
the O O
full B-DNA B-DNA
- I-DNA I-DNA
length I-DNA I-DNA
cDNA I-DNA I-DNA
clone I-DNA I-DNA
encoding O O
NF O O
- O O
X2 O O
. O O

This O O
cDNA B-DNA B-DNA
clone I-DNA I-DNA
was O O
isolated O O
by O O
expression O B-DNA
cDNA B-DNA I-DNA
cloning O O
, O O
and O O
encodes O O
the O O
human O O
c O O
- O O
Jun O O
protein O O
, O O
which O O
together O O
with O O
c O O
- O O
Fos O O
forms O O
the O O
heterodimeric O O
activator O O
protein O O
- O O
1 O O
transcription O O
complex O O
. O O

Whereas O O
c O O
- O O
Fos O O
/ O O
c O O
- O O
Jun O O
heterodimers O O
do O O
not O O
exist O O
in O O
B O O
cells O O
, O O
they O O
form O O
and O O
bind O O
to O O
the O O
X2 B-DNA B-DNA
- I-DNA I-DNA
box I-DNA I-DNA
in O O
class O O
II O O
nonexpressing O O
cells O O
. O O

Thus O O
, O O
c O O
- O O
Fos O O
/ O O
c O O
- O O
Jun O O
heterodimers O O
might O O
contribute O O
to O O
the O O
repression O O
of O O
DRA B-DNA B-DNA
gene I-DNA I-DNA
expression O O
. O O

Synthesis O O
of O O
4 O O
, O O
19 O O
- O O
disubstituted O O
derivatives O O
of O O
DOC O O
. O O

Radioreceptor O O
assay O O
of O O
some O O
corticosteroid O O
derivatives O O
in O O
human O O
mononuclear O O
leukocytes O O
. O O

Several O O
new O O
4 O O
, O O
19 O O
- O O
substituted O O
steroids O O
and O O
previously O O
synthesized O O
corticosteroids O O
were O O
assayed O O
for O O
affinity O O
to O O
type O O
1 O O
receptors O O
in O O
human O O
mononuclear O O
leukocytes O O
. O O

11 O O
beta O O
, O O
19 O O
- O O
epoxy O O
- O O
4 O O
, O O
21 O O
- O O
dihydroxypregn O O
- O O
4 O O
- O O
ene O O
- O O
3 O O
, O O
20 O O
- O O
dione O O
( O O
2 O O
) O O
was O O
hydrogenated O O
with O O
Pd O O
- O O
C O O
to O O
yield O O
a O O
mixture O O
of O O
all O O
four O O
dihydro O O
derivatives O O
5 O O
, O O
accompanied O O
by O O
4 O O
, O O
21 O O
- O O
diacetoxy O O
- O O
11 O O
beta O O
, O O
19 O O
- O O
epoxy O O
- O O
3 O O
- O O
hydroxypregnan O O
- O O
20 O O
- O O
one O O
( O O
6 O O
) O O
and O O
21 O O
- O O
acetoxy O O
- O O
11 O O
beta O O
, O O
19 O O
- O O
epoxy O O
- O O
4 O O
- O O
hydroxypregnane O O
- O O
3 O O
, O O
20 O O
- O O
dione O O
( O O
7 O O
) O O
. O O

With O O
hot O O
acetic O O
+ O O
p O O
- O O
toluenesulfonic O O
acid O O
5 O O
underwent O O
rearrangement O O
to O O
21 O O
- O O
acetoxy O O
- O O
11 O O
beta O O
, O O
19 O O
- O O
epoxypregn O O
- O O
5 O O
- O O
ene O O
- O O
4 O O
, O O
20 O O
- O O
dione O O
( O O
8 O O
) O O
Pd O O
- O O
C O O
hydrogenation O O
of O O
3 O O
, O O
21 O O
- O O
diacetoxy O O
- O O
5 O O
beta O O
, O O
19 O O
- O O
cyclopregna O O
- O O
2 O O
, O O
9 O O
( O O
11 O O
) O O
- O O
diene O O
- O O
4 O O
, O O
20 O O
- O O
dione O O
( O O
10 O O
) O O
gave O O
3 O O
, O O
21 O O
- O O
diacetoxy O O
- O O
5 O O
beta O O
, O O
19 O O
- O O
cyclopregn O O
- O O
5 O O
- O O
ene O O
- O O
4 O O
, O O
20 O O
- O O
dione O O
( O O
11 O O
) O O
and O O
the O O
9 O O
, O O
11 O O
- O O
dihydro O O
derivative O O
of O O
the O O
latter O O
. O O

Treatment O O
of O O
10 O O
with O O
warm O O
HCl O O
furnished O O
19 O O
- O O
chloro O O
- O O
4 O O
, O O
21 O O
- O O
dihydroxypregna O O
- O O
4 O O
, O O
9 O O
( O O
11 O O
) O O
- O O
diene O O
- O O
3 O O
, O O
20 O O
- O O
dione O O
( O O
13 O O
) O O
. O O

Pd O O
- O O
C O O
hydrogenation O O
of O O
its O O
diacetate O O
14 O O
afforded O O
the O O
4 O O
, O O
5 O O
- O O
dihydro O O
derivative O O
18 O O
, O O
19 O O
- O O
chloro O O
- O O
21 O O
- O O
acetoxypregn O O
- O O
9 O O
( O O
11 O O
) O O
- O O
en O O
- O O
20 O O
- O O
one O O
( O O
15 O O
) O O
, O O
its O O
4 O O
- O O
acetoxy O O
derivative O O
16 O O
and O O
the O O
3 O O
, O O
4 O O
- O O
diacetoxy O O
derivative O O
17 O O
. O O

When O O
tested O O
in O O
a O O
radioreceptor O O
assay O O
in O O
human O O
mononuclear O O
leukocytes O O
the O O
synthesized O O
compounds O O
showed O O
only O O
low O O
relative O O
binding O O
affinities O O
( O O
RBA O O
) O O
to O O
type O O
1 O O
receptor O O
, O O
the O O
highest O O
being O O
0 O O
. O O
72 O O
% O O
for O O
13 O O
( O O
aldosterone O O
= O O
100 O O
% O O
) O O
. O O

For O O
comparison O O
, O O
other O O
RBA O O
in O O
this O O
system O O
were O O
: O O
19 O O
- O O
noraldosterone O O
, O O
20 O O
% O O
; O O
18 O O
- O O
deoxyaldosterone O O
, O O
5 O O
. O O
8 O O
% O O
; O O
18 O O
- O O
deoxy O O
- O O
19 O O
- O O
noraldosterone O O
, O O
4 O O
. O O
7 O O
% O O
; O O
18 O O
, O O
21 O O
- O O
anhydroaldosterone O O
, O O
0 O O
. O O
37 O O
% O O
; O O
17 O O
- O O
isoaldosterone O O
, O O
7 O O
. O O
6 O O
% O O
and O O
apoaldosterone O O
, O O
4 O O
. O O
3 O O
% O O
. O O

Cell O O
type O O
specificity O O
and O O
activation O O
requirements O O
for O O
NFAT O O
- O O
1 O O
( O O
nuclear O O
factor O O
of O O
activated O O
T O O
- O O
cells O O
) O O
transcriptional O O
activity O O
determined O O
by O O
a O O
new O O
method O O
using O O
transgenic O O
mice O O
to O O
assay O O
transcriptional O O
activity O O
of O O
an O O
individual O O
nuclear O O
factor O O
. O O

Nuclear O O
factor O O
of O O
activated O O
T O O
- O O
cells O O
( O O
NFAT O O
- O O
1 O O
) O O
is O O
a O O
transcription O O
factor O O
which O O
is O O
considered O O
to O O
be O O
an O O
important O O
regulator O O
in O O
early O O
T O O
- O O
cell O O
activation O O
. O O

We O O
have O O
developed O O
a O O
system O O
to O O
monitor O O
the O O
transcriptional O O
activity O O
of O O
NFAT O O
- O O
1 O O
at O O
the O O
single O O
cell O O
level O O
in O O
whole O O
animals O O
. O O

The O O
system O O
is O O
based O O
on O O
the O O
use O O
of O O
an O O
oligomerized O O
NFAT O B-DNA
- O I-DNA
1 O I-DNA
binding O I-DNA
motif O I-DNA
that O O
directs O O
transcription O O
of O O
SV40 O O
T O O
- O O
antigen O O
in O O
transgenic O O
mice O O
. O O

This O O
report O O
represents O O
the O O
first O O
demonstration O O
that O O
a O O
multimerized O B-DNA
short O I-DNA
binding O I-DNA
motif O I-DNA
can O O
function O O
appropriately O O
in O O
transgenic O O
mice O O
. O O

NFAT O O
- O O
1 O O
activity O O
had O O
previously O O
been O O
thought O O
to O O
be O O
confined O O
to O O
activated O O
T O O
- O O
lymphocytes O O
upon O O
release O O
of O O
intracellular O O
calcium O O
. O O

By O O
targeting O O
NFAT O O
- O O
1 O O
- O O
dependent O O
gene O O
expression O O
in O O
transgenic O O
mice O O
we O O
discovered O O
new O O
sites O O
of O O
NFAT O O
- O O
1 O O
activity O O
. O O

Besides O O
in O O
T O O
- O O
lymphocytes O O
NFAT O O
- O O
1 O O
activity O O
could O O
also O O
be O O
induced O O
in O O
T O O
- O O
lymphocyte O O
- O O
depleted O O
spleen O O
cells O O
and O O
purified O O
B O O
- O O
lymphocytes O O
and O O
requires O O
agents O O
that O O
both O O
release O O
intracellular O O
calcium O O
and O O
activate O O
protein O O
kinase O O
C O O
. O O

A O O
difference O O
in O O
the O O
time O O
course O O
of O O
appearance O O
of O O
NFAT O O
- O O
1 O O
activity O O
between O O
T O O
- O O
lymphocytes O O
and O O
non O O
- O O
T O O
- O O
lymphocytes O O
was O O
revealed O O
. O O

Constitutive O O
expression O O
was O O
observed O O
in O O
a O O
small O O
population O O
of O O
cells O O
in O O
the O O
dermis O O
and O O
some O O
mice O O
have O O
developed O O
skin O O
lesions O O
. O O

Interestingly O O
, O O
the O O
tissue O O
pattern O O
of O O
expression O O
of O O
the O O
NFAT O O
- O O
1 O O
activity O O
resembles O O
the O O
expression O O
pattern O O
described O O
for O O
HIV O O
- O O
LTR O O
/ O O
tat O O
transgenic O O
mice O O
( O O
Vogel O O
, O O
J O O
. O O
, O O
Hinrichs O O
, O O
S O O
. O O
H O O
. O O
, O O
Reynolds O O
, O O
R O O
. O O
K O O
. O O
, O O
Luciw O O
, O O
P O O
. O O
A O O
. O O
, O O
and O O
Jay O O
, O O
G O O
. O O
( O O
1988 O O
) O O
Nature O O
335 O O
, O O
606 O O
- O O
611 O O
) O O
. O O

This O O
similarity O O
in O O
expression O O
and O O
the O O
fact O O
that O O
NFAT O O
- O O
1 O O
has O O
been O O
shown O O
to O O
bind O O
functional B-DNA O
sequences I-DNA O
in O O
HIV B-DNA B-DNA
- I-DNA I-DNA
LTR I-DNA I-DNA
suggest O O
a O O
role O O
for O O
NFAT O O
- O O
1 O O
in O O
dermal O O
activation O O
of O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
LTR I-DNA I-DNA
. O O

A O O
novel O O
T O O
- O O
cell O O
protein O O
which O O
recognizes O O
a O O
palindromic B-DNA B-DNA
sequence I-DNA I-DNA
in O O
the O O
negative B-DNA B-DNA
regulatory I-DNA I-DNA
element I-DNA I-DNA
of O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
. O O

Two O O
major B-DNA O
protein I-DNA B-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
within O O
the O O
negative B-DNA B-DNA
regulatory I-DNA I-DNA
element I-DNA I-DNA
of O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
1 I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
have O O
been O O
identified O O
. O O

One O O
( O O
site B-DNA B-DNA
B I-DNA I-DNA
) O O
contained O O
a O O
palindromic B-DNA B-DNA
sequence I-DNA I-DNA
with O O
homology O O
to O O
steroid B-DNA B-DNA
/ I-DNA I-DNA
thyroid I-DNA I-DNA
hormone I-DNA I-DNA
response I-DNA I-DNA
elements I-DNA I-DNA
but O O
was O O
distinct O O
from O O
previously O O
described O O
binding O B-DNA
sites O I-DNA
of O O
this O O
class O O
. O O

A O O
novel O O
T O O
- O O
cell O O
protein O O
recognized O O
the O O
palindromic B-DNA B-DNA
sequence I-DNA I-DNA
within O O
site B-DNA B-DNA
B I-DNA I-DNA
and O O
also O O
bound O O
estrogen O O
- O O
or O O
thyroid O O
hormone O O
- O O
response O O
elements O O
with O O
lower O O
affinity O O
. O O

A O O
7 O O
- O O
base O O
- O O
pair O O
mutation O O
in O O
the O O
site B-DNA B-DNA
B I-DNA I-DNA
palindrome I-DNA I-DNA
, O O
which O O
destroyed O O
protein O O
binding O O
, O O
resulted O O
in O O
increased O O
expression O O
from O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
1 I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
in O O
T O O
cells O O
. O O

Progesterone O O
suppression O O
of O O
pregnancy O O
lymphocytes O O
is O O
not O O
mediated O O
by O O
glucocorticoid O O
effect O O
. O O

This O O
study O O
investigated O O
whether O O
the O O
suppressive O O
effect O O
of O O
progesterone O O
on O O
pregnancy O O
lymphocytes O O
is O O
mediated O O
by O O
specific O O
progesterone O O
receptors O O
. O O

The O O
effects O O
of O O
a O O
competitive O O
progesterone O O
antagonist O O
( O O
RU486 O O
) O O
and O O
a O O
specific O O
glucocorticoid O O
receptor O O
blocker O O
( O O
RU43044 O O
) O O
were O O
tested O O
on O O
the O O
release O O
of O O
a O O
blocking O O
factor O O
by O O
progesterone O O
- O O
treated O O
pregnancy O O
lymphocytes O O
. O O

RU O O
486 O O
tested O O
at O O
an O O
equal O O
concentration O O
as O O
progesterone O O
significantly O O
inhibited O O
the O O
production O O
of O O
the O O
blocking O O
factor O O
, O O
while O O
RU O O
43044 O O
was O O
without O O
effect O O
. O O

These O O
data O O
suggest O O
that O O
in O O
pregnancy O O
, O O
lymphocyte O O
progesterone O O
acts O O
on O O
specific O O
progesterone O O
receptors O O
and O O
glucocorticoid O O
binding O O
sites O O
are O O
not O O
involved O O
. O O

The O O
56 O O
- O O
59 O O
- O O
kilodalton O O
protein O O
identified O O
in O O
untransformed O O
steroid O O
receptor O O
complexes O O
is O O
a O O
unique O O
protein O O
that O O
exists O O
in O O
cytosol O O
in O O
a O O
complex O O
with O O
both O O
the O O
70 O O
- O O
and O O
90 O O
- O O
kilodalton O O
heat O O
shock O O
proteins O O
. O O

It O O
has O O
previously O O
been O O
shown O O
that O O
9S O O
, O O
untransformed O O
progestin O O
, O O
estrogen O O
, O O
androgen O O
, O O
and O O
glucocorticoid O O
receptor O O
complexes O O
in O O
rabbit O O
uterine O O
and O O
liver O O
cytosols O O
contain O O
a O O
59 O O
- O O
kDa O O
protein O O
[ O O
Tai O O
, O O
P O O
. O O
K O O
. O O
, O O
Maeda O O
, O O
Y O O
. O O
, O O
Nakao O O
, O O
K O O
. O O
, O O
Wakim O O
, O O
N O O
. O O
G O O
. O O
, O O
Duhring O O
, O O
J O O
. O O
L O O
. O O
, O O
& O O
Faber O O
, O O
L O O
. O O
E O O
. O O
( O O
1986 O O
) O O
Biochemistry O O
25 O O
, O O
5269 O O
- O O
5275 O O
] O O
. O O

In O O
this O O
work O O
we O O
show O O
that O O
the O O
monoclonal O O
antibody O O
KN O O
382 O O
/ O O
EC1 O O
raised O O
against O O
the O O
rabbit O O
59 O O
- O O
kDa O O
protein O O
reacts O O
with O O
9S O O
, O O
untransformed O O
glucocorticoid O O
receptor O O
complexes O O
in O O
cytosol O O
prepared O O
from O O
human O O
IM O O
- O O
9 O O
lymphocytes O O
but O O
not O O
with O O
4S O O
salt O O
- O O
transformed O O
receptors O O
. O O

The O O
human O O
protein O O
recognized O O
by O O
the O O
EC1 O O
antibody O O
is O O
a O O
56 O O
- O O
kDa O O
protein O O
( O O
p56 O O
) O O
of O O
moderate O O
abundance O O
located O O
predominantly O O
in O O
the O O
cytoplasm O O
by O O
indirect O O
immunofluorescence O O
. O O

There O O
are O O
at O O
least O O
six O O
isomorphs O O
of O O
p56 O O
by O O
two O O
- O O
dimensional O O
gel O O
analysis O O
. O O

N O O
- O O
Terminal O O
sequencing O O
( O O
20 O O
amino O O
acids O O
) O O
shows O O
that O O
p56 O O
is O O
a O O
unique O O
human O O
protein O O
. O O

When O O
p56 O O
is O O
immunoadsorbed O O
from O O
IM O O
- O O
9 O O
cell O O
cytosol O O
, O O
both O O
the O O
70 O O
- O O
and O O
90 O O
- O O
kDa O O
heat O O
shock O O
proteins O O
are O O
coadsorbed O O
in O O
an O O
immune O O
- O O
specific O O
manner O O
. O O

Neither O O
heat O O
shock O O
protein O O
reacts O O
directly O O
with O O
the O O
EC1 O O
antibody O O
. O O

We O O
conclude O O
that O O
p56 O O
exists O O
in O O
cytosol O O
in O O
a O O
higher O O
order O O
complex O O
containing O O
hsp70 O O
and O O
hsp90 O O
, O O
both O O
of O O
which O O
in O O
turn O O
have O O
been O O
found O O
to O O
be O O
associated O O
with O O
untransformed O O
steroid O O
receptors O O
. O O

Sequence O O
- O O
specific O O
DNA O O
binding O O
of O O
the O O
proto O B-DNA
- O I-DNA
oncoprotein O I-DNA
ets O I-DNA
- O I-DNA
1 O I-DNA
defines O O
a O O
transcriptional B-DNA B-DNA
activator I-DNA I-DNA
sequence I-DNA I-DNA
within O O
the O O
long B-DNA B-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
of O O
the O O
Moloney O O
murine O O
sarcoma O O
virus O O
. O O

The O O
ets B-DNA B-DNA
proto I-DNA I-DNA
- I-DNA I-DNA
oncogene I-DNA I-DNA
family I-DNA I-DNA
is O O
a O O
group O O
of O O
sequence B-DNA B-DNA
- I-DNA I-DNA
related I-DNA I-DNA
genes I-DNA I-DNA
whose O O
normal O O
cellular O O
function O O
is O O
unknown O O
. O O

In O O
a O O
study O O
of O O
cellular O O
proteins O O
involved O O
in O O
the O O
transcriptional O O
regulation O O
of O O
murine O O
retroviruses O O
in O O
T O O
lymphocytes O O
, O O
we O O
have O O
discovered O O
that O O
a O O
member O O
of O O
the O O
ets B-DNA B-DNA
gene I-DNA I-DNA
family I-DNA I-DNA
encodes O O
a O O
sequence O O
- O O
specific O O
DNA O O
- O O
binding O O
protein O O
. O O

A O O
mouse B-DNA B-DNA
ets I-DNA I-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
cDNA I-DNA I-DNA
clone I-DNA I-DNA
was O O
obtained O O
by O O
screening O O
a O O
mouse B-DNA B-DNA
thymus I-DNA I-DNA
cDNA I-DNA I-DNA
expression I-DNA I-DNA
library I-DNA I-DNA
with O O
a O O
double B-DNA B-DNA
- I-DNA I-DNA
stranded I-DNA I-DNA
oligonucleotide I-DNA I-DNA
probe I-DNA I-DNA
representing O O
20 O O
bp O O
of O O
the O O
Moloney O B-DNA
murine O I-DNA
sarcoma O I-DNA
virus O I-DNA
( O I-DNA
MSV O I-DNA
) O I-DNA
long B-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
. O O

The O O
cDNA B-DNA B-DNA
sequence I-DNA I-DNA
has O O
an O O
813 B-DNA B-DNA
- I-DNA I-DNA
bp I-DNA I-DNA
open I-DNA I-DNA
reading I-DNA I-DNA
frame I-DNA I-DNA
( O O
ORF B-DNA B-DNA
) O O
whose O O
predicted O O
amino O O
acid O O
sequence O O
is O O
97 O O
. O O
6 O O
% O O
identical O O
to O O
the O O
272 O O
carboxy O O
- O O
terminal O O
amino O O
acids O O
of O O
the O O
human O O
ets O O
- O O
1 O O
protein O O
. O O

The O O
ORF B-DNA B-DNA
was O O
expressed O O
in O O
bacteria O O
, O O
and O O
the O O
30 O O
- O O
kD O O
protein O O
product O O
was O O
shown O O
to O O
bind O O
DNA B-DNA O
in O O
a O O
sequence O O
- O O
specific O O
manner O O
by O O
mobility O O
- O O
shift O O
assays O O
, O O
Southwestern O O
blot O O
analysis O O
, O O
and O O
methylation O O
interference O O
. O O

A O O
mutant B-DNA B-DNA
LTR I-DNA I-DNA
containing O O
four O O
base O B-DNA
pair O I-DNA
substitutions O I-DNA
in O O
the O O
ets B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
was O O
constructed O O
and O O
was O O
shown O O
to O O
have O O
reduced O O
binding O O
in O O
vitro O O
. O O

Transcriptional O O
efficiency O O
of O O
the O O
MSV B-DNA B-DNA
LTR I-DNA I-DNA
promoter I-DNA I-DNA
containing O O
this O O
disrupted O O
ets B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
was O O
compared O O
to O O
the O O
activity O O
of O O
a O O
wild B-DNA B-DNA
- I-DNA I-DNA
type I-DNA I-DNA
promoter I-DNA I-DNA
in O O
mouse O O
T O O
lymphocytes O O
in O O
culture O O
, O O
and O O
15 O O
- O O
to O O
20 O O
- O O
fold O O
reduction O O
in O O
expression O O
of O O
a O O
reporter B-DNA B-DNA
gene I-DNA I-DNA
was O O
observed O O
. O O

We O O
propose O O
that O O
ets O B-DNA
- O I-DNA
1 O I-DNA
functions O O
as O O
a O O
transcriptional O O
activator O O
of O O
mammalian O O
type O O
- O O
C O O
retroviruses O O
and O O
speculate O O
that O O
ets B-DNA B-DNA
- I-DNA I-DNA
related I-DNA I-DNA
genes I-DNA I-DNA
constitute O O
a O O
new O O
group O O
of O O
eukaryotic O O
DNA O O
- O O
binding O O
proteins O O
. O O

Type O O
II O O
estrogen O O
binding O O
sites O O
in O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
: O O
variations O O
during O O
the O O
menstrual O O
cycle O O
. O O

We O O
have O O
previously O O
reported O O
that O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
contain O O
type O B-DNA
II O I-DNA
estrogen O I-DNA
binding O I-DNA
sites O I-DNA
( O O
type O B-DNA
II O I-DNA
EBS O I-DNA
) O O
. O O

In O O
this O O
study O O
, O O
the O O
fluctuations O O
of O O
type O O
II O O
EBS O O
during O O
the O O
menstrual O O
cycle O O
were O O
analyzed O O
in O O
6 O O
normally O O
menstruating O O
women O O
. O O

Approximately O O
3 O O
times O O
higher O O
levels O O
of O O
type O O
II O O
EBS O O
were O O
found O O
in O O
the O O
periovulatory O O
period O O
with O O
respect O O
to O O
both O O
follicular O O
and O O
luteal O O
phases O O
. O O

In O O
postmenopausal O O
women O O
the O O
mean O O
type O O
II O O
EBS O O
levels O O
were O O
similar O O
to O O
those O O
observed O O
in O O
the O O
follicular O O
phase O O
of O O
the O O
cycle O O
. O O

However O O
, O O
in O O
3 O O
postmenopausal O O
patients O O
a O O
short O O
course O O
of O O
estrogen O O
or O O
tamoxifen O O
resulted O O
in O O
a O O
marked O O
increase O O
of O O
type O O
II O O
EBS O O
levels O O
. O O

Tamoxifen O O
was O O
also O O
found O O
to O O
compete O O
with O O
17 O O
beta O O
- O O
estradiol O O
for O O
type O O
II O O
EBS O O
in O O
PBMC O O
, O O
although O O
to O O
a O O
lesser O O
extent O O
than O O
diethylstilbestrol O O
. O O

Mononuclear O O
leukocyte O O
glucocorticoid O O
receptor O O
binding O O
characteristics O O
and O O
down O O
- O O
regulation O O
in O O
major O O
depression O O
. O O

Some O O
patients O O
with O O
major O O
depressive O O
disorder O O
( O O
MDD O O
) O O
have O O
elevated O O
plasma O O
cortisol O O
concentrations O O
and O O
show O O
failure O O
to O O
suppress O O
cortisol O O
secretion O O
upon O O
administration O O
of O O
dexamethasone O O
( O O
DEX O O
) O O
, O O
yet O O
they O O
do O O
not O O
have O O
Cushingoid O O
features O O
. O O

To O O
study O O
whether O O
this O O
represents O O
glucocorticoid O O
( O O
GC O O
) O O
resistance O O
, O O
[ O O
3H O O
] O O
- O O
DEX O O
- O O
binding O O
assays O O
were O O
used O O
to O O
measure O O
, O O
in O O
vitro O O
, O O
the O O
GC O O
receptor O O
affinity O O
( O O
1 O O
/ O O
Kd O O
) O O
and O O
number O O
( O O
Bmax O O
) O O
in O O
mononuclear O O
leukocytes O O
of O O
11 O O
MDD O O
patients O O
and O O
15 O O
control O O
subjects O O
. O O

No O O
receptor O O
abnormalities O O
were O O
detected O O
in O O
the O O
MDD O O
group O O
; O O
thus O O
any O O
cellular O O
defect O O
leading O O
to O O
a O O
lack O O
of O O
responsiveness O O
to O O
GC O O
in O O
the O O
MDD O O
patients O O
, O O
if O O
present O O
, O O
probably O O
lies O O
beyond O O
the O O
initial O O
receptor O O
binding O O
. O O

DEX O O
( O O
1 O O
. O O
0 O O
mg O O
orally O O
) O O
was O O
administered O O
to O O
study O O
in O O
vivo O O
GC O O
receptor O O
down O O
- O O
regulation O O
. O O

Compared O O
to O O
the O O
control O O
group O O
, O O
fewer O O
depressed O O
subjects O O
down O O
- O O
regulated O O
Bmax O O
after O O
DEX O O
. O O

By O O
paired O O
t O O
- O O
test O O
, O O
Bmax O O
decreased O O
significantly O O
in O O
the O O
control O O
group O O
but O O
not O O
in O O
the O O
depressed O O
group O O
. O O

Receptor O O
number O O
on O O
the O O
control O O
day O O
did O O
not O O
correlate O O
significantly O O
with O O
the O O
degree O O
of O O
receptor O O
down O O
- O O
regulation O O
, O O
severity O O
of O O
depression O O
or O O
cortisol O O
concentrations O O
across O O
all O O
the O O
subjects O O
. O O

These O O
results O O
do O O
not O O
lend O O
support O O
to O O
previous O O
reports O O
suggesting O O
that O O
GC O O
resistance O O
in O O
MDD O O
results O O
from O O
a O O
GC O O
receptor O O
- O O
binding O O
abnormality O O
, O O
and O O
they O O
emphasize O O
the O O
importance O O
of O O
considering O O
receptor O O
studies O O
in O O
the O O
context O O
of O O
GC O O
- O O
mediated O O
cell O O
processes O O
in O O
order O O
to O O
identify O O
the O O
exact O O
cellular O O
defect O O
( O O
s O O
) O O
leading O O
to O O
GC O O
resistance O O
. O O

Ras O O
- O O
related O O
GTP O O
- O O
binding O O
proteins O O
and O O
leukocyte O O
signal O O
transduction O O
. O O

Many O O
aspects O O
of O O
leukocyte O O
function O O
are O O
regulated O O
by O O
both O O
heterotrimeric O O
and O O
Ras O O
- O O
related O O
GTP O O
- O O
binding O O
proteins O O
, O O
but O O
there O O
is O O
little O O
definite O O
information O O
about O O
their O O
roles O O
in O O
the O O
specialized O O
processes O O
utilized O O
by O O
leukocytes O O
for O O
cell O O
killing O O
. O O

Recent O O
progress O O
in O O
understanding O O
the O O
regulation O O
of O O
the O O
phagocyte O O
NADPH O O
oxidase O O
by O O
the O O
Rac O O
GTP O O
- O O
binding O O
proteins O O
provides O O
a O O
basis O O
for O O
defining O O
the O O
operational O O
characteristics O O
of O O
one O O
such O O
phagocyte O O
system O O
. O O

It O O
is O O
clear O O
from O O
various O O
studies O O
that O O
the O O
activity O O
of O O
the O O
NADPH O O
oxidase O O
can O O
be O O
modulated O O
through O O
the O O
regulation O O
of O O
the O O
GTP O O
- O O
GDP O O
state O O
of O O
Rac O O
. O O

Proteins O O
exist O O
in O O
leukocytes O O
able O O
to O O
modify O O
GTP O O
- O O
binding O O
protein O O
function O O
in O O
this O O
manner O O
, O O
and O O
their O O
activity O O
may O O
be O O
regulated O O
by O O
signals O O
generated O O
on O O
phagocyte O O
stimulation O O
. O O

Proteins O O
of O O
the O O
Ras O O
superfamily O O
are O O
likely O O
to O O
be O O
involved O O
in O O
a O O
variety O O
of O O
normal O O
phagocyte O O
functions O O
through O O
their O O
ability O O
to O O
modulate O O
the O O
assembly O O
of O O
actin O O
filaments O O
, O O
direct O O
vesicle O O
trafficking O O
and O O
fusion O O
, O O
and O O
so O O
forth O O
. O O

BSAP O O
: O O
a O O
key O O
regulator O O
of O O
B O O
- O O
cell O O
development O O
and O O
differentiation O O
. O O

B O O
- O O
cell O O
- O O
specific O O
activator O O
protein O O
( O O
BSAP O O
) O O
is O O
a O O
recently O O
identified O O
member O O
of O O
the O O
Pax B-DNA B-DNA
- I-DNA I-DNA
gene I-DNA I-DNA
family I-DNA I-DNA
of O O
transcription O O
factors O O
; O O
in O O
the O O
lymphoid O O
system O O
, O O
BSAP O O
is O O
produced O O
only O O
in O O
B O O
cells O O
. O O

Here O O
, O O
Markus O O
Neurath O O
, O O
Eckhard O O
Stuber O O
and O O
Warren O O
Strober O O
describe O O
the O O
molecular O O
structure O O
of O O
BSAP O O
and O O
focus O O
on O O
the O O
ability O O
of O O
this O O
protein O O
to O O
regulate O O
the O O
expression O O
of O O
B B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
genes I-DNA I-DNA
. O O

They O O
propose O O
that O O
BSAP O O
is O O
a O O
key O O
protein O O
of O O
B O O
cells O O
and O O
that O O
it O O
not O O
only O O
influence O O
B O O
- O O
cell O O
development O O
but O O
also O O
influences O O
the O O
balance O O
between O O
B O O
- O O
cell O O
proliferation O O
and O O
immunoglobulin O O
secretion O O
at O O
later O O
stages O O
of O O
B O O
- O O
cell O O
differentiation O O
. O O

Down O O
- O O
regulation O O
of O O
NF O O
- O O
kappa O O
B O O
protein O O
levels O O
in O O
activated O O
human O O
lymphocytes O O
by O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
[ O O
published O O
erratum O O
appears O O
in O O
Proc O O
Natl O O
Acad O O
Sci O O
U O O
S O O
A O O
1996 O O
Jan O O
9 O O
; O O
93 O O
( O O
1 O O
) O O
: O O
524 O O
] O O
. O O

The O O
effect O O
of O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
[ O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2 O O
) O O
D3 O O
] O O
, O O
a O O
steroid O O
hormone O O
with O O
immunomodulating O O
properties O O
, O O
on O O
nuclear O O
factor O O
kappa O O
B O O
( O O
NF O O
- O O
kappa O O
B O O
) O O
proteins O O
was O O
examined O O
in O O
in O O
vitro O O
activated O O
normal O O
human O O
lymphocytes O O
by O O
Western O O
blot O O
analysis O O
. O O

Over O O
a O O
72 O O
- O O
hr O O
period O O
of O O
activation O O
, O O
the O O
expression O O
of O O
the O O
50 O O
- O O
kDa O O
NF O O
- O O
kappa O O
B O O
, O O
p50 O O
, O O
and O O
its O O
precursor O O
, O O
p105 O O
, O O
was O O
increased O O
progressively O O
. O O

When O O
cells O O
were O O
activated O O
in O O
the O O
presence O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
, O O
the O O
levels O O
of O O
the O O
mature O O
protein O O
as O O
well O O
as O O
its O O
precursor O O
were O O
decreased O O
. O O

The O O
effect O O
of O O
the O O
hormone O O
on O O
the O O
levels O O
of O O
p50 O O
was O O
demonstrable O O
in O O
the O O
cytosolic O O
and O O
nuclear O O
compartments O O
; O O
it O O
required O O
between O O
4 O O
and O O
8 O O
hr O O
and O O
was O O
specific O O
, O O
as O O
25 O O
- O O
hydroxyvitamin O O
D3 O O
and O O
24 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
were O O
ineffective O O
. O O

Besides O O
p50 O O
, O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
decreased O O
the O O
levels O O
of O O
another O O
NF O O
- O O
kappa O O
B O O
protein O O
, O O
namely O O
c O O
- O O
rel O O
. O O

In O O
addition O O
, O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
decreased O O
the O O
abundance O O
of O O
a O O
specific O O
DNA O O
- O O
protein O O
complex O O
formed O O
upon O O
incubation O O
of O O
nuclear O O
extracts O O
from O O
activated O O
lymphocytes O O
with O O
a O O
labeled O O
NF O B-DNA
- O I-DNA
kappa O I-DNA
B O I-DNA
DNA O I-DNA
binding O I-DNA
motif O I-DNA
. O O

Further O O
, O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
inhibited O O
the O O
transcriptional O O
activity O O
of O O
NF O O
- O O
kappa O O
B O O
in O O
Jurkat O O
cells O O
transiently O O
transfected O O
with O O
a O O
construct B-DNA O
containing O O
four O O
tandem B-DNA B-DNA
repeats I-DNA I-DNA
of O O
the O O
NF B-DNA B-DNA
- I-DNA I-DNA
kappa I-DNA I-DNA
B I-DNA I-DNA
binding I-DNA I-DNA
sequence I-DNA I-DNA
of O O
the O O
immunoglobulin B-DNA B-DNA
kappa I-DNA I-DNA
light I-DNA I-DNA
chain I-DNA I-DNA
gene I-DNA I-DNA
linked O O
to O O
the O O
chloramphenicol B-DNA B-DNA
acetyltransferase I-DNA I-DNA
reporter I-DNA I-DNA
gene I-DNA I-DNA
. O O

These O O
observations O O
demonstrate O O
directly O O
that O O
there O O
is O O
de O O
novo O O
synthesis O O
of O O
NF O O
- O O
kappa O O
B O O
during O O
human O O
lymphocyte O O
activation O O
and O O
suggest O O
that O O
this O O
process O O
is O O
hormonally O O
regulated O O
. O O

The O O
myeloid B-DNA B-DNA
zinc I-DNA I-DNA
finger I-DNA I-DNA
gene I-DNA I-DNA
, O O
MZF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
, O O
regulates O O
the O O
CD34 B-DNA B-DNA
promoter I-DNA I-DNA
in O O
vitro O O
. O O

MZF B-DNA O
- I-DNA O
1 I-DNA O
is O O
a O O
C2H2 B-DNA B-DNA
zinc I-DNA I-DNA
finger I-DNA I-DNA
gene I-DNA I-DNA
encoding O O
a O O
putative O O
transcriptional O O
regulator O O
of O O
myeloid O O
differentiation O O
. O O

The O O
MZF B-DNA O
- I-DNA O
1 I-DNA O
protein O O
contains O O
13 O O
C2H2 O O
zinc O O
fingers O O
arranged O O
in O O
bipartite O O
DNA O O
binding O O
domains O O
containing O O
zinc O O
fingers O O
through O O
4 O O
and O O
, O O
in O O
the O O
carboxy O O
- O O
terminus O O
, O O
5 O O
through O O
13 O O
. O O

We O O
previously O O
identified O O
the O O
DNA B-DNA B-DNA
consensus I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
recognized O O
by O O
the O O
two O O
DNA O B-DNA
binding O I-DNA
domains O I-DNA
. O O

To O O
assess O O
the O O
transcription O O
regulatory O O
function O O
of O O
MZF B-DNA O
- I-DNA O
1 I-DNA O
, O O
the O O
full O O
- O O
length O O
MZF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
coding O I-DNA
region O I-DNA
was O O
fused O O
to O O
the O O
DNA O O
binding O O
domain O O
of O O
the O O
yeast O O
transactivator O O
GAL4 O O
. O O

The O O
expression O B-DNA
vector O I-DNA
was O O
cotransfected O O
with O O
the O O
chloramphenicol B-DNA B-DNA
acetyl I-DNA I-DNA
transferase I-DNA I-DNA
( I-DNA I-DNA
CAT I-DNA I-DNA
) I-DNA I-DNA
reporter I-DNA I-DNA
gene I-DNA I-DNA
regulated O O
by O O
the O O
thymidine B-DNA B-DNA
kinase I-DNA I-DNA
promoter I-DNA I-DNA
containing O O
GAL4 B-DNA B-DNA
DNA I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
into O O
NIH O O
3T3 O O
, O O
293 O O
, O O
K562 O O
, O O
and O O
Jurkat O O
cell O O
lines O O
. O O

MZF B-DNA O
- I-DNA O
1 I-DNA O
represses O O
CAT B-DNA B-DNA
reporter I-DNA I-DNA
gene I-DNA I-DNA
expression O O
via O O
GAL4 O B-DNA
binding O I-DNA
sites O I-DNA
in O O
the O O
nonhematopoietic O O
cell O O
lines O O
NIH O O
3T3 O O
and O O
293 O O
. O O

In O O
contrast O O
, O O
MZF B-DNA O
- I-DNA O
1 I-DNA O
activates O O
CAT B-DNA B-DNA
reporter I-DNA I-DNA
gene I-DNA I-DNA
expression O O
in O O
the O O
hematopoietic O O
cell O O
lines O O
K562 O O
and O O
Jurkat O O
. O O

The O O
MZF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
are O O
present O O
in O O
the O O
promoters B-DNA B-DNA
of O O
several O O
genes B-DNA O
expressed O O
during O O
myeloid O O
differentiation O O
, O O
including O O
the O O
CD34 B-DNA B-DNA
promoter I-DNA I-DNA
. O O

MZF B-DNA O
- I-DNA O
1 I-DNA O
transcriptional O O
regulation O O
of O O
this O O
physiologically B-DNA O
relevant I-DNA O
promoter I-DNA O
was O O
assessed O O
in O O
both O O
hematopoietic O O
and O O
nonhematopoietic O O
cell O O
lines O O
. O O

Recombinant O O
MZF B-DNA O
- I-DNA O
1 I-DNA O
protein O O
specifically O O
binds O O
to O O
the O O
consensus B-DNA B-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
in O O
the O O
CD34 B-DNA B-DNA
promoter I-DNA I-DNA
in O O
mobility O O
shift O O
assays O O
. O O

MZF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
expression O I-DNA
vectors O I-DNA
were O O
cotransfected O O
with O O
the O O
luciferase B-DNA B-DNA
reporter I-DNA I-DNA
plasmids I-DNA I-DNA
regulated O O
by O O
the O O
CD34 B-DNA B-DNA
promoter I-DNA I-DNA
into O O
both O O
nonhematopoietic O O
and O O
hematopoietic O O
cell O O
lines O O
. O O

As O O
with O O
the O O
heterologous O O
DNA O O
binding O O
domain O O
, O O
MZF B-DNA O
- I-DNA O
1 I-DNA O
represses O O
reporter B-DNA B-DNA
gene I-DNA I-DNA
expression O O
in O O
nonhematopoietic O O
cell O O
lines O O
and O O
activates O O
expression O O
in O O
hematopoietic O O
cell O O
lines O O
. O O

Activation O O
of O O
CD34 O O
expression O O
in O O
hematopoietic O O
cell O O
lines O O
is O O
dependent O O
on O O
the O O
presence O O
of O O
intact O O
MZF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
. O O

The O O
cell O O
type O O
- O O
specific O O
regulation O O
of O O
the O O
CD34 B-DNA B-DNA
promoter I-DNA I-DNA
by O O
MZF B-DNA O
- I-DNA O
1 I-DNA O
suggests O O
the O O
presence O O
of O O
tissue O O
- O O
specific O O
regulators O O
/ O O
adapters O O
or O O
differential O O
MZF B-DNA O
- I-DNA O
1 I-DNA O
modifications O O
that O O
determine O O
MZF B-DNA O
- I-DNA O
1 I-DNA O
transcriptional O O
regulatory O O
function O O
. O O

The O O
murine O B-DNA
BCL6 B-DNA I-DNA
gene I-DNA I-DNA
is O O
induced O O
in O O
activated O O
lymphocytes O O
as O O
an O O
immediate B-DNA B-DNA
early I-DNA I-DNA
gene I-DNA I-DNA
. O O

The O O
chromosomal O O
translocation O O
involving O O
3q27 B-DNA B-DNA
is O O
often O O
detected O O
in O O
human O O
B O O
- O O
cell O O
lymphomas O O
, O O
especially O O
diffuse O O
lymphomas O O
with O O
a O O
large O O
- O O
cell O O
component O O
. O O

The O O
BCL6 B-DNA B-DNA
gene I-DNA I-DNA
has O O
been O O
isolated O O
from O O
the O O
chromosomal O O
breakpoint O O
in O O
these O O
lymphomas O O
. O O

Here O O
we O O
cloned O O
the O O
murine B-DNA B-DNA
BCL6 I-DNA I-DNA
( I-DNA I-DNA
mBCL6 I-DNA I-DNA
) I-DNA I-DNA
cDNA I-DNA I-DNA
from O O
the O O
muscle B-DNA B-DNA
cDNA I-DNA I-DNA
library I-DNA I-DNA
using O O
the O O
human B-DNA B-DNA
BCL6 I-DNA I-DNA
( I-DNA I-DNA
hBCL6 I-DNA I-DNA
) I-DNA I-DNA
cDNA I-DNA I-DNA
as O O
a O O
probe O O
. O O

The O O
predicted O O
amino O O
acid O O
sequence O O
was O O
95 O O
% O O
identical O O
to O O
that O O
of O O
hBCL6 O O
. O O

It O O
contains O O
six O O
repeats O O
of O O
the O O
Kruppel O B-DNA
- O I-DNA
like O I-DNA
zinc O I-DNA
- O I-DNA
finger O I-DNA
motif O I-DNA
that O O
are O O
completely O O
identical O O
to O O
those O O
of O O
hBCL6 O O
, O O
indicating O O
that O O
the O O
BCL6 B-DNA B-DNA
gene I-DNA I-DNA
is O O
well O O
conserved O O
between O O
humans O O
and O O
mice O O
. O O

Expression O O
of O O
the O O
mBCL6 B-DNA B-DNA
gene I-DNA I-DNA
was O O
ubiquitously O O
detected O O
in O O
adult O O
mouse O O
tissues O O
including O O
lymphatic O O
organs O O
. O O

Furthermore O O
, O O
it O O
was O O
induced O O
in O O
lymphocytes O O
activated O O
with O O
phorbol O O
ester O O
and O O
Ca2 O O
+ O O
ionophore O O
within O O
30 O O
min O O
after O O
stimulation O O
. O O

This O O
induction O O
was O O
not O O
inhibited O O
by O O
treatment O O
of O O
the O O
cells O O
with O O
a O O
protein O O
synthesis O O
inhibitor O O
, O O
cycloheximide O O
. O O

These O O
results O O
suggest O O
that O O
BCL6 O O
plays O O
a O O
role O O
in O O
activated O O
lymphocytes O O
as O O
an O O
immediate O B-DNA
early O I-DNA
gene O I-DNA
. O O

The O O
role O O
of O O
BSAP O O
( O O
Pax O O
- O O
5 O O
) O O
in O O
B O O
- O O
cell O O
development O O
. O O

The O O
hierarchy O O
of O O
transcriptional O O
control O O
in O O
B O O
- O O
cell O O
development O O
has O O
recently O O
been O O
analyzed O O
by O O
targeted O O
gene O O
inactivation O O
in O O
the O O
mouse O O
. O O

In O O
this O O
manner O O
, O O
the O O
paired B-DNA B-DNA
box I-DNA I-DNA
containing I-DNA O
gene I-DNA B-DNA
Pax B-DNA I-DNA
- I-DNA I-DNA
5 I-DNA I-DNA
, O O
encoding O O
the O O
B O O
cell O O
specific O O
transcription O O
factor O O
BSAP O O
, O O
has O O
been O O
shown O O
to O O
play O O
a O O
key O O
role O O
in O O
early O O
B O O
lymphopoiesis O O
. O O

Other O O
experimental O O
strategies O O
have O O
implicated O O
BSAP O O
in O O
the O O
control O O
of O O
cell O O
proliferation O O
, O O
isotype O O
switching O O
and O O
transcription O O
of O O
the O O
immunoglobulin B-DNA B-DNA
heavy I-DNA I-DNA
- I-DNA I-DNA
chain I-DNA I-DNA
gene I-DNA I-DNA
at O O
late O O
stages O O
of O O
B O O
- O O
cell O O
differentiation O O
. O O

The O O
DNA O O
- O O
binding O O
properties O O
of O O
two O O
heat O O
shock O O
factors O O
, O O
HSF1 O O
and O O
HSF3 O O
, O O
are O O
induced O O
in O O
the O O
avian O O
erythroblast O O
cell O O
line O O
HD6 O O
. O O

Avian O O
cells O O
express O O
three O O
heat B-DNA B-DNA
shock I-DNA I-DNA
transcription I-DNA I-DNA
factor I-DNA I-DNA
( I-DNA I-DNA
HSF I-DNA I-DNA
) I-DNA I-DNA
genes I-DNA I-DNA
corresponding O O
to O O
a O O
novel O O
factor O O
, O O
HSF3 O O
, O O
and O O
homologs O O
of O O
mouse O O
and O O
human O O
HSF1 O O
and O O
HSF2 O O
. O O

Analysis O O
of O O
the O O
biochemical O O
and O O
cell O O
biological O O
properties O O
of O O
these O O
HSFs O O
reveals O O
that O O
HSF3 O O
has O O
properties O O
in O O
common O O
with O O
both O O
HSF1 O O
and O O
HSF2 O O
and O O
yet O O
has O O
features O O
which O O
are O O
distinct O O
from O O
both O O
. O O

HSF3 O O
is O O
constitutively O O
expressed O O
in O O
the O O
erythroblast O O
cell O O
line O O
HD6 O O
, O O
the O O
lymphoblast O O
cell O O
line O O
MSB O O
, O O
and O O
embryo O O
fibroblasts O O
, O O
and O O
yet O O
its O O
DNA O O
- O O
binding O O
activity O O
is O O
induced O O
only O O
upon O O
exposure O O
of O O
HD6 O O
cells O O
to O O
heat O O
shock O O
. O O

Acquisition O O
of O O
HSF3 O O
DNA O O
- O O
binding O O
activity O O
in O O
HD6 O O
cells O O
is O O
accompanied O O
by O O
oligomerization O O
from O O
a O O
non O O
- O O
DNA O O
- O O
binding O O
dimer O O
to O O
a O O
DNA O O
- O O
binding O O
trimer O O
, O O
whereas O O
the O O
effect O O
of O O
heat O O
shock O O
on O O
HSF1 O O
is O O
oligomerization O O
of O O
an O O
inert O O
monomer O O
to O O
a O O
DNA O O
- O O
binding O O
trimer O O
. O O

Induction O O
of O O
HSF3 O O
DNA O O
- O O
binding O O
activity O O
is O O
delayed O O
compared O O
with O O
that O O
of O O
HSF1 O O
. O O

As O O
occurs O O
for O O
HSF1 O O
, O O
heat O O
shock O O
leads O O
to O O
the O O
translocation O O
of O O
HSF3 O O
to O O
the O O
nucleus O O
. O O

HSF O O
exhibits O O
the O O
properties O O
of O O
a O O
transcriptional O O
activator O O
, O O
as O O
judged O O
from O O
the O O
stimulatory O O
activity O O
of O O
transiently O O
overexpressed O O
HSF3 O O
measured O O
by O O
using O O
a O O
heat B-DNA B-DNA
shock I-DNA I-DNA
element I-DNA I-DNA
- I-DNA I-DNA
containing I-DNA I-DNA
reporter I-DNA I-DNA
construct I-DNA I-DNA
and O O
as O O
independently O O
assayed O O
by O O
the O O
activity O O
of O O
a O O
chimeric O O
GAL4 O O
- O O
HSF3 O O
protein O O
on O O
a O O
GAL4 B-DNA B-DNA
reporter I-DNA I-DNA
construct I-DNA I-DNA
. O O

These O O
results O O
reveal O O
that O O
HSF3 O O
is O O
negatively O O
regulated O O
in O O
avian O O
cells O O
and O O
acquires O O
DNA O O
- O O
binding O O
activity O O
in O O
certain O O
cells O O
upon O O
heat O O
shock O O
. O O

Direct O O
demonstration O O
of O O
NFATp O O
dephosphorylation O O
and O O
nuclear O O
localization O O
in O O
activated O O
HT O O
- O O
2 O O
cells O O
using O O
a O O
specific O O
NFATp O O
polyclonal O O
antibody O O
. O O

Nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
( O O
NFAT O O
) O O
regulates O O
transcription O O
of O O
a O O
number O O
of O O
cytokine O B-DNA
genes O I-DNA
, O O
and O O
NFAT O O
DNA O O
binding O O
activity O O
is O O
stimulated O O
following O O
T O O
cell O O
activation O O
. O O

Several O O
lines O O
of O O
evidence O O
have O O
suggested O O
that O O
NFAT O O
is O O
a O O
substrate O O
for O O
calcineurin O O
, O O
a O O
serine O O
/ O O
threonine O O
phosphatase O O
. O O

Using O O
a O O
polyclonal O O
antibody O O
to O O
murine O O
NFATp O O
, O O
Western O O
blot O O
analysis O O
of O O
various O O
mouse O O
tissues O O
demonstrated O O
that O O
the O O
110 O O
- O O
130 O O
- O O
kDa O O
NFATp O O
protein O O
was O O
highly O O
expressed O O
in O O
thymus O O
and O O
spleen O O
. O O

Treatment O O
of O O
immunoprecipitated O O
NFATp O O
from O O
untreated O O
HT O O
- O O
2 O O
cells O O
with O O
calcineurin O O
resulted O O
in O O
the O O
dephosphorylation O O
of O O
NFATp O O
, O O
demonstrating O O
that O O
NFATp O O
is O O
an O O
in O O
vitro O O
substrate O O
for O O
calcineurin O O
. O O

NFATp O O
immunoprecipitated O O
from O O
32P O O
- O O
labeled O O
HT O O
- O O
2 O O
cells O O
migrated O O
as O O
an O O
approximately O O
120 O O
- O O
kDa O O
protein O O
that O O
was O O
localized O O
to O O
the O O
cytosol O O
of O O
the O O
cells O O
. O O

Treatment O O
of O O
the O O
cells O O
with O O
ionomycin O O
resulted O O
in O O
a O O
decrease O O
in O O
the O O
molecular O O
weight O O
of O O
NFATp O O
and O O
a O O
loss O O
of O O
32P O O
, O O
consistent O O
with O O
NFATp O O
dephosphorylation O O
. O O

The O O
dephosphorylation O O
of O O
NFATp O O
was O O
accompanied O O
by O O
localization O O
of O O
the O O
protein O O
to O O
the O O
nuclear O O
fraction O O
. O O

Both O O
of O O
these O O
events O O
were O O
blocked O O
by O O
preincubation O O
of O O
the O O
cells O O
with O O
FK506 O O
, O O
a O O
calcineurin O O
inhibitor O O
, O O
consistent O O
with O O
the O O
hypothesis O O
that O O
NFATp O O
is O O
a O O
calcineurin O O
substrate O O
in O O
cells O O
. O O

Activation O O
and O O
expression O O
of O O
the O O
nuclear O O
factors O O
of O O
activated O O
T O O
cells O O
, O O
NFATp O O
and O O
NFATc O O
, O O
in O O
human O O
natural O O
killer O O
cells O O
: O O
regulation O O
upon O O
CD16 O O
ligand O O
binding O O
. O O

The O O
putative O O
factors O O
that O O
couple O O
the O O
signal O O
transduction O O
from O O
surface O O
receptors O O
to O O
the O O
activation O O
of O O
cytokine O O
synthesis O O
in O O
natural O O
killer O O
( O O
NK O O
) O O
cells O O
have O O
not O O
been O O
elucidated O O
. O O

We O O
report O O
here O O
that O O
the O O
nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
( O O
NFATp O O
) O O
, O O
a O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
- O O
sensitive O O
factor O O
that O O
regulates O O
the O O
transcription O O
of O O
several O O
cytokines O O
, O O
mediates O O
CD16 O O
- O O
induced O O
activation O O
of O O
cytokine O B-DNA
genes O I-DNA
in O O
human O O
NK O O
cells O O
. O O

CD16 O O
( O O
Fc O O
gamma O O
RIIIA O O
) O O
- O O
induced O O
expression O O
of O O
cytokine O O
mRNA O O
in O O
NK O O
cells O O
occurs O O
via O O
a O O
CsA O O
- O O
sensitive O O
and O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
mechanism O O
. O O

Stimulation O O
of O O
NK O O
cells O O
with O O
CD16 O O
ligands O O
induces O O
NFAT O O
- O O
like O O
DNA O O
binding O O
activity O O
in O O
the O O
nuclear O O
extracts O O
from O O
these O O
cells O O
, O O
as O O
detected O O
in O O
electrophoretic O O
mobility O O
shift O O
assays O O
. O O

This O O
occurs O O
with O O
fast O O
kinetics O O
after O O
stimulation O O
, O O
via O O
a O O
CsA O O
- O O
sensitive O O
and O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
mechanism O O
that O O
does O O
not O O
require O O
de O O
novo O O
protein O O
synthesis O O
. O O

NK O O
cell O O
NFAT O O
is O O
present O O
in O O
the O O
cytosol O O
of O O
nonstimulated O O
cells O O
, O O
migrates O O
to O O
the O O
nucleus O O
upon O O
stimulation O O
, O O
and O O
can O O
associate O O
with O O
AP O O
- O O
1 O O
. O O

Two O O
distinct O O
molecules O O
, O O
NFATp O O
and O O
NFATc O O
, O O
have O O
been O O
reported O O
to O O
mediate O O
NFAT O O
activity O O
. O O

The O O
results O O
of O O
supershift O O
assays O O
using O O
NFATp O O
- O O
and O O
NFATc O O
- O O
specific O O
antibodies O O
indicate O O
that O O
NK O O
cell O O
activation O O
early O O
after O O
CD16 O O
ligand O O
binding O O
involves O O
primarily O O
, O O
if O O
not O O
exclusively O O
, O O
NFATp O O
, O O
and O O
Western O O
blot O O
analysis O O
shows O O
that O O
this O O
has O O
the O O
same O O
electrophoretic O O
mobility O O
( O O
approximately O O
120 O O
kD O O
) O O
as O O
that O O
of O O
T O O
lymphocytes O O
. O O

NK O O
cells O O
do O O
not O O
express O O
NFATc O O
constitutively O O
, O O
but O O
NFATc O O
mRNA O O
accumulation O O
is O O
induced O O
in O O
these O O
cells O O
within O O
2 O O
h O O
of O O
stimulation O O
with O O
CD16 O O
ligands O O
. O O

However O O
, O O
supershift O O
assays O O
using O O
the O O
available O O
mAb O O
recognizing O O
the O O
T O O
cell O O
NFATc O O
revealed O O
no O O
detectable O O
NFATc O O
protein O O
in O O
nuclear O O
and O O
cytoplasmic O O
extracts O O
from O O
CD16 O O
- O O
or O O
phorbol O O
ester O O
- O O
stimulated O O
cells O O
at O O
any O O
time O O
tested O O
, O O
up O O
to O O
4 O O
h O O
. O O

These O O
results O O
provide O O
the O O
first O O
direct O O
evidence O O
that O O
both O O
CsA O O
- O O
sensitive O O
transcription O O
factors O O
, O O
NFATp O O
and O O
NFATc O O
, O O
are O O
expressed O O
in O O
human O O
NK O O
cells O O
, O O
and O O
that O O
their O O
activation O O
and O O
/ O O
or O O
expression O O
can O O
be O O
regulated O O
in O O
primary O O
cells O O
by O O
a O O
single O O
stimulus O O
, O O
that O O
, O O
in O O
the O O
case O O
of O O
CD16 O O
in O O
NK O O
cells O O
, O O
results O O
in O O
early O O
activation O O
of O O
NFATp O O
and O O
subsequently O O
induced O O
expression O O
of O O
NFATc O O
mRNA O O
. O O

Interleukin O O
2 O O
signaling O O
involves O O
the O O
phosphorylation O O
of O O
Stat O O
proteins O O
. O O

One O O
of O O
the O O
most O O
important O O
cytokines O O
involved O O
in O O
immune O O
response O O
regulation O O
is O O
interleukin O O
2 O O
( O O
IL O O
- O O
2 O O
) O O
, O O
a O O
potent O O
activator O O
of O O
the O O
proliferation O O
and O O
function O O
of O O
T O O
lymphocytes O O
and O O
natural O O
killer O O
cells O O
. O O

The O O
mechanisms O O
by O O
which O O
the O O
effects O O
of O O
IL O O
- O O
2 O O
are O O
propagated O O
within O O
cells O O
are O O
not O O
understood O O
. O O

While O O
the O O
binding O O
of O O
IL O O
- O O
2 O O
to O O
its O O
receptor O O
was O O
recently O O
shown O O
to O O
lead O O
to O O
the O O
activation O O
of O O
two O O
kinases O O
, O O
Jak O O
- O O
1 O O
and O O
Jak O O
- O O
3 O O
, O O
subsequent O O
steps O O
in O O
the O O
signaling O O
pathway O O
to O O
the O O
nucleus O O
that O O
lead O O
to O O
the O O
activation O O
of O O
specific O O
genes O O
had O O
not O O
been O O
characterized O O
. O O

Since O O
many O O
cytokines O O
that O O
activate O O
Jak O O
kinases O O
also O O
lead O O
to O O
the O O
tyrosine O O
phosphorylation O O
and O O
activation O O
of O O
members O O
of O O
the O O
Stat O O
family O O
of O O
transcription O O
factors O O
, O O
the O O
ability O O
of O O
IL O O
- O O
2 O O
to O O
trigger O O
Stat O O
phosphorylation O O
was O O
examined O O
. O O

Exposure O O
of O O
activated O O
human O O
T O O
lymphocytes O O
or O O
of O O
a O O
natural O O
killer O O
cell O O
line O O
( O O
NKL O O
) O O
to O O
IL O O
- O O
2 O O
leads O O
to O O
the O O
phosphorylation O O
of O O
Stat1 O O
alpha O O
, O O
Stat1 O O
beta O O
, O O
and O O
Stat3 O O
, O O
as O O
well O O
as O O
of O O
two O O
Stat O O
- O O
related O O
proteins O O
, O O
p94 O O
and O O
p95 O O
. O O

p94 O O
and O O
p95 O O
share O O
homology O O
with O O
Stat1 O O
at O O
the O O
phosphorylation O O
site O O
and O O
in O O
the O O
Src O O
homology O O
2 O O
( O O
SH2 O O
) O O
domain O O
, O O
but O O
otherwise O O
are O O
immunologically O O
distinct O O
from O O
Stat1 O O
. O O

These O O
Stat O O
proteins O O
were O O
found O O
to O O
translocate O O
to O O
the O O
nucleus O O
and O O
to O O
bind O O
to O O
a O O
specific B-DNA O
DNA I-DNA B-DNA
sequence I-DNA I-DNA
. O O

These O O
findings O O
suggest O O
a O O
mechanism O O
by O O
which O O
IL O O
- O O
2 O O
binding O O
to O O
its O O
receptor O O
may O O
activate O O
specific B-DNA O
genes I-DNA O
involved O O
in O O
immune O O
cell O O
function O O
. O O

Expression O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
fos I-DNA I-DNA
correlates O O
with O O
IFN O O
- O O
alpha O O
responsiveness O O
in O O
Philadelphia O B-DNA
chromosome O I-DNA
positive O O
chronic O O
myelogenous O O
leukemia O O
. O O

This O O
study O O
evaluates O O
( O O
i O O
) O O
constitutive O O
levels O O
of O O
oncogene B-DNA B-DNA
and O O
p53 O O
transcripts O O
in O O
chronic O O
phase O O
CML O O
patients O O
and O O
( O O
ii O O
) O O
their O O
modulations O O
subsequent O O
to O O
in O O
vivo O O
therapy O O
with O O
rIFN O O
- O O
alpha O O
2c O O
. O O

Peripheral O O
blood O O
mononuclear O O
cells O O
( O O
pbmc O O
) O O
and O O
bone O O
marrow O O
cells O O
of O O
26 O O
patients O O
were O O
examined O O
for O O
c O B-DNA
- O I-DNA
fos O I-DNA
, O O
c O B-DNA
- O I-DNA
myc O I-DNA
, O O
p53 O B-DNA
and O O
the O O
hybrid O O
bcr O O
/ O O
abl O O
mRNA O O
levels O O
. O O

Results O O
indicated O O
that O O
( O O
i O O
) O O
constitutive O O
c O B-DNA
- O I-DNA
fos O I-DNA
transcript O O
levels O O
are O O
significantly O O
higher O O
in O O
patients O O
subsequently O O
responding O O
to O O
IFN O O
- O O
alpha O O
therapy O O
( O O
p O O
< O O
0 O O
. O O
01 O O
) O O
and O O
positively O O
correlated O O
with O O
the O O
proportion O O
of O O
lymphocytes O O
( O O
r O O
= O O
0 O O
. O O
6895 O O
, O O
p O O
< O O
0 O O
. O O
01 O O
) O O
and O O
negatively O O
with O O
the O O
proportion O O
of O O
immature O O
cells O O
( O O
r O O
= O O
- O O
0 O O
. O O
568 O O
, O O
p O O
< O O
0 O O
. O O
01 O O
) O O
contained O O
in O O
the O O
pbmc O O
preparations O O
tested O O
, O O
( O O
ii O O
) O O
constitutive O O
mRNA O O
levels O O
of O O
the O O
hybrid B-DNA O
bcr I-DNA O
/ I-DNA O
abl I-DNA O
, O O
c B-DNA O
- I-DNA O
myc I-DNA O
and O O
p53 B-DNA O
are O O
positively O O
correlated O O
with O O
each O O
other O O
, O O
but O O
failed O O
to O O
relate O O
to O O
disease O O
parameters O O
, O O
and O O
( O O
iii O O
) O O
acute O O
and O O
chronic O O
in O O
vivo O O
exposure O O
to O O
IFN O O
- O O
alpha O O
is O O
accompanied O O
by O O
upregulation O O
of O O
c O B-DNA
- O I-DNA
fos O I-DNA
and O O
downregulation O O
of O O
c O O
- O O
myc O O
mRNA O O
levels O O
in O O
responder O O
patients O O
. O O

Menopause O O
is O O
associated O O
with O O
a O O
significant O O
increase O O
in O O
blood O O
monocyte O O
number O O
and O O
a O O
relative O O
decrease O O
in O O
the O O
expression O O
of O O
estrogen O O
receptors O O
in O O
human O O
peripheral O O
monocytes O O
. O O

PROBLEM O O
: O O
The O O
clinical O O
significance O O
of O O
the O O
differential O O
expression O O
of O O
estrogen O O
receptor O O
( O O
ER O O
) O O
in O O
human O O
monocytes O O
was O O
evaluated O O
. O O

METHOD O O
: O O
Two O O
color O O
flow O O
cytometry O O
analysis O O
was O O
used O O
on O O
peripheral O O
blood O O
samples O O
of O O
young O O
and O O
postmenopausal O O
females O O
and O O
postmenopausal O O
females O O
treated O O
with O O
estrogen O O
replacement O O
therapy O O
. O O

In O O
addition O O
, O O
the O O
monocyte O O
and O O
lymphocyte O O
counts O O
and O O
the O O
blood O O
estrogen O O
levels O O
of O O
each O O
patient O O
were O O
determine O O
. O O

RESULTS O O
: O O
During O O
menopause O O
there O O
is O O
a O O
significant O O
decrease O O
in O O
the O O
percentage O O
of O O
ER O O
positive O O
monocytes O O
, O O
and O O
an O O
increase O O
in O O
blood O O
monocyte O O
number O O
, O O
which O O
declines O O
following O O
estrogen O O
replacement O O
therapy O O
to O O
values O O
of O O
the O O
young O O
. O O

CONCLUSIONS O O
: O O
These O O
findings O O
suggest O O
that O O
estrogen O O
modulates O O
the O O
monocyte O O
numbers O O
and O O
its O O
effects O O
may O O
be O O
mediated O O
through O O
the O O
ER O O
in O O
the O O
monocytes O O
. O O

Staphylococcal O O
enterotoxins O O
modulate O O
interleukin O O
2 O O
receptor O O
expression O O
and O O
ligand O O
- O O
induced O O
tyrosine O O
phosphorylation O O
of O O
the O O
Janus O O
protein O O
- O O
tyrosine O O
kinase O O
3 O O
( O O
Jak3 O O
) O O
and O O
signal O O
transducers O O
and O O
activators O O
of O O
transcription O O
( O O
Stat O O
proteins O O
) O O
. O O

Staphylococcal O O
enterotoxins O O
( O O
SE O O
) O O
stimulate O O
T O O
cells O O
expressing O O
the O O
appropriate O O
variable O O
region O O
beta O O
chain O O
of O O
( O O
V O O
beta O O
) O O
T O O
- O O
cell O O
receptors O O
and O O
have O O
been O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
several O O
autoimmune O O
diseases O O
. O O

Depending O O
on O O
costimulatory O O
signals O O
, O O
SE O O
induce O O
either O O
proliferation O O
or O O
anergy O O
in O O
T O O
cells O O
. O O

In O O
addition O O
, O O
SE O O
can O O
induce O O
an O O
interleukin O O
- O O
2 O O
( O O
IL O O
- O O
2 O O
) O O
nonresponsive O O
state O O
and O O
apoptosis O O
. O O

Here O O
, O O
we O O
show O O
that O O
SE O O
induce O O
dynamic O O
changes O O
in O O
the O O
expression O O
of O O
and O O
signal O O
transduction O O
through O O
the O O
IL O O
- O O
2 O O
receptor O O
( O O
IL O O
- O O
2R O O
) O O
beta O O
and O O
gamma O O
chains O O
( O O
IL O O
- O O
2R O O
beta O O
and O O
IL O O
- O O
2R O O
gamma O O
) O O
in O O
human O O
antigen O O
- O O
specific O O
CD4 O O
+ O O
T O O
- O O
cell O O
lines O O
. O O

Thus O O
, O O
after O O
4 O O
hr O O
of O O
exposure O O
to O O
SEA O O
and O O
SEB O O
, O O
the O O
expression O O
of O O
IL O O
- O O
2R O O
beta O O
was O O
down O O
- O O
regulated O O
, O O
IL O O
- O O
2R O O
gamma O O
was O O
slightly O O
up O O
- O O
regulated O O
, O O
while O O
IL O O
- O O
2R O O
alpha O O
remained O O
largely O O
unaffected O O
. O O

The O O
changes O O
in O O
the O O
composition O O
of O O
IL O O
- O O
2Rs O O
were O O
accompanied O O
by O O
inhibition O O
of O O
IL O O
- O O
2 O O
- O O
induced O O
tyrosine O O
phosphorylation O O
of O O
the O O
Janus O O
protein O O
- O O
tyrosine O O
kinase O O
3 O O
( O O
Jak3 O O
) O O
and O O
signal O O
transducers O O
and O O
activators O O
of O O
transcription O O
called O O
Stat3 O O
and O O
Stat5 O O
. O O

In O O
parallel O O
experiments O O
, O O
IL O O
- O O
2 O O
- O O
driven O O
proliferation O O
was O O
inhibited O O
significantly O O
. O O

After O O
16 O O
hr O O
of O O
exposure O O
to O O
SE O O
, O O
the O O
expression O O
of O O
IL O O
- O O
2R O O
beta O O
remained O O
low O O
, O O
while O O
that O O
of O O
IL2R O O
alpha O O
and O O
IL2R O O
gamma O O
was O O
further O O
up O O
- O O
regulated O O
, O O
and O O
ligand O O
- O O
induced O O
tyrosine O O
phosphorylation O O
of O O
Jak3 O O
and O O
Stat O O
proteins O O
was O O
partly O O
normalized O O
. O O

Yet O O
, O O
IL O O
- O O
2 O O
- O O
driven O O
proliferation O O
remained O O
profoundly O O
inhibited O O
, O O
suggesting O O
that O O
signaling O O
events O O
other O O
than O O
Jak3 O O
/ O O
Stat O O
activation O O
had O O
also O O
been O O
changed O O
following O O
SE O O
stimulation O O
. O O

In O O
conclusion O O
, O O
our O O
data O O
suggest O O
that O O
SE O O
can O O
modulate O O
IL O O
- O O
2R O O
expression O O
and O O
signal O O
transduction O O
involving O O
the O O
Jak O O
/ O O
Stat O O
pathway O O
in O O
CD4 O O
+ O O
T O O
- O O
cell O O
lines O O
. O O

Constitutive O O
NF O O
- O O
kappa O O
B O O
activation O O
, O O
enhanced O O
granulopoiesis O O
, O O
and O O
neonatal O O
lethality O O
in O O
I O O
kappa O O
B O O
alpha O O
- O O
deficient O O
mice O O
. O O

Transcription O O
factors O O
belonging O O
to O O
the O O
NF O O
- O O
kappa O O
B O O
family O O
are O O
controlled O O
by O O
inhibitory O O
I O O
kappa O O
B O O
proteins O O
, O O
mainly O O
I O O
kappa O O
B O O
alpha O O
and O O
I O O
kappa O O
B O O
beta O O
. O O

Apparently O O
normal O O
at O O
birth O O
, O O
I O O
kappa O O
B O O
alpha O O
- O O
/ O O
- O O
mice O O
exhibit O O
severe O O
runting O O
, O O
skin O O
defects O O
, O O
and O O
extensive O O
granulopoiesis O O
postnatally O O
, O O
typically O O
dying O O
by O O
8 O O
days O O
. O O

Hematopoietic O O
tissues O O
from O O
these O O
mice O O
display O O
elevated O O
levels O O
of O O
both O O
nuclear O O
NF O O
- O O
kappa O O
B O O
and O O
mRNAs O O
of O O
some O O
, O O
but O O
not O O
all O O
, O O
genes O O
thought O O
to O O
be O O
regulated O O
by O O
NF O O
- O O
kappa O O
B O O
. O O

NF O O
- O O
kappa O O
B O O
elevation O O
results O O
in O O
these O O
phenotypic O O
abnormalities O O
because O O
mice O O
lacking O O
both O O
I O O
kappa O O
B O O
alpha O O
and O O
the O O
p50 O O
subunit O O
of O O
NF O O
- O O
kappa O O
B O O
show O O
a O O
dramatically O O
delayed O O
onset O O
of O O
abnormalities O O
. O O

In O O
contrast O O
to O O
hematopoietic O O
cells O O
, O O
I O O
kappa O O
B O O
alpha O O
- O O
/ O O
- O O
embryonic O O
fibroblasts O O
show O O
minimal O O
constitutive O O
NF O O
- O O
kappa O O
B O O
, O O
as O O
well O O
as O O
normal O O
signal O O
- O O
dependent O O
NF O O
- O O
kappa O O
B O O
activation O O
that O O
is O O
concomitant O O
with O O
I O O
kappa O O
B O O
beta O O
degradation O O
. O O

Our O O
results O O
indicate O O
that O O
I O O
kappa O O
b O O
beta O O
, O O
but O O
not O O
I O O
kappa O O
B O O
alpha O O
, O O
is O O
required O O
for O O
the O O
signal O O
- O O
dependent O O
activation O O
of O O
NF O O
- O O
kappa O O
B O O
in O O
fibroblasts O O
. O O

However O O
, O O
I O O
kappa O O
B O O
alpha O O
is O O
required O O
for O O
the O O
postinduction O O
repression O O
of O O
NF O O
- O O
kappa O O
B O O
in O O
fibroblasts O O
. O O

These O O
results O O
define O O
distinct O O
roles O O
for O O
the O O
two O O
forms O O
of O O
I O O
kappa O O
B O O
and O O
demonstrate O O
the O O
necessity O O
for O O
stringent O O
control O O
of O O
NF O O
- O O
kappa O O
B O O
. O O

Interleukin O O
- O O
7 O O
can O O
induce O O
the O O
activation O O
of O O
Jak O O
1 O O
, O O
Jak O O
3 O O
and O O
STAT O O
5 O O
proteins O O
in O O
murine O O
T O O
cells O O
. O O

The O O
activation O O
of O O
Janus O O
protein O O
tyrosine O O
kinases O O
( O O
Jak O O
) O O
and O O
STAT O O
( O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
) O O
proteins O O
has O O
recently O O
been O O
linked O O
to O O
the O O
signal O O
transduction O O
mechanism O O
of O O
several O O
cytokines O O
. O O

IL O O
- O O
7 O O
was O O
observed O O
to O O
induce O O
a O O
rapid O O
and O O
dose O O
- O O
dependent O O
tyrosine O O
phosphorylation O O
of O O
Jak O O
1 O O
and O O
Jak O O
3 O O
and O O
concomitantly O O
, O O
the O O
tyrosine O O
phosphorylation O O
and O O
DNA O O
binding O O
activity O O
of O O
multiple O O
STAT O O
proteins O O
. O O

The O O
STAT O O
proteins O O
utilized O O
by O O
IL O O
- O O
7 O O
were O O
identical O O
to O O
those O O
induced O O
by O O
IL O O
- O O
2 O O
and O O
could O O
be O O
identified O O
as O O
various O O
STAT O O
5 O O
isoforms O O
. O O

Moreover O O
, O O
the O O
induction O O
of O O
both O O
Jak O O
1 O O
and O O
3 O O
, O O
and O O
STAT O O
5 O O
activity O O
strongly O O
correlated O O
with O O
the O O
growth O O
- O O
promoting O O
effects O O
of O O
IL O O
- O O
7 O O
, O O
suggesting O O
that O O
this O O
signal O O
transduction O O
mechanism O O
may O O
play O O
a O O
key O O
role O O
in O O
IL O O
- O O
7 O O
- O O
induced O O
proliferation O O
. O O

Cytokine O O
- O O
modulating O O
activity O O
of O O
tepoxalin O O
, O O
a O O
new O O
potential O O
antirheumatic O O
. O O

Tepoxalin O O
is O O
a O O
new O O
dual O O
cyclooxygenase O O
/ O O
5 O O
- O O
lipoxygenase O O
anti O O
- O O
inflammatory O O
compound O O
currently O O
under O O
clinical O O
investigation O O
. O O

It O O
has O O
been O O
shown O O
to O O
possess O O
anti O O
- O O
inflammatory O O
activity O O
in O O
a O O
variety O O
of O O
animal O O
models O O
and O O
more O O
recently O O
to O O
inhibit O O
IL O O
- O O
2 O O
induced O O
signal O O
transduction O O
. O O

The O O
current O O
study O O
was O O
conducted O O
to O O
evaluate O O
the O O
cytokine O O
modulating O O
activity O O
of O O
tepoxalin O O
and O O
the O O
role O O
of O O
iron O O
in O O
these O O
effects O O
. O O

In O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
stimulated O O
with O O
OKT3 O O
/ O O
PMA O O
, O O
tepoxalin O O
inhibited O O
lymphocyte O O
proliferation O O
with O O
an O O
IC50 O O
of O O
6 O O
microM O O
. O O

Additionally O O
, O O
it O O
inhibited O O
the O O
production O O
of O O
LTB4 O O
( O O
IC50 O O
= O O
0 O O
. O O
5 O O
microM O O
) O O
and O O
the O O
cytokines O O
IL O O
- O O
2 O O
, O O
IL O O
- O O
6 O O
and O O
TNF O O
alpha O O
( O O
IC50 O O
= O O
10 O O
- O O
12 O O
microM O O
) O O
. O O

Cytotoxicity O O
was O O
not O O
demonstrated O O
at O O
these O O
concentrations O O
. O O

Add O O
- O O
back O O
experiments O O
with O O
either O O
cytokines O O
( O O
IL O O
- O O
2 O O
or O O
IL O O
- O O
6 O O
) O O
, O O
LTB4 O O
or O O
conditioned O O
media O O
failed O O
to O O
restore O O
the O O
proliferative O O
response O O
in O O
the O O
presence O O
of O O
tepoxalin O O
. O O

However O O
, O O
the O O
concurrent O O
addition O O
of O O
iron O O
( O O
in O O
the O O
form O O
of O O
ferrous O O
or O O
ferric O O
chloride O O
and O O
other O O
iron O O
salts O O
) O O
reversed O O
the O O
inhibition O O
of O O
proliferation O O
caused O O
by O O
tepoxalin O O
. O O

Tepoxalin O O
also O O
inhibits O O
the O O
activation O O
of O O
NF O O
kappa O O
B O O
, O O
a O O
transcription O O
factor O O
which O O
acts O O
on O O
several O O
cytokine B-DNA B-DNA
genes I-DNA I-DNA
. O O

Tepoxalin O O
' O O
s O O
effect O O
on O O
NF O O
kappa O O
B O O
is O O
also O O
reversed O O
by O O
the O O
addition O O
of O O
iron O O
salts O O
. O O

These O O
data O O
suggest O O
that O O
the O O
action O O
of O O
tepoxalin O O
to O O
inhibit O O
proliferation O O
in O O
PBMC O O
may O O
be O O
at O O
least O O
in O O
part O O
due O O
to O O
its O O
ability O O
to O O
reduce O O
the O O
amount O O
of O O
available O O
iron O O
resulting O O
in O O
decreased O O
activation O O
of O O
NF O O
kappa O O
B O O
and O O
subsequent O O
inhibition O O
of O O
cytokine O O
production O O
. O O

N O O
- O O
and O O
C O O
- O O
terminal O O
sequences O O
control O O
degradation O O
of O O
MAD3 O O
/ O O
I O O
kappa O O
B O O
alpha O O
in O O
response O O
to O O
inducers O O
of O O
NF O O
- O O
kappa O O
B O O
activity O O
. O O

The O O
proteolytic O O
degradation O O
of O O
the O O
inhibitory O O
protein O O
MAD3 O O
/ O O
I O O
kappa O O
B O O
alpha O O
in O O
response O O
to O O
extracellular O O
stimulation O O
is O O
a O O
prerequisite O O
step O O
in O O
the O O
activation O O
of O O
the O O
transcription O O
factor O O
NF O O
- O O
kappa O O
B O O
. O O

Analysis O O
of O O
the O O
expression O O
of O O
human O O
I O O
kappa O O
B O O
alpha O O
protein O O
in O O
stable O O
transfectants O O
of O O
mouse O O
70Z O O
/ O O
3 O O
cells O O
shows O O
that O O
, O O
as O O
for O O
the O O
endogenous O O
murine O O
protein O O
, O O
exogenous O O
I O O
kappa O O
B O O
alpha O O
is O O
degraded O O
in O O
response O O
to O O
inducers O O
of O O
NF O O
- O O
kappa O O
B O O
activity O O
, O O
such O O
as O O
phorbol O O
myristate O O
acetate O O
or O O
lipopolysaccharide O O
. O O

In O O
addition O O
, O O
pretreatment O O
of O O
the O O
cells O O
with O O
the O O
proteasome O O
inhibitor O O
N O O
- O O
Ac O O
- O O
Leu O O
- O O
Leu O O
- O O
norleucinal O O
inhibits O O
this O O
ligand O O
- O O
induced O O
degradation O O
and O O
, O O
in O O
agreement O O
with O O
previous O O
studies O O
, O O
stabilizes O O
a O O
hyperphosphorylated O O
form O O
of O O
the O O
human O O
I O O
kappa O O
B O O
alpha O O
protein O O
. O O

By O O
expressing O O
mutant O O
forms O O
of O O
the O O
human O O
protein O O
in O O
this O O
cell O O
line O O
, O O
we O O
have O O
been O O
able O O
to O O
delineate O O
the O O
sequences O O
responsible O O
for O O
both O O
the O O
ligand O O
- O O
induced O O
phosphorylation O O
and O O
the O O
degradation O O
of O O
I O O
kappa O O
B O O
alpha O O
. O O

Our O O
results O O
show O O
that O O
deletion O O
of O O
the O O
C O O
terminus O O
of O O
the O O
I O O
kappa O O
B O O
alpha O O
molecule O O
up O O
to O O
amino O O
acid O O
279 O O
abolishes O O
constitutive O O
but O O
not O O
ligand O O
- O O
inducible O O
phosphorylation O O
and O O
inhibits O O
ligand O O
- O O
inducible O O
degradation O O
. O O

Further O O
analysis O O
reveals O O
that O O
the O O
inducible O O
phosphorylation O O
of O O
I O O
kappa O O
B O O
alpha O O
maps O O
to O O
two O O
serines O O
in O O
the O O
N O O
terminus O O
of O O
the O O
protein O O
( O O
residues O O
32 O O
and O O
36 O O
) O O
and O O
that O O
the O O
mutation O O
of O O
either O O
residue O O
is O O
sufficient O O
to O O
abolish O O
ligand O O
- O O
induced O O
degradation O O
, O O
whereas O O
both O O
residues O O
must O O
be O O
mutated O O
to O O
abolish O O
inducible O O
phosphorylation O O
of O O
the O O
protein O O
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O
. O O

Microtubules O O
mediate O O
cellular O O
25 O O
- O O
hydroxyvitamin O O
D3 O O
trafficking O O
and O O
the O O
genomic O O
response O O
to O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
in O O
normal O O
human O O
monocytes O O
. O O

The O O
genomic O O
actions O O
of O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
( O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
) O O
are O O
mediated O O
by O O
the O O
intracellular O O
vitamin O O
D O O
receptor O O
( O O
VDR O O
) O O
. O O

Although O O
immunocytochemistry O O
has O O
shown O O
that O O
disruption O O
of O O
microtubular O O
assembly O O
prevents O O
nuclear O O
access O O
of O O
the O O
sterol O O
- O O
VDR O O
complex O O
, O O
the O O
role O O
of O O
microtubules O O
in O O
the O O
response O O
to O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
has O O
not O O
been O O
studied O O
in O O
viable O O
cells O O
. O O

Our O O
studies O O
examined O O
this O O
interaction O O
in O O
normal O O
human O O
monocytes O O
. O O

Monocytes O O
convert O O
25 O O
( O O
OH O O
) O O
D3 O O
to O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
and O O
to O O
24 O O
- O O
hydroxylated O O
metabolites O O
more O O
polar O O
than O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
. O O

Microtubule O O
disruption O O
totally O O
abolished O O
the O O
ability O O
of O O
exogenous O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
to O O
suppress O O
its O O
own O O
synthesis O O
and O O
to O O
induce O O
24 O O
- O O
hydroxylase O O
mRNA O O
and O O
activity O O
, O O
without O O
affecting O O
either O O
total O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
uptake O O
or O O
maximal O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
- O O
VDR O O
binding O O
. O O

Thus O O
, O O
intact O O
microtubules O O
are O O
essential O O
for O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
- O O
dependent O O
modulation O O
of O O
gene O O
transcription O O
. O O

Interestingly O O
, O O
microtubule O O
disruption O O
also O O
decreased O O
monocyte O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
synthesis O O
, O O
not O O
by O O
decreasing O O
the O O
Vmax O O
of O O
monocyte O O
mitochondrial O O
1 O O
alpha O O
- O O
hydroxylase O O
but O O
through O O
an O O
increase O O
in O O
the O O
Km O O
for O O
25 O O
( O O
OH O O
) O O
2D3 O O
. O O

We O O
examined O O
25 O O
( O O
OH O O
) O O
D3 O O
transport O O
. O O

Microtubule O O
disruption O O
did O O
not O O
affect O O
total O O
cellular O O
25 O O
( O O
OH O O
) O O
D3 O O
uptake O O
but O O
reduced O O
its O O
intracellular O O
trafficking O O
to O O
the O O
mitochondria O O
. O O

Thus O O
, O O
microtubules O O
participate O O
in O O
intracellular O O
25 O O
( O O
OH O O
) O O
D3 O O
transport O O
, O O
and O O
their O O
integrity O O
determines O O
normal O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
synthesis O O
. O O

Relationship O O
between O O
Rap1 O O
protein O O
phosphorylation O O
and O O
regulation O O
of O O
Ca2 O O
+ O O
transport O O
in O O
platelets O O
: O O
a O O
new O O
approach O O
. O O

Although O O
the O O
interrelationship O O
between O O
the O O
two O O
messengers O O
Ca2 O O
+ O O
and O O
cyclic O O
AMP O O
in O O
platelet O O
function O O
is O O
well O O
documented O O
, O O
its O O
mechanism O O
of O O
action O O
still O O
remains O O
to O O
be O O
established O O
. O O

We O O
investigated O O
here O O
the O O
question O O
of O O
the O O
regulation O O
of O O
platelet O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
ATPases O O
by O O
cyclic O O
AMP O O
through O O
the O O
phosphorylation O O
of O O
the O O
Rap1 O O
protein O O
using O O
a O O
pathological O O
model O O
. O O

We O O
first O O
found O O
experimental O O
conditions O O
where O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
transport O O
by O O
platelet O O
membrane O O
vesicles O O
appeared O O
to O O
be O O
dependent O O
on O O
the O O
phosphorylation O O
of O O
the O O
Rap1 O O
protein O O
. O O

Then O O
, O O
we O O
studied O O
platelets O O
of O O
patients O O
with O O
congestive O O
heart O O
failure O O
for O O
their O O
expression O O
of O O
the O O
potential O O
97 O O
kDa O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
ATPase O O
target O O
of O O
regulation O O
through O O
the O O
Rap1 O O
protein O O
as O O
well O O
as O O
the O O
phosphorylation O O
of O O
the O O
Rap1 O O
protein O O
using O O
the O O
catalytic O O
subunit O O
of O O
the O O
cyclic O O
AMP O O
- O O
dependent O O
protein O O
kinase O O
( O O
C O O
. O O
Sub O O
. O O
) O O
. O O

In O O
the O O
first O O
patients O O
studied O O
, O O
we O O
found O O
no O O
significant O O
modification O O
in O O
the O O
expression O O
of O O
the O O
97 O O
kDa O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
ATPase O O
by O O
Western O O
blotting O O
using O O
the O O
PL O O
/ O O
IM O O
430 O O
monoclonal O O
antibody O O
which O O
specifically O O
recognized O O
this O O
isoform O O
. O O

In O O
contrast O O
, O O
the O O
Rap1 O O
protein O O
was O O
differentially O O
phosphorylated O O
when O O
using O O
15 O O
micrograms O O
/ O O
ml O O
of O O
the O O
C O O
. O O
Sub O O
. O O

These O O
results O O
allowed O O
us O O
to O O
use O O
these O O
pathological O O
platelets O O
to O O
study O O
the O O
relationship O O
between O O
the O O
expression O O
of O O
Rap1 O O
protein O O
and O O
the O O
regulation O O
of O O
Ca2 O O
+ O O
transport O O
by O O
selecting O O
a O O
patient O O
with O O
severe O O
heart O O
failure O O
. O O

We O O
could O O
show O O
a O O
decrease O O
in O O
the O O
expression O O
as O O
well O O
as O O
in O O
the O O
phosphorylation O O
of O O
Rap1 O O
protein O O
and O O
demonstrate O O
a O O
lower O O
effect O O
of O O
C O O
. O O
Sub O O
. O O
on O O
Ca2 O O
+ O O
transport O O
. O O

Finally O O
, O O
by O O
studying O O
a O O
further O O
series O O
of O O
patients O O
, O O
we O O
could O O
confirm O O
that O O
the O O
decrease O O
in O O
Rap1 O O
protein O O
expression O O
in O O
heart O O
failure O O
, O O
whatever O O
its O O
extent O O
, O O
was O O
variable O O
, O O
and O O
could O O
strictly O O
correlate O O
the O O
expression O O
of O O
Rap1 O O
protein O O
with O O
the O O
stimulatory O O
effect O O
of O O
C O O
. O O
Sub O O
. O O
on O O
Ca2 O O
+ O O
transport O O
. O O

Besides O O
the O O
evidence O O
for O O
regulation O O
of O O
the O O
expression O O
of O O
the O O
Rap1 O O
protein O O
in O O
platelets O O
from O O
patients O O
with O O
heart O O
failure O O
, O O
these O O
findings O O
constitute O O
a O O
new O O
approach O O
in O O
favour O O
of O O
the O O
regulation O O
of O O
platelet O O
Ca2 O O
+ O O
transport O O
through O O
the O O
phosphorylation O O
of O O
the O O
Rap1 O O
protein O O
. O O

An O O
IRF O O
- O O
1 O O
- O O
dependent O O
pathway O O
of O O
DNA O O
damage O O
- O O
induced O O
apoptosis O O
in O O
mitogen O O
- O O
activated O O
T O O
lymphocytes O O
. O O

Lymphocytes O O
are O O
particularly O O
susceptible O O
to O O
DNA O O
damage O O
- O O
induced O O
apoptosis O O
, O O
a O O
response O O
which O O
may O O
serve O O
as O O
a O O
form O O
of O O
' O O
altruistic O O
suicide O O
' O O
to O O
counter O O
their O O
intrinsic O O
high O O
potential O O
for O O
mutation O O
and O O
clonal O O
expansion O O
. O O

The O O
tumour O O
suppressor O O
p53 O O
has O O
been O O
shown O O
to O O
regulate O O
this O O
type O O
of O O
apoptosis O O
in O O
thymocytes O O
, O O
but O O
an O O
as O O
yet O O
unknown O O
, O O
p53 O O
- O O
independent O O
pathway O O
( O O
s O O
) O O
appears O O
to O O
mediate O O
the O O
same O O
event O O
in O O
mitogen O O
- O O
activated O O
mature O O
T O O
lymphocytes O O
. O O

Here O O
we O O
show O O
DNA O O
damage O O
- O O
induced O O
apoptosis O O
in O O
these O O
T O O
lymphocytes O O
is O O
dependent O O
on O O
the O O
antioncogenic O O
transcription O O
factor O O
interferon O O
regulatory O O
factor O O
( O O
IRF O O
) O O
- O O
1 O O
. O O

Thus O O
two O O
different O O
anti O O
- O O
onco O O
- O O
genic O O
transcription O O
factors O O
, O O
p53 O O
and O O
IRF O O
- O O
1 O O
, O O
are O O
required O O
for O O
distinct O O
apoptotic O O
pathways O O
in O O
T O O
lymphocytes O O
. O O

We O O
also O O
show O O
that O O
mitogen O O
induction O O
of O O
the O O
interleukin B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
beta I-DNA I-DNA
converting I-DNA I-DNA
enzyme I-DNA I-DNA
( I-DNA I-DNA
ICE I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
, O O
a O O
mammalian O O
homologue O O
of O O
the O O
Caenorhabditis B-DNA B-DNA
elegans I-DNA I-DNA
cell I-DNA I-DNA
death I-DNA I-DNA
gene I-DNA I-DNA
ced B-DNA B-DNA
- I-DNA I-DNA
3 I-DNA I-DNA
, O O
is O O
IRF O O
- O O
1 O O
- O O
dependent O O
. O O

Ectopic O O
overexpression O O
of O O
IRF O O
- O O
1 O O
results O O
in O O
the O O
activation O O
of O O
the O O
endogenous B-DNA B-DNA
gene I-DNA I-DNA
for O O
ICE O O
and O O
enhances O O
the O O
sensitivity O O
of O O
cells O O
to O O
radiation O O
- O O
induced O O
apoptosis O O
. O O

Circadian O O
rhythm O O
of O O
glucocorticoid O O
receptors O O
in O O
human O O
peripheral O O
leukocytes O O
and O O
their O O
reactivity O O
to O O
glucocorticoids O O
. O O

1 O O
) O O
There O O
exists O O
a O O
CR O O
of O O
GR O O
in O O
human O O
leukocytes O O
, O O
PMN O O
, O O
and O O
monocytes O O
with O O
the O O
peak O O
values O O
from O O
0400 O O
to O O
0800 O O
hr O O
and O O
the O O
trough O O
values O O
between O O
2300 O O
and O O
0000 O O
hr O O
. O O

The O O
difference O O
between O O
them O O
was O O
significant O O
statistically O O
. O O

2 O O
) O O
The O O
FI O O
of O O
the O O
chemotactic O O
migration O O
rate O O
of O O
PMN O O
by O O
cortisol O O
also O O
showed O O
diurnal O O
changes O O
which O O
were O O
synchronous O O
with O O
that O O
of O O
GR O O
. O O

This O O
indicates O O
that O O
the O O
CR O O
of O O
GR O O
may O O
be O O
of O O
functional O O
significance O O
. O O

3 O O
) O O
In O O
Cushing O O
' O O
s O O
syndrome O O
, O O
the O O
CR O O
of O O
GR O O
was O O
normal O O
in O O
spite O O
of O O
the O O
fact O O
that O O
the O O
CR O O
of O O
plasma O O
cortisol O O
was O O
disturbed O O
. O O

This O O
indicates O O
the O O
independency O O
of O O
the O O
CR O O
of O O
GR O O
from O O
that O O
of O O
cortisol O O
. O O

4 O O
) O O
In O O
apoplexy O O
caused O O
by O O
brain O O
ischemia O O
, O O
the O O
CR O O
of O O
GR O O
was O O
abolished O O
in O O
patients O O
with O O
basal O O
lesions O O
but O O
preserved O O
when O O
the O O
lesions O O
were O O
located O O
in O O
the O O
cerebral O O
cortex O O
. O O

These O O
results O O
strongly O O
suggest O O
that O O
the O O
main O O
" O O
circadian O O
pacemaker O O
" O O
of O O
GR O O
is O O
located O O
in O O
the O O
basal O O
brain O O
, O O
most O O
probably O O
in O O
the O O
suprachiasmatic O O
nuclei O O
as O O
has O O
been O O
suggested O O
for O O
rodents O O
. O O

B O O
- O O
lymphoblastoid O O
cell O O
lines O O
from O O
multiple O O
sclerosis O O
patients O O
and O O
a O O
healthy O O
control O O
producing O O
a O O
putative O O
new O O
human O O
retrovirus O O
and O O
Epstein O O
- O O
Barr O O
virus O O
. O O

On O O
several O O
occasions O O
we O O
have O O
observed O O
retrovirus O O
- O O
like O O
particles O O
( O O
RVLPs O O
) O O
by O O
transmission O O
electron O O
microscopy O O
( O O
EM O O
) O O
of O O
cultured O O
T O O
cells O O
from O O
a O O
patient O O
with O O
MS O O
. O O

Later O O
we O O
established O O
spontaneously O O
formed O O
B O O
- O O
lymphoblastoid O O
cell O O
lines O O
( O O
LCLs O O
) O O
from O O
a O O
patient O O
with O O
an O O
MS O O
- O O
like O O
disease O O
and O O
from O O
another O O
patient O O
with O O
MS O O
who O O
had O O
a O O
reactivated O O
Epstein O O
- O O
Barr O O
virus O O
( O O
EBV O O
) O O
infection O O
. O O

Both O O
LCLs O O
were O O
found O O
by O O
EM O O
to O O
produce O O
RVLP O O
and O O
EBV O O
particles O O
. O O

Reverse O O
transcriptase O O
( O O
RT O O
) O O
assays O O
were O O
positive O O
in O O
purified O O
viral O O
material O O
from O O
both O O
LCLs O O
. O O

To O O
substantiate O O
these O O
findings O O
we O O
initiated O O
an O O
intensified O O
culturing O O
procedure O O
and O O
were O O
able O O
to O O
establish O O
LCLs O O
from O O
5 O O
out O O
of O O
21 O O
consecutive O O
MS O O
patients O O
and O O
1 O O
out O O
of O O
13 O O
consecutive O O
healthy O O
controls O O
. O O

All O O
LCLs O O
were O O
found O O
to O O
produce O O
both O O
RVLP O O
and O O
EBV O O
particles O O
by O O
EM O O
. O O

Whether O O
the O O
putative O O
new O O
retrovirus O O
( O O
es O O
) O O
and O O
EBV O O
have O O
any O O
causal O O
relationship O O
to O O
MS O O
is O O
still O O
not O O
known O O
, O O
but O O
the O O
findings O O
support O O
this O O
possibility O O
. O O

Identification O O
of O O
an O O
ionomycin B-DNA B-DNA
/ I-DNA I-DNA
cyclosporin I-DNA I-DNA
A I-DNA I-DNA
- I-DNA I-DNA
responsive I-DNA I-DNA
element I-DNA I-DNA
within O O
the O O
human B-DNA B-DNA
T I-DNA I-DNA
cell I-DNA I-DNA
receptor I-DNA I-DNA
gamma I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

Activation O O
through O O
the O O
Ca2 O O
+ O O
/ O O
calcineurin O O
pathway O O
is O O
essential O O
to O O
the O O
transcription O O
of O O
many O O
cytokine B-DNA B-DNA
genes I-DNA I-DNA
. O O

The O O
conserved B-DNA O
cis I-DNA B-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
sequence I-DNA I-DNA
, O O
GGAAAA O O
, O O
and O O
transcription O O
factors O O
binding O O
to O O
this O O
sequence O O
are O O
involved O O
in O O
the O O
response O O
to O O
increased O O
intracellular O O
Ca2 O O
+ O O
concentrations O O
. O O

Here O O
we O O
report O O
the O O
identification O O
and O O
importance O O
of O O
the O O
same O O
sequence O O
in O O
a O O
non B-DNA B-DNA
- I-DNA I-DNA
cytokine I-DNA I-DNA
gene I-DNA I-DNA
, O O
the O O
human B-DNA B-DNA
T I-DNA I-DNA
cell I-DNA I-DNA
receptor I-DNA I-DNA
gamma I-DNA I-DNA
( I-DNA I-DNA
TCRG I-DNA I-DNA
) I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

Results O O
from O O
site O O
- O O
directed O O
mutations O O
and O O
electrophoretic O O
mobility O O
shift O O
assays O O
strongly O O
suggest O O
that O O
this O O
sequence O O
mediates O O
the O O
ionomycin O O
- O O
induced O O
activation O O
of O O
the O O
TCRG B-DNA B-DNA
enhancer I-DNA I-DNA
. O O

Our O O
studies O O
provide O O
an O O
explanation O O
for O O
a O O
previous O O
observation O O
that O O
TCRG O O
mRNA O O
levels O O
, O O
but O O
not O O
mRNA O O
levels O O
for O O
T O O
cell O O
receptor O O
alpha O O
and O O
- O O
beta O O
, O O
are O O
increased O O
by O O
ionomycin O O
treatment O O
. O O

Coexpression O O
of O O
NF O O
- O O
kappa O O
B O O
/ O O
Rel O O
and O O
Sp1 O O
transcription O O
factors O O
in O O
human O O
immunodeficiency O O
virus O O
1 O O
- O O
induced O O
, O O
dendritic O O
cell O O
- O O
T O O
- O O
cell O O
syncytia O O
. O O

Productive O O
infection O O
of O O
T O O
cells O O
with O O
human O O
immunodeficiency O O
virus O O
1 O O
( O O
HIV O O
- O O
1 O O
) O O
typically O O
requires O O
that O O
the O O
T O O
cells O O
be O O
stimulated O O
with O O
antigens O O
or O O
mitogens O O
. O O

This O O
requirement O O
has O O
been O O
attributed O O
to O O
the O O
activation O O
of O O
the O O
transcription O O
factor O O
NF O O
- O O
kappa O O
B O O
, O O
which O O
synergizes O O
with O O
the O O
constitutive O O
transcription O O
factor O O
Sp1 O O
to O O
drive O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Recently O O
, O O
we O O
have O O
found O O
that O O
vigorous O O
replication O O
of O O
HIV O O
- O O
1 O O
takes O O
place O O
in O O
nonactivated O O
memory O O
T O O
cells O O
after O O
syncytium O O
formation O O
with O O
dendritic O O
cells O O
( O O
DCs O O
) O O
. O O

These O O
syncytia O O
lack O O
activated O O
cells O O
as O O
determined O O
by O O
an O O
absence O O
of O O
staining O O
for O O
Ki O O
- O O
67 O O
cell O O
cycle O O
antigen O O
. O O

The O O
expression O O
and O O
activity O O
of O O
NF O O
- O O
kappa O O
B O O
and O O
Sp1 O O
were O O
, O O
therefore O O
, O O
analyzed O O
in O O
isolated O O
T O O
cells O O
and O O
DCs O O
from O O
humans O O
and O O
mice O O
. O O

We O O
have O O
used O O
immunolabeling O O
, O O
Western O O
blot O O
analysis O O
, O O
and O O
electrophoretic O O
mobility O O
shift O O
and O O
supershift O O
assays O O
. O O

T O O
cells O O
lack O O
active O O
NF O O
- O O
kappa O O
B O O
but O O
express O O
Sp1 O O
as O O
expected O O
. O O

DCs O O
express O O
high O O
levels O O
of O O
all O O
known O O
NF O O
- O O
kappa O O
B O O
and O O
Rel O O
proteins O O
, O O
with O O
activity O O
residing O O
primarily O O
within O O
RelB O O
, O O
p50 O O
, O O
and O O
p65 O O
. O O

However O O
, O O
DCs O O
lack O O
Sp1 O O
, O O
which O O
may O O
explain O O
the O O
failure O O
of O O
HIV O O
- O O
1 O O
to O O
replicate O O
in O O
purified O O
DCs O O
. O O

Coexpression O O
of O O
NF O O
- O O
kappa O O
B O O
and O O
Sp1 O O
occurs O O
in O O
the O O
heterologous O O
DC O O
- O O
T O O
- O O
cell O O
syncytia O O
that O O
are O O
induced O O
by O O
HIV O O
- O O
1 O O
. O O

Therefore O O
, O O
HIV O O
- O O
1 O O
- O O
induced O O
cell O O
fusion O O
brings O O
together O O
factors O O
that O O
upregulate O O
virus O O
transcription O O
. O O

Since O O
DCs O O
and O O
memory O O
T O O
cells O O
frequently O O
traffic O O
together O O
in O O
situ O O
, O O
these O O
unusual O O
heterologous O O
syncytia O O
could O O
develop O O
in O O
infected O O
individuals O O
and O O
lead O O
to O O
chronic O O
HIV O O
- O O
1 O O
replication O O
without O O
ostensible O O
immune O O
stimulation O O
. O O

Cupric O O
ion O O
blocks O O
NF O O
kappa O O
B O O
activation O O
through O O
inhibiting O O
the O O
signal O O
- O O
induced O O
phosphorylation O O
of O O
I O O
kappa O O
B O O
alpha O O
. O O

A O O
transcription O O
factor O O
NF O O
kappa O O
B O O
, O O
which O O
regulates O O
expression O O
of O O
various O O
cellular O B-DNA
genes O I-DNA
involved O O
in O O
immune O O
responses O O
and O O
viral B-DNA B-DNA
genes I-DNA I-DNA
including O O
HIV O O
, O O
is O O
sequestered O O
in O O
the O O
cytoplasm O O
as O O
a O O
complex O O
with O O
an O O
inhibitory O O
protein O O
I O O
kappa O O
B O O
. O O

Various O O
extracellular O O
signals O O
induce O O
phosphorylation O O
and O O
rapid O O
degradation O O
of O O
I O O
kappa O O
B O O
alpha O O
to O O
release O O
NF O O
kappa O O
B O O
. O O

Cu2 O O
+ O O
was O O
found O O
to O O
inhibit O O
the O O
activation O O
of O O
NF O O
kappa O O
B O O
induced O O
by O O
TNF O O
- O O
alpha O O
, O O
TPA O O
, O O
or O O
H2O2 O O
. O O

Deoxycholate O O
treatment O O
of O O
the O O
cytoplasmic O O
extract O O
prepared O O
from O O
cells O O
stimulated O O
by O O
TNF O O
- O O
alpha O O
in O O
the O O
presence O O
of O O
Cu2 O O
+ O O
resulted O O
in O O
the O O
release O O
of O O
NF O O
kappa O O
B O O
from O O
I O O
kappa O O
B O O
alpha O O
, O O
indicating O O
that O O
Cu2 O O
+ O O
interferes O O
with O O
the O O
dissociation O O
of O O
the O O
NF O O
kappa O O
B O O
- O O
I O O
kappa O O
B O O
complex O O
. O O

Neither O O
phosphorylation O O
nor O O
degradation O O
of O O
I O O
kappa O O
B O O
alpha O O
was O O
observed O O
upon O O
TNF O O
- O O
alpha O O
stimulation O O
in O O
the O O
presence O O
of O O
Cu2 O O
+ O O
. O O

These O O
results O O
indicate O O
that O O
Cu2 O O
+ O O
inhibits O O
the O O
release O O
of O O
NF O O
kappa O O
B O O
by O O
blockade O O
of O O
a O O
signal O O
leading O O
to O O
the O O
phosphorylation O O
of O O
I O O
kappa O O
B O O
alpha O O
. O O

Cloning O O
a O O
cDNA B-DNA B-DNA
from O O
human O O
NK O O
/ O O
T O O
cells O O
which O O
codes O O
for O O
a O O
protein O O
with O O
high O O
proline O O
content O O
. O O

A O O
cDNA B-DNA B-DNA
clone I-DNA I-DNA
, O O
B4 B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
, O O
was O O
isolated O O
from O O
a O O
natural B-DNA B-DNA
killer I-DNA I-DNA
( I-DNA I-DNA
NK I-DNA I-DNA
) I-DNA I-DNA
minus I-DNA I-DNA
T I-DNA I-DNA
cell I-DNA I-DNA
subtractive I-DNA I-DNA
library I-DNA I-DNA
. O O

The O O
B4 B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
clone O I-DNA
coded O O
for O O
an O O
mRNA O O
of O O
2061 O O
bp O O
in O O
length O O
. O O

It O O
encodes O O
a O O
deduced O O
327 O O
aa O O
protein O O
with O O
a O O
calculated O O
molecular O O
mass O O
of O O
35 O O
. O O
2 O O
kDa O O
. O O

Searching O O
of O O
B4 B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
DNA I-DNA I-DNA
and O O
protein O O
sequences O O
against O O
various O O
databases O O
revealed O O
no O O
high O O
homology O O
to O O
other O O
sequences O O
. O O

However O O
, O O
B4 B-DNA O
- I-DNA O
2 I-DNA O
has O O
an O O
unusually O O
high O O
proline O O
content O O
( O O
13 O O
% O O
) O O
, O O
contains O O
a O O
putative O B-DNA
nuclear O I-DNA
targeting O I-DNA
sequence O I-DNA
, O O
and O O
has O O
several O O
SPXX O B-DNA
motifs O I-DNA
which O O
are O O
frequently O O
found O O
in O O
gene O O
regulatory O O
proteins O O
. O O

One O O
of O O
the O O
stretches O O
of O O
prolines O O
in O O
B4 B-DNA O
- I-DNA O
2 I-DNA O
closely O O
resembles O O
the O O
ligand O O
for O O
proteins O O
with O O
SH3 O O
domains O O
. O O

Northern O O
hybridization O O
data O O
showed O O
that O O
B4 B-DNA O
- I-DNA O
2 I-DNA O
is O O
not O O
a O O
lymphoid B-DNA B-DNA
specific I-DNA I-DNA
gene I-DNA I-DNA
and O O
is O O
expressed O O
in O O
a O O
hepatoma O O
cell O O
line O O
and O O
also O O
weakly O O
transcribed O O
or O O
absent O O
in O O
a O O
variety O O
of O O
other O O
cells O O
. O O

A O O
polyclonal O O
antiserum O O
raised O O
against O O
recombinant O O
B4 B-DNA O
- I-DNA O
2 I-DNA O
recognizes O O
a O O
32 O O
- O O
34 O O
kDa O O
protein O O
in O O
lymphocytes O O
. O O

Activation O O
of O O
JAK3 O O
, O O
but O O
not O O
JAK1 O O
, O O
is O O
critical O O
for O O
IL O O
- O O
2 O O
- O O
induced O O
proliferation O O
and O O
STAT5 O O
recruitment O O
by O O
a O O
COOH O O
- O O
terminal O O
region O O
of O O
the O O
IL O O
- O O
2 O O
receptor O O
beta O O
- O O
chain O O
. O O

A O O
number O O
of O O
cytokines O O
and O O
growth O O
factors O O
use O O
the O O
JAK O O
- O O
STAT O O
pathway O O
to O O
signal O O
from O O
the O O
cell O O
membrane O O
to O O
the O O
nucleus O O
. O O

While O O
homodimerizing O O
cytokine O O
receptors O O
may O O
transmit O O
signal O O
via O O
a O O
single O O
form O O
of O O
JAK O O
( O O
i O O
. O O
e O O
. O O
growth O O
hormone O O
receptors O O
) O O
, O O
several O O
multicomponent O O
cytokine O O
receptors O O
have O O
been O O
shown O O
to O O
require O O
simultaneous O O
activation O O
of O O
pairs O O
of O O
different O O
JAK O O
kinases O O
( O O
i O O
. O O
e O O
. O O
interferon O O
receptors O O
) O O
. O O

Recent O O
evidence O O
for O O
a O O
preferential O O
coupling O O
of O O
JAK3 O O
to O O
interleukin O O
- O O
2 O O
receptor O O
- O O
gamma O O
( O O
IL O O
- O O
2R O O
gamma O O
) O O
and O O
JAK1 O O
to O O
IL O O
- O O
2R O O
beta O O
supports O O
the O O
concept O O
of O O
heterotrans O O
- O O
activation O O
of O O
JAK1 O O
and O O
JAK3 O O
caused O O
by O O
IL O O
- O O
2 O O
- O O
induced O O
heterodimerization O O
of O O
their O O
receptor O O
partners O O
. O O

The O O
present O O
study O O
verified O O
the O O
ability O O
of O O
IL O O
- O O
2 O O
to O O
cause O O
tyrosine O O
phosphorylation O O
and O O
activation O O
of O O
JAK1 O O
and O O
JAK3 O O
, O O
but O O
demonstrated O O
that O O
IL O O
- O O
2 O O
stimulated O O
JAK3 O O
to O O
a O O
significantly O O
larger O O
extent O O
than O O
JAK1 O O
in O O
human O O
T O O
lymphocytes O O
and O O
the O O
YT O O
cell O O
line O O
. O O

This O O
conclusion O O
was O O
based O O
upon O O
several O O
independent O O
criteria O O
, O O
including O O
more O O
vigorous O O
tyrosine O O
phosphorylation O O
of O O
JAK3 O O
, O O
more O O
marked O O
enzymatic O O
activation O O
of O O
JAK3 O O
as O O
well O O
as O O
higher O O
abundance O O
of O O
JAK3 O O
in O O
activated O O
IL O O
- O O
2 O O
receptor O O
complexes O O
. O O

Furthermore O O
, O O
when O O
human O O
IL O O
- O O
2R O O
beta O O
was O O
stably O O
expressed O O
in O O
murine O O
BA O O
/ O O
F3 O O
cells O O
, O O
robust O O
IL O O
- O O
2 O O
- O O
induced O O
proliferation O O
and O O
JAK3 O O
activation O O
occurred O O
without O O
detectable O O
involvement O O
of O O
either O O
JAK1 O O
, O O
JAK2 O O
or O O
TYK2 O O
. O O

We O O
therefore O O
propose O O
that O O
IL O O
- O O
2 O O
receptor O O
signal O O
transduction O O
does O O
not O O
depend O O
on O O
equimolar O O
heterodimerization O O
of O O
JAK1 O O
and O O
JAK3 O O
following O O
IL O O
- O O
2 O O
- O O
induced O O
heterodimerization O O
of O O
IL O O
- O O
2R O O
beta O O
and O O
IL O O
- O O
2R O O
gamma O O
. O O

Nonetheless O O
, O O
a O O
membrane O O
- O O
proximal O O
region O O
of O O
human O O
IL O O
- O O
2R O O
beta O O
( O O
Asn240 O O
- O O
Leu335 O O
) O O
was O O
critical O O
for O O
JAK3 O O
activation O O
, O O
and O O
the O O
amount O O
of O O
JAK3 O O
present O O
in O O
activated O O
IL O O
- O O
2 O O
receptor O O
complexes O O
increased O O
with O O
time O O
, O O
suggesting O O
that O O
stabilization O O
of O O
JAK3 O O
binding O O
to O O
the O O
receptor O O
complex O O
relies O O
on O O
both O O
IL O O
- O O
2R O O
beta O O
and O O
IL O O
- O O
2R O O
gamma O O
. O O

Moreover O O
, O O
STAT5 O O
was O O
found O O
to O O
be O O
the O O
predominant O O
STAT O O
transcription O O
factor O O
used O O
by O O
IL O O
- O O
2 O O
in O O
human O O
T O O
cells O O
, O O
and O O
specifically O O
required O O
a O O
COOH O O
- O O
terminal O O
region O O
of O O
IL O O
- O O
2R O O
beta O O
( O O
Ser386 O O
- O O
Val525 O O
) O O
, O O
while O O
STAT5 O O
recruitment O O
was O O
not O O
correlated O O
to O O
activation O O
of O O
IL O O
- O O
2R O O
gamma O O
or O O
JAK3 O O
. O O

Up O O
- O O
regulation O O
of O O
high O O
- O O
affinity O O
dehydroepiandrosterone O O
binding O O
activity O O
by O O
dehydroepiandrosterone O O
in O O
activated O O
human O O
T O O
lymphocytes O O
. O O

Although O O
evidence O O
indicates O O
that O O
dehydroepiandrosterone O O
( O O
DHEA O O
) O O
exerts O O
direct O O
physiological O O
effects O O
, O O
its O O
mechanism O O
of O O
action O O
remains O O
unknown O O
. O O

DHEA O O
binding O O
sites O O
were O O
examined O O
using O O
a O O
whole O O
- O O
cell O O
binding O O
assay O O
in O O
a O O
human O O
T O O
lymphoid O O
cell O O
line O O
, O O
PEER O O
, O O
revealing O O
that O O
a O O
single O O
class O O
of O O
high O O
- O O
affinity O O
binding O O
sites O O
for O O
DHEA O O
( O O
dissociation O O
constant O O
= O O
7 O O
. O O
4 O O
+ O O
/ O O
- O O
0 O O
. O O
53 O O
nmol O O
/ O O
L O O
, O O
mean O O
+ O O
/ O O
- O O
SE O O
, O O
n O O
= O O
4 O O
) O O
was O O
greatly O O
increased O O
when O O
treated O O
with O O
DHEA O O
, O O
phorbol O O
- O O
12 O O
- O O
myristate O O
- O O
13 O O
- O O
acetate O O
, O O
and O O
the O O
Ca2 O O
+ O O
ionophore O O
A23187 O O
. O O

Bound O O
[ O O
3H O O
] O O
DHEA O O
was O O
displaced O O
sensitively O O
by O O
DHEA O O
and O O
secondarily O O
by O O
dihydrotestosterone O O
, O O
but O O
not O O
effectively O O
by O O
other O O
steroids O O
, O O
including O O
DHEA O O
sulfate O O
. O O

These O O
results O O
not O O
only O O
indicate O O
the O O
existence O O
of O O
a O O
DHEA O O
receptor O O
, O O
but O O
also O O
suggest O O
that O O
T O O
cells O O
become O O
susceptible O O
to O O
regulation O O
by O O
DHEA O O
during O O
the O O
process O O
of O O
signal O O
- O O
induced O O
activation O O
. O O

Ubiquitin O O
- O O
mediated O O
processing O O
of O O
NF O O
- O O
kappa O O
B O O
transcriptional O O
activator O O
precursor O O
p105 O O
. O O

Reconstitution O O
of O O
a O O
cell O O
- O O
free O O
system O O
and O O
identification O O
of O O
the O O
ubiquitin O O
- O O
carrier O O
protein O O
, O O
E2 O O
, O O
and O O
a O O
novel O O
ubiquitin O O
- O O
protein O O
ligase O O
, O O
E3 O O
, O O
involved O O
in O O
conjugation O O
. O O

In O O
most O O
cases O O
, O O
the O O
transcriptional O O
factor O O
NF O O
- O O
kappa O O
B O O
is O O
a O O
heterodimer O O
consisting O O
of O O
two O O
subunits O O
, O O
p50 O O
and O O
p65 O O
, O O
which O O
are O O
encoded O O
by O O
two O O
distinct O O
genes O O
of O O
the O O
Rel B-DNA O
family I-DNA O
. O O

p50 O O
is O O
translated O O
as O O
a O O
precursor O O
of O O
105 O O
kDa O O
. O O

The O O
C O O
- O O
terminal O O
domain O O
of O O
the O O
precursor O O
is O O
rapidly O O
degraded O O
, O O
forming O O
the O O
mature O O
p50 O O
subunit O O
consisted O O
of O O
the O O
N O O
- O O
terminal O O
region O O
of O O
the O O
molecule O O
. O O

The O O
mechanism O O
of O O
generation O O
of O O
p50 O O
is O O
not O O
known O O
. O O

It O O
has O O
been O O
suggested O O
that O O
the O O
ubiquitin O O
- O O
proteasome O O
system O O
is O O
involved O O
in O O
the O O
process O O
; O O
however O O
, O O
the O O
specific O O
enzymes O O
involved O O
and O O
the O O
mechanism O O
of O O
limited O O
proteolysis O O
, O O
in O O
which O O
half O O
of O O
the O O
molecule O O
is O O
spared O O
, O O
have O O
been O O
obscure O O
. O O

Palombella O O
and O O
colleagues O O
( O O
Palombella O O
, O O
V O O
. O O
J O O
. O O
, O O
Rando O O
, O O
O O O
. O O
J O O
. O O
, O O
Goldberg O O
, O O
A O O
. O O
L O O
. O O
, O O
and O O
Maniatis O O
, O O
T O O
. O O
( O O
1994 O O
) O O
Cell O O
78 O O
, O O
773 O O
- O O
785 O O
) O O
have O O
shown O O
that O O
ubiquitin O O
is O O
required O O
for O O
the O O
processing O O
in O O
a O O
cell O O
- O O
free O O
system O O
of O O
a O O
truncated O O
, O O
artificially O O
constructed O O
, O O
60 O O
- O O
kDa O O
precursor O O
. O O

They O O
have O O
also O O
shown O O
that O O
proteasome O O
inhibitors O O
block O O
the O O
processing O O
both O O
in O O
vitro O O
and O O
in O O
vivo O O
. O O

In O O
this O O
study O O
, O O
we O O
demonstrate O O
reconstitution O O
of O O
a O O
cell O O
- O O
free O O
processing O O
system O O
and O O
demonstrate O O
directly O O
that O O
: O O
( O O
a O O
) O O
the O O
ubiquitin O O
- O O
proteasome O O
system O O
is O O
involved O O
in O O
processing O O
of O O
the O O
intact O O
p105 O O
precursor O O
, O O
( O O
b O O
) O O
conjugation O O
of O O
ubiquitin O O
to O O
the O O
precursor O O
is O O
an O O
essential O O
intermediate O O
step O O
in O O
the O O
processing O O
, O O
( O O
c O O
) O O
the O O
recently O O
discovered O O
novel O O
species O O
of O O
the O O
ubiquitin O O
- O O
carrier O O
protein O O
, O O
E2 O O
- O O
F1 O O
, O O
that O O
is O O
involved O O
in O O
the O O
conjugation O O
and O O
degradation O O
of O O
p53 O O
, O O
is O O
also O O
required O O
for O O
the O O
limited O O
processing O O
of O O
the O O
p105 O O
precursor O O
, O O
and O O
( O O
d O O
) O O
a O O
novel O O
, O O
approximately O O
320 O O
- O O
kDa O O
species O O
of O O
ubiquitin O O
- O O
protein O O
ligase O O
, O O
is O O
involved O O
in O O
the O O
process O O
. O O

This O O
novel O O
enzyme O O
is O O
distinct O O
from O O
E6 O O
- O O
AP O O
, O O
the O O
p53 O O
- O O
conjugating O O
ligase O O
, O O
and O O
from O O
E3 O O
alpha O O
, O O
the O O
" O O
N O O
- O O
end O O
rule O O
" O O
ligase O O
. O O

Flutamide O O
in O O
the O O
treatment O O
of O O
hirsutism O O
: O O
long O O
- O O
term O O
clinical O O
effects O O
, O O
endocrine O O
changes O O
, O O
and O O
androgen O O
receptor O O
behavior O O
. O O

OBJECTIVE O O
: O O
To O O
investigate O O
the O O
long O O
- O O
term O O
effects O O
of O O
treatment O O
with O O
low O O
doses O O
of O O
flutamide O O
on O O
clinical O O
and O O
hormonal O O
parameters O O
, O O
as O O
well O O
as O O
on O O
the O O
androgen O O
receptor O O
status O O
, O O
in O O
hirsute O O
women O O
. O O

DESIGN O O
: O O
Eighteen O O
hirsute O O
patients O O
with O O
regular O O
menses O O
were O O
studied O O
basally O O
and O O
during O O
treatment O O
with O O
125 O O
mg O O
flutamide O O
, O O
three O O
times O O
per O O
day O O
for O O
12 O O
months O O
. O O

Barrier O O
or O O
intrauterine O O
contraception O O
was O O
used O O
during O O
the O O
study O O
in O O
sexually O O
active O O
women O O
. O O

Safety O O
parameters O O
were O O
assessed O O
throughout O O
the O O
study O O
. O O

Hirsutism O O
, O O
graded O O
by O O
the O O
modified O O
Ferriman O O
- O O
Gallwey O O
score O O
, O O
and O O
hormonal O O
parameters O O
were O O
evaluated O O
basally O O
and O O
at O O
4 O O
- O O
month O O
intervals O O
during O O
treatment O O
. O O

Gonadotropin O O
- O O
releasing O O
hormone O O
and O O
ACTH O O
stimulation O O
tests O O
were O O
performed O O
before O O
and O O
after O O
3 O O
to O O
4 O O
months O O
of O O
therapy O O
. O O

In O O
addition O O
, O O
the O O
concentration O O
of O O
androgen O O
receptors O O
in O O
mononuclear O O
leukocytes O O
was O O
measured O O
, O O
in O O
both O O
the O O
follicular O O
and O O
luteal O O
phases O O
of O O
the O O
menstrual O O
cycle O O
, O O
basally O O
and O O
after O O
4 O O
months O O
of O O
flutamide O O
treatment O O
. O O

RESULTS O O
: O O
Flutamide O O
was O O
well O O
tolerated O O
in O O
all O O
women O O
, O O
with O O
the O O
noticeable O O
exception O O
of O O
one O O
patient O O
who O O
presented O O
increased O O
serum O O
transaminase O O
after O O
8 O O
months O O
of O O
therapy O O
. O O

Hirsutism O O
markedly O O
improved O O
in O O
all O O
women O O
during O O
the O O
treatment O O
( O O
Ferriman O O
- O O
Gallwey O O
score O O
after O O
1 O O
year O O
: O O
4 O O
. O O
1 O O
+ O O
/ O O
- O O
0 O O
. O O
5 O O
versus O O
14 O O
. O O
1 O O
+ O O
/ O O
- O O
0 O O
. O O
9 O O
) O O
. O O

A O O
reduction O O
of O O
serum O O
androgens O O
was O O
found O O
, O O
whereas O O
no O O
change O O
was O O
observed O O
in O O
either O O
basal O O
or O O
GnRH O O
- O O
stimulated O O
gonadotropins O O
or O O
in O O
the O O
cortisol O O
and O O
17 O O
alpha O O
- O O
hydroxyprogesterone O O
response O O
to O O
ACTH O O
. O O

Cycles O O
remained O O
ovulatory O O
. O O

Before O O
treatment O O
, O O
the O O
number O O
of O O
androgen O O
receptors O O
was O O
higher O O
in O O
the O O
luteal O O
than O O
in O O
the O O
follicular O O
phase O O
. O O

This O O
rhythmic O O
differentiation O O
disappeared O O
after O O
the O O
patients O O
had O O
been O O
given O O
the O O
antiandrogen O O
drug O O
. O O

CONCLUSIONS O O
: O O
Flutamide O O
is O O
effective O O
in O O
the O O
treatment O O
of O O
hirsutism O O
but O O
requires O O
constant O O
surveillance O O
of O O
liver O O
function O O
. O O

Androgen O O
receptor O O
blockade O O
might O O
be O O
potentiated O O
by O O
a O O
reduction O O
of O O
serum O O
androgens O O
. O O

Flutamide O O
affects O O
androgen O O
receptor O O
behavior O O
during O O
the O O
menstrual O O
cycle O O
. O O

The O O
meaning O O
of O O
this O O
finding O O
remains O O
to O O
be O O
elucidated O O
. O O

Constitutive O O
expression O O
of O O
HIV O O
- O O
1 O O
tat O O
protein O O
in O O
human O O
Jurkat O O
T O O
cells O O
using O O
a O O
BK O O
virus O O
vector O O
. O O

The O O
production O O
and O O
characterization O O
of O O
Jurkat O O
cell O O
lines O O
that O O
constitutively O O
express O O
functional O O
human O O
immune O O
deficiency O O
virus O O
type O O
1 O O
( O O
HIV O O
- O O
1 O O
) O O
tat O O
protein O O
, O O
using O O
a O O
BK O B-DNA
virus O I-DNA
plasmid O I-DNA
expression O I-DNA
vector O I-DNA
and O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
tat I-DNA I-DNA
cDNA I-DNA I-DNA
, O O
is O O
described O O
. O O

An O O
increased O O
growth O O
rate O O
of O O
these O O
Jurkat O O
- O O
tat O O
cell O O
lines O O
as O O
compared O O
with O O
control O O
cell O O
lines O O
was O O
observed O O
. O O

A O O
PEBP2 O O
alpha O O
/ O O
AML O O
- O O
1 O O
- O O
related O O
factor O O
increases O O
osteocalcin B-DNA B-DNA
promoter I-DNA I-DNA
activity O O
through O O
its O O
binding O O
to O O
an O O
osteoblast B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
cis I-DNA I-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
element I-DNA I-DNA
. O O

To O O
identify O O
osteoblast B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
cis I-DNA I-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
elements I-DNA I-DNA
and O O
trans O O
- O O
acting O O
factors O O
, O O
we O O
initiated O O
an O O
analysis O O
of O O
the O O
promoter B-DNA B-DNA
of O O
a O O
mouse B-DNA B-DNA
osteocalcin I-DNA I-DNA
gene I-DNA I-DNA
, O O
an O O
osteoblast B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
gene I-DNA I-DNA
. O O

In O O
this O O
promoter O O
, O O
we O O
identified O O
two O O
osteoblast B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
cis I-DNA I-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
elements I-DNA I-DNA
( O O
Ducy O B-DNA
, O O
P O B-DNA
. O O
and O O
Karsenty O O
, O O
G O O
. O O
( O O
1995 O O
) O O
Mol O O
. O O
Cell O O
. O O
Biol O O
. O O
15 O O
, O O
1858 O O
- O O
1869 O O
) O O
. O O

The O O
sequence O O
of O O
one O O
of O O
these O O
elements B-DNA O
, O O
OSE2 B-DNA B-DNA
, O O
is O O
identical O O
to O O
the O O
DNA B-DNA B-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
of O O
the O O
PEBP2 O O
alpha O O
/ O O
AML O O
- O O
1 O O
transcription O O
factors O O
, O O
the O O
mammalian O O
homologues O O
of O O
the O O
Drosophila O O
Runt O O
protein O O
. O O

Here O O
we O O
show O O
, O O
using O O
nuclear O O
extracts O O
, O O
recombinant O O
protein O O
, O O
and O O
a O O
specific O O
antiserum O O
against O O
AML O O
- O O
1 O O
proteins O O
in O O
DNA O O
- O O
binding O O
assays O O
, O O
that O O
one O O
member O O
of O O
this O O
family O O
, O O
AML O O
- O O
1B O O
, O O
binds O O
specifically O O
to O O
OSE2 B-DNA B-DNA
and O O
is O O
immunologically O O
related O O
to O O
OSF2 O O
, O O
the O O
factor O O
present O O
in O O
osteoblast O O
nuclear O O
extracts O O
that O O
binds O O
to O O
OSE2 B-DNA B-DNA
. O O

By O O
DNA O O
cotransfection O O
experiments O O
, O O
we O O
also O O
demonstrate O O
that O O
AML O O
- O O
1B O O
can O O
increase O O
the O O
activity O O
of O O
a O O
short O B-DNA
osteocalcin B-DNA I-DNA
promoter I-DNA I-DNA
through O O
its O O
binding O O
to O O
OSE2 B-DNA B-DNA
. O O

Lastly O O
, O O
the O O
different O O
mobilities O O
of O O
osteoblast O O
nuclear O O
extract O O
- O O
DNA O O
complexes O O
compared O O
with O O
T O O
- O O
cell O O
nuclear O O
extract O O
- O O
DNA O O
complexes O O
, O O
along O O
with O O
the O O
inability O O
of O O
OSF2 O O
to O O
be O O
upregulated O O
by O O
retinoic O O
acid O O
, O O
unlike O O
the O O
other O O
PEBP2 O O
alpha O O
factors O O
, O O
suggest O O
that O O
OSF2 O O
is O O
a O O
new O O
member O O
of O O
this O O
family O O
of O O
transcription O O
factors O O
. O O

Thus O O
, O O
this O O
study O O
demonstrates O O
that O O
AML O O
- O O
1B O O
can O O
increase O O
gene O O
expression O O
of O O
an O O
osteoblast B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
gene I-DNA I-DNA
through O O
its O O
binding O O
to O O
an O O
osteoblast B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
cis I-DNA I-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
element I-DNA I-DNA
and O O
presents O O
evidence O O
that O O
OSF2 O O
is O O
a O O
member O O
of O O
the O O
PEBP2 O O
alpha O O
/ O O
AML O O
- O O
1 O O
family O O
of O O
transcription O O
factors O O
. O O

Initiation O O
binding O O
repressor O O
, O O
a O O
factor O O
that O O
binds O O
to O O
the O O
transcription B-DNA B-DNA
initiation I-DNA I-DNA
site I-DNA I-DNA
of O O
the O O
histone B-DNA B-DNA
h5 I-DNA I-DNA
gene I-DNA I-DNA
, O O
is O O
a O O
glycosylated O O
member O O
of O O
a O O
family O O
of O O
cell O O
growth O O
regulators O O
[ O O
corrected O O
] O O
[ O O
published O O
erratum O O
appears O O
in O O
Mol O O
Cell O O
Biol O O
1996 O O
Feb O O
; O O
16 O O
( O O
2 O O
) O O
: O O
735 O O
] O O
. O O

Initiation O O
binding O O
repressor O O
[ O O
corrected O O
] O O
( O O
IBR O O
) O O
is O O
a O O
chicken O O
erythrocyte O O
factor O O
( O O
apparent O O
molecular O O
mass O O
, O O
70 O O
to O O
73 O O
kDa O O
) O O
that O O
binds O O
to O O
the O O
sequences O O
spanning O O
the O O
transcription B-DNA B-DNA
initiation I-DNA I-DNA
site I-DNA I-DNA
of O O
the O O
histone B-DNA B-DNA
h5 I-DNA I-DNA
gene I-DNA I-DNA
, O O
repressing O O
its O O
transcription O O
. O O

A O O
variety O O
of O O
other O O
cells O O
, O O
including O O
transformed O O
erythroid O O
precursors O O
, O O
do O O
not O O
have O O
IBR O O
but O O
a O O
factor O O
referred O O
to O O
as O O
IBF O O
( O O
68 O O
to O O
70 O O
kDa O O
) O O
that O O
recognizes O O
the O O
same O O
IBR O B-DNA
sites O I-DNA
. O O

We O O
have O O
cloned O O
the O O
IBR B-DNA B-DNA
cDNA I-DNA I-DNA
and O O
studied O O
the O O
relationship O O
of O O
IBR O O
and O O
IBF O O
. O O

IBR O O
is O O
a O O
503 O O
- O O
amino O O
- O O
acid O O
- O O
long O O
acidic O O
protein O O
which O O
is O O
99 O O
. O O
0 O O
% O O
identical O O
to O O
the O O
recently O O
reported O O
human O O
NRF O O
- O O
1 O O
/ O O
alpha O O
- O O
Pal O O
factor O O
and O O
highly O O
related O O
to O O
the O O
invertebrate O O
transcription O O
factors O O
P3A2 O O
and O O
erected O O
wing O O
gene O O
product O O
( O O
EWG O O
) O O
. O O

We O O
present O O
evidence O O
that O O
IBR O O
and O O
IBF O O
are O O
most O O
likely O O
identical O O
proteins O O
, O O
differing O O
in O O
their O O
degree O O
of O O
glycosylation O O
. O O

We O O
have O O
analyzed O O
several O O
molecular O O
aspects O O
of O O
IBR O O
/ O O
F O O
and O O
shown O O
that O O
the O O
factor O O
associates O O
as O O
stable O O
homodimers O O
and O O
that O O
the O O
dimer O O
is O O
the O O
relevant O O
DNA O O
- O O
binding O O
species O O
. O O

The O O
evolutionarily O O
conserved O O
N O O
- O O
terminal O O
half O O
of O O
IBR O O
/ O O
F O O
harbors O O
the O O
DNA O O
- O O
binding O O
/ O O
dimerization O O
domain O O
( O O
outer O O
limits O O
, O O
127 O O
to O O
283 O O
) O O
, O O
one O O
or O O
several O O
casein O O
kinase O O
II O O
sites O O
( O O
37 O O
to O O
67 O O
) O O
, O O
and O O
a O O
bipartite O O
nuclear O O
localization O O
signal O O
( O O
89 O O
to O O
106 O O
) O O
which O O
appears O O
to O O
be O O
necessary O O
for O O
nuclear O O
targeting O O
. O O

Binding O O
site O O
selection O O
revealed O O
that O O
the O O
alternating O O
RCGCRYGCGY O B-DNA
consensus O I-DNA
constitutes O O
high O B-DNA
- O I-DNA
affinity O I-DNA
IBR B-DNA I-DNA
/ I-DNA I-DNA
F I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
and O O
that O O
the O O
direct B-DNA B-DNA
- I-DNA I-DNA
repeat I-DNA I-DNA
palindrome I-DNA I-DNA
TGCGCATGCGCA O O
is O O
the O O
optimal B-DNA B-DNA
site I-DNA I-DNA
. O O

A O O
survey O O
of O O
genes B-DNA O
potentially O O
regulated O O
by O O
this O O
family O O
of O O
factors O O
primarily O O
revealed O O
genes B-DNA O
involved O O
in O O
growth O O
- O O
related O O
metabolism O O
. O O

Triggering O O
of O O
the O O
human O B-DNA
interleukin O I-DNA
- O I-DNA
6 O I-DNA
gene O I-DNA
by O O
interferon O O
- O O
gamma O O
and O O
tumor O O
necrosis O O
factor O O
- O O
alpha O O
in O O
monocytic O O
cells O O
involves O O
cooperation O O
between O O
interferon O O
regulatory O O
factor O O
- O O
1 O O
, O O
NF O O
kappa O O
B O O
, O O
and O O
Sp1 O O
transcription O O
factors O O
. O O

We O O
investigated O O
the O O
molecular O O
basis O O
of O O
the O O
synergistic O O
induction O O
by O O
interferon O O
- O O
gamma O O
( O O
IFN O O
- O O
gamma O O
) O O
/ O O
tumor O O
necrosis O O
factor O O
- O O
alpha O O
( O O
TNF O O
- O O
alpha O O
) O O
of O O
human B-DNA B-DNA
interleukin I-DNA I-DNA
- I-DNA I-DNA
6 I-DNA I-DNA
( I-DNA I-DNA
IL I-DNA I-DNA
- I-DNA I-DNA
6 I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
in O O
THP O O
- O O
1 O O
monocytic O O
cells O O
, O O
and O O
compared O O
it O O
with O O
the O O
basis O O
of O O
this O O
induction O O
by O O
lipopolysaccharide O O
( O O
LPS O O
) O O
. O O

Functional O O
studies O O
with O O
IL B-DNA B-DNA
- I-DNA I-DNA
6 I-DNA I-DNA
promoter I-DNA I-DNA
demonstrated O O
that O O
three O O
regions O O
are O O
the O O
targets O O
of O O
the O O
IFN O O
- O O
gamma O O
and O O
/ O O
or O O
TNF O O
- O O
alpha O O
action O O
, O O
whereas O O
only O O
one O O
of O O
these O O
regions O O
seemed O O
to O O
be O O
implicated O O
in O O
LPS O O
activation O O
. O O

The O O
three O O
regions O O
concerned O O
are O O
: O O
1 O O
) O O
a O O
region O O
between O O
- O B-DNA
73 O I-DNA
and O I-DNA
- O I-DNA
36 O I-DNA
, O O
which O O
is O O
the O O
minimal B-DNA O
element I-DNA O
inducible O O
by O O
LPS O O
or O O
TNF O O
- O O
alpha O O
; O O
2 O O
) O O
an O O
element O O
located O O
between O O
- O B-DNA
181 O I-DNA
and O I-DNA
- O I-DNA
73 O I-DNA
, O O
which O O
appeared O O
to O O
regulate O O
the O O
response O O
to O O
IFN O O
- O O
gamma O O
and O O
TNF O O
- O O
alpha O O
negatively O O
; O O
and O O
3 O O
) O O
a O O
distal B-DNA B-DNA
element I-DNA I-DNA
upstream I-DNA O
of O O
- O O
224 O O
, O O
which O O
was O O
inducible O O
by O O
IFN O O
- O O
gamma O O
alone O O
. O O

LPS O O
signaling O O
was O O
found O O
to O O
involve O O
NF O O
kappa O O
B O O
activation O O
by O O
the O O
p50 O O
/ O O
p65 O O
heterodimers O O
. O O

Synergistic O O
induction O O
of O O
the O O
IL B-DNA B-DNA
- I-DNA I-DNA
6 I-DNA I-DNA
gene I-DNA I-DNA
by O O
IFN O O
- O O
gamma O O
and O O
TNF O O
- O O
alpha O O
, O O
in O O
monocytic O O
cells O O
, O O
involved O O
cooperation O O
between O O
the O O
IRF O O
- O O
1 O O
and O O
NF O O
kappa O O
B O O
p65 O O
homodimers O O
with O O
concomitant O O
removal O O
of O O
the O O
negative O O
effect O O
of O O
the O O
retinoblastoma B-DNA B-DNA
control I-DNA I-DNA
element I-DNA I-DNA
present O O
in O O
the O O
IL B-DNA B-DNA
- I-DNA I-DNA
6 I-DNA I-DNA
promoter I-DNA I-DNA
. O O

This O O
removal O O
occurred O O
by O O
activation O O
of O O
the O O
constitutive O O
Sp1 O O
factor O O
, O O
whose O O
increased O O
binding O O
activity O O
and O O
phosphorylation O O
were O O
mediated O O
by O O
IFN O O
- O O
gamma O O
. O O

Mutation O O
of O O
Jak3 O O
in O O
a O O
patient O O
with O O
SCID O O
: O O
essential O O
role O O
of O O
Jak3 O O
in O O
lymphoid O O
development O O
. O O

Males O O
with O O
X O O
- O O
linked O O
severe O O
combined O O
immunodeficiency O O
( O O
XSCID O O
) O O
have O O
defects O O
in O O
the O O
common O B-DNA
cytokine B-DNA I-DNA
receptor I-DNA I-DNA
gamma I-DNA I-DNA
chain I-DNA I-DNA
( I-DNA I-DNA
gamma I-DNA I-DNA
c I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
that O O
encodes O O
a O O
shared O O
, O O
essential O O
component O O
of O O
the O O
receptors O O
of O O
interleukin O O
- O O
2 O O
( O O
IL O O
- O O
2 O O
) O O
, O O
IL O O
- O O
4 O O
, O O
IL O O
- O O
7 O O
, O O
IL O O
- O O
9 O O
, O O
and O O
IL O O
- O O
15 O O
. O O

The O O
Janus O O
family O O
tyrosine O O
kinase O O
Jak3 O O
is O O
the O O
only O O
signaling O O
molecule O O
known O O
to O O
be O O
associated O O
with O O
gamma O O
c O O
, O O
so O O
it O O
was O O
hypothesized O O
that O O
defects O O
in O O
Jak3 O O
might O O
cause O O
an O O
XSCID O O
- O O
like O O
phenotype O O
. O O

A O O
girl O O
with O O
immunological O O
features O O
indistinguishable O O
from O O
those O O
of O O
XSCID O O
was O O
therefore O O
selected O O
for O O
analysis O O
. O O

An O O
Epstein O O
- O O
Barr O O
virus O O
( O O
EBV O O
) O O
- O O
transformed O O
cell O O
line O O
derived O O
from O O
her O O
lymphocytes O O
had O O
normal O O
gamma O O
c O O
expression O O
but O O
lacked O O
Jak3 O O
protein O O
and O O
had O O
greatly O O
diminished O O
Jak3 O O
messenger O O
RNA O O
. O O

Sequencing O O
revealed O O
a O O
different O O
mutation O O
on O O
each O O
allele O B-DNA
: O O
a O O
single O O
nucleotide O O
insertion O O
resulting O O
in O O
a O O
frame O O
shift O O
and O O
premature O O
termination O O
in O O
the O O
Jak3 O B-DNA
JH4 O I-DNA
domain O I-DNA
and O O
a O O
nonsense O O
mutation O O
in O O
the O O
Jak3 O B-DNA
JH2 O I-DNA
domain O I-DNA
. O O

The O O
lack O O
of O O
Jak3 O O
expression O O
correlated O O
with O O
impaired O O
B O O
cell O O
signaling O O
, O O
as O O
demonstrated O O
by O O
the O O
inability O O
of O O
IL O O
- O O
4 O O
to O O
activate O O
Stat6 O O
in O O
the O O
EBV O O
- O O
transformed O O
cell O O
line O O
from O O
the O O
patient O O
. O O
These O O
observations O O
indicate O O
that O O
the O O
functions O O
of O O
gamma O O
c O O
are O O
dependent O O
on O O
Jak3 O O
and O O
that O O
Jak3 O O
is O O
essential O O
for O O
lymphoid O O
development O O
and O O
signaling O O
. O O

Constitutive O O
overexpression O O
of O O
the O O
L B-DNA B-DNA
- I-DNA I-DNA
selectin I-DNA I-DNA
gene I-DNA I-DNA
in O O
fresh O O
leukemic O O
cells O O
of O O
adult O O
T O O
- O O
cell O O
leukemia O O
that O O
can O O
be O O
transactivated O O
by O O
human O O
T O O
- O O
cell O O
lymphotropic O O
virus O O
type O O
1 O O
Tax O O
. O O

L O O
- O O
selectin O O
is O O
an O O
adhesion O O
molecule O O
of O O
the O O
selectin O O
family O O
that O O
mediates O O
the O O
initial O O
step O O
of O O
leukocyte O O
adhesion O O
to O O
vascular O O
endothelium O O
. O O

Upon O O
cellular O O
activation O O
, O O
expression O O
of O O
the O O
L B-DNA B-DNA
- I-DNA I-DNA
selectin I-DNA I-DNA
gene I-DNA I-DNA
is O O
downregulated O O
at O O
both O O
the O O
protein O O
and O O
mRNA O O
levels O O
. O O

To O O
understand O O
the O O
mechanism O O
of O O
leukemic O O
cell O O
infiltration O O
into O O
organs O O
, O O
we O O
studied O O
the O O
expression O O
and O O
regulation O O
of O O
L O O
- O O
selectin O O
mRNA O O
in O O
fresh O O
leukemic O O
cells O O
of O O
adult O O
T O O
- O O
cell O O
leukemia O O
( O O
ATL O O
) O O
patients O O
and O O
investigated O O
the O O
response O O
of O O
the O O
L B-DNA B-DNA
- I-DNA I-DNA
selectin I-DNA I-DNA
promoter I-DNA I-DNA
to O O
human O O
T O O
- O O
cell O O
lymphotropic O O
virus O O
type O O
1 O O
( O O
HTLV O O
- O O
1 O O
) O O
Tax O O
, O O
which O O
is O O
a O O
viral O O
transcriptional O O
transactivator O O
. O O

Flow O O
cytometry O O
showed O O
that O O
L O O
- O O
selectin O O
was O O
expressed O O
on O O
fresh O O
ATL O O
cells O O
along O O
with O O
other O O
activation O O
antigens O O
. O O

Northern O O
blot O O
analysis O O
showed O O
that O O
ATL O O
cells O O
overexpressed O O
that O O
L O O
- O O
selectin O O
mRNA O O
and O O
that O O
the O O
level O O
was O O
aberrantly O O
upregulated O O
after O O
PMA O O
stimulation O O
. O O

Studies O O
using O O
in O O
situ O O
hybridization O O
showed O O
expression O O
of O O
the O O
L O O
- O O
selectin O O
mRNA O O
in O O
the O O
infiltrating O O
leukemic O O
cells O O
in O O
the O O
liver O O
of O O
two O O
ATL O O
patients O O
. O O

Intravenous O O
injection O O
of O O
a O O
rat O O
T O O
- O O
cell O O
line O O
that O O
overexpresses O O
L O O
- O O
selectin O O
showed O O
increased O O
organ O O
infiltration O O
. O O

The O O
induction O O
of O O
Tax O O
expression O O
in O O
JPX9 O O
cells O O
resulted O O
in O O
about O O
a O O
twofold O O
increase O O
in O O
the O O
mRNA O O
expression O O
levels O O
compared O O
with O O
the O O
basal O O
level O O
. O O

Chloramphenicol O O
acetyltransferase O O
( O O
CAT O O
) O O
assay O O
after O O
transient O O
cotransfection O O
showed O O
about O O
a O O
fivefold O O
transactivation O O
of O O
the O O
L B-DNA B-DNA
- I-DNA I-DNA
selectin I-DNA I-DNA
promoter I-DNA I-DNA
by O O
Tax O O
. O O

The O O
serum O O
level O O
of O O
the O O
shed O O
form O O
of O O
L O O
- O O
selectin O O
was O O
significantly O O
increased O O
in O O
ATL O O
patients O O
( O O
mean O O
+ O O
/ O O
- O O
SD O O
, O O
4 O O
, O O
215 O O
. O O
4 O O
+ O O
/ O O
- O O
4 O O
, O O
111 O O
ng O O
/ O O
mL O O
) O O
compared O O
with O O
those O O
of O O
asymptomatic O O
carriers O O
and O O
healthy O O
blood O O
donors O O
( O O
mean O O
+ O O
/ O O
- O O
SD O O
, O O
1 O O
, O O
148 O O
. O O
0 O O
+ O O
/ O O
- O O
269 O O
. O O
0 O O
ng O O
/ O O
mL O O
and O O
991 O O
. O O
9 O O
+ O O
/ O O
- O O
224 O O
ng O O
/ O O
mL O O
, O O
respectively O O
) O O
. O O

These O O
results O O
indicated O O
that O O
ATL O O
cells O O
constitutively O O
overexpress O O
the O O
L B-DNA B-DNA
- I-DNA I-DNA
selectin I-DNA I-DNA
gene I-DNA I-DNA
that O O
can O O
be O O
transactivated O O
by O O
HTLV O O
- O O
1 O O
Tax O O
. O O

The O O
overexpression O O
of O O
L O O
- O O
selectin O O
, O O
as O O
well O O
as O O
of O O
inflammatory O O
cytokines O O
, O O
by O O
ATL O O
cells O O
may O O
provide O O
a O O
basis O O
for O O
ATL O O
cells O O
to O O
attach O O
the O O
vascular O O
endothelium O O
, O O
leading O O
to O O
transmigration O O
and O O
organ O O
infitration O O
. O O

Human O O
herpesvirus O O
6 O O
variant O O
A O O
, O O
but O O
not O O
variant O O
B O O
, O O
infects O O
EBV O O
- O O
positive O O
B O O
lymphoid O O
cells O O
, O O
activating O O
the O O
latent B-DNA B-DNA
EBV I-DNA I-DNA
genome I-DNA I-DNA
through O O
a O O
BZLF O O
- O O
1 O O
- O O
dependent O O
mechanism O O
. O O

Human O O
herpesvirus O O
6 O O
, O O
a O O
predominantly O O
T O O
lymphotropic O O
virus O O
, O O
has O O
been O O
recently O O
shown O O
to O O
infect O O
some O O
EBV O O
- O O
positive O O
B O O
cell O O
lines O O
, O O
and O O
to O O
induce O O
in O O
them O O
the O O
activation O O
of O O
the O O
EBV O O
lytic O O
cycle O O
. O O

Here O O
we O O
have O O
confirmed O O
and O O
extended O O
such O O
observations O O
, O O
showing O O
that O O
( O O
1 O O
) O O
this O O
phenomenon O O
is O O
restricted O O
to O O
the O O
variant O O
A O O
of O O
HHV O O
- O O
6 O O
: O O
in O O
fact O O
two O O
isolates O O
belonging O O
to O O
the O O
HHV O O
- O O
6 O O
variant O O
B O O
( O O
BA92 O O
and O O
Z29 O O
) O O
were O O
neither O O
able O O
to O O
infect O O
any O O
B O O
cell O O
line O O
, O O
independently O O
of O O
the O O
EBV O O
status O O
, O O
nor O O
to O O
induce O O
the O O
EBV O B-DNA
genome O I-DNA
expression O O
. O O

The O O
only O O
exception O O
is O O
represented O O
by O O
the O O
P3HR1 O O
cells O O
, O O
in O O
which O O
, O O
however O O
, O O
the O O
infection O O
by O O
the O O
variant O O
B O O
does O O
not O O
determine O O
induction O O
of O O
EBV O O
antigens O O
; O O
( O O
2 O O
) O O
the O O
presence O O
of O O
the O O
EBV B-DNA B-DNA
genome I-DNA I-DNA
contributes O O
to O O
the O O
susceptibility O O
of O O
the O O
B O O
cell O O
lines O O
to O O
HHV O O
- O O
6 O O
infection O O
, O O
increasing O O
the O O
binding O B-DNA
sites O I-DNA
and O O
the O O
percentage O O
of O O
infectable O O
cells O O
, O O
as O O
detected O O
by O O
immunoelectron O O
microscopy O O
; O O
and O O
( O O
3 O O
) O O
HHV O O
- O O
6 O O
infected O O
T O O
cells O O
, O O
transfected O O
with O O
plasmids B-DNA B-DNA
bearing O O
the O O
promoter B-DNA B-DNA
regions I-DNA I-DNA
of O O
the O O
EBV O B-DNA
early O I-DNA
genes O I-DNA
BZLF1 B-DNA B-DNA
and O O
BMRF1 B-DNA B-DNA
, O O
show O O
a O O
strong O O
transactivation O O
of O O
these O O
promoters B-DNA B-DNA
. O O

Evidence O O
for O O
normal O O
vitamin O O
D O O
receptor O O
messenger O O
ribonucleic O O
acid O O
and O O
genotype O O
in O O
absorptive O O
hypercalciuria O O
. O O

Absorptive O O
hypercalciuria O O
( O O
a O O
stone O O
- O O
forming O O
condition O O
) O O
is O O
characterized O O
by O O
gut O O
hyperabsorption O O
of O O
calcium O O
, O O
hypercalciuria O O
, O O
and O O
reduced O O
bone O O
density O O
. O O

Inasmuch O O
as O O
these O O
features O O
implicate O O
enhanced O O
calcitriol O O
action O O
in O O
gut O O
and O O
bone O O
, O O
we O O
analyzed O O
the O O
vitamin B-DNA B-DNA
D I-DNA I-DNA
receptor I-DNA I-DNA
( I-DNA I-DNA
VDR I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
to O O
ascertain O O
whether O O
an O O
abnormality O O
of O O
this O O
gene O O
marks O O
patients O O
with O O
intestinal O O
hyperabsorption O O
of O O
calcium O O
. O O

We O O
have O O
compared O O
the O O
frequency O O
of O O
a O O
restriction B-DNA B-DNA
fragment I-DNA I-DNA
length I-DNA I-DNA
polymorphism I-DNA I-DNA
( O O
Bsm B-DNA B-DNA
I I-DNA I-DNA
) O O
associated O O
with O O
different O O
alleles O B-DNA
of O O
the O O
VDR B-DNA B-DNA
gene I-DNA I-DNA
in O O
a O O
group O O
of O O
33 O O
well O O
characterized O O
absorptive O O
hypercalciuric O O
patients O O
and O O
a O O
group O O
of O O
36 O O
normal O O
race O O
- O O
and O O
age O O
- O O
matched O O
control O O
subjects O O
. O O

There O O
was O O
no O O
difference O O
between O O
the O O
distribution O O
of O O
the O O
VDR O B-DNA
alleles O I-DNA
in O O
the O O
patient O O
population O O
when O O
compared O O
with O O
the O O
normal O O
population O O
. O O

The O O
coding O O
region O O
of O O
VDR O O
messenger O O
RNA O O
was O O
also O O
normal O O
, O O
as O O
determined O O
by O O
both O O
DNA B-DNA O
sequence I-DNA O
analysis O O
and O O
chemical O O
mismatch O O
cleavage O O
analysis O O
of O O
copy O B-DNA
DNA O I-DNA
from O O
11 O O
index O O
absorptive O O
hypercalciuric O O
patients O O
. O O

On O O
the O O
basis O O
of O O
these O O
results O O
, O O
we O O
propose O O
that O O
the O O
enhanced O O
intestinal O O
calcium O O
absorption O O
invariably O O
seen O O
in O O
absorptive O O
hypercalciuria O O
and O O
attendant O O
symptoms O O
of O O
this O O
disorder O O
are O O
not O O
attributable O O
to O O
mutations O O
of O O
the O O
VDR O O
and O O
are O O
not O O
linked O O
to O O
a O O
common O O
VDR B-DNA O
genotype I-DNA O
. O O

Transcriptional O O
regulation O O
of O O
the O O
gene O O
encoding O O
the O O
human O O
C O O
- O O
type O O
lectin O O
leukocyte O O
receptor O O
AIM O O
/ O O
CD69 O O
and O O
functional O O
characterization O O
of O O
its O O
tumor O B-DNA
necrosis O I-DNA
factor O I-DNA
- O I-DNA
alpha O I-DNA
- O I-DNA
responsive O I-DNA
elements B-DNA I-DNA
. O O

The O O
human O O
activation O O
antigen O O
CD69 O O
is O O
a O O
member O O
of O O
the O O
C O O
- O O
type O O
animal O O
lectin O O
superfamily O O
that O O
functions O O
as O O
a O O
signal O O
- O O
transmitting O O
receptor O O
. O O

Although O O
the O O
expression O O
of O O
CD69 O O
can O O
be O O
induced O O
in O O
vitro O O
on O O
cells O O
of O O
most O O
hematopoietic O O
lineages O O
with O O
a O O
wide O O
variety O O
of O O
stimuli O O
, O O
in O O
vivo O O
it O O
is O O
mainly O O
expressed O O
by O O
T O O
- O O
lymphocytes O O
located O O
in O O
the O O
inflammatory O O
infiltrates O O
of O O
several O O
human O O
diseases O O
. O O

To O O
elucidate O O
the O O
mechanisms O O
that O O
regulate O O
the O O
constitutive O O
and O O
inducible O O
expression O O
of O O
CD69 O O
by O O
leukocytes O O
, O O
we O O
isolated O O
the O O
promoter B-DNA B-DNA
region I-DNA I-DNA
of O O
the O O
CD69 O B-DNA
gene O I-DNA
and O O
carried O O
out O O
its O O
functional O O
characterization O O
. O O

Sequence O O
analysis O O
of O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
- I-DNA I-DNA
flanking I-DNA I-DNA
region I-DNA I-DNA
of O O
the O O
CD69 B-DNA B-DNA
gene I-DNA I-DNA
revealed O O
the O O
presence O O
of O O
a O O
potential O O
TATA B-DNA B-DNA
element I-DNA I-DNA
30 B-DNA B-DNA
base I-DNA I-DNA
pairs I-DNA I-DNA
upstream I-DNA O
of O O
the O O
major O B-DNA
transcription B-DNA I-DNA
initiation I-DNA I-DNA
site I-DNA I-DNA
and O O
several O O
putative O B-DNA
binding O I-DNA
sequences O I-DNA
for O O
inducible O O
transcription O O
factors O O
( O O
NF O O
- O O
kappa O O
B O O
, O O
Egr O O
- O O
1 O O
, O O
AP O O
- O O
1 O O
) O O
, O O
which O O
might O O
mediate O O
the O O
inducible O O
expression O O
of O O
this O O
gene O O
. O O

Transient O O
expression O O
of O O
CD69 B-DNA B-DNA
promoter I-DNA I-DNA
- I-DNA I-DNA
based I-DNA I-DNA
reporter I-DNA I-DNA
gene I-DNA I-DNA
constructs I-DNA I-DNA
in O O
K562 O O
cells O O
indicated O O
that O O
the O O
proximal B-DNA B-DNA
promoter I-DNA I-DNA
region I-DNA I-DNA
spanning O O
positions O O
- O B-DNA
78 O I-DNA
to O I-DNA
+ O I-DNA
16 O I-DNA
contained O O
the O O
cis B-DNA B-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
sequences I-DNA I-DNA
necessary O O
for O O
basal O O
and O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
- O O
inducible O O
transcription O O
of O O
the O O
CD69 B-DNA B-DNA
gene I-DNA I-DNA
. O O

Removal O O
of O O
the O O
upstream O B-DNA
sequences O I-DNA
located O O
between O O
positions O O
- O B-DNA
78 O I-DNA
and O I-DNA
- O I-DNA
38 O I-DNA
resulted O O
in O O
decreased O O
promoter O O
strength O O
and O O
abolished O O
the O O
response O O
to O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
. O O

We O O
also O O
found O O
that O O
tumor O O
necrosis O O
factor O O
- O O
alpha O O
( O O
TNF O O
- O O
alpha O O
) O O
is O O
capable O O
of O O
inducing O O
the O O
surface O O
expression O O
of O O
the O O
CD69 O O
molecule O O
as O O
well O O
as O O
the O O
promoter O O
activity O O
of O O
fusion O B-DNA
plasmids O I-DNA
that O O
contain O O
5 O B-DNA
' O I-DNA
- O I-DNA
flanking O I-DNA
sequences O I-DNA
of O O
the O O
CD69 O B-DNA
gene O I-DNA
, O O
suggesting O O
that O O
this O O
cytokine O O
may O O
regulate O O
in O O
vivo O O
the O O
expression O O
of O O
CD69 O O
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
250 O O
WORDS O O
) O O
. O O

Characterization O O
of O O
5 B-DNA B-DNA
' I-DNA I-DNA
end I-DNA I-DNA
of I-DNA O
human I-DNA B-DNA
thromboxane I-DNA I-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
. O O

Organizational O O
analysis O O
and O O
mapping O O
of O O
protein B-DNA B-DNA
kinase I-DNA I-DNA
C I-DNA I-DNA
- I-DNA I-DNA
- I-DNA I-DNA
responsive I-DNA I-DNA
elements I-DNA I-DNA
regulating O O
expression O O
in O O
platelets O O
. O O

Platelet O O
thromboxane O O
receptors O O
are O O
acutely O O
and O O
reversibly O O
upregulated O O
after O O
acute O O
myocardial O O
infarction O O
. O O

To O O
determine O O
if O O
platelet O O
thromboxane O O
receptors O O
are O O
under O O
transcriptional O O
control O O
, O O
we O O
isolated O O
and O O
characterized O O
human B-DNA B-DNA
genomic I-DNA I-DNA
DNA I-DNA I-DNA
clones I-DNA I-DNA
containing O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
flanking I-DNA I-DNA
region I-DNA I-DNA
of O O
the O O
thromboxane B-DNA B-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
. O O

The O O
exon B-DNA B-DNA
- I-DNA I-DNA
intron I-DNA I-DNA
structure I-DNA I-DNA
of O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
portion I-DNA I-DNA
of O O
the O O
thromboxane B-DNA B-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
was O O
determined O O
initially O O
by O O
comparing O O
the O O
nucleotide B-DNA O
sequence I-DNA O
of O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
flanking I-DNA I-DNA
genomic I-DNA I-DNA
clone I-DNA I-DNA
with O O
that O O
of O O
a O O
novel B-DNA O
human I-DNA B-DNA
uterine I-DNA I-DNA
thromboxane I-DNA I-DNA
receptor I-DNA I-DNA
cDNA I-DNA I-DNA
that O O
extended O O
the O O
mRNA O B-DNA
141 B-DNA I-DNA
bp I-DNA I-DNA
further I-DNA O
upstream I-DNA O
than O O
the O O
previously B-DNA O
identified I-DNA O
human I-DNA B-DNA
placental I-DNA I-DNA
cDNA I-DNA I-DNA
. O O

A O O
major O B-DNA
transcription B-DNA I-DNA
initiation I-DNA I-DNA
site I-DNA I-DNA
was O O
located O O
in O O
three O O
human O O
tissues O O
approximately O O
560 B-DNA B-DNA
bp I-DNA I-DNA
upstream I-DNA I-DNA
from O O
the O O
translation B-DNA B-DNA
initiation I-DNA I-DNA
codon I-DNA I-DNA
and O O
380 B-DNA B-DNA
bp I-DNA I-DNA
upstream I-DNA I-DNA
from O O
any O O
previously O O
identified O O
transcription B-DNA B-DNA
initiation I-DNA I-DNA
site I-DNA I-DNA
. O O

The O O
thromboxane B-DNA B-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
has O O
neither O O
a O O
TATA B-DNA B-DNA
nor O O
a O O
CAAT B-DNA B-DNA
consensus I-DNA I-DNA
site I-DNA I-DNA
. O O

Promoter O O
function O O
of O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
flanking I-DNA I-DNA
region I-DNA I-DNA
of O O
the O O
thromboxane B-DNA B-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
was O O
evaluated O O
by O O
transfection O O
of O O
thromboxane B-DNA B-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
/ I-DNA I-DNA
chloramphenicol I-DNA I-DNA
acetyltransferase I-DNA I-DNA
( I-DNA I-DNA
CAT I-DNA I-DNA
) I-DNA I-DNA
chimera I-DNA I-DNA
plasmids I-DNA I-DNA
into O O
platelet O O
- O O
like O O
K562 O O
cells O O
. O O

Thromboxane O O
receptor B-DNA O
promoter I-DNA O
activity O O
, O O
as O O
assessed O O
by O O
CAT O O
expression O O
, O O
was O O
relatively O O
weak O O
but O O
was O O
significantly O O
enhanced O O
by O O
phorbol O O
ester O O
treatment O O
. O O

Functional O O
analysis O O
of O O
5 B-DNA B-DNA
' I-DNA I-DNA
deletion I-DNA I-DNA
constructs I-DNA I-DNA
in O O
transfected O O
K562 O O
cells O O
and O O
gel O O
mobility O O
shift O O
localized O O
the O O
major O B-DNA
phorbol O I-DNA
ester O I-DNA
- O I-DNA
responsive O I-DNA
motifs O I-DNA
in O O
the O O
thromboxane B-DNA B-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
promoter O I-DNA
to O O
a O O
cluster O O
of O O
activator B-DNA B-DNA
protein I-DNA I-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
( I-DNA I-DNA
AP I-DNA I-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
) I-DNA I-DNA
binding I-DNA I-DNA
consensus I-DNA I-DNA
sites I-DNA I-DNA
located O O
approximately O O
1 O O
. O O
8 O O
kb O O
5 O O
' O O
from O O
the O O
transcription B-DNA B-DNA
initiation I-DNA I-DNA
site I-DNA I-DNA
. O O

These O O
studies O O
are O O
the O O
first O O
to O O
determine O O
the O O
structure O O
and O O
organization O O
of O O
the O O
5 O B-DNA
' O I-DNA
end O I-DNA
of O O
the O O
thromboxane B-DNA B-DNA
receptor I-DNA I-DNA
gene I-DNA I-DNA
and O O
demonstrate O O
that O O
thromboxane B-DNA O
receptor I-DNA O
gene I-DNA O
expression O O
can O O
be O O
regulated O O
by O O
activation O O
of O O
protein O O
kinase O O
C O O
via O O
induction O O
of O O
an O O
AP O O
- O O
2 O O
- O O
like O O
nuclear O O
factor O O
binding O O
to O O
upstream B-DNA B-DNA
promoter I-DNA I-DNA
elements I-DNA I-DNA
. O O

These O O
findings O O
strongly O O
suggest O O
that O O
the O O
mechanism O O
for O O
previously O O
described O O
upregulation O O
of O O
platelet O O
thromboxane O O
receptors O O
after O O
acute O O
myocardial O O
infarction O O
is O O
increased O O
thromboxane B-DNA O
receptor I-DNA O
gene I-DNA O
transcription O O
in O O
platelet O O
- O O
progenitor O O
cells O O
. O O

Estrogen O O
receptor O O
concentration O O
and O O
social O O
factors O O
as O O
predictors O O
of O O
natural O O
killer O O
cell O O
activity O O
in O O
early O O
- O O
stage O O
breast O O
cancer O O
patients O O
. O O

Confirmation O O
of O O
a O O
model O O
. O O

Previous O O
work O O
of O O
ours O O
has O O
demonstrated O O
that O O
a O O
significant O O
amount O O
of O O
natural O O
killer O O
( O O
NK O O
) O O
activity O O
variance O O
after O O
surgery O O
in O O
stage O O
I O O
and O O
II O O
breast O O
cancer O O
patients O O
could O O
be O O
accounted O O
for O O
by O O
both O O
the O O
estrogen O O
receptor O O
( O O
ER O O
) O O
status O O
of O O
the O O
tumor O O
and O O
by O O
social O O
factors O O
, O O
namely O O
, O O
perceived O O
social O O
support O O
and O O
seeking O O
social O O
support O O
as O O
a O O
general O O
coping O O
strategy O O
. O O

As O O
considerable O O
evidence O O
has O O
accumulated O O
that O O
social O O
support O O
in O O
both O O
animal O O
and O O
human O O
populations O O
may O O
have O O
survival O O
value O O
, O O
we O O
sought O O
to O O
test O O
the O O
reliability O O
of O O
this O O
regression O O
model O O
, O O
using O O
coping O O
and O O
perceived O O
support O O
factor O O
values O O
obtained O O
at O O
3 O O
months O O
after O O
surgery O O
to O O
account O O
for O O
concurrent O O
follow O O
- O O
up O O
NK O O
activity O O
in O O
this O O
serially O O
assessed O O
group O O
of O O
patients O O
. O O

It O O
was O O
found O O
that O O
the O O
most O O
significant O O
variable O O
predicting O O
NK O O
activity O O
at O O
follow O O
- O O
up O O
was O O
tumor O O
ER O O
concentration O O
, O O
with O O
higher O O
NK O O
activity O O
associated O O
with O O
ER O O
- O O
status O O
. O O

In O O
addition O O
, O O
seeking O O
social O O
support O O
as O O
a O O
coping O O
strategy O O
, O O
as O O
well O O
as O O
the O O
perceived O O
quality O O
of O O
support O O
, O O
also O O
entered O O
the O O
model O O
to O O
account O O
for O O
a O O
significant O O
amount O O
of O O
NK O O
activity O O
variance O O
( O O
multivariate O O
F O O
= O O
5 O O
. O O
25 O O
, O O
p O O
less O O
than O O
0 O O
. O O
001 O O
) O O
. O O

If O O
, O O
as O O
the O O
literature O O
suggests O O
, O O
NK O O
activity O O
is O O
relevant O O
to O O
breast O O
cancer O O
control O O
, O O
and O O
since O O
ER O O
- O O
tumors O O
have O O
a O O
worse O O
prognosis O O
, O O
we O O
suggest O O
here O O
that O O
perhaps O O
such O O
tumors O O
are O O
resistant O O
to O O
control O O
by O O
NK O O
cells O O
because O O
they O O
lack O O
the O O
ability O O
to O O
attract O O
an O O
accumulation O O
of O O
effector O O
cells O O
to O O
the O O
tumor O O
site O O
, O O
or O O
because O O
blocking O O
factors O O
at O O
the O O
site O O
of O O
the O O
tumor O O
prevent O O
local O O
tumor O O
control O O
at O O
the O O
site O O
of O O
action O O
. O O

The O O
finding O O
related O O
to O O
social O O
support O O
also O O
replicates O O
results O O
from O O
an O O
independent O O
sample O O
of O O
breast O O
cancer O O
patients O O
. O O

This O O
finding O O
, O O
taken O O
together O O
with O O
other O O
evidence O O
that O O
this O O
social O O
variable O O
is O O
associated O O
with O O
longer O O
survival O O
in O O
breast O O
cancer O O
populations O O
, O O
underscores O O
the O O
potential O O
importance O O
of O O
this O O
social O O
support O O
variable O O
. O O

Our O O
findings O O
also O O
suggest O O
one O O
possible O O
immunological O O
variable O O
involved O O
, O O
with O O
potential O O
clinical O O
significance O O
, O O
for O O
this O O
patient O O
population O O
. O O

Solution O O
structure O O
of O O
the O O
sequence B-DNA O
- I-DNA O
specific I-DNA O
HMG I-DNA O
box I-DNA O
of O O
the O O
lymphocyte O O
transcriptional O O
activator O O
Sox O O
- O O
4 O O
. O O

Two O O
groups O O
of O O
HMG O O
box O O
proteins O O
are O O
distinguished O O
. O O

Proteins O O
in O O
the O O
first O O
group O O
contain O O
multiple O O
HMG O O
boxes O O
, O O
are O O
non O O
- O O
sequence O O
- O O
specific O O
, O O
and O O
recognize O O
structural O O
features O O
as O O
found O O
in O O
cruciform B-DNA B-DNA
DNA I-DNA I-DNA
and O O
cross B-DNA O
- I-DNA O
over I-DNA O
DNA I-DNA O
. O O

The O O
abundant O O
chromosomal O O
protein O O
HMG O O
- O O
1 O O
belongs O O
to O O
this O O
subgroup O O
. O O

Proteins O O
in O O
the O O
second O O
group O O
carry O O
a O O
single O O
HMG O O
box O O
with O O
affinity O O
for O O
the O O
minor B-DNA B-DNA
groove I-DNA I-DNA
of O O
the O O
heptamer B-DNA B-DNA
motif I-DNA I-DNA
AACAAAG O O
or O O
variations O O
thereof O O
. O O

A O O
solution O O
structure O O
for O O
the O O
non O O
- O O
sequence O O
- O O
specific O O
C O O
- O O
terminal O O
HMG O O
box O O
of O O
HMG O O
- O O
1 O O
has O O
recently O O
been O O
proposed O O
. O O

Now O O
, O O
we O O
report O O
the O O
solution O O
structure O O
of O O
the O O
sequence O O
- O O
specific O O
HMG O O
- O O
box O O
of O O
the O O
SRY O B-DNA
- O O
related O O
protein O O
Sox O O
- O O
4 O O
. O O

NMR O O
analysis O O
demonstrated O O
the O O
presence O O
of O O
three O O
alpha O O
- O O
helices O O
( O O
Val10 O O
- O O
Gln22 O O
, O O
Glu30 O O
- O O
Leu41 O O
and O O
Phe50 O O
- O O
Tyr65 O O
) O O
connected O O
by O O
loop O O
regions O O
( O O
Ser23 O O
- O O
Ala49 O O
and O O
Leu42 O O
- O O
Pro49 O O
) O O
. O O

Helices O O
I O O
and O O
II O O
are O O
positioned O O
in O O
an O O
antiparallel O O
mode O O
and O O
form O O
one O O
arm O O
of O O
the O O
HMG O O
box O O
. O O

Helix O O
III O O
is O O
less O O
rigid O O
, O O
makes O O
an O O
average O O
angle O O
of O O
about O O
90 O O
degrees O O
with O O
helices O O
I O O
and O O
II O O
, O O
and O O
constitutes O O
the O O
other O O
arm O O
of O O
the O O
molecule O O
. O O

As O O
in O O
HMG1B O O
, O O
the O O
overall O O
structure O O
of O O
the O O
Sox O B-DNA
- O I-DNA
4 O I-DNA
HMG O I-DNA
box O I-DNA
is O O
L O O
- O O
shaped O O
and O O
is O O
maintained O O
by O O
a O O
cluster O O
of O O
conserved O O
, O O
mainly O O
aromatic O O
residues O O
. O O

Nuclear O O
factor O O
- O O
IL6 O O
activates O O
the O O
human B-DNA B-DNA
IL I-DNA I-DNA
- I-DNA I-DNA
4 I-DNA I-DNA
promoter I-DNA I-DNA
in O O
T O O
cells O O
. O O

Positive B-DNA B-DNA
regulatory I-DNA I-DNA
element I-DNA I-DNA
I I-DNA I-DNA
( O O
PRE B-DNA B-DNA
- I-DNA I-DNA
I I-DNA I-DNA
) O O
is O O
a O O
strong O O
enhancer B-DNA B-DNA
element I-DNA I-DNA
essential O O
for O O
expression O O
of O O
the O O
human B-DNA B-DNA
IL I-DNA I-DNA
- I-DNA I-DNA
4 I-DNA I-DNA
gene I-DNA I-DNA
. O O

To O O
identify O O
transcription O O
factors O O
binding O O
to O O
PRE B-DNA B-DNA
- I-DNA I-DNA
I I-DNA I-DNA
, O O
we O O
screened O O
a O O
cDNA B-DNA B-DNA
expression I-DNA I-DNA
library I-DNA I-DNA
from O O
Jurkat O O
T O O
cells O O
and O O
isolated O O
a O O
cDNA B-DNA B-DNA
encoding O O
nuclear O O
factor O O
( O O
NF O O
) O O
- O O
IL6 O O
( O O
also O O
known O O
as O O
C O O
/ O O
EBP O O
beta O O
) O O
. O O

NF O O
- O O
IL6 O O
mRNA O O
was O O
found O O
in O O
human O O
Jurkat O O
T O O
cells O O
and O O
in O O
the O O
mouse O O
Th2 O O
clone O O
D10 O O
, O O
but O O
not O O
in O O
Th1 O O
clone O O
29 O O
. O O

rNF O O
- O O
IL6 O O
expressed O O
in O O
bacteria O O
was O O
shown O O
to O O
specifically O O
bind O O
to O O
PRE B-DNA B-DNA
- I-DNA I-DNA
I I-DNA I-DNA
. O O

PRE B-DNA B-DNA
- I-DNA I-DNA
I I-DNA I-DNA
forms O O
multiple O O
DNA O O
- O O
protein O O
complexes O O
with O O
nuclear O O
extracts O O
from O O
Jurkat O O
cells O O
. O O

Some O O
of O O
these O O
complexes O O
were O O
demonstrated O O
to O O
contain O O
NF O O
- O O
IL6 O O
by O O
using O O
anti O O
- O O
C O O
/ O O
EBP O O
beta O O
Abs O O
. O O

Overexpression O O
of O O
NF O O
- O O
IL6 O O
enhanced O O
expression O O
of O O
the O O
chloramphenicol B-DNA B-DNA
acetyl I-DNA I-DNA
transferase I-DNA I-DNA
reporter I-DNA I-DNA
gene I-DNA I-DNA
linked O O
to O O
the O O
PRE B-DNA B-DNA
- I-DNA I-DNA
I I-DNA I-DNA
- O I-DNA
thymidine O I-DNA
kinase O I-DNA
or O O
the O O
human B-DNA B-DNA
IL I-DNA I-DNA
- I-DNA I-DNA
4 I-DNA I-DNA
promoter I-DNA I-DNA
more O O
than O O
10 O O
- O O
fold O O
in O O
Jurkat O O
cells O O
. O O

Promoter O O
deletion O O
studies O O
revealed O O
two O O
additional O O
NF B-DNA B-DNA
- I-DNA I-DNA
IL6 I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
located O O
at O O
positions O O
- O B-DNA
44 O I-DNA
to O I-DNA
- O I-DNA
36 O I-DNA
( O O
C O B-DNA
/ O I-DNA
EBP O I-DNA
proximal O I-DNA
) O O
and O O
- O B-DNA
87 O I-DNA
to O I-DNA
- O I-DNA
79 O I-DNA
( O O
C O B-DNA
/ O I-DNA
EBP O I-DNA
medial O I-DNA
) O O
, O O
respectively O O
. O O

Our O O
results O O
demonstrate O O
that O O
NF O O
- O O
IL6 O O
is O O
involved O O
in O O
transcriptional O O
activation O O
of O O
the O O
human B-DNA B-DNA
IL I-DNA I-DNA
- I-DNA I-DNA
4 I-DNA I-DNA
promoter I-DNA I-DNA
in O O
T O O
cells O O
. O O

Identification O O
of O O
an O O
I O O
kappa O O
B O O
alpha O O
- O O
associated O O
protein O O
kinase O O
in O O
a O O
human O O
monocytic O O
cell O O
line O O
and O O
determination O O
of O O
its O O
phosphorylation O O
sites O O
on O O
I O O
kappa O O
B O O
alpha O O
. O O

Nuclear O O
factor O O
kappa O O
B O O
( O O
NF O O
- O O
kappa O O
B O O
) O O
is O O
stored O O
in O O
the O O
cytoplasm O O
as O O
an O O
inactive O O
form O O
through O O
interaction O O
with O O
I O O
kappa O O
B O O
. O O

Stimulation O O
of O O
cells O O
leads O O
to O O
a O O
rapid O O
phosphorylation O O
of O O
I O O
kappa O O
B O O
alpha O O
, O O
which O O
is O O
presumed O O
to O O
be O O
important O O
for O O
the O O
subsequent O O
degradation O O
. O O

We O O
have O O
recently O O
reported O O
the O O
establishment O O
of O O
a O O
lipopolysaccharide O O
( O O
LPS O O
) O O
- O O
dependent O O
cell O O
- O O
free O O
activation O O
system O O
of O O
NF O O
- O O
kappa O O
B O O
in O O
association O O
with O O
the O O
induction O O
of O O
I O O
kappa O O
B O O
alpha O O
phosphorylation O O
. O O

In O O
this O O
study O O
, O O
we O O
have O O
identified O O
a O O
kinase O O
in O O
cell O O
extracts O O
from O O
the O O
LPS O O
- O O
stimulated O O
human O O
monocytic O O
cell O O
line O O
, O O
THP O O
- O O
1 O O
, O O
that O O
specifically O O
binds O O
and O O
phosphorylates O O
I O O
kappa O O
B O O
alpha O O
. O O

LPS O O
stimulation O O
transiently O O
enhanced O O
the O O
I O O
kappa O O
B O O
alpha O O
- O O
bound O O
kinase O O
activity O O
in O O
THP O O
- O O
1 O O
cells O O
. O O

Mutational O O
analyses O O
of O O
I O O
kappa O O
B O O
alpha O O
and O O
competition O O
experiments O O
with O O
the O O
synthetic O O
peptides O O
identified O O
major O O
phosphorylation O O
sites O O
by O O
the O O
bound O O
kinase O O
as O O
Ser O O
and O O
Thr O O
residues O O
in O O
the O O
C O O
- O O
terminal O O
acidic O O
domain O O
of O O
I O O
kappa O O
B O O
alpha O O
. O O

Moreover O O
, O O
we O O
show O O
that O O
the O O
peptide O O
, O O
corresponding O O
to O O
the O O
C O O
- O O
terminal O O
acidic O O
domain O O
of O O
I O O
kappa O O
B O O
alpha O O
, O O
blocked O O
the O O
LPS O O
- O O
induced O O
NF O O
- O O
kappa O O
B O O
activation O O
as O O
well O O
as O O
inducible O O
phosphorylation O O
of O O
endogenous O O
I O O
kappa O O
B O O
alpha O O
in O O
a O O
cell O O
- O O
free O O
system O O
using O O
THP O O
- O O
1 O O
cells O O
. O O

These O O
results O O
suggested O O
that O O
the O O
bound O O
kinase O O
is O O
involved O O
in O O
the O O
signaling O O
pathway O O
of O O
LPS O O
by O O
inducing O O
the O O
phosphorylation O O
of O O
the O O
C O O
- O O
terminal O O
region O O
of O O
I O O
kappa O O
B O O
alpha O O
and O O
subsequent O O
dissociation O O
of O O
the O O
NF O O
- O O
kappa O O
B O O
. O O
I O O
kappa O O
B O O
alpha O O
complex O O
. O O

Bik O O
, O O
a O O
novel O O
death O O
- O O
inducing O O
protein O O
shares O O
a O O
distinct O O
sequence O O
motif O O
with O O
Bcl O O
- O O
2 O O
family O O
proteins O O
and O O
interacts O O
with O O
viral O O
and O O
cellular O O
survival O O
- O O
promoting O O
proteins O O
. O O

The O O
survival O O
- O O
promoting O O
activity O O
of O O
the O O
Bcl O O
- O O
2 O O
family O O
of O O
proteins O O
appears O O
to O O
be O O
modulated O O
by O O
interactions O O
between O O
various O O
cellular O O
proteins O O
. O O

We O O
have O O
identified O O
a O O
novel O O
cellular O O
protein O O
, O O
Bik O O
, O O
that O O
interacts O O
with O O
the O O
cellular O O
survival O O
- O O
promoting O O
proteins O O
, O O
Bcl O O
- O O
2 O O
and O O
Bcl O O
- O O
xL O O
, O O
as O O
well O O
as O O
the O O
viral O O
survival O O
- O O
promoting O O
proteins O O
, O O
Epstein O O
Barr O O
virus O O
- O O
BHRF1 O O
and O O
adenovirus O O
E1B O O
- O O
19 O O
kDa O O
. O O

In O O
transient O O
transfection O O
assays O O
, O O
Bik O O
promotes O O
cell O O
death O O
in O O
a O O
manner O O
similar O O
to O O
the O O
death O O
- O O
promoting O O
members O O
of O O
the O O
Bcl O O
- O O
2 O O
family O O
, O O
Bax O O
and O O
Bak O O
. O O

This O O
death O O
- O O
promoting O O
activity O O
of O O
Bik O O
can O O
be O O
suppressed O O
by O O
coexpression O O
of O O
Bcl O O
- O O
2 O O
, O O
Bcl O O
- O O
XL O O
, O O
EBV O O
- O O
BHRF1 O O
and O O
E1B O O
- O O
19 O O
kDa O O
proteins O O
suggesting O O
that O O
Bik O O
may O O
be O O
a O O
common O O
target O O
for O O
both O O
cellular O O
and O O
viral O O
anti O O
- O O
apoptotic O O
proteins O O
. O O

While O O
Bik O O
does O O
not O O
show O O
overt O O
homology O O
to O O
the O O
BH1 O O
and O O
BH2 O O
conserved O O
domains O O
characteristic O O
of O O
the O O
Bcl O O
- O O
2 O O
family O O
, O O
it O O
does O O
share O O
a O O
9 O O
amino O O
acid O O
domain O O
( O O
BH3 O O
) O O
with O O
Bax O O
and O O
Bak O O
which O O
may O O
be O O
a O O
critical O O
determinant O O
for O O
the O O
death O O
- O O
promoting O O
activity O O
of O O
these O O
proteins O O
. O O

The O O
human B-DNA B-DNA
TCF I-DNA I-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
gene I-DNA I-DNA
encodes O O
a O O
nuclear O O
DNA O O
- O O
binding O O
protein O O
uniquely O O
expressed O O
in O O
normal O O
and O O
neoplastic O O
T O O
- O O
lineage O O
lymphocytes O O
. O O

The O O
TCF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
gene I-DNA I-DNA
encodes O O
a O O
putative O O
transcription O O
factor O O
with O O
affinity O O
for O O
a O O
sequence B-DNA O
motif I-DNA O
occurring O O
in O O
a O O
number O O
of O O
T B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
enhancers I-DNA I-DNA
. O O

TCF O O
- O O
1 O O
mRNA O O
was O O
originally O O
found O O
to O O
be O O
expressed O O
in O O
a O O
T O O
cell O O
- O O
specific O O
fashion O O
within O O
a O O
set O O
of O O
human O O
and O O
mouse O O
cell O O
lines O O
. O O

In O O
contrast O O
, O O
expression O O
reportedly O O
occurs O O
in O O
multiple O O
nonlymphoid O O
tissues O O
during O O
murine O O
embryogenesis O O
. O O

We O O
have O O
now O O
raised O O
a O O
monoclonal O O
antibody O O
to O O
document O O
expression O O
and O O
biochemistry O O
of O O
the O O
human O O
TCF O O
- O O
1 O O
protein O O
. O O

As O O
expected O O
, O O
the O O
TCF O O
- O O
1 O O
protein O O
was O O
detectable O O
only O O
in O O
cell O O
lines O O
of O O
T O O
lineage O O
. O O

Its O O
expression O O
was O O
always O O
restricted O O
to O O
the O O
nucleus O O
. O O

Immunohistochemistry O O
on O O
a O O
panel O O
of O O
human O O
tissues O O
revealed O O
that O O
the O O
TCF O O
- O O
1 O O
protein O O
was O O
found O O
exclusively O O
in O O
thymocytes O O
and O O
in O O
CD3 O O
+ O O
T O O
cells O O
in O O
peripheral O O
lymphoid O O
tissues O O
. O O

Western O O
blotting O O
yielded O O
a O O
set O O
of O O
bands O O
ranging O O
from O O
25 O O
kD O O
to O O
55 O O
kD O O
, O O
resulting O O
from O O
extensive O O
alternative O O
splicing O O
. O O

The O O
TCF O O
- O O
1 O O
protein O O
was O O
detectable O O
in O O
all O O
samples O O
of O O
a O O
set O O
of O O
22 O O
T O O
- O O
cell O O
malignancies O O
of O O
various O O
stages O O
of O O
maturation O O
, O O
but O O
was O O
absent O O
from O O
a O O
large O O
number O O
of O O
other O O
hematologic O O
neoplasms O O
. O O

These O O
observations O O
imply O O
a O O
T O O
cell O O
- O O
specific O O
function O O
for O O
TCF O O
- O O
1 O O
, O O
a O O
notion O O
corroborated O O
by O O
recent O O
observations O O
on O O
Tcf O O
- O O
1 O O
knock O O
- O O
out O O
mice O O
. O O

In O O
addition O O
, O O
these O O
results O O
indicate O O
that O O
nuclear O O
TCF O O
- O O
1 O O
expression O O
can O O
serve O O
as O O
a O O
pan O O
- O O
T O O
- O O
lineage O O
marker O O
in O O
the O O
diagnosis O O
of O O
lymphoid O O
malignancies O O
. O O

Cross O O
- O O
linking O O
of O O
Fc O O
gamma O O
receptors O O
activates O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
- O O
driven O O
transcription O O
in O O
human O O
monocytes O O
. O O

Elevation O O
of O O
the O O
levels O O
of O O
circulating O O
immune O O
complexes O O
frequently O O
accompanies O O
HIV O O
- O O
1 O O
infection O O
and O O
is O O
a O O
prognostic O O
indicator O O
of O O
clinical O O
progression O O
from O O
asymptomatic O O
infection O O
to O O
AIDS O O
. O O

Here O O
we O O
report O O
that O O
cross O O
- O O
linking O O
of O O
Fc O O
gamma O O
RI O O
or O O
Fc O O
gamma O O
RII O O
by O O
adherent O O
human O O
IgG O O
or O O
by O O
specific O O
anti O O
- O O
Fc O O
gamma O O
R O O
mAb O O
activates O O
HIV O B-DNA
- O I-DNA
1 O I-DNA
gene O I-DNA
expression O O
in O O
the O O
human O O
monocytic O O
cell O O
line O O
BF24 O O
and O O
increased O O
HIV O O
RNA O O
expression O O
in O O
monocytes O O
from O O
HIV O O
infected O O
patients O O
as O O
assayed O O
by O O
reverse O O
transcription O O
- O O
PCR O O
. O O

In O O
THP O O
- O O
1 O O
cells O O
, O O
Fc O O
gamma O O
R O O
cross O O
- O O
linking O O
induced O O
NF O O
- O O
kappa O O
B O O
, O O
which O O
is O O
known O O
to O O
bind O O
to O O
the O O
regulatory B-DNA B-DNA
region I-DNA I-DNA
of O O
the O O
long B-DNA B-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
of O O
HIV O O
- O O
1 O O
and O O
to O O
activate O O
HIV O O
- O O
1 O O
transcription O O
. O O
Anti O O
- O O
TNF O O
- O O
alpha O O
antibody O O
but O O
not O O
anti O O
- O O
IL O O
- O O
1 O O
beta O O
antibody O O
strongly O O
inhibited O O
both O O
the O O
induction O O
of O O
HIV O O
- O O
1 O O
- O O
LTR B-DNA B-DNA
- O O
driven O O
transcription O O
and O O
the O O
induction O O
of O O
NF O O
- O O
kappa O O
B O O
by O O
Fc O O
gamma O O
R O O
cross O O
- O O
linking O O
. O O

These O O
results O O
indicate O O
that O O
Fc O O
gamma O O
R O O
can O O
mediate O O
a O O
TNF O O
- O O
alpha O O
- O O
dependent O O
induction O O
of O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
gene I-DNA I-DNA
transcription O O
and O O
suggest O O
that O O
immune O O
complexes O O
may O O
contribute O O
to O O
the O O
pathophysiology O O
of O O
HIV O O
- O O
1 O O
infection O O
by O O
augmenting O O
viral O O
replication O O
in O O
monocytes O O
. O O

Signalling O O
via O O
CD28 O O
of O O
human O O
naive O O
neonatal O O
T O O
lymphocytes O O
. O O

Accessory O O
molecules O O
play O O
a O O
crucial O O
role O O
in O O
the O O
development O O
of O O
the O O
T O O
cell O O
response O O
to O O
antigenic O O
challenge O O
. O O

We O O
have O O
examined O O
the O O
role O O
of O O
CD28 O O
in O O
modulating O O
the O O
' O O
naive O O
' O O
neonatal O O
T O O
cell O O
response O O
to O O
anti O O
- O O
CD2 O O
- O O
mediated O O
activation O O
. O O

To O O
compare O O
the O O
role O O
of O O
CD28 O O
, O O
neonatal O O
and O O
adult O O
T O O
cells O O
were O O
stimulated O O
with O O
a O O
pair O O
of O O
mitogenic O O
anti O O
- O O
CD2 O O
antibodies O O
in O O
the O O
presence O O
or O O
absence O O
of O O
anti O O
- O O
CD28 O O
MoAb O O
. O O

With O O
anti O O
- O O
CD2 O O
alone O O
, O O
neonatal O O
T O O
cells O O
proliferated O O
slightly O O
but O O
produced O O
no O O
detectable O O
IL O O
- O O
2 O O
, O O
whereas O O
adult O O
T O O
cells O O
proliferated O O
vigorously O O
, O O
with O O
significant O O
IL O O
- O O
2 O O
production O O
. O O

Costimulation O O
with O O
anti O O
- O O
CD28 O O
MoAb O O
greatly O O
enhanced O O
the O O
proliferative O O
response O O
of O O
neonatal O O
T O O
cells O O
to O O
levels O O
equivalent O O
to O O
those O O
of O O
adult O O
T O O
cells O O
, O O
whereas O O
adult O O
T O O
cells O O
showed O O
only O O
slight O O
increases O O
. O O

Although O O
IL O O
- O O
2 O O
secretion O O
was O O
increased O O
in O O
the O O
presence O O
of O O
anti O O
- O O
CD28 O O
MoAb O O
, O O
neonatal O O
T O O
cell O O
IL O O
- O O
2 O O
production O O
remained O O
lower O O
than O O
in O O
adults O O
. O O

In O O
contrast O O
, O O
enhancement O O
of O O
IL O O
- O O
2 O O
mRNA O O
expression O O
in O O
neonates O O
was O O
similar O O
to O O
adult O O
levels O O
. O O

Anti O O
- O O
CD28 O O
MoAb O O
costimulation O O
increased O O
NF O O
kappa O O
B O O
levels O O
in O O
neonates O O
, O O
albeit O O
to O O
levels O O
lower O O
than O O
that O O
of O O
adults O O
. O O

The O O
cellular O O
mechanism O O
governing O O
the O O
diminished O O
proliferative O O
response O O
of O O
neonatal O O
T O O
lymphocytes O O
to O O
anti O O
- O O
CD2 O O
may O O
therefore O O
be O O
due O O
to O O
decreased O O
NF O O
kappa O O
B O O
induction O O
, O O
reduced O O
IL O O
- O O
2 O O
mRNA O O
expression O O
and O O
deficient O O
IL O O
- O O
2 O O
production O O
. O O

Although O O
anti O O
- O O
CD28 O O
MoAb O O
costimulation O O
enhances O O
all O O
of O O
the O O
above O O
signals O O
, O O
NF O O
kappa O O
B O O
and O O
IL O O
- O O
2 O O
levels O O
remain O O
lower O O
than O O
in O O
adults O O
, O O
suggesting O O
the O O
need O O
for O O
further O O
activation O O
requirements O O
in O O
the O O
neonate O O
. O O

TCL1 O B-DNA
oncogene O I-DNA
activation O O
in O O
preleukemic O O
T O O
cells O O
from O O
a O O
case O O
of O O
ataxia O O
- O O
telangiectasia O O
. O O

The O O
TCL1 B-DNA B-DNA
oncogene I-DNA I-DNA
on O O
human B-DNA B-DNA
chromosome I-DNA I-DNA
14q32 B-DNA I-DNA
. I-DNA I-DNA
1 I-DNA I-DNA
is O O
involved O O
in O O
chromosome O B-DNA
translocations O I-DNA
[ O O
t B-DNA B-DNA
( I-DNA I-DNA
14 I-DNA I-DNA
; I-DNA I-DNA
14 I-DNA I-DNA
) I-DNA I-DNA
( I-DNA I-DNA
q11 I-DNA I-DNA
; I-DNA I-DNA
q32 I-DNA I-DNA
. I-DNA I-DNA
1 I-DNA I-DNA
) I-DNA I-DNA
and O O
t B-DNA B-DNA
( I-DNA I-DNA
7 I-DNA I-DNA
; I-DNA I-DNA
14 I-DNA I-DNA
) I-DNA I-DNA
( I-DNA I-DNA
q35 I-DNA I-DNA
; I-DNA I-DNA
q32 I-DNA I-DNA
. I-DNA I-DNA
1 I-DNA I-DNA
) I-DNA I-DNA
] O O
and O O
inversions O O
[ O O
inv14 B-DNA B-DNA
( I-DNA I-DNA
q11 I-DNA I-DNA
; I-DNA I-DNA
q32 I-DNA I-DNA
. I-DNA I-DNA
1 I-DNA I-DNA
) I-DNA I-DNA
] O O
with O O
TCR B-DNA B-DNA
alpha I-DNA I-DNA
/ I-DNA I-DNA
beta I-DNA I-DNA
loci I-DNA I-DNA
in O O
T O O
- O O
cell O O
leukemias O O
, O O
such O O
as O O
T O O
- O O
prolymphocytic O O
( O O
T O O
- O O
PLL O O
) O O
. O O

It O O
is O O
also O O
involved O O
in O O
T O O
- O O
acute O O
and O O
- O O
chronic O O
leukemias O O
arising O O
in O O
cases O O
of O O
ataxia O O
- O O
telangiectasia O O
( O O
AT O O
) O O
, O O
an O O
immunodeficiency O O
syndrome O O
. O O

Similar O O
chromosomal O O
rearrangements O O
occur O O
also O O
in O O
the O O
clonally O O
expanded O O
T O O
cells O O
in O O
AT O O
patients O O
before O O
the O O
appearance O O
of O O
the O O
overt O O
leukemia O O
. O O

We O O
have O O
analyzed O O
the O O
expression O O
of O O
TCL1 O O
mRNA O O
and O O
protein O O
in O O
peripheral O O
blood O O
lymphocytes O O
( O O
PBLs O O
) O O
from O O
four O O
AT O O
cases O O
and O O
from O O
healthy O O
controls O O
. O O

We O O
found O O
that O O
the O O
TCL1 B-DNA B-DNA
gene I-DNA I-DNA
was O O
overexpressed O O
in O O
the O O
PBLs O O
of O O
an O O
AT O O
patient O O
with O O
a O O
large O O
clonal O O
T O O
- O O
cell O O
population O O
exhibiting O O
the O O
t O B-DNA
( O I-DNA
14 O I-DNA
; O I-DNA
14 O I-DNA
) O I-DNA
translocation O I-DNA
but O O
not O O
in O O
the O O
lymphocytes O O
of O O
the O O
other O O
cases O O
. O O

Fluorescence O O
in O O
situ O O
hybridization O O
of O O
the O O
TCL1 B-DNA B-DNA
genomic I-DNA I-DNA
locus I-DNA I-DNA
to O O
lymphocyte O O
metaphases O O
from O O
the O O
AT O O
patient O O
with O O
the O O
T O O
- O O
cell O O
clonal O O
expansion O O
showed O O
that O O
the O O
breakpoint O O
of O O
the O O
t O B-DNA
( O I-DNA
14 O I-DNA
; O I-DNA
14 O I-DNA
) O I-DNA
translocation O I-DNA
lies O O
within O O
the O O
TCL1 B-DNA B-DNA
locus I-DNA I-DNA
and O O
is O O
accompanied O O
by O O
an O O
inverted B-DNA O
duplication I-DNA O
of O O
the O O
distal B-DNA B-DNA
part I-DNA I-DNA
of O I-DNA
chromosome B-DNA I-DNA
14 I-DNA I-DNA
. O O

These O O
data O O
indicate O O
that O O
TCL1 B-DNA O
is O O
activated O O
in O O
preleukemic O O
clonal O O
cells O O
as O O
a O O
consequence O O
of O O
chromosome O O
translocation O O
involving O O
sequences O O
from O O
the O O
TCR B-DNA B-DNA
locus I-DNA I-DNA
at O O
14q11 B-DNA B-DNA
. O O

Deregulation O O
of O O
TCL1 B-DNA O
is O O
the O O
first O O
event O O
in O O
the O O
initiation O O
of O O
malignancy O O
in O O
these O O
types O O
of O O
leukemias O O
and O O
represents O O
a O O
potential O O
tool O O
for O O
clinical O O
evaluation O O
. O O

C O O
/ O O
EBP O O
proteins O O
activate O O
transcription O O
from O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
1 I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
in O O
macrophages O O
/ O O
monocytes O O
. O O

Three O O
binding O B-DNA
sites O I-DNA
for O O
C O O
/ O O
EBP O O
proteins O O
are O O
found O O
in O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
type I-DNA I-DNA
1 I-DNA I-DNA
( I-DNA I-DNA
HIV I-DNA I-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
) I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
( O O
LTR B-DNA B-DNA
) O O
( O O
V O O
. O O
M O O
. O O
Tesmer O O
, O O
A O O
. O O
Rajadhyaksha O O
, O O
J O O
. O O
Babin O O
, O O
and O O
M O O
. O O
Bina O O
, O O
Proc O O
. O O
Natl O O
. O O
Acad O O
. O O
Sci O O
. O O
USA O O
90 O O
: O O
7298 O O
- O O
7302 O O
, O O
1993 O O
) O O
. O O

We O O
have O O
determined O O
the O O
functional O O
role O O
of O O
C O O
/ O O
EBP O O
proteins O O
and O O
C B-DNA O
/ I-DNA O
EBP I-DNA O
sites I-DNA O
in O O
regulating O O
transcription O O
from O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
LTR I-DNA I-DNA
in O O
monocytes O O
/ O O
macrophages O O
. O O

Inhibition O O
of O O
endogenous O O
C O O
/ O O
EBP O O
proteins O O
, O O
using O O
either O O
an O O
excess O O
of O O
C B-DNA B-DNA
/ I-DNA I-DNA
EBP I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
or O O
a O O
trans B-DNA O
- I-DNA O
dominant I-DNA O
negative I-DNA O
inhibitor I-DNA O
, O O
demonstrated O O
that O O
C O O
/ O O
EBP O O
proteins O O
are O O
required O O
for O O
basal O O
and O O
activated O O
levels O O
of O O
HIV O B-DNA
- O I-DNA
1 O I-DNA
LTR B-DNA I-DNA
transcription O O
in O O
the O O
promonocytic O O
cell O O
line O O
U937 O O
. O O

Northern O O
( O O
RNA O O
) O O
blots O O
and O O
binding O O
assays O O
showed O O
that O O
NF O O
- O O
IL6 O O
is O O
the O O
only O O
known O O
C O O
/ O O
EBP O O
family O O
member O O
which O O
is O O
increased O O
when O O
U937 O O
cells O O
are O O
activated O O
. O O

Mutational O O
analyses O O
of O O
the O O
HIV O B-DNA
- O I-DNA
1 O I-DNA
LTR B-DNA I-DNA
showed O O
that O O
one O O
C B-DNA B-DNA
/ I-DNA I-DNA
EBP I-DNA I-DNA
site I-DNA I-DNA
is O O
required O O
for O O
normal O O
LTR B-DNA B-DNA
transcription O O
both O O
before O O
and O O
after O O
cellular O O
activation O O
and O O
that O O
the O O
two O O
3 O B-DNA
' O I-DNA
C B-DNA I-DNA
/ I-DNA I-DNA
EBP I-DNA I-DNA
sites I-DNA I-DNA
are O O
functionally O O
equivalent O O
. O O

However O O
, O O
transcription O O
from O O
crippled B-DNA O
HIV I-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
LTRs I-DNA I-DNA
lacking O O
C B-DNA B-DNA
/ I-DNA I-DNA
EBP I-DNA I-DNA
sites I-DNA I-DNA
can O O
still O O
be O O
induced O O
following O O
activation O O
of O O
U937 O O
cells O O
. O O

Several O O
models O O
are O O
suggested O O
for O O
how O O
elevated O O
NF O O
- O O
IL6 O O
may O O
participate O O
in O O
an O O
autostimulatory O O
loop O O
involving O O
HIV O O
infection O O
, O O
macrophage O O
activation O O
, O O
cytokine O O
expression O O
, O O
and O O
HIV O O
replication O O
. O O

Human O B-DNA
immunodeficiency O I-DNA
virus O I-DNA
type O I-DNA
- O I-DNA
2 O I-DNA
gene O I-DNA
expression O O
: O O
two O O
enhancers B-DNA B-DNA
and O O
their O O
activation O O
by O O
T O O
- O O
cell O O
activators O O
. O O

The O O
human O O
immunodeficiency O O
viruses O O
( O O
HIVs O O
) O O
may O O
include O O
a O O
spectrum O O
of O O
retroviruses O O
with O O
varying O O
potential O O
to O O
infect O O
their O O
host O O
, O O
undergo O O
long O O
periods O O
of O O
latent O O
infection O O
, O O
and O O
induce O O
pathology O O
. O O

Since O O
expression O O
of O O
the O O
viruses O O
is O O
in O O
large O O
part O O
regulated O O
by O O
the O O
sequence B-DNA B-DNA
elements I-DNA I-DNA
in O O
their O O
long B-DNA B-DNA
terminal I-DNA I-DNA
repeats I-DNA I-DNA
( O O
LTRs B-DNA B-DNA
) O O
, O O
this O O
study O O
was O O
directed O O
to O O
an O O
analysis O O
of O O
the O O
regulatory B-DNA B-DNA
elements I-DNA I-DNA
in O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
LTR I-DNA I-DNA
. O O

The O O
HIV B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
LTR I-DNA I-DNA
was O O
found O O
to O O
contain O O
two O O
enhancers B-DNA B-DNA
. O O

One O O
of O O
these O O
enhancers B-DNA B-DNA
is O O
, O O
in O O
part O O
, O O
identical O O
to O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

This O O
enhancer B-DNA O
in O O
HIV O O
- O O
1 O O
is O O
the O O
T B-DNA B-DNA
- I-DNA I-DNA
cell I-DNA I-DNA
activation I-DNA I-DNA
response I-DNA I-DNA
element I-DNA I-DNA
; O O
in O O
HIV O O
- O O
2 O O
, O O
however O O
, O O
it O O
is O O
the O O
second B-DNA O
enhancer I-DNA O
that O O
is O O
mainly O O
responsible O O
for O O
activation O O
in O O
response O O
to O O
T O O
- O O
cell O O
activators O O
. O O

The O O
second O O
enhancer B-DNA O
interacts O O
with O O
two O O
nuclear O O
binding O O
proteins O O
( O O
85 O O
kD O O
and O O
27 O O
kD O O
mobility O O
) O O
that O O
appear O O
to O O
be O O
required O O
for O O
optimal O O
enhancer O O
function O O
and O O
activation O O
. O O

Observations O O
such O O
as O O
these O O
encourage O O
the O O
speculation O O
that O O
there O O
may O O
be O O
subtle O O
differences O O
in O O
the O O
regulation O O
of O O
HIV O O
- O O
1 O O
and O O
HIV O O
- O O
2 O O
expression O O
that O O
may O O
be O O
relevant O O
to O O
the O O
possible O O
longer O O
latency O O
and O O
reduced O O
pathogenicity O O
of O O
HIV O O
- O O
2 O O
. O O

NF O O
- O O
M O O
( O O
chicken O O
C O O
/ O O
EBP O O
beta O O
) O O
induces O O
eosinophilic O O
differentiation O O
and O O
apoptosis O O
in O O
a O O
hematopoietic O O
progenitor O O
cell O O
line O O
. O O

CAAT B-DNA O
/ I-DNA O
enhancer I-DNA O
binding O O
proteins O O
( O O
C O O
/ O O
EBPs O O
) O O
are O O
transcriptional O O
activators O O
implicated O O
in O O
the O O
differentiation O O
processes O O
of O O
various O O
cell O O
lineages O O
. O O

We O O
have O O
shown O O
earlier O O
that O O
NF O O
- O O
M O O
, O O
the O O
chicken O O
homolog O O
of O O
C O O
/ O O
EBP O O
beta O O
, O O
is O O
specifically O O
expressed O O
in O O
myelomonocytic O O
and O O
eosinophilic O O
cells O O
of O O
the O O
hematopoietic O O
system O O
. O O

To O O
investigate O O
the O O
role O O
of O O
NF O O
- O O
M O O
in O O
hematopoietic O O
cell O O
lineage O O
commitment O O
, O O
we O O
constructed O O
a O O
conditional O O
form O O
of O O
the O O
protein O O
by O O
fusing O O
it O O
to O O
the O O
hormone O O
binding O O
domain O O
of O O
the O O
human O O
estrogen O O
receptor O O
. O O

This O O
construct O O
was O O
stably O O
expressed O O
in O O
a O O
multipotent O O
progenitor O O
cell O O
line O O
transformed O O
by O O
the O O
Myb O O
- O O
Ets O O
oncoprotein O O
. O O

We O O
report O O
here O O
that O O
both O O
NF B-DNA B-DNA
- I-DNA I-DNA
M I-DNA I-DNA
- I-DNA I-DNA
dependent I-DNA I-DNA
promoter I-DNA I-DNA
constructs I-DNA I-DNA
and O O
resident O B-DNA
genes O I-DNA
could O O
be O O
activated O O
by O O
addition O O
of O O
beta O O
- O O
estradiol O O
to O O
the O O
NF O O
- O O
M O O
- O O
estrogen O O
receptor O O
expressing O O
progenitors O O
. O O

At O O
the O O
same O O
time O O
, O O
we O O
observed O O
a O O
down O O
- O O
regulation O O
of O O
progenitor O O
- O O
specific O O
surface O O
markers O O
and O O
the O O
up O O
- O O
regulation O O
of O O
differentiation O O
markers O O
restricted O O
to O O
the O O
eosinophil O O
and O O
myeloid O O
lineages O O
. O O

In O O
addition O O
to O O
the O O
onset O O
of O O
differentiation O O
, O O
cell O O
death O O
was O O
induced O O
with O O
typical O O
apoptotic O O
features O O
. O O

Our O O
results O O
suggest O O
that O O
NF O O
- O O
M O O
plays O O
an O O
important O O
role O O
in O O
commitment O O
along O O
the O O
eosinophil O O
lineage O O
and O O
in O O
the O O
induction O O
of O O
apoptosis O O
. O O

Prolactin O O
and O O
interleukin O O
- O O
2 O O
receptors O O
in O O
T O O
lymphocytes O O
signal O O
through O O
a O O
MGF O O
- O O
STAT5 O O
- O O
like O O
transcription O O
factor O O
. O O

The O O
cell O O
surface O O
receptors O O
for O O
PRL O O
and O O
interleukin O O
- O O
2 O O
( O O
IL O O
- O O
2 O O
) O O
are O O
structurally O O
distinct O O
, O O
but O O
share O O
regulatory O O
tasks O O
in O O
T O O
lymphocytes O O
. O O

They O O
can O O
stimulate O O
proliferation O O
and O O
activate O O
transcription O O
of O O
over O O
- O O
lapping O O
sets O O
of O O
genes O O
of O O
T O O
cells O O
. O O

PRL O O
and O O
IL O O
- O O
2 O O
receptor O O
activation O O
are O O
both O O
linked O O
to O O
the O O
Jak O O
/ O O
Stat O O
( O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
) O O
pathway O O
. O O

We O O
investigated O O
the O O
ability O O
of O O
PRL O O
and O O
IL O O
- O O
2 O O
to O O
activate O O
Stat O O
proteins O O
in O O
different O O
T O O
cell O O
lines O O
. O O

The O O
DNA O O
binding O O
specificities O O
, O O
the O O
reactivities O O
toward O O
Stat O O
- O O
specific O O
antisera O O
, O O
and O O
the O O
mol O O
wt O O
of O O
IL O O
- O O
2 O O
- O O
and O O
PRL O O
- O O
induced O O
DNA O O
- O O
binding O O
proteins O O
in O O
Nb2 O O
and O O
C196 O O
T O O
cell O O
lines O O
were O O
investigated O O
. O O

A O O
comparison O O
with O O
the O O
Stat O O
proteins O O
induced O O
by O O
interferon O O
- O O
gamma O O
, O O
PRL O O
, O O
and O O
IL O O
- O O
6 O O
in O O
T47D O O
mammary O O
tumor O O
cells O O
was O O
made O O
. O O

We O O
found O O
that O O
these O O
parameters O O
were O O
indistinguishable O O
for O O
one O O
of O O
the O O
PRL O O
- O O
and O O
IL O O
- O O
2 O O
- O O
induced O O
factors O O
. O O

A O O
transcription O O
factor O O
closely O O
related O O
to O O
mammary O O
gland O O
factor O O
- O O
Stat5 O O
is O O
rapidly O O
activated O O
upon O O
interaction O O
of O O
IL O O
- O O
2 O O
and O O
PRL O O
with O O
their O O
respective O O
receptors O O
. O O

Activation O O
of O O
a O O
second O O
protein O O
related O O
to O O
Stat1 O O
was O O
also O O
observed O O
. O O

Our O O
results O O
emphasize O O
the O O
role O O
of O O
PRL O O
as O O
a O O
regulator O O
of O O
the O O
immune O O
response O O
and O O
indicate O O
that O O
the O O
Stat O O
factors O O
mammary O O
gland O O
factor O O
- O O
Stat5 O O
and O O
Stat1 O O
play O O
a O O
role O O
in O O
the O O
regulation O O
of O O
gene O O
expression O O
during O O
T O O
cell O O
development O O
. O O

ETS1 O O
transactivates O O
the O O
human B-DNA B-DNA
GM I-DNA I-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
promoter I-DNA I-DNA
in O O
Jurkat O O
T O O
cells O O
stimulated O O
with O O
PMA O O
and O O
ionomycin O O
. O O

Activation O O
of O O
T O O
helper O O
cells O O
results O O
in O O
coordinate O O
expression O O
of O O
a O O
number O O
of O O
cytokines O O
involved O O
in O O
differentiation O O
, O O
proliferation O O
and O O
activation O O
of O O
the O O
haematopoietic O O
system O O
. O O

Granulocyte O O
- O O
macrophage O O
colony O O
- O O
stimulating O O
factor O O
( O O
GM O O
- O O
CSF O O
) O O
is O O
one O O
such O O
cytokine O O
whose O O
increased O O
expression O O
results O O
partly O O
from O O
increases O O
in O O
transcription O O
. O O

Cis B-DNA B-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
elements I-DNA I-DNA
with O O
NF B-DNA O
kappa I-DNA O
B I-DNA O
, O O
AP B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
and O O
ETS B-DNA B-DNA
- I-DNA I-DNA
like I-DNA I-DNA
motifs I-DNA I-DNA
have O O
been O O
identified O O
in O O
the O O
promoter O B-DNA
region O I-DNA
of O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
gene I-DNA I-DNA
, O O
which O O
are O O
important O O
for O O
transcriptional O O
activity O O
following O O
PMA O O
and O O
ionomycin O O
stimulation O O
. O O

A O O
number O O
of O O
the O O
ETS O O
family O O
of O O
transcription O O
factors O O
are O O
expressed O O
in O O
T O O
cells O O
, O O
including O O
ETS1 O O
and O O
ELF1 O O
. O O

Here O O
we O O
describe O O
the O O
ability O O
of O O
these O O
factors O O
to O O
interact O O
with O O
a O O
site O O
( O O
GM5 B-DNA O
) O O
, O O
located O O
within O O
the O O
CLE0 B-DNA B-DNA
element I-DNA I-DNA
, O O
- B-DNA B-DNA
47 I-DNA I-DNA
to I-DNA I-DNA
- I-DNA I-DNA
40 I-DNA I-DNA
upstream I-DNA O
of O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
transcription I-DNA I-DNA
initiation I-DNA I-DNA
site I-DNA I-DNA
. O O

Exogenous O O
ETS1 O O
, O O
but O O
not O O
ELF1 O O
, O O
can O O
transactivate O O
GM O O
- O O
CSF O O
, O O
through O O
the O O
GM5 B-DNA B-DNA
site O I-DNA
, O O
in O O
a O O
PMA O O
/ O O
ionomycin O O
dependent O O
manner O O
. O O

Other O O
unidentified O O
ETS O O
- O O
like O O
factors O O
present O O
in O O
Jurkat O O
cells O O
are O O
also O O
capable O O
of O O
binding O O
GM5 B-DNA O
. O O

Mutation O O
of O O
the O O
core O O
ETS B-DNA B-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
from O O
- B-DNA O
GGAA I-DNA O
- I-DNA O
to I-DNA O
- I-DNA O
GGAT I-DNA O
- I-DNA O
prevents O O
the O O
binding O O
of O O
ETS O O
- O O
like O O
factors O O
with O O
the O O
exception O O
of O O
ETS1 O O
. O O

The O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
promoter I-DNA I-DNA
, O O
modified O O
in O O
this O O
way O O
to O O
be O O
ETS1 O O
specific O O
, O O
is O O
fully O O
responsive O O
to O O
PMA O O
/ O O
ionomycin O O
induction O O
, O O
in O O
addition O O
to O O
ETS1 O O
transactivation O O
in O O
the O O
presence O O
of O O
PMA O O
and O O
ionomycin O O
. O O

Together O O
these O O
data O O
suggest O O
that O O
ETS1 O O
may O O
be O O
involved O O
in O O
mediating O O
the O O
increased O O
GM O O
- O O
CSF O O
production O O
associated O O
with O O
T O O
cell O O
activation O O
. O O

Quantitation O O
of O O
beta O O
1 O O
triiodothyronine O O
receptor O O
mRNA O O
in O O
human O O
tissues O O
by O O
competitive O O
reverse O O
transcription O O
polymerase O O
chain O O
reaction O O
. O O

Thyroid O O
hormones O O
act O O
by O O
binding O O
to O O
nuclear O O
receptor O O
proteins O O
, O O
the O O
thyroid O O
hormone O O
receptors O O
( O O
TR O O
) O O
alpha O O
and O O
beta O O
. O O

Data O O
from O O
cell O O
culture O O
and O O
animal O O
studies O O
indicate O O
that O O
TR O O
expression O O
may O O
be O O
regulated O O
to O O
modulate O O
target O O
organ O O
responsiveness O O
to O O
thyroid O O
hormone O O
. O O

To O O
investigate O O
whether O O
such O O
adaptive O O
changes O O
in O O
TR O O
expression O O
occur O O
in O O
humans O O
, O O
we O O
determined O O
the O O
mRNA O O
levels O O
of O O
the O O
hTR O O
beta O O
1 O O
in O O
various O O
thyroid O O
states O O
. O O

Patients O O
with O O
overt O O
hypo O O
- O O
or O O
hyperthyroidism O O
were O O
enrolled O O
in O O
the O O
study O O
. O O

Total O O
RNA O O
was O O
isolated O O
from O O
peripheral O O
blood O O
mononuclear O O
cells O O
and O O
hTR O O
beta O O
1 O O
mRNA O O
levels O O
determined O O
by O O
quantitative O O
competitive O O
reverse O O
transcription O O
PCR O O
. O O

For O O
comparison O O
, O O
hTR O O
beta O O
1 O O
mRNA O O
levels O O
were O O
determined O O
in O O
lymphocytes O O
and O O
normal O O
thyroid O O
tissue O O
of O O
euthyroid O O
patients O O
. O O

Human O O
TR O O
beta O O
1 O O
mRNA O O
levels O O
in O O
lymphocytes O O
were O O
1 O O
. O O
8 O O
+ O O
/ O O
- O O
0 O O
. O O
4 O O
, O O
1 O O
. O O
9 O O
+ O O
/ O O
- O O
0 O O
. O O
5 O O
, O O
1 O O
. O O
1 O O
+ O O
/ O O
- O O
0 O O
. O O
4 O O
10 O O
( O O
- O O
18 O O
) O O
mol O O
/ O O
microgram O O
RNA O O
in O O
hypo O O
- O O
, O O
eu O O
- O O
and O O
hyperthyroid O O
patients O O
, O O
respectively O O
, O O
corresponding O O
to O O
an O O
estimated O O
0 O O
. O O
5 O O
- O O
2 O O
molecules O O
per O O
cell O O
. O O

Although O O
the O O
mean O O
hTR O O
beta O O
1 O O
mRNA O O
levels O O
were O O
40 O O
% O O
lower O O
in O O
hyperthyroid O O
than O O
in O O
euthyroid O O
subjects O O
, O O
this O O
difference O O
did O O
not O O
reach O O
statistical O O
significance O O
. O O

Similar O O
levels O O
of O O
hTR O O
beta O O
1 O O
mRNA O O
levels O O
were O O
detected O O
in O O
thyroid O O
gland O O
from O O
euthyroid O O
patients O O
. O O

In O O
summary O O
, O O
we O O
developed O O
an O O
assay O O
for O O
the O O
quantitative O O
determination O O
of O O
hTR O O
beta O O
1 O O
mRNA O O
levels O O
in O O
small O O
human O O
tissue O O
samples O O
, O O
containing O O
as O O
little O O
as O O
50 O O
ng O O
of O O
total O O
RNA O O
. O O

Absolute O O
hTR O O
beta O O
1 O O
mRNA O O
levels O O
are O O
very O O
low O O
with O O
an O O
estimated O O
one O O
molecule O O
of O O
mRNA O O
being O O
present O O
in O O
a O O
mononuclear O O
blood O O
cell O O
or O O
thyrocyte O O
. O O

No O O
up O O
- O O
regulation O O
of O O
hTR O O
beta O O
1 O O
was O O
seen O O
in O O
hypothyroid O O
relative O O
to O O
euthyroid O O
patients O O
. O O

However O O
, O O
there O O
is O O
a O O
non O O
- O O
significant O O
trend O O
towards O O
a O O
down O O
- O O
regulation O O
of O O
hTR O O
beta O O
1 O O
mRNA O O
levels O O
in O O
hyperthyroid O O
patients O O
. O O

Multiple O O
proteins O O
interact O O
with O O
the O O
nuclear B-DNA B-DNA
inhibitory I-DNA I-DNA
protein I-DNA I-DNA
repressor I-DNA I-DNA
element I-DNA I-DNA
in O O
the O O
human B-DNA B-DNA
interleukin I-DNA I-DNA
- I-DNA I-DNA
3 I-DNA I-DNA
promoter I-DNA I-DNA
. O O

T O O
cell O O
expression O O
of O O
interleukin O O
3 O O
( O O
IL O O
- O O
3 O O
) O O
is O O
directed O O
by O O
positive O O
and O O
negative O B-DNA
cis O I-DNA
- O I-DNA
acting O I-DNA
DNA O I-DNA
elements O I-DNA
clustered O O
within O O
300 O B-DNA
base O I-DNA
pairs O I-DNA
of O O
the O O
transcriptional B-DNA B-DNA
start I-DNA I-DNA
site I-DNA I-DNA
. O O

A O O
strong O O
repressor O B-DNA
element O I-DNA
, O O
termed O O
nuclear O O
inhibitory O O
protein O O
( O O
NIP O O
) O O
, O O
was O O
previously O O
mapped O O
to O O
a O O
segment O O
of O O
the O O
IL B-DNA B-DNA
- I-DNA I-DNA
3 I-DNA I-DNA
promoter I-DNA I-DNA
between O O
nucleotides B-DNA B-DNA
- I-DNA I-DNA
271 I-DNA I-DNA
and I-DNA I-DNA
- I-DNA I-DNA
250 I-DNA I-DNA
. O O

Functional O O
characterization O O
of O O
this O O
element O O
demonstrates O O
that O O
it O O
can O O
mediate O O
repression O O
when O O
linked O O
in O O
cis O O
to O O
a O O
heterologous B-DNA B-DNA
promoter I-DNA I-DNA
. O O

DNA O O
binding O O
experiments O O
were O O
carried O O
out O O
to O O
characterize O O
the O O
repressor O O
activity O O
. O O

Using O O
varying O O
conditions O O
, O O
three O O
distinct O O
complexes O O
were O O
shown O O
to O O
interact O O
specifically O O
with O O
the O O
NIP B-DNA O
region I-DNA O
, O O
although O O
only O O
one O O
correlates O O
with O O
repressor O O
activity O O
. O O

Complex O O
1 O O
results O O
from O O
binding O O
of O O
a O O
ubiquitous O O
polypeptide O O
that O O
recognizes O O
the O O
3 B-DNA B-DNA
' I-DNA I-DNA
portion I-DNA I-DNA
of O O
this O O
sequence O O
and O O
is O O
not O O
required O O
for O O
repression O O
. O O

Complex O O
2 O O
corresponds O O
to O O
binding O O
of O O
transcription O O
factor O O
( O O
upstream O O
stimulatory O O
factor O O
) O O
to O O
an O O
E B-DNA B-DNA
- I-DNA I-DNA
box I-DNA I-DNA
motif I-DNA I-DNA
in O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
portion I-DNA I-DNA
of O O
the O O
NIP B-DNA B-DNA
region I-DNA I-DNA
. O O

DNA O O
binding O O
specificity O O
of O O
complex O O
3 O O
overlaps O O
with O O
that O O
of O O
upstream O O
stimulatory O O
factor O O
but O O
is O O
clearly O O
distinct O O
. O O

To O O
determine O O
which O O
of O O
the O O
latter O O
two O O
complexes O O
represents O O
NIP O O
activity O O
, O O
we O O
incorporated O O
small O O
alterations O O
into O O
the O O
NIP B-DNA B-DNA
site I-DNA I-DNA
of O O
an O O
IL B-DNA B-DNA
- I-DNA I-DNA
3 I-DNA I-DNA
promoter I-DNA I-DNA
- I-DNA I-DNA
linked I-DNA I-DNA
reporter I-DNA I-DNA
construct I-DNA I-DNA
and O O
examined O O
their O O
effects O O
on O O
NIP O O
- O O
mediated O O
repression O O
. O O

Functional O O
specificity O O
for O O
repression O O
matches O O
the O O
DNA O O
binding O O
specificity O O
of O O
complex O O
3 O O
; O O
both O O
repressor O O
activity O O
and O O
complex O O
3 O O
binding O O
require O O
the O O
consensus B-DNA B-DNA
sequence I-DNA I-DNA
CTCACNTNC O O
. O O

The O O
hematopoietic O O
transcription O O
factor O O
PU O O
. O O
1 O O
is O O
downregulated O O
in O O
human O O
multiple O O
myeloma O O
cell O O
lines O O
. O O

PU O O
. O O
1 O O
is O O
a O O
hematopoietic O O
transcription O O
factor O O
belonging O O
to O O
the O O
Ets O O
- O O
family O O
. O O

It O O
is O O
identical O O
to O O
the O O
Spi B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
oncogene I-DNA I-DNA
, O O
which O O
is O O
implicated O O
in O O
spleen O O
focus O O
- O O
forming O O
virus O O
- O O
induced O O
murine O O
erythroleukemias O O
. O O

PU O O
. O O
1 O O
seems O O
to O O
be O O
required O O
for O O
early O O
development O O
of O O
multiple O O
hematopoietic O O
lineages O O
, O O
but O O
its O O
expression O O
in O O
mature O O
cells O O
is O O
preferentially O O
observed O O
in O O
cells O O
of O O
the O O
B O O
- O O
cell O O
- O O
and O O
monocyte O O
/ O O
macrophage O O
- O O
differentiation O O
lineage O O
. O O

It O O
binds O O
the O O
so O O
- O O
called O O
Pu B-DNA B-DNA
box I-DNA I-DNA
, O O
an O O
important O O
tissue B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
regulatory I-DNA I-DNA
DNA I-DNA I-DNA
element I-DNA I-DNA
present O O
in O O
a O O
number O O
of O O
genes O O
expressed O O
in O O
these O O
cell O O
lineages O O
. O O

We O O
have O O
analyzed O O
the O O
expression O O
and O O
activity O O
of O O
PU O O
. O O
1 O O
during O O
human O O
B O O
- O O
cell O O
development O O
using O O
a O O
panel O O
of O O
B O O
- O O
cell O O
lines O O
representing O O
different O O
stages O O
of O O
maturation O O
, O O
from O O
early O O
precursors O O
to O O
differentiated O O
plasma O O
cells O O
. O O

PU O O
. O O
1 O O
mRNA O O
expression O O
and O O
PU O O
. O O
1 O O
DNA O O
binding O O
activity O O
, O O
as O O
measured O O
by O O
Northern O O
blot O O
analysis O O
and O O
electrophoretic O O
mobility O O
shift O O
assay O O
, O O
respectively O O
, O O
were O O
evident O O
in O O
cell O O
lines O O
representing O O
pro O O
- O O
B O O
, O O
pre O O
- O O
B O O
, O O
and O O
mature O O
B O O
cells O O
. O O

We O O
could O O
also O O
show O O
Pu B-DNA B-DNA
box I-DNA I-DNA
- O O
dependent O O
transactivation O O
of O O
a O O
reporter O B-DNA
gene O I-DNA
in O O
transient O O
transfections O O
in O O
these O O
cell O O
lines O O
. O O

In O O
contrast O O
, O O
in O O
a O O
number O O
of O O
multiple O O
myeloma O O
cell O O
lines O O
, O O
representing O O
differentiated O O
, O O
plasma O O
cell O O
- O O
like O O
B O O
cells O O
, O O
PU O O
. O O
1 O O
DNA O O
binding O O
activity O O
, O O
mRNA O O
expression O O
, O O
and O O
Pu B-DNA B-DNA
box I-DNA I-DNA
- O O
dependent O O
transactivation O O
were O O
absent O O
or O O
detectable O O
at O O
a O O
very O O
low O O
level O O
. O O

In O O
lymphoblastoid O O
cell O O
lines O O
, O O
which O O
exemplify O O
an O O
intermediate O O
stage O O
of O O
B O O
- O O
cell O O
differentiation O O
, O O
a O O
reduced O O
expression O O
and O O
activity O O
were O O
observed O O
. O O

The O O
findings O O
in O O
the O O
human O O
multiple O O
myeloma O O
cell O O
lines O O
represent O O
the O O
first O O
examples O O
of O O
B O O
cells O O
with O O
downregulated O O
PU O O
. O O
1 O O
expression O O
and O O
apparently O O
contradict O O
observations O O
in O O
the O O
murine O O
system O O
in O O
which O O
PU O O
. O O
1 O O
is O O
expressed O O
and O O
active O O
in O O
plasmacytoma O O
cell O O
lines O O
. O O

At O O
present O O
, O O
it O O
is O O
unclear O O
whether O O
the O O
lack O O
of O O
PU O O
. O O
1 O O
expression O O
and O O
activity O O
in O O
human O O
multiple O O
myeloma O O
cell O O
lines O O
represents O O
a O O
malignancy O O
- O O
associated O O
defect O O
in O O
these O O
cells O O
or O O
exemplifies O O
a O O
normal O O
developmental O O
regulation O O
in O O
terminally O O
differentiated O O
B O O
cells O O
. O O

Regulation O O
of O O
granulocyte O O
- O O
macrophage O O
colony O O
- O O
stimulating O O
factor O O
and O O
E O O
- O O
selectin O O
expression O O
in O O
endothelial O O
cells O O
by O O
cyclosporin O O
A O O
and O O
the O O
T O O
- O O
cell O O
transcription O O
factor O O
NFAT O O
. O O

Nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
( O O
NFAT O O
) O O
was O O
originally O O
described O O
as O O
a O O
T O O
- O O
cell O O
- O O
specific O O
transcription O O
factor O O
athat O O
supported O O
the O O
activation O O
of O O
cytokine O B-DNA
gene O I-DNA
expression O O
and O O
mediated O O
the O O
immunoregulatory O O
effects O O
of O O
cyclosporin O O
A O O
( O O
CsA O O
) O O
. O O

As O O
we O O
observed O O
that O O
activated O O
endothelial O O
cells O O
also O O
expressed O O
NFAT O O
, O O
we O O
tested O O
the O O
antiinflammatory O O
properties O O
of O O
CsA O O
in O O
endothelial O O
cells O O
. O O

Significantly O O
, O O
CsA O O
completely O O
suppressed O O
the O O
induction O O
of O O
NFAT O O
in O O
endothelial O O
cells O O
and O O
inhibited O O
the O O
activity O O
of O O
granulocyte B-DNA B-DNA
- I-DNA I-DNA
macrophage I-DNA I-DNA
colony I-DNA I-DNA
- I-DNA I-DNA
stimulating I-DNA I-DNA
factor I-DNA I-DNA
( I-DNA I-DNA
GM I-DNA I-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
regulatory I-DNA I-DNA
elements I-DNA I-DNA
that O O
use O O
NFAT O O
by O O
60 O O
% O O
. O O

CsA O O
similarly O O
mediated O O
a O O
reduction O O
of O O
up O O
to O O
65 O O
% O O
in O O
GM O O
- O O
CSF O O
mRNA O O
and O O
protein O O
expression O O
in O O
activated O O
endothelial O O
cells O O
. O O

CsA O O
also O O
suppressed O O
E O O
- O O
selectin O O
, O O
but O O
not O O
vascular O O
cell O O
adhesion O O
molecule O O
- O O
1 O O
( O O
VCAM O O
- O O
1 O O
) O O
expression O O
in O O
endothelial O O
cells O O
, O O
even O O
though O O
the O O
E B-DNA B-DNA
- I-DNA I-DNA
selectin I-DNA I-DNA
promoter I-DNA I-DNA
is O O
activated O O
by O O
NF O O
- O O
kappa O O
B O O
rather O O
than O O
NFAT O O
. O O

Hence O O
, O O
induction O O
of O O
cell O O
surface O O
expression O O
of O O
this O O
leukocyte O O
adhesion O O
molecule O O
by O O
tumor O O
necrosis O O
factor O O
( O O
TNF O O
) O O
- O O
alpha O O
was O O
reduced O O
by O O
40 O O
% O O
in O O
the O O
presence O O
of O O
CsA O O
, O O
and O O
this O O
was O O
reflected O O
by O O
a O O
29 O O
% O O
decrease O O
in O O
neutrophil O O
adhesion O O
. O O

The O O
effects O O
of O O
CsA O O
on O O
endothelial O O
cells O O
were O O
also O O
detected O O
at O O
the O O
chromatin B-DNA B-DNA
structure O I-DNA
level O O
, O O
as O O
DNasel B-DNA B-DNA
hypersensitive I-DNA I-DNA
sites I-DNA I-DNA
within O O
both O O
the O O
GM O B-DNA
- O I-DNA
CSF O I-DNA
enhancer O I-DNA
and O O
the O O
E B-DNA B-DNA
- I-DNA I-DNA
selectin I-DNA I-DNA
promoter I-DNA I-DNA
were O O
suppressed O O
by O O
CsA O O
. O O

This O O
represents O O
the O O
first O O
report O O
of O O
NFAT O O
in O O
endothelial O O
cells O O
and O O
suggests O O
mechanisms O O
by O O
which O O
CsA O O
could O O
function O O
as O O
an O O
antiinflammatory O O
agent O O
. O O

Costimulation O O
requirement O O
for O O
AP O O
- O O
1 O O
and O O
NF O O
- O O
kappa O O
B O O
transcription O O
factor O O
activation O O
in O O
T O O
cells O O
. O O

The O O
transcriptional O O
activity O O
of O O
the O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
promoter I-DNA I-DNA
requires O O
T O O
- O O
cell O O
costimulation O O
delivered O O
by O O
the O O
TCR O O
and O O
the O O
auxiliary O O
receptor O O
CD28 O O
. O O

Several O O
transcription O O
factors O O
participate O O
in O O
IL O B-DNA
- O I-DNA
2 O I-DNA
promoter O I-DNA
activation O O
, O O
among O O
which O O
are O O
AP O O
- O O
1 O O
- O O
like O O
factors O O
and O O
NF O O
- O O
kappa O O
B O O
. O O

Protein O O
phosphorylation O O
has O O
an O O
important O O
role O O
in O O
the O O
regulation O O
of O O
these O O
two O O
factors O O
: O O
( O O
1 O O
) O O
it O O
induces O O
the O O
transactivating O O
capacity O O
of O O
the O O
AP O O
- O O
1 O O
protein O O
c O O
- O O
Jun O O
; O O
and O O
( O O
2 O O
) O O
it O O
is O O
involved O O
in O O
the O O
release O O
of O O
the O O
cytoplasmic O O
inhibitor O O
, O O
I O O
kappa O O
B O O
, O O
from O O
NF O O
- O O
kappa O O
B O O
, O O
allowing O O
translocation O O
of O O
the O O
latter O O
into O O
the O O
nucleus O O
. O O

We O O
have O O
recently O O
shown O O
that O O
both O O
phosphorylation O O
processes O O
require O O
T O O
- O O
cell O O
costimulation O O
. O O

Furthermore O O
, O O
in O O
activated O O
T O O
cells O O
, O O
the O O
kinetics O O
of O O
the O O
two O O
phosphorylation O O
events O O
are O O
essentially O O
similar O O
. O O

According O O
to O O
our O O
results O O
, O O
however O O
, O O
the O O
kinases O O
responsible O O
for O O
the O O
two O O
processes O O
are O O
distinct O O
entities O O
. O O

Whereas O O
TPCK O O
inhibits O O
phosphorylation O O
of O O
I O O
kappa O O
B O O
and O O
, O O
consequently O O
, O O
activation O O
of O O
NF O O
- O O
kappa O O
B O O
, O O
it O O
markedly O O
enhances O O
the O O
activity O O
of O O
JNK O O
, O O
the O O
MAP O O
kinase O O
- O O
related O O
kinase O O
that O O
phosphorylates O O
the O O
transactivation O O
domain O O
of O O
c O O
- O O
Jun O O
. O O

We O O
, O O
therefore O O
, O O
propose O O
the O O
activation O O
scheme O O
presented O O
in O O
FIGURE O B-DNA
3 O I-DNA
for O O
T O O
- O O
cell O O
costimulation O O
. O O

Costimulation O O
results O O
in O O
the O O
activation O O
of O O
a O O
signaling O O
pathway O O
that O O
leads O O
to O O
the O O
simultaneous O O
induction O O
of O O
the O O
two O O
transcription O O
factors O O
, O O
AP O O
- O O
1 O O
and O O
NF O O
- O O
kappa O O
B O O
. O O

Integration O O
of O O
the O O
signals O O
generated O O
by O O
TCR O O
and O O
CD28 O O
engagement O O
occurs O O
along O O
this O O
pathway O O
, O O
which O O
then O O
bifurcates O O
to O O
induce O O
I O O
kappa O O
B O O
phosphorylation O O
and O O
NF O O
- O O
kappa O O
B O O
activation O O
on O O
the O O
one O O
hand O O
, O O
and O O
JNK O O
activation O O
and O O
c O O
- O O
Jun O O
phosphorylation O O
on O O
the O O
other O O
. O O

We O O
are O O
currently O O
engaged O O
in O O
defining O O
where O O
the O O
two O O
signals O O
integrate O O
along O O
the O O
AP O O
- O O
1 O O
/ O O
NF O O
- O O
kappa O O
B O O
pathway O O
. O O

Regulation O O
of O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
and O O
cytokine O B-DNA
gene O I-DNA
expression O O
in O O
myeloid O O
cells O O
by O O
NF O O
- O O
kappa O O
B O O
/ O O
Rel O O
transcription O O
factors O O
. O O

CD4 O O
+ O O
macrophages O O
in O O
tissues O O
such O O
as O O
lung O O
, O O
skin O O
, O O
and O O
lymph O O
nodes O O
, O O
promyelocytic O O
cells O O
in O O
bone O O
marrow O O
, O O
and O O
peripheral O O
blood O O
monocytes O O
serve O O
as O O
important O O
targets O O
and O O
reservoirs O O
for O O
human O O
immunodeficiency O O
virus O O
type O O
1 O O
( O O
HIV O O
- O O
1 O O
) O O
replication O O
. O O

HIV O O
- O O
1 O O
- O O
infected O O
myeloid O O
cells O O
are O O
often O O
diminished O O
in O O
their O O
ability O O
to O O
participate O O
in O O
chemotaxis O O
, O O
phagocytosis O O
, O O
and O O
intracellular O O
killing O O
. O O

HIV O O
- O O
1 O O
infection O O
of O O
myeloid O O
cells O O
can O O
lead O O
to O O
the O O
expression O O
of O O
surface O O
receptors O O
associated O O
with O O
cellular O O
activation O O
and O O
/ O O
or O O
differentiation O O
that O O
increase O O
the O O
responsiveness O O
of O O
these O O
cells O O
to O O
cytokines O O
secreted O O
by O O
neighboring O O
cells O O
as O O
well O O
as O O
to O O
bacteria O O
or O O
other O O
pathogens O O
. O O

Enhancement O O
of O O
HIV O O
- O O
1 O O
replication O O
is O O
related O O
in O O
part O O
to O O
increased O O
DNA O O
- O O
binding O O
activity O O
of O O
cellular O O
transcription O O
factors O O
such O O
as O O
NF O O
- O O
kappa O O
B O O
. O O

NF O O
- O O
kappa O O
B O O
binds O O
to O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
enhancer I-DNA I-DNA
region O I-DNA
of O O
the O O
long B-DNA B-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
and O O
contributes O O
to O O
the O O
inducibility O O
of O O
HIV O B-DNA
- O I-DNA
1 O I-DNA
gene O I-DNA
expression O O
in O O
response O O
to O O
multiple O O
activating O O
agents O O
. O O

Phosphorylation O O
and O O
degradation O O
of O O
the O O
cytoplasmic O O
inhibitor O O
I O O
kappa O O
B O O
alpha O O
are O O
crucial O O
regulatory O O
events O O
in O O
the O O
activation O O
of O O
NF O O
- O O
kappa O O
B O O
DNA O O
- O O
binding O O
activity O O
. O O

Both O O
N O O
- O O
and O O
C O O
- O O
terminal O O
residues O O
of O O
I O O
kappa O O
B O O
alpha O O
are O O
required O O
for O O
inducer O O
- O O
mediated O O
degradation O O
. O O

Chronic O O
HIV O O
- O O
1 O O
infection O O
of O O
myeloid O O
cells O O
leads O O
to O O
constitutive O O
NF O O
- O O
kappa O O
B O O
DNA O O
- O O
binding O O
activity O O
and O O
provides O O
an O O
intranuclear O O
environment O O
capable O O
of O O
perpetuating O O
HIV O O
- O O
1 O O
replication O O
. O O

Increased O O
intracellular O O
stores O O
of O O
latent O O
NF O O
- O O
kappa O O
B O O
may O O
also O O
result O O
in O O
rapid O O
inducibility O O
of O O
NF O O
- O O
kappa O O
B O O
- O O
dependent O O
cytokine O B-DNA
gene O I-DNA
expression O O
. O O

In O O
response O O
to O O
secondary O O
pathogenic O O
infections O O
or O O
antigenic O O
challenge O O
, O O
cytokine O B-DNA
gene O I-DNA
expression O O
is O O
rapidly O O
induced O O
, O O
enhanced O O
, O O
and O O
sustained O O
over O O
prolonged O O
periods O O
in O O
HIV O O
- O O
1 O O
- O O
infected O O
myeloid O O
cells O O
compared O O
with O O
uninfected O O
cells O O
. O O

Elevated O O
levels O O
of O O
several O O
inflammatory O O
cytokines O O
have O O
been O O
detected O O
in O O
the O O
sera O O
of O O
HIV O O
- O O
1 O O
- O O
infected O O
individuals O O
. O O

Secretion O O
of O O
myeloid O O
cell O O
- O O
derived O O
cytokines O O
may O O
both O O
increase O O
virus O O
production O O
and O O
contribute O O
to O O
AIDS O O
- O O
associated O O
disorders O O
. O O

Steroid O O
mediated O O
lysis O O
of O O
lymphoblasts O O
requires O O
the O O
DNA O O
binding O O
region O O
of O O
the O O
steroid O O
hormone O O
receptor O O
. O O

Glucocorticoids O O
kill O O
certain O O
types O O
of O O
lymphoblasts O O
, O O
but O O
the O O
mechanisms O O
are O O
unknown O O
. O O

It O O
is O O
clear O O
that O O
sufficient O O
numbers O O
of O O
functional O O
glucocorticoid O O
receptors O O
are O O
required O O
to O O
mediate O O
lysis O O
, O O
but O O
whether O O
they O O
do O O
so O O
through O O
the O O
classical O O
model O O
of O O
steroid O O
hormone O O
activation O O
and O O
modulation O O
of O O
gene O O
expression O O
has O O
not O O
been O O
established O O
. O O

In O O
this O O
report O O
we O O
have O O
asked O O
which O O
region O O
( O O
s O O
) O O
of O O
the O O
steroid O O
receptor O O
are O O
important O O
for O O
mediating O O
lysis O O
in O O
leukemic O O
T O O
lymphoblasts O O
. O O

CEM O O
- O O
ICR O O
27 O O
leukemic O O
lymphoblasts O O
, O O
a O O
clone O O
of O O
CEM O O
cells O O
which O O
lack O O
functional O O
glucocorticoid O O
receptors O O
and O O
therefore O O
are O O
neither O O
lysed O O
by O O
dexamethasone O O
nor O O
capable O O
of O O
showing O O
glutamine O O
synthetase O O
induction O O
, O O
were O O
provided O O
with O O
steroid O O
receptors O O
by O O
DNA O O
transfections O O
of O O
various O B-DNA
receptor O I-DNA
gene O I-DNA
constructs O I-DNA
. O O

We O O
measured O O
steroid O O
mediated O O
lysis O O
, O O
receptor O O
number O O
and O O
induction O O
of O O
glutamine O O
synthetase O O
in O O
the O O
transfected O O
cells O O
. O O

Our O O
results O O
provide O O
evidence O O
that O O
the O O
lysis O O
mechanism O O
in O O
the O O
ICR27 O O
lymphoblasts O O
is O O
restored O O
when O O
functional O O
receptor O O
number O O
is O O
restored O O
. O O

The O O
DNA O B-DNA
binding O I-DNA
region O I-DNA
specifying O O
high O O
affinity O O
for O O
GRE B-DNA B-DNA
sites I-DNA I-DNA
is O O
required O O
. O O

Lysis O O
is O O
mediated O O
by O O
any O O
steroid O O
that O O
allows O O
for O O
activation O O
of O O
the O O
receptor O O
containing O O
such O O
a O O
region O O
. O O

Our O O
data O O
support O O
the O O
view O O
that O O
steroid O O
- O O
mediated O O
cell O O
death O O
occurs O O
by O O
a O O
process O O
requiring O O
direct O O
interaction O O
of O O
steroid O O
- O O
receptor O O
complexes O O
with O O
the O O
genome O O
. O O

Functional O O
characterization O O
of O O
the O O
murine O O
homolog O O
of O O
the O O
B O O
cell O O
- O O
specific O O
coactivator O O
BOB O O
. O O
1 O O
/ O O
OBF O O
. O O
1 O O
. O O

B O O
cell O O
- O O
specific O O
transcriptional O O
promoter O O
activity O O
mediated O O
by O O
the O O
octamer B-DNA B-DNA
motif I-DNA I-DNA
requires O O
the O O
Oct1 O O
or O O
Oct2 O O
protein O O
and O O
additional O O
B O O
cell O O
- O O
restricted O O
cofactors O O
. O O

One O O
such O O
cofactor O O
, O O
BOB O O
. O O
1 O O
/ O O
OBF O O
. O O
1 O O
, O O
was O O
recently O O
isolated O O
from O O
human O O
B O O
cells O O
. O O

Here O O
, O O
we O O
describe O O
the O O
isolation O O
and O O
detailed O O
characterization O O
of O O
the O O
murine O O
homolog O O
. O O

Full O B-DNA
- O I-DNA
length O I-DNA
cDNAs B-DNA I-DNA
and O O
genomic B-DNA B-DNA
clones I-DNA I-DNA
were O O
isolated O O
, O O
and O O
the O O
gene O O
structure O O
was O O
determined O O
. O O
Comparison O O
of O O
the O O
deduced O O
amino O O
acids O O
shows O O
88 O O
% O O
sequence O O
identity O O
between O O
mouse O O
and O O
human O O
BOB O O
. O O
1 O O
/ O O
OBF O O
. O O
1 O O
. O O

The O O
NH2 O O
- O O
terminal O O
126 O O
amino O O
acids O O
of O O
BOB O O
. O O
1 O O
/ O O
OBF O O
. O O
1 O O
are O O
both O O
essential O O
and O O
sufficient O O
for O O
interaction O O
with O O
the O O
POU O O
domains O O
of O O
either O O
Oct1 O O
or O O
Oct2 O O
. O O

This O O
protein O O
- O O
protein O O
interaction O O
does O O
not O O
require O O
the O O
simultaneous O O
binding O O
of O O
Oct O O
proteins O O
to O O
DNA O O
, O O
and O O
high O O
resolution O O
footprinting O O
of O O
the O O
Oct B-DNA O
- O O
DNA O O
interaction O O
reveals O O
that O O
binding O O
of O O
BOB O O
. O O
1 O O
/ O O
OBF O O
. O O
1 O O
to O O
Oct1 O O
or O O
Oct2 O O
does O O
not O O
alter O O
the O O
interaction O O
with O O
DNA O O
. O O

BOB O O
. O O
1 O O
/ O O
OBF O O
. O O
1 O O
can O O
efficiently O O
activate O O
octamer O B-DNA
- O I-DNA
dependent O I-DNA
promoters O I-DNA
in O O
fibroblasts O O
; O O
however O O
, O O
it O O
fails O O
to O O
stimulate O O
octamer B-DNA O
- I-DNA O
dependent I-DNA O
enhancer I-DNA O
activity O O
. O O

Fusion O O
of O O
subdomains O O
of O O
BOB O O
. O O
1 O O
/ O O
OBF O O
. O O
1 O O
with O O
the O O
GAL4 O O
DNA O O
binding O O
domain O O
reveals O O
that O O
both O O
NH2 O O
- O O
and O O
COOH O O
- O O
terminal O O
domains O O
of O O
BOB O O
. O O
1 O O
/ O O
OBF O O
. O O
1 O O
contribute O O
to O O
full O O
transactivation O O
function O O
, O O
the O O
COOH O O
- O O
terminal O O
domain O O
is O O
more O O
efficient O O
in O O
this O O
transactivation O O
assay O O
. O O

Consistent O O
with O O
the O O
failure O O
of O O
full O O
- O O
length O O
BOB O O
. O O
1 O O
/ O O
OBF O O
. O O
1 O O
to O O
stimulate O O
octamer B-DNA B-DNA
- I-DNA I-DNA
dependent I-DNA I-DNA
enhancer I-DNA I-DNA
elements I-DNA I-DNA
in O O
non O O
B O O
cells O O
, O O
the O O
GAL4 O B-DNA
fusions O I-DNA
likewise O O
only O O
stimulate O O
from O O
a O O
promoter O B-DNA
- O I-DNA
proximal O I-DNA
position O I-DNA
. O O

Anti O O
- O O
immunoglobulin O O
M O O
activates O O
nuclear O O
calcium O O
/ O O
calmodulin O O
- O O
dependent O O
protein O O
kinase O O
II O O
in O O
human O O
B O O
lymphocytes O O
. O O

We O O
and O O
others O O
have O O
previously O O
shown O O
that O O
the O O
nuclear O O
protein O O
, O O
Ets O O
- O O
1 O O
, O O
is O O
phosphorylated O O
in O O
a O O
calcium O O
- O O
dependent O O
manner O O
after O O
ligation O O
of O O
immunoglobulin O O
( O O
Ig O O
) O O
M O O
on O O
B O O
lymphocytes O O
. O O

As O O
this O O
phosphorylation O O
was O O
independent O O
of O O
protein O O
kinase O O
C O O
activity O O
, O O
we O O
tested O O
whether O O
a O O
calcium O O
/ O O
calmodulin O O
- O O
dependent O O
protein O O
kinase O O
( O O
CaM O O
kinase O O
) O O
might O O
phosphorylate O O
the O O
Ets O O
- O O
1 O O
protein O O
after O O
elevation O O
of O O
intracellular O O
free O O
calcium O O
concentrations O O
. O O

The O O
dephosphorylated O O
form O O
of O O
Ets O O
- O O
1 O O
has O O
been O O
shown O O
to O O
bind O O
to O O
chromatin B-DNA B-DNA
, O O
suggesting O O
that O O
the O O
operative O O
kinase O O
should O O
be O O
detectable O O
in O O
the O O
nucleus O O
. O O

We O O
prepared O O
nuclear O O
extracts O O
from O O
two O O
human O O
B O O
cell O O
lines O O
in O O
which O O
increased O O
intracellular O O
free O O
calcium O O
levels O O
correlated O O
with O O
increased O O
phosphorylation O O
of O O
the O O
Ets O O
- O O
1 O O
protein O O
. O O

Activity O O
of O O
the O O
CaM O O
kinases O O
was O O
determined O O
using O O
a O O
synthetic O O
peptide O O
substrate O O
both O O
in O O
the O O
absence O O
and O O
presence O O
of O O
an O O
inhibitor O O
specific O O
for O O
the O O
CaM O O
kinase O O
family O O
, O O
KN O O
- O O
62 O O
. O O

Stimulation O O
of O O
cells O O
with O O
anti O O
- O O
IgM O O
led O O
to O O
increased O O
activity O O
of O O
a O O
nuclear O O
kinase O O
that O O
could O O
phosphorylate O O
the O O
peptide O O
, O O
and O O
this O O
activity O O
was O O
reduced O O
by O O
10 O O
microM O O
KN O O
- O O
62 O O
. O O

Kinase O O
activity O O
was O O
reduced O O
in O O
lysates O O
preadsorbed O O
using O O
an O O
antibody O O
specific O O
for O O
CaM O O
kinase O O
II O O
. O O

Two O O
- O O
dimensional O O
phosphopeptide O O
maps O O
of O O
the O O
Ets O O
- O O
1 O O
protein O O
from O O
cells O O
incubated O O
with O O
ionomycin O O
or O O
anti O O
- O O
IgM O O
contained O O
two O O
unique O O
phosphopeptides O O
that O O
were O O
absent O O
in O O
untreated O O
cells O O
. O O

Incubation O O
of O O
isolated O O
Ets O O
- O O
1 O O
protein O O
with O O
purified O O
CaM O O
kinase O O
II O O
produced O O
phosphorylation O O
of O O
peptides O O
that O O
migrated O O
identically O O
to O O
those O O
found O O
in O O
cells O O
incubated O O
with O O
either O O
anti O O
- O O
IgM O O
or O O
ionomycin O O
. O O

These O O
data O O
suggest O O
a O O
model O O
of O O
signal O O
transduction O O
by O O
the O O
antigen O O
receptor O O
on O O
B O O
lymphocytes O O
in O O
which O O
increased O O
intracellular O O
free O O
calcium O O
can O O
rapidly O O
activate O O
nuclear O O
CaM O O
kinase O O
II O O
, O O
potentially O O
resulting O O
in O O
phosphorylation O O
and O O
regulation O O
of O O
DNA O O
- O O
binding O O
proteins O O
. O O

Transcriptional O O
activation O O
and O O
repression O O
, O O
two O O
properties O O
of O O
the O O
lymphoid O O
- O O
specific O O
transcription O O
factor O O
Oct O O
- O O
2a O O
. O O

The O O
lymphoid O O
- O O
specific O O
transcription O O
factor O O
Oct O O
- O O
2a O O
contains O O
two O O
transcriptional O O
activation O O
domains O O
which O O
are O O
located O O
within O O
the O O
N O O
- O O
terminal O O
and O O
C O O
- O O
terminal O O
regions O O
. O O

To O O
study O O
their O O
differential O O
activation O O
properties O O
, O O
we O O
linked O O
the O O
isolated O O
effector O O
domains O O
to O O
the O O
GAL4 O O
DNA O O
- O O
binding O O
domain O O
. O O

We O O
have O O
shown O O
that O O
both O O
activating O O
regions O O
of O O
Oct O O
- O O
2a O O
, O O
isolated O O
from O O
their O O
natural O O
context O O
, O O
can O O
activate O O
transcription O O
as O O
promoter O O
factors O O
. O O

In O O
contrast O O
to O O
the O O
C O O
- O O
terminus O O
, O O
activation O O
by O O
the O O
N O O
- O O
terminal O O
domain O O
is O O
dependent O O
on O O
a O O
yet O O
unidentified O O
factor O O
( O O
s O O
) O O
binding O O
to O O
the O O
simian B-DNA B-DNA
virus I-DNA I-DNA
40 I-DNA I-DNA
enhancer I-DNA I-DNA
. O O

The O O
results O O
obtained O O
by O O
duplication O O
of O O
activation O O
domains O O
or O O
their O O
mixed O O
combination O O
suggest O O
that O O
the O O
domains O O
are O O
functionally O O
independent O O
. O O

However O O
, O O
activation O O
from O O
a O O
remote O O
position O O
could O O
only O O
be O O
achieved O O
with O O
the O O
C O O
- O O
terminus O O
of O O
Oct O O
- O O
2a O O
in O O
B O O
cells O O
. O O

In O O
lymphoid O O
cells O O
, O O
higher O O
activation O O
levels O O
were O O
observed O O
, O O
suggesting O O
that O O
distinct O O
B O O
- O O
cell O O
- O O
specific O O
cofactors O O
in O O
concert O O
with O O
the O O
effector O O
domains O O
of O O
Oct O O
- O O
2a O O
might O O
be O O
involved O O
in O O
mediating O O
transcription O O
from O O
proximal O O
and O O
remote O O
positions O O
. O O

Furthermore O O
, O O
we O O
identified O O
a O O
repression O O
domain O O
at O O
the O O
N O O
- O O
terminus O O
of O O
Oct O O
- O O
2a O O
. O O

When O O
transferred O O
to O O
a O O
potent O O
activator O O
, O O
transcriptional O O
stimulation O O
was O O
inhibited O O
efficiently O O
. O O

These O O
results O O
underscore O O
the O O
modular O O
structure O O
of O O
Oct O O
- O O
2a O O
with O O
separable O O
domains O O
for O O
activation O O
and O O
repression O O
and O O
suggest O O
that O O
Oct O O
- O O
2a O O
might O O
have O O
complex O O
regulatory O O
functions O O
in O O
vivo O O
. O O

Nonopsonic O O
phagocytosis O O
of O O
Pseudomonas O O
aeruginosa O O
by O O
macrophages O O
and O O
polymorphonuclear O O
leukocytes O O
requires O O
the O O
presence O O
of O O
the O O
bacterial O O
flagellum O O
. O O

Whereas O O
the O O
mechanism O O
of O O
nonopsonic O O
phagocytosis O O
of O O
Pseudomonas O O
aeruginosa O O
has O O
been O O
described O O
, O O
the O O
bacterial O O
ligands O O
required O O
are O O
poorly O O
understood O O
. O O

To O O
identify O O
the O O
requisite O O
bacterial O O
ligands O O
, O O
studies O O
with O O
isogenic O O
mutants O O
of O O
P O O
. O O
aeruginosa O O
PAK O O
lacking O O
pili O O
, O O
flagella O O
, O O
and O O
the O O
RpoN O O
sigma O O
factor O O
were O O
undertaken O O
. O O

The O O
RpoN O O
mutant O O
, O O
lacking O O
pili O O
, O O
flagella O O
, O O
and O O
nonpilus O O
adhesins O O
, O O
bound O O
poorly O O
and O O
was O O
resistant O O
to O O
ingestion O O
by O O
both O O
macrophages O O
and O O
neutrophils O O
. O O

Pili O O
were O O
not O O
absolutely O O
required O O
for O O
binding O O
or O O
phagocytosis O O
of O O
P O O
. O O
aeruginosa O O
. O O

The O O
presence O O
of O O
a O O
flagellum O O
was O O
not O O
required O O
for O O
binding O O
of O O
P O O
. O O
aeruginosa O O
to O O
macrophages O O
but O O
was O O
critical O O
for O O
the O O
subsequent O O
internalization O O
of O O
the O O
bacterium O O
, O O
suggesting O O
that O O
this O O
factor O O
or O O
a O O
surface O O
ligand O O
associated O O
with O O
its O O
assembly O O
was O O
responsible O O
for O O
stimulation O O
of O O
nonopsonic O O
phagocytosis O O
. O O

Identification O O
of O O
essential O O
GATA B-DNA O
and O O
Ets B-DNA O
binding I-DNA O
motifs I-DNA O
within O O
the O O
promoter O B-DNA
of O O
the O O
platelet B-DNA B-DNA
glycoprotein I-DNA I-DNA
Ib I-DNA I-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
. O O

Platelet O O
glycoprotein O O
( O O
GP O O
) O O
Ib O O
- O O
IX O O
- O O
V O O
is O O
a O O
multisubunit O O
adhesion O O
receptor O O
that O O
supports O O
platelet O O
attachment O O
to O O
thrombogenic O O
surfaces O O
at O O
sites O O
of O O
vascular O O
injury O O
. O O

The O O
congenital O O
absence O O
of O O
the O O
receptor O O
results O O
in O O
a O O
bleeding O O
disorder O O
associated O O
with O O
" O O
giant O O
" O O
platelets O O
, O O
a O O
condition O O
linking O O
the O O
expression O O
of O O
the O O
complex O O
to O O
platelet O O
morphogenesis O O
. O O

To O O
understand O O
better O O
the O O
expression O O
of O O
the O O
GP O O
Ib O O
- O O
IX O O
- O O
V O O
complex O O
, O O
studies O O
were O O
undertaken O O
to O O
define O O
the O O
essential O O
genetic B-DNA O
elements I-DNA O
supporting O O
the O O
expression O O
of O O
the O O
alpha O O
- O O
subunit O O
of O O
the O O
complex O O
( O O
GP O O
Ib O O
alpha O O
) O O
. O O

GP B-DNA B-DNA
Ib I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
activity O O
was O O
evaluated O O
by O O
transfection O O
of O O
human O O
erythroleukemia O O
cells O O
with O O
reporter O B-DNA
plasmids O I-DNA
coding O O
for O O
the O O
enzyme O O
, O O
luciferase O O
. O O

Studies O O
were O O
initiated O O
with O O
a O O
fragment O O
extending O O
2 O O
, O O
738 O O
nucleotides O O
5 O O
' O O
to O O
the O O
transcription B-DNA B-DNA
start I-DNA I-DNA
site I-DNA I-DNA
and O O
lead O O
to O O
the O O
identification O O
of O O
253 O B-DNA
nucleotides O I-DNA
retaining O O
full O O
promoter O O
activity O O
in O O
human O O
erythroleukemia O O
cells O O
. O O

In O O
cells O O
of O O
nonhematopoietic O O
lineage O O
, O O
human O O
endothelial O O
and O O
HeLa O O
cells O O
, O O
the O O
GP B-DNA B-DNA
Ib I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
activity O O
was O O
no O O
greater O O
than O O
background O O
levels O O
obtained O O
with O O
promoterless B-DNA B-DNA
constructs I-DNA I-DNA
. O O

Gel O O
shift O O
assays O O
and O O
site O O
- O O
directed O O
mutagenesis O O
studies O O
defined O O
essential O O
GATA B-DNA O
and O O
Ets B-DNA O
binding I-DNA O
motifs I-DNA O
93 B-DNA O
and I-DNA O
150 I-DNA O
nucleotides I-DNA O
upstream I-DNA O
of O O
the O O
transcription B-DNA B-DNA
start I-DNA I-DNA
site I-DNA I-DNA
, O O
a O O
finding O O
which O O
further O O
substantiates O O
these O O
elements O O
as O O
important O O
determinants O O
of O O
megakaryocytic O B-DNA
gene O I-DNA
expression O O
. O O

The O O
results O O
define O O
essential O O
cis B-DNA B-DNA
- I-DNA I-DNA
acting I-DNA I-DNA
elements I-DNA I-DNA
responsible O O
for O O
the O O
expression O O
of O O
GP O O
Ib O O
alpha O O
and O O
provide O O
insights O O
into O O
molecular O O
events O O
coinciding O O
with O O
the O O
release O O
of O O
normal O O
platelets O O
into O O
the O O
bloodstream O O
. O O

CD30 O O
ligation O O
induces O O
nuclear O O
factor O O
- O O
kappa O O
B O O
activation O O
in O O
human O O
T O O
cell O O
lines O O
. O O

CD30 O O
is O O
a O O
recently O O
described O O
member O O
of O O
the O O
tumor O O
necrosis O O
factor O O
/ O O
nerve O O
growth O O
factor O O
receptor O O
superfamily O O
. O O

In O O
this O O
report O O
, O O
we O O
show O O
that O O
following O O
incubation O O
of O O
L540 O O
cells O O
( O O
Hodgkin O O
' O O
s O O
disease O O
- O O
derived O O
, O O
T O O
cell O O
- O O
like O O
, O O
CD30 O O
+ O O
cells O O
) O O
with O O
the O O
agonistic O O
anti O O
- O O
CD30 O O
monoclonal O O
antibodies O O
( O O
mAb O O
) O O
M44 O O
and O O
M67 O O
, O O
two O O
nuclear O O
factor O O
( O O
NF O O
) O O
- O O
kappa O O
B O O
DNA O O
binding O O
activities O O
were O O
induced O O
in O O
nuclear O O
extracts O O
, O O
as O O
determined O O
in O O
gel O O
retardation O O
assays O O
. O O

The O O
effect O O
of O O
the O O
mAb O O
towards O O
NF O O
- O O
kappa O O
B O O
activation O O
was O O
rapid O O
, O O
as O O
it O O
occurred O O
within O O
20 O O
min O O
, O O
and O O
was O O
sustained O O
for O O
up O O
to O O
6 O O
h O O
. O O

By O O
comparison O O
, O O
an O O
isotype O O
- O O
matched O O
antibody O O
had O O
no O O
effect O O
on O O
NF O O
- O O
kappa O O
B O O
activation O O
. O O

Moreover O O
, O O
in O O
human O O
T O O
helper O O
( O O
Th O O
) O O
clones O O
functionally O O
characterized O O
as O O
being O O
of O O
the O O
type O O
0 O O
, O O
type O O
1 O O
and O O
type O O
2 O O
( O O
28 O O
% O O
, O O
< O O
1 O O
% O O
und O O
93 O O
% O O
CD30 O O
+ O O
, O O
respectively O O
) O O
, O O
the O O
extent O O
of O O
CD30 O O
- O O
mediated O O
NF O O
- O O
kappa O O
B O O
activation O O
correlated O O
with O O
the O O
proportion O O
of O O
CD30 O O
+ O O
cells O O
. O O

In O O
all O O
cell O O
lines O O
investigated O O
, O O
the O O
NF O O
- O O
kappa O O
B O O
complexes O O
induced O O
following O O
CD30 O O
engagement O O
were O O
shown O O
to O O
contain O O
p50 O O
NF O O
- O O
kappa O O
B1 O O
, O O
p65 O O
RelA O O
, O O
and O O
possibly O O
other O O
transcription O O
factors O O
. O O

Collectively O O
, O O
our O O
results O O
demonstrate O O
that O O
nuclear O O
translocation O O
and O O
activation O O
of O O
NF O O
- O O
kappa O O
B O O
rank O O
among O O
the O O
short O O
- O O
term O O
cellular O O
responses O O
elicited O O
following O O
CD30 O O
ligation O O
. O O

Pathogenesis O O
of O O
atherosclerosis O O
. O O

The O O
earliest O O
lesion O O
in O O
the O O
development O O
of O O
an O O
atherosclerotic O O
plaque O O
is O O
the O O
fatty O O
streak O O
. O O

This O O
chronic O O
inflammatory O O
reaction O O
results O O
from O O
a O O
sequence O O
of O O
events O O
that O O
begins O O
with O O
the O O
trapping O O
of O O
low O O
density O O
lipoprotein O O
( O O
LDL O O
) O O
in O O
the O O
subendothelial O O
space O O
of O O
the O O
artery O O
wall O O
. O O

The O O
trapped O O
LDL O O
is O O
seeded O O
with O O
oxidative O O
species O O
released O O
by O O
the O O
overlying O O
endothelium O O
, O O
and O O
lipid O O
oxidation O O
is O O
initiated O O
within O O
the O O
LDL O O
particle O O
. O O
Some O O
of O O
the O O
lipids O O
that O O
result O O
lead O O
to O O
the O O
activation O O
of O O
NFkB O O
- O O
like O O
transcription O O
factors O O
that O O
cause O O
the O O
expression O O
of O O
genes O O
whose O O
protein O O
products O O
mediate O O
monocyte O O
binding O O
, O O
monocyte O O
chemotaxis O O
into O O
the O O
subendothelial O O
space O O
, O O
and O O
conversion O O
into O O
macrophages O O
. O O

At O O
least O O
1 O O
major B-DNA O
gene I-DNA O
modulates O O
the O O
oxidation O O
of O O
LDL O O
lipids O O
and O O
/ O O
or O O
the O O
biologic O O
response O O
to O O
these O O
lipids O O
. O O

The O O
inverse O O
relation O O
between O O
high O O
density O O
lipoprotein O O
( O O
HDL O O
) O O
and O O
atherosclerotic O O
events O O
may O O
in O O
part O O
be O O
due O O
to O O
enzymes O O
associated O O
with O O
HDL O O
that O O
destroy O O
the O O
biologically O O
active O O
lipids O O
generated O O
in O O
LDL O O
. O O

Estrogen O O
and O O
progesterone O O
receptors O O
in O O
vernal O O
keratoconjunctivitis O O
. O O

PURPOSE O O
: O O
Sex O O
- O O
related O O
influences O O
have O O
been O O
implicated O O
in O O
the O O
pathogenesis O O
of O O
vernal O O
keratoconjunctivitis O O
( O O
VKC O O
) O O
, O O
an O O
allergic O O
eosinophilic O O
disease O O
. O O

METHODS O O
: O O
The O O
authors O O
evaluated O O
tarsal O O
and O O
bulbar O O
conjunctival O O
biopsies O O
from O O
seven O O
patients O O
with O O
severe O O
and O O
symptomatic O O
VKC O O
for O O
the O O
presence O O
of O O
estrogen O O
and O O
progesterone O O
receptors O O
by O O
using O O
monoclonal O O
antibodies O O
with O O
a O O
peroxidase O O
- O O
antiperoxidase O O
technique O O
. O O

RESULTS O O
: O O
Both O O
the O O
epithelium O O
and O O
subepithelium O O
of O O
the O O
tarsal O O
and O O
bulbar O O
conjunctiva O O
of O O
patients O O
with O O
VKC O O
, O O
but O O
not O O
those O O
of O O
four O O
nonatopic O O
control O O
subjects O O
, O O
showed O O
intense O O
positive O O
staining O O
for O O
estrogen O O
and O O
progesterone O O
receptors O O
. O O

Immunofluorescence O O
colocalization O O
of O O
both O O
estrogen O O
and O O
progesterone O O
receptors O O
with O O
eosinophil O O
cationic O O
protein O O
showed O O
that O O
approximately O O
70 O O
% O O
of O O
positive O O
cells O O
were O O
eosinophils O O
. O O

CONCLUSIONS O O
: O O
Sexual O O
hormones O O
, O O
through O O
their O O
receptors O O
, O O
may O O
influence O O
the O O
activity O O
of O O
eosinophils O O
in O O
patients O O
with O O
VKC O O
. O O

CIITA O O
activates O O
the O O
expression O O
of O O
MHC B-DNA B-DNA
class I-DNA I-DNA
II I-DNA I-DNA
genes I-DNA I-DNA
in O O
mouse O O
T O O
cells O O
. O O

It O O
has O O
long O O
been O O
a O O
puzzle O O
that O O
MHC O O
class O O
II O O
molecules O O
are O O
expressed O O
in O O
human O O
T O O
cells O O
after O O
activation O O
but O O
not O O
in O O
mouse O O
T O O
cells O O
; O O
this O O
expression O O
is O O
believed O O
to O O
play O O
a O O
role O O
in O O
the O O
cell O O
mediated O O
immune O O
response O O
. O O

Recently O O
the O O
MHC O O
class O O
II O O
transactivator O O
( O O
CIITA O O
) O O
has O O
been O O
reported O O
to O O
be O O
a O O
major O O
regulatory O O
factor O O
for O O
both O O
the O O
constitutive O O
and O O
IFN O O
inducible O O
expression O O
of O O
MHC B-DNA B-DNA
class I-DNA I-DNA
II I-DNA I-DNA
genes I-DNA I-DNA
. O O

Here O O
we O O
show O O
that O O
human O O
T O O
cells O O
expressing O O
MHC O O
class O O
II O O
have O O
CIITA O O
transcripts O O
while O O
MHC O O
class O O
II O O
- O O
negative O O
human O O
T O O
cells O O
and O O
mouse O O
T O O
cells O O
do O O
not O O
. O O

The O O
expression O O
of O O
MHC B-DNA B-DNA
class I-DNA I-DNA
II I-DNA I-DNA
genes I-DNA I-DNA
in O O
mouse O O
T O O
cells O O
can O O
be O O
reconstituted O O
upon O O
transfection O O
with O O
the O O
human B-DNA B-DNA
CIITA I-DNA I-DNA
cDNA I-DNA I-DNA
. O O

These O O
data O O
indicate O O
that O O
the O O
expression O O
of O O
CIITA O O
explains O O
the O O
expression O O
or O O
lack O O
of O O
expression O O
of O O
MHC O O
class O O
II O O
in O O
human O O
and O O
mouse O O
T O O
cells O O
respectively O O
. O O

Anti O O
- O O
Ro O O
( O O
SSA O O
) O O
autoantibodies O O
are O O
associated O O
with O O
T B-DNA B-DNA
cell I-DNA I-DNA
receptor I-DNA I-DNA
beta I-DNA I-DNA
genes I-DNA I-DNA
in O O
systemic O O
lupus O O
erythematosus O O
patients O O
. O O

Several O O
of O O
the O O
heterogeneous O O
clinical O O
manifestations O O
of O O
systemic O O
lupus O O
erythematosus O O
have O O
been O O
associated O O
with O O
specific O O
autoantibodies O O
. O O

Associations O O
between O O
HLA O O
class O O
II O O
antigens O O
and O O
autoantibodies O O
to O O
the O O
ribonucleoproteins O O
Ro O O
( O O
SSA O O
) O O
and O O
La O O
( O O
SSB O O
) O O
have O O
been O O
reported O O
in O O
these O O
patients O O
. O O

Because O O
HLA O O
class O O
II O O
molecules O O
present O O
antigen O O
to O O
T O O
cell O O
receptors O O
( O O
TCRs O O
) O O
, O O
we O O
have O O
searched O O
for O O
a O O
TCR B-DNA B-DNA
gene I-DNA I-DNA
associated O O
with O O
the O O
production O O
of O O
anti O O
- O O
Ro O O
( O O
SSA O O
) O O
antibodies O O
. O O

A O O
pair O O
of O O
restriction B-DNA B-DNA
fragment I-DNA I-DNA
length I-DNA I-DNA
polymorphisms I-DNA I-DNA
( O O
RFLPs B-DNA B-DNA
) O O
, O O
one O O
of O O
which O O
hybridizes O O
to O O
the O O
TCR B-DNA B-DNA
constant I-DNA I-DNA
region I-DNA I-DNA
C I-DNA B-DNA
beta I-DNA I-DNA
1 I-DNA I-DNA
and O O
the O O
other O O
to O O
the O O
C B-DNA B-DNA
beta I-DNA I-DNA
2 I-DNA I-DNA
gene I-DNA I-DNA
, O O
has O O
been O O
identified O O
, O O
suggesting O O
these O O
may O O
be O O
genotypic O O
markers O O
for O O
an O O
extended O O
region O O
of O O
the O O
TCR B-DNA B-DNA
beta I-DNA I-DNA
locus I-DNA I-DNA
. O O

This O O
RFLP B-DNA B-DNA
pair I-DNA I-DNA
occurs O O
in O O
76 O O
% O O
of O O
patients O O
with O O
Ro O O
( O O
SSA O O
) O O
precipitins O O
, O O
84 O O
% O O
of O O
anti O O
- O O
Ro O O
( O O
SSA O O
) O O
- O O
positive O O
patients O O
lacking O O
La O O
( O O
SSB O O
) O O
precipitins O O
, O O
but O O
only O O
41 O O
% O O
of O O
the O O
patients O O
lacking O O
both O O
precipitins O O
( O O
P O O
= O O
0 O O
. O O
0004 O O
) O O
. O O

This O O
disproportionate O O
occurrence O O
in O O
a O O
subset O O
of O O
lupus O O
patients O O
indicates O O
that O O
these O O
RFLPs B-DNA B-DNA
are O O
not O O
disease O O
susceptibility O O
markers O O
, O O
but O O
rather O O
are O O
important O O
markers O O
for O O
TCR B-DNA B-DNA
genes I-DNA I-DNA
whose O O
products O O
are O O
involved O O
in O O
the O O
production O O
of O O
anti O O
- O O
Ro O O
( O O
SSA O O
) O O
antibodies O O
. O O

The O O
majority O O
of O O
patients O O
who O O
have O O
these O O
RFLPs B-DNA B-DNA
and O O
HLA O O
class O O
II O O
antigens O O
previously O O
associated O O
with O O
the O O
anti O O
- O O
Ro O O
( O O
SSA O O
) O O
response O O
make O O
this O O
antibody O O
, O O
suggesting O O
that O O
interactions O O
between O O
products O O
of O O
these O O
loci B-DNA O
occur I-DNA O
in O O
response O O
to O O
Ro O O
( O O
SSA O O
) O O
. O O

Inhibition O O
of O O
NF O O
- O O
AT O O
- O O
dependent O O
transcription O O
by O O
NF O O
- O O
kappa O O
B O O
: O O
implications O O
for O O
differential O O
gene O O
expression O O
in O O
T O O
helper O O
cell O O
subsets O O
. O O

Activation O O
of O O
individual O O
CD4 O O
+ O O
T O O
cells O O
results O O
in O O
differential O O
lymphokine O O
expression O O
: O O
interleukin O O
2 O O
( O O
IL O O
- O O
2 O O
) O O
is O O
preferentially O O
produced O O
by O O
T O O
helper O O
type O O
1 O O
( O O
TH1 O O
) O O
cells O O
, O O
which O O
are O O
involved O O
in O O
cell O O
- O O
mediated O O
immune O O
responses O O
, O O
whereas O O
IL O O
- O O
4 O O
is O O
synthesized O O
by O O
TH2 O O
cells O O
, O O
which O O
are O O
essential O O
for O O
humoral O O
immunity O O
. O O

The O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
factor O O
NF O O
- O O
ATp O O
plays O O
a O O
key O O
role O O
in O O
the O O
inducible O O
transcription O O
of O O
both O O
these O O
lymphokine B-DNA B-DNA
genes I-DNA I-DNA
. O O

However O O
, O O
while O O
IL2 O O
expression O O
requires O O
the O O
contribution O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
and O O
protein O O
kinase O O
C O O
- O O
dependent O O
signals O O
, O O
we O O
report O O
that O O
activation O O
of O O
human O O
IL4 O O
transcription O O
through O O
the O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
pathway O O
is O O
diminished O O
by O O
protein O O
kinase O O
C O O
stimulation O O
in O O
Jurkat O O
T O O
cells O O
. O O

This O O
phenomenon O O
is O O
due O O
to O O
mutually O O
exclusive O O
binding O O
of O O
NF O O
- O O
ATp O O
and O O
NF O O
- O O
kappa O O
B O O
to O O
the O O
P B-DNA B-DNA
sequence I-DNA I-DNA
, O O
an O O
element O O
located O O
69 B-DNA B-DNA
bp I-DNA I-DNA
upstream I-DNA I-DNA
of O O
the O O
IL4 B-DNA B-DNA
transcription I-DNA I-DNA
initiation I-DNA I-DNA
site I-DNA I-DNA
. O O

Human B-DNA B-DNA
IL4 I-DNA I-DNA
promoter I-DNA I-DNA
- O O
mediated O O
transcription O O
is O O
downregulated O O
in O O
Jurkat O O
cells O O
stimulated O O
with O O
the O O
NF O O
- O O
kappa O O
B O O
- O O
activating O O
cytokine O O
tumor O O
necrosis O O
factor O O
alpha O O
and O O
suppressed O O
in O O
RelA O O
- O O
overexpressing O O
cells O O
. O O

In O O
contrast O O
, O O
protein O O
kinase O O
C O O
stimulation O O
or O O
RelA O O
overexpression O O
does O O
not O O
affect O O
the O O
activity O O
of O O
a O O
human B-DNA B-DNA
IL4 I-DNA I-DNA
promoter I-DNA I-DNA
containing O O
a O O
mouse B-DNA B-DNA
P I-DNA I-DNA
sequence I-DNA I-DNA
, O O
which O O
is O O
a O O
higher B-DNA B-DNA
- I-DNA I-DNA
affinity I-DNA I-DNA
site I-DNA I-DNA
for O O
NF O O
- O O
ATp O O
and O O
a O O
lower B-DNA B-DNA
- I-DNA I-DNA
affinity I-DNA I-DNA
site I-DNA I-DNA
for O O
RelA O O
. O O

Thus O O
, O O
competition O O
between O O
two O O
general O O
transcriptional O O
activators O O
, O O
RelA O O
and O O
NF O O
- O O
ATp O O
, O O
mediates O O
the O O
inhibitory O O
effect O O
of O O
protein O O
kinase O O
C O O
stimulation O O
on O O
IL4 O O
expression O O
and O O
may O O
contribute O O
to O O
differential O O
gene O O
expression O O
in O O
TH O O
cells O O
. O O

Regulation O O
of O O
the O O
balance O O
of O O
cytokine O O
production O O
and O O
the O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
( O O
STAT O O
) O O
transcription O O
factor O O
activity O O
by O O
cytokines O O
and O O
inflammatory O O
synovial O O
fluids O O
. O O

The O O
balance O O
between O O
type O O
1 O O
and O O
2 O O
T O O
helper O O
cell O O
cytokine O O
production O O
plays O O
an O O
important O O
role O O
in O O
several O O
animal O O
models O O
of O O
autoimmunity O O
, O O
and O O
skewed O O
patterns O O
of O O
cytokine O O
expression O O
have O O
been O O
described O O
in O O
human O O
inflammatory O O
diseases O O
. O O

Many O O
cytokines O O
activate O O
signal O O
transducer O O
and O O
activation O O
of O O
transcription O O
( O O
STAT O O
) O O
transcription O O
factors O O
, O O
which O O
, O O
in O O
turn O O
, O O
activate O O
transcription O O
of O O
inflammatory O B-DNA
effector O I-DNA
genes O I-DNA
. O O

We O O
used O O
mononuclear O O
cell O O
priming O O
cultures O O
and O O
inflammatory O O
synovial O O
fluids O O
( O O
SFs O O
) O O
derived O O
from O O
arthritis O O
patients O O
to O O
examine O O
the O O
regulation O O
of O O
cytokine O O
production O O
and O O
STAT O O
activity O O
by O O
an O O
inflammatory O O
synovial O O
microenvironment O O
. O O

Exposure O O
to O O
SFs O O
during O O
priming O O
resulted O O
in O O
an O O
81 O O
% O O
inhibition O O
of O O
interferon O O
( O O
IFN O O
) O O
- O O
gamma O O
, O O
but O O
not O O
interleukin O O
( O O
IL O O
) O O
4 O O
, O O
production O O
by O O
effector O O
cells O O
generated O O
in O O
priming O O
cultures O O
. O O

SF O O
suppression O O
was O O
mediated O O
by O O
IL O O
- O O
4 O O
and O O
IL O O
- O O
10 O O
and O O
inhibition O O
of O O
IL O O
- O O
12 O O
expression O O
, O O
and O O
it O O
was O O
reversed O O
in O O
a O O
dominant O O
fashion O O
by O O
exogenous O O
IL O O
- O O
12 O O
. O O

SFs O O
blocked O O
the O O
sustained O O
activity O O
of O O
transcription O O
factor O O
Stat1 O O
, O O
but O O
not O O
Stat3 O O
, O O
during O O
the O O
priming O O
period O O
, O O
and O O
Stat1 O O
activity O O
was O O
differentially O O
regulated O O
by O O
cytokines O O
in O O
parallel O O
with O O
their O O
positive O O
or O O
negative O O
regulation O O
of O O
IFN O O
- O O
gamma O O
production O O
. O O

Active O O
Stat3 O O
, O O
but O O
not O O
Stat1 O O
, O O
was O O
detected O O
in O O
cells O O
from O O
inflamed O O
joints O O
. O O

These O O
results O O
suggest O O
a O O
role O O
for O O
altered O O
balance O O
of O O
Stat1 O O
and O O
Stat3 O O
transcriptional O O
activity O O
in O O
the O O
regulation O O
of O O
T O O
cell O O
differentiation O O
and O O
in O O
the O O
pathogenesis O O
of O O
inflammatory O O
synovitis O O
. O O

Triggering O O
of O O
complement O O
receptors O O
CR1 O O
( O O
CD35 O O
) O O
and O O
CR3 O O
( O O
CD11b O O
/ O O
CD18 O O
) O O
induces O O
nuclear O O
translocation O O
of O O
NF O O
- O O
kappa O O
B O O
( O O
p50 O O
/ O O
p65 O O
) O O
in O O
human O O
monocytes O O
and O O
enhances O O
viral O O
replication O O
in O O
HIV O O
- O O
infected O O
monocytic O O
cells O O
. O O

Monocyte O O
/ O O
macrophages O O
may O O
harbor O O
HIV O O
in O O
a O O
nonproductive O O
fashion O O
for O O
prolonged O O
periods O O
of O O
time O O
. O O

Viral O O
gene O O
expression O O
may O O
be O O
reactivated O O
by O O
stimulation O O
of O O
the O O
cells O O
with O O
LPS O O
or O O
cytokines O O
such O O
as O O
TNF O O
- O O
alpha O O
in O O
vitro O O
. O O

The O O
effect O O
of O O
LPS O O
and O O
TNF O O
- O O
alpha O O
is O O
mediated O O
by O O
their O O
ability O O
to O O
induce O O
nuclear O O
translocation O O
of O O
the O O
DNA O O
- O O
binding O O
heterodimer O O
NF O O
- O O
kappa O O
B O O
( O O
p50 O O
/ O O
p65 O O
) O O
, O O
which O O
binds O O
to O O
a O O
specific O O
sequence O O
in O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
long I-DNA I-DNA
terminal I-DNA I-DNA
repeat I-DNA I-DNA
. O O

The O O
present O O
study O O
demonstrates O O
that O O
triggering O O
of O O
complement O O
receptors O O
CR1 O O
( O O
CD35 O O
) O O
and O O
CR3 O O
( O O
CD11b O O
/ O O
CD18 O O
) O O
enhances O O
viral O O
replication O O
in O O
HIV O O
- O O
infected O O
human O O
monocytic O O
cells O O
. O O

Monocytic O O
cell O O
lines O O
and O O
normal O O
peripheral O O
blood O O
monocytes O O
were O O
infected O O
with O O
HIV O O
- O O
1 O O
in O O
vitro O O
and O O
cultured O O
in O O
the O O
presence O O
or O O
absence O O
of O O
F O O
( O O
ab O O
' O O
) O O
2 O O
fragments O O
of O O
monoclonal O O
anti O O
- O O
CR1 O O
or O O
anti O O
- O O
CR3 O O
Abs O O
or O O
with O O
C3 O O
fragments O O
. O O

Stimulation O O
of O O
CR1 O O
or O O
CR3 O O
induces O O
a O O
two O O
- O O
to O O
fourfold O O
increase O O
in O O
the O O
amount O O
of O O
cell O O
- O O
associated O O
and O O
released O O
p24 O O
Ag O O
in O O
cell O O
cultures O O
that O O
was O O
equivalent O O
to O O
that O O
observed O O
in O O
control O O
cultures O O
triggered O O
with O O
LPS O O
. O O

We O O
further O O
observed O O
that O O
stimulation O O
of O O
CR1 O O
or O O
CR3 O O
induces O O
the O O
nuclear O O
translocation O O
of O O
NF O O
- O O
kappa O O
B O O
p50 O O
/ O O
p65 O O
in O O
infected O O
cells O O
. O O

Translocation O O
of O O
NF O O
- O O
kappa O O
B O O
p50 O O
/ O O
p65 O O
was O O
also O O
observed O O
following O O
stimulation O O
of O O
CR1 O O
or O O
CR3 O O
of O O
uninfected O O
peripheral O O
blood O O
monocytes O O
from O O
HIV O O
- O O
seronegative O O
donors O O
. O O

The O O
amount O O
of O O
protein O O
translocated O O
was O O
similar O O
to O O
that O O
observed O O
when O O
cells O O
were O O
stimulated O O
with O O
rhTNF O O
- O O
alpha O O
. O O

TNF O O
- O O
alpha O O
did O O
not O O
mediate O O
the O O
translocation O O
of O O
NF O O
- O O
kappa O O
B O O
p50 O O
/ O O
p65 O O
induced O O
by O O
triggering O O
of O O
complement O O
receptors O O
. O O

Taken O O
together O O
, O O
these O O
observations O O
suggest O O
that O O
HIV O O
gene O O
expression O O
may O O
be O O
activated O O
in O O
infected O O
monocytes O O
through O O
interaction O O
of O O
the O O
cells O O
with O O
complement O O
- O O
opsonized O O
particles O O
and O O
that O O
enhanced O O
viral O O
replication O O
is O O
associated O O
with O O
C3 O O
receptor O O
- O O
mediated O O
nuclear O O
translocation O O
of O O
the O O
NF O O
- O O
kappa O O
B O O
complex O O
. O O

Attenuation O O
of O O
gamma O O
interferon O O
- O O
induced O O
tyrosine O O
phosphorylation O O
in O O
mononuclear O O
phagocytes O O
infected O O
with O O
Leishmania O O
donovani O O
: O O
selective O O
inhibition O O
of O O
signaling O O
through O O
Janus O O
kinases O O
and O O
Stat1 O O
. O O

The O O
induction O O
of O O
gene O O
transcription O O
in O O
response O O
to O O
gamma O O
interferon O O
is O O
impaired O O
in O O
mononuclear O O
phagocytes O O
infected O O
with O O
Leishmania O O
donovani O O
, O O
and O O
the O O
mechanisms O O
involved O O
are O O
not O O
fully O O
understood O O
. O O

The O O
changes O O
in O O
gene O O
expression O O
brought O O
about O O
by O O
gamma O O
interferon O O
are O O
thought O O
to O O
involve O O
transient O O
increases O O
in O O
the O O
activities O O
of O O
cellular O O
protein O O
tyrosine O O
kinases O O
, O O
including O O
the O O
Janus O O
kinases O O
Jak1 O O
and O O
Jak2 O O
, O O
leading O O
to O O
tyrosine O O
phosphorylation O O
of O O
the O O
transcription O O
factor O O
Stat1 O O
. O O

To O O
investigate O O
the O O
mechanisms O O
accounting O O
for O O
the O O
impaired O O
responses O O
to O O
gamma O O
interferon O O
, O O
a O O
model O O
system O O
for O O
examining O O
overall O O
changes O O
in O O
protein O O
tyrosine O O
phosphorylation O O
, O O
activation O O
of O O
Jak1 O O
and O O
Jak2 O O
and O O
phosphorylation O O
of O O
Stat1 O O
was O O
developed O O
in O O
phorbol O O
12 O O
- O O
myristate O O
13 O O
- O O
acetate O O
- O O
differentiated O O
U O O
- O O
937 O O
cells O O
. O O

Analysis O O
of O O
whole O O
- O O
cell O O
lysates O O
by O O
antiphosphotyrosine O O
immunoblotting O O
showed O O
that O O
incubation O O
with O O
gamma O O
interferon O O
brought O O
about O O
specific O O
increases O O
in O O
phosphotyrosine O O
labeling O O
of O O
several O O
proteins O O
. O O

Increased O O
labeling O O
of O O
these O O
proteins O O
occurred O O
to O O
similar O O
extents O O
in O O
control O O
cells O O
and O O
in O O
cells O O
that O O
had O O
been O O
infected O O
with O O
L O O
. O O
donovani O O
for O O
16 O O
h O O
. O O

Jak1 O O
, O O
Jak2 O O
, O O
and O O
Stat1 O O
were O O
immunoprecipitated O O
from O O
control O O
and O O
interferon O O
- O O
treated O O
cells O O
, O O
and O O
tyrosine O O
phosphorylation O O
of O O
these O O
proteins O O
, O O
detected O O
by O O
antiphosphotyrosine O O
immunoblotting O O
was O O
used O O
to O O
measured O O
their O O
activation O O
. O O

Tyrosine O O
phosphorylation O O
of O O
Jak1 O O
, O O
Jak2 O O
, O O
and O O
Stat1 O O
increased O O
markedly O O
, O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
, O O
in O O
U O O
- O O
937 O O
cells O O
incubated O O
with O O
gamma O O
interferon O O
. O O

In O O
contrast O O
, O O
in O O
cells O O
infected O O
with O O
L O O
. O O
donovani O O
, O O
tyrosine O O
phosphorylation O O
of O O
Jak1 O O
, O O
Jak2 O O
, O O
and O O
Stat1 O O
was O O
markedly O O
impaired O O
. O O

This O O
effect O O
was O O
dependent O O
upon O O
the O O
duration O O
of O O
exposure O O
to O O
L O O
. O O
donovani O O
and O O
was O O
maximal O O
and O O
complete O O
at O O
16 O O
h O O
. O O

Results O O
similar O O
to O O
those O O
observed O O
with O O
U O O
- O O
937 O O
cells O O
were O O
also O O
obtained O O
with O O
human O O
peripheral O O
blood O O
monocytes O O
. O O

These O O
findings O O
indicate O O
that O O
infection O O
of O O
human O O
mononuclear O O
phagocytes O O
with O O
L O O
. O O
donovani O O
leads O O
to O O
impaired O O
gamma O O
interferon O O
- O O
mediated O O
tyrosine O O
phosphorylation O O
and O O
selective O O
effects O O
on O O
the O O
Jak O O
- O O
Stat1 O O
pathway O O
. O O

Unresponsiveness O O
to O O
gamma O O
interferon O O
for O O
activation O O
of O O
this O O
pathway O O
may O O
explain O O
impaired O O
transcriptional O O
responses O O
in O O
leishmania O O
- O O
infected O O
cells O O
. O O

Mutually O O
exclusive O O
interaction O O
of O O
a O O
novel O O
matrix O O
attachment O O
region O O
binding O O
protein O O
and O O
the O O
NF O B-DNA
- O I-DNA
muNR O I-DNA
enhancer O I-DNA
repressor O I-DNA
. O O

Implications O O
for O O
regulation O O
of O O
immunoglobulin O O
heavy O O
chain O O
expression O O
. O O

The O O
immunoglobulin O B-DNA
heavy O I-DNA
chain O I-DNA
( O I-DNA
IgH O I-DNA
) O I-DNA
intronic O I-DNA
enhancer O I-DNA
stimulates O O
transcription O O
from O O
functional O B-DNA
promoters O I-DNA
in O O
B O O
lymphocytes O O
but O O
not O O
other O O
cell O O
types O O
. O O

The O O
observation O O
that O O
binding O B-DNA
sites O I-DNA
for O O
the O O
nuclear O B-DNA
factor O I-DNA
- O I-DNA
mu O I-DNA
negative O I-DNA
regulator O I-DNA
( O I-DNA
NF O I-DNA
- O I-DNA
muNR O I-DNA
) O I-DNA
enhancer O I-DNA
repressor O I-DNA
overlap O O
nuclear O B-DNA
matrix O I-DNA
attachment O I-DNA
regions O I-DNA
( O O
MARs O B-DNA
) O O
in O O
this O O
enhancer B-DNA B-DNA
has O O
lead O O
to O O
the O O
hypothesis O O
that O O
the O O
cell O O
type O O
specificity O O
of O O
the O O
enhancer B-DNA O
might O O
be O O
controlled O O
by O O
regulating O O
nuclear O O
matrix O O
attachment O O
( O O
Scheuermann O O
, O O
R O O
. O O
H O O
. O O
, O O
and O O
Chen O O
, O O
U O O
. O O
( O O
1989 O O
) O O
Genes O O
& O O
Dev O O
. O O
3 O O
, O O
1255 O O
- O O
1266 O O
) O O
. O O

To O O
understand O O
the O O
role O O
of O O
MARs O B-DNA
in O O
IgH B-DNA B-DNA
enhancer I-DNA I-DNA
regulation O O
, O O
we O O
have O O
identified O O
a O O
novel O O
MAR O B-DNA
- O O
binding O O
protein O O
, O O
MAR O O
- O O
BP1 O O
, O O
from O O
soluble O O
nuclear O O
matrix O O
preparations O O
based O O
on O O
its O O
ability O O
to O O
bind O O
to O O
the O O
MARs O B-DNA
associated O O
with O O
the O O
IgH B-DNA B-DNA
enhancer I-DNA I-DNA
. O O

Purified O O
MAR O O
- O O
BP1 O O
migrates O O
as O O
a O O
33 O O
- O O
kDa O O
protein O O
, O O
and O O
it O O
can O O
be O O
found O O
in O O
nuclear O O
matrix O O
preparations O O
from O O
a O O
number O O
of O O
different O O
types O O
of O O
lymphoid O O
cell O O
lines O O
. O O

Although O O
specific O O
binding O B-DNA
sites O I-DNA
have O O
been O O
difficult O O
to O O
localize O O
by O O
chemical O O
or O O
enzymatic O O
footprinting O O
procedures O O
, O O
NF O B-DNA
- O I-DNA
muNR O I-DNA
binding O I-DNA
sites O I-DNA
are O O
critical O O
for O O
efficient O O
MAR O B-DNA
- O I-DNA
BP1 O I-DNA
binding O O
. O O

Indeed O O
, O O
binding O O
of O O
the O O
IgH B-DNA B-DNA
enhancer I-DNA I-DNA
to O O
either O O
intact O O
nuclear O O
matrix O O
preparations O O
or O O
to O O
MAR O O
- O O
BP1 O O
is O O
mutually O O
exclusive O O
to O O
NF O O
- O O
muNR O O
binding O O
. O O

These O O
results O O
are O O
consistent O O
with O O
a O O
model O O
for O O
cell O O
- O O
type O O
specific O O
regulation O O
in O O
which O O
binding O O
of O O
the O O
NF O O
- O O
muNR O O
repressor O O
to O O
the O O
IgH B-DNA B-DNA
enhancer I-DNA I-DNA
prevents O O
nuclear O O
matrix O O
attachment O O
in O O
inappropriate O O
cells O O
by O O
interfering O O
with O O
MAR O B-DNA
- O I-DNA
BP1 O I-DNA
/ B-DNA I-DNA
enhancer I-DNA I-DNA
interaction O O
. O O

PU O O
. O O
1 O O
( O O
Spi O O
- O O
1 O O
) O O
and O O
C O O
/ O O
EBP O O
alpha O O
regulate O O
expression O O
of O O
the O O
granulocyte B-DNA B-DNA
- I-DNA I-DNA
macrophage I-DNA I-DNA
colony I-DNA I-DNA
- I-DNA I-DNA
stimulating I-DNA I-DNA
factor I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
. O O

Growth O O
factor O O
receptors O O
play O O
an O O
important O O
role O O
in O O
hematopoiesis O O
. O O

In O O
order O O
to O O
further O O
understand O O
the O O
mechanisms O O
directing O O
the O O
expression O O
of O O
these O O
key O O
regulators O O
of O O
hematopoiesis O O
, O O
we O O
initiated O O
a O O
study O O
investigating O O
the O O
transcription O O
factors O O
activating O O
the O O
expression O O
of O O
the O O
granulocyte B-DNA B-DNA
- I-DNA I-DNA
macrophage I-DNA I-DNA
colony I-DNA I-DNA
- I-DNA I-DNA
stimulating I-DNA I-DNA
factor I-DNA I-DNA
( I-DNA I-DNA
GM I-DNA I-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
) I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
gene I-DNA I-DNA
. O O

Here O O
, O O
we O O
demonstrate O O
that O O
the O O
human B-DNA B-DNA
GM I-DNA I-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
directs O O
reporter B-DNA O
gene I-DNA O
activity O O
in O O
a O O
tissue O O
- O O
specific O O
fashion O O
in O O
myelomonocytic O O
cells O O
, O O
which O O
correlates O O
with O O
its O O
expression O O
pattern O O
as O O
analyzed O O
by O O
reverse O O
transcription O O
PCR O O
. O O

The O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
contains O O
an O O
important O O
functional O B-DNA
site O I-DNA
between O O
positions O O
- O B-DNA
53 O I-DNA
and O I-DNA
- O I-DNA
41 O I-DNA
as O O
identified O O
by O O
deletion O O
analysis O O
of O O
reporter B-DNA B-DNA
constructs I-DNA I-DNA
. O O

We O O
show O O
that O O
the O O
myeloid O O
and O O
B O O
cell O O
transcription O O
factor O O
PU O O
. O O
1 O O
binds O O
specifically O O
to O O
this O O
site O O
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
a O O
CCAAT B-DNA B-DNA
site I-DNA I-DNA
located O O
upstream O O
of O O
the O O
PU B-DNA B-DNA
. I-DNA I-DNA
1 I-DNA I-DNA
site I-DNA I-DNA
between O O
positions O O
- O B-DNA
70 O I-DNA
and O I-DNA
- O I-DNA
54 O I-DNA
is O O
involved O O
in O O
positive O O
- O O
negative O O
regulation O O
of O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
activity O O
. O O

C O O
/ O O
EBP O O
alpha O O
is O O
the O O
major O O
CCAAT B-DNA O
/ I-DNA O
enhancer I-DNA O
- O O
binding O O
protein O O
( O O
C O O
/ O O
EBP O O
) O O
form O O
binding O O
to O O
this O O
site O O
in O O
nuclear O O
extracts O O
of O O
U937 O O
cells O O
. O O

Point O O
mutations O O
of O O
either O O
the O O
PU B-DNA B-DNA
. I-DNA I-DNA
1 I-DNA I-DNA
site I-DNA I-DNA
or O O
the O O
C B-DNA B-DNA
/ I-DNA I-DNA
EBP I-DNA I-DNA
site I-DNA I-DNA
that O O
abolish O O
the O O
binding O O
of O O
the O O
respective O O
factors O O
result O O
in O O
a O O
significant O O
decrease O O
of O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
activity O O
in O O
myelomonocytic O O
cells O O
only O O
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
in O O
myeloid O O
and O O
B O O
cell O O
extracts O O
, O O
PU O O
. O O
1 O O
forms O O
a O O
novel O O
, O O
specific O O
, O O
more O O
slowly O O
migrating O O
complex O O
( O O
PU O O
- O O
SF O O
) O O
when O O
binding O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
PU B-DNA I-DNA
. I-DNA I-DNA
1 I-DNA I-DNA
site I-DNA I-DNA
. O O

This O O
is O O
the O O
first O O
demonstration O O
of O O
a O O
specific O O
interaction O O
with O O
PU O O
. O O
1 O O
on O O
a O O
myeloid B-DNA B-DNA
PU I-DNA I-DNA
. I-DNA I-DNA
1 I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
. O O

The O O
novel O O
complex O O
is O O
distinct O O
from O O
that O O
described O O
previously O O
as O O
binding O O
to O O
B B-DNA B-DNA
cell I-DNA I-DNA
enhancer I-DNA I-DNA
sites I-DNA I-DNA
and O O
can O O
be O O
formed O O
by O O
addition O O
of O O
PU O O
. O O
1 O O
to O O
extracts O O
from O O
certain O O
nonmyeloid O O
cell O O
types O O
which O O
do O O
not O O
express O O
PU O O
. O O
1 O O
, O O
including O O
T O O
cells O O
and O O
epithelial O O
cells O O
, O O
but O O
not O O
from O O
erythroid O O
cells O O
. O O

Furthermore O O
, O O
we O O
demonstrate O O
that O O
the O O
PU O O
- O O
SF O O
complex O O
binds O O
to O O
PU O B-DNA
. O I-DNA
1 O I-DNA
sites O I-DNA
found O O
on O O
a O O
number O O
of O O
myeloid B-DNA B-DNA
promoters I-DNA I-DNA
, O O
and O O
its O O
formation O O
requires O O
an O O
intact O O
PU B-DNA B-DNA
. I-DNA I-DNA
1 I-DNA I-DNA
site I-DNA I-DNA
adjacent O O
to O O
a O O
single O O
- O O
stranded O O
region O O
. O O

Expression O O
of O O
PU O O
. O O
1 O O
in O O
nonmyeloid O O
cells O O
can O O
activate O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Deletion O O
of O O
the O O
amino O O
- O O
terminal O O
region O O
of O O
PU O O
. O O
1 O O
results O O
in O O
a O O
failure O O
to O O
form O O
the O O
PU O O
- O O
SF O O
complex O O
and O O
in O O
a O O
concomitant O O
loss O O
of O O
transactivation O O
, O O
suggesting O O
that O O
formation O O
of O O
the O O
PU O O
- O O
SF O O
complex O O
is O O
of O O
functional O O
importance O O
for O O
the O O
activity O O
of O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
. O O

Finally O O
, O O
we O O
demonstrate O O
that O O
C O O
/ O O
EBP O O
alpha O O
can O O
also O O
active O O
the O O
GM B-DNA B-DNA
- I-DNA I-DNA
CSF I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
promoter I-DNA I-DNA
in O O
nonmyeloid O O
cells O O
. O O

( O O
ABSTRACT O O
TRUNCATED O O
AT O O
400 O O
WORDS O O
) O O
. O O

HMG O O
- O O
I O O
binds O O
to O O
GATA B-DNA B-DNA
motifs I-DNA I-DNA
: O O
implications O O
for O O
an O O
HPFH O O
syndrome O O
. O O

We O O
have O O
examined O O
binding O O
of O O
the O O
nuclear O O
protein O O
HMG O O
- O O
I O O
to O O
the O O
human B-DNA B-DNA
gamma I-DNA I-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
promoter I-DNA I-DNA
. O O

We O O
find O O
that O O
HMG O O
- O O
I O O
binds O O
preferentially O O
to O O
the O O
more O O
3 O O
' O O
of O O
a O O
pair O O
of O O
GATA B-DNA B-DNA
motifs I-DNA I-DNA
in O O
the O O
gamma B-DNA B-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
promoter I-DNA I-DNA
; O O
this O O
paired O O
motif O O
is O O
bound O O
by O O
the O O
erythroid O O
factor O O
GATA O O
- O O
1 O O
. O O

A O O
naturally O O
occurring O O
mutation O O
( O O
- O O
175 O O
T O O
- O O
C O O
) O O
in O O
the O O
area O O
bound O O
by O O
HMG O O
- O O
I O O
results O O
in O O
overexpression O O
of O O
gamma O O
- O O
globin O O
in O O
adult O O
red O O
blood O O
cells O O
( O O
HPFH O O
) O O
and O O
up O O
- O O
regulation O O
of O O
the O O
gamma B-DNA B-DNA
- I-DNA I-DNA
globin I-DNA I-DNA
promoter I-DNA I-DNA
in O O
in O O
vitro O O
expression O O
assays O O
; O O
HMG O O
- O O
I O O
does O O
not O O
bind O O
to O O
this O O
mutant B-DNA B-DNA
sequence I-DNA I-DNA
. O O

A O O
survey O O
of O O
GATA B-DNA B-DNA
motifs I-DNA I-DNA
from O O
other O O
globin B-DNA B-DNA
cis I-DNA I-DNA
- I-DNA I-DNA
elements I-DNA I-DNA
demonstrates O O
HMG O O
- O O
I O O
binding O O
to O O
most O O
of O O
them O O
. O O

These O O
findings O O
implicate O O
HMG O O
- O O
I O O
in O O
the O O
HPFH O O
phenotype O O
; O O
we O O
speculate O O
that O O
it O O
may O O
participate O O
in O O
the O O
formation O O
of O O
multiprotein O O
complexes O O
that O O
regulate O O
globin O B-DNA
gene O I-DNA
expression O O
. O O

Constitutive O O
activation O O
of O O
different O O
Jak O O
tyrosine O O
kinases O O
in O O
human O O
T O O
cell O O
leukemia O O
virus O O
type O O
1 O O
( O O
HTLV O O
- O O
1 O O
) O O
tax O O
protein O O
or O O
virus O O
- O O
transformed O O
cells O O
. O O

HTLV O O
- O O
1 O O
infection O O
causes O O
an O O
adult O O
T O O
cell O O
leukemia O O
in O O
humans O O
. O O

The O O
viral O O
encoded O O
protein O O
tax O O
, O O
is O O
thought O O
to O O
play O O
an O O
important O O
role O O
in O O
oncogenesis O O
. O O

Our O O
previous O O
data O O
obtained O O
from O O
a O O
tax O O
transgenic O O
mouse O O
model O O
revealed O O
that O O
tax O O
transforms O O
mouse O O
fibroblasts O O
but O O
not O O
thymocytes O O
, O O
despite O O
comparable O O
levels O O
of O O
tax O O
expression O O
in O O
both O O
tissues O O
. O O

Constitutive O O
tyrosine O O
phosphorylation O O
of O O
a O O
130 O O
- O O
kD O O
protein O O
( O O
s O O
) O O
was O O
observed O O
in O O
the O O
tax O O
transformed O O
fibroblast O O
B O O
line O O
and O O
in O O
HTLV O O
- O O
1 O O
transformed O O
human O O
lymphoid O O
lines O O
, O O
but O O
not O O
in O O
thymocytes O O
from O O
Thy O O
- O O
tax O O
transgenic O O
mice O O
. O O

Phosphotyrosine O O
immunoprecipitation O O
followed O O
by O O
Western O O
blot O O
analysis O O
with O O
a O O
set O O
of O O
Jak O O
kinase O O
specific O O
antibodies O O
, O O
identified O O
p130 O O
as O O
Jak2 O O
in O O
the O O
tax O O
transformed O O
mouse O O
fibroblastic O O
cell O O
line O O
and O O
Jak3 O O
in O O
HTLV O O
- O O
1 O O
transformed O O
human O O
T O O
cell O O
lines O O
. O O

Phosphorylation O O
of O O
Jak2 O O
in O O
tax O O
transformed O O
cells O O
resulted O O
from O O
high O O
expression O O
of O O
IL O O
- O O
6 O O
. O O

Tyrosine O O
phosphorylation O O
of O O
this O O
protein O O
could O O
also O O
be O O
induced O O
in O O
Balb O O
/ O O
c3T3 O O
cells O O
using O O
a O O
supernatant O O
from O O
the O O
B O O
line O O
, O O
which O O
was O O
associated O O
with O O
induction O O
of O O
cell O O
proliferation O O
. O O

Both O O
phosphorylation O O
and O O
proliferation O O
were O O
inhibited O O
by O O
IL O O
- O O
6 O O
neutralizing O O
antibodies O O
. O O

Constitutive O O
phosphorylation O O
of O O
Jak O O
kinases O O
may O O
facilitate O O
tumor O O
growth O O
in O O
both O O
HTLV O O
- O O
1 O O
infected O O
human O O
T O O
cells O O
and O O
the O O
transgenic O O
mouse O O
model O O
. O O

Regulation O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
mRNA O O
expression O O
by O O
hydroxyurea O O
in O O
human O O
K562 O O
cells O O
during O O
erythroid O O
differentiation O O
[ O O
published O O
erratum O O
appears O O
in O O
Biochim O O
Biophys O O
Acta O O
1995 O O
Dec O O
27 O O
; O O
1264 O O
( O O
3 O O
) O O
: O O
409 O O
] O O
. O O

Hydroxyurea O O
( O O
HU O O
) O O
is O O
an O O
antitumor O O
agent O O
which O O
also O O
induces O O
hemoglobinization O O
during O O
erythroid O O
differentiation O O
. O O

In O O
addition O O
, O O
HU O O
stimulates O O
the O O
synthesis O O
of O O
fetal O O
hemoglobin O O
in O O
sickle O O
cell O O
anemia O O
patients O O
. O O

To O O
further O O
understand O O
its O O
mechanism O O
of O O
action O O
, O O
we O O
investigated O O
the O O
effects O O
of O O
HU O O
on O O
regulation O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
expression O O
prior O O
to O O
the O O
onset O O
of O O
erythroid O O
differentiation O O
of O O
K562 O O
cells O O
. O O

HU O O
induced O O
a O O
dose O O
- O O
dependent O O
stimulation O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
synthesis O O
. O O

The O O
levels O O
of O O
c B-DNA O
- I-DNA O
jun I-DNA O
mRNA O O
was O O
elevated O O
4 O O
to O O
7 O O
. O O
5 O O
- O O
fold O O
by O O
HU O O
within O O
2 O O
h O O
. O O

This O O
was O O
followed O O
by O O
a O O
gradual O O
decline O O
to O O
the O O
basal O O
level O O
by O O
24 O O
h O O
. O O

Both O O
nuclear O O
run O O
- O O
on O O
and O O
actinomycin O O
D O O
pulse O O
experiments O O
strongly O O
indicate O O
that O O
HU O O
regulates O O
c O B-DNA
- O I-DNA
jun O I-DNA
mRNA O O
expression O O
by O O
increasing O O
the O O
rate O O
of O O
synthesis O O
as O O
well O O
as O O
stabilizing O O
the O O
c B-DNA O
- I-DNA O
jun I-DNA O
mRNA O O
. O O

In O O
addition O O
, O O
the O O
level O O
of O O
jun O O
protein O O
was O O
elevated O O
by O O
2 O O
to O O
5 O O
- O O
fold O O
within O O
4 O O
h O O
in O O
HU O O
treated O O
cells O O
. O O

Furthermore O O
, O O
concentrations O O
of O O
HU O O
below O O
250 O O
microM O O
slightly O O
increased O O
the O O
5X O O
AP O O
- O O
1 O O
/ O O
CAT O O
activity O O
. O O

These O O
results O O
strongly O O
suggest O O
that O O
HU O O
induces O O
both O O
transcriptional O O
and O O
post O O
- O O
transcription O O
regulation O O
of O O
c B-DNA B-DNA
- I-DNA I-DNA
jun I-DNA I-DNA
during O O
erythroid O O
differentiation O O
. O O

In O O
vivo O O
and O O
in O O
vitro O O
effects O O
of O O
glucocorticoids O O
on O O
lymphocyte O O
proliferation O O
in O O
man O O
: O O
relationship O O
to O O
glucocorticoid O O
receptors O O
. O O

Interrelations O O
between O O
the O O
hypothalamic O O
- O O
pituitary O O
- O O
adrenal O O
system O O
( O O
HPA O O
) O O
and O O
the O O
immune O O
system O O
represent O O
a O O
well O O
- O O
documented O O
biological O O
phenomenon O O
. O O

While O O
in O O
vitro O O
administration O O
of O O
glucocorticoids O O
may O O
inhibit O O
concanavalin O O
A O O
( O O
Con O O
A O O
) O O
- O O
and O O
phytohemagglutinin O O
( O O
PHA O O
) O O
- O O
induced O O
T O O
- O O
cell O O
proliferation O O
, O O
pokeweed O O
mitogen O O
( O O
PWM O O
) O O
- O O
driven O O
B O O
- O O
cell O O
mitogenesis O O
is O O
relatively O O
resistant O O
to O O
glucocorticoids O O
. O O

To O O
further O O
explore O O
the O O
link O O
between O O
the O O
HPA O O
and O O
the O O
immune O O
system O O
in O O
relation O O
to O O
glucocorticoid O O
receptor O O
function O O
, O O
dose O O
- O O
response O O
curves O O
were O O
obtained O O
for O O
Con O O
A O O
- O O
and O O
PHA O O
- O O
induced O O
T O O
- O O
cell O O
mitogenesis O O
, O O
PWM O O
- O O
generated O O
B O O
- O O
cell O O
mitogenesis O O
and O O
spontaneous O O
lymphocyte O O
proliferation O O
in O O
13 O O
healthy O O
controls O O
. O O

Glucocorticoid O O
effects O O
were O O
assessed O O
in O O
vivo O O
by O O
depletion O O
of O O
endogenous O O
glucocorticoids O O
after O O
oral O O
administration O O
of O O
1 O O
. O O
5 O O
g O O
metyrapone O O
( O O
MET O O
) O O
and O O
subsequent O O
glucocorticoid O O
replacement O O
, O O
and O O
in O O
vitro O O
by O O
incubation O O
of O O
the O O
cells O O
with O O
different O O
doses O O
of O O
dexamethasone O O
( O O
DEX O O
) O O
. O O

There O O
was O O
a O O
significant O O
decrease O O
in O O
PWM O O
- O O
induced O O
B O O
- O O
cell O O
mitogenesis O O
and O O
a O O
more O O
pronounced O O
effect O O
of O O
DEX O O
administered O O
in O O
vitro O O
on O O
spontaneous O O
lymphocyte O O
proliferation O O
after O O
MET O O
treatment O O
when O O
compared O O
with O O
the O O
DEX O O
plus O O
MET O O
pretreated O O
condition O O
in O O
vivo O O
. O O

These O O
data O O
suggest O O
that O O
the O O
inhibition O O
of O O
spontaneous O O
lymphocyte O O
proliferation O O
by O O
glucocorticoids O O
in O O
vitro O O
is O O
related O O
to O O
glucocorticoid O O
receptor O O
function O O
. O O

The O O
decrease O O
in O O
PWM O O
- O O
generated O O
B O O
- O O
cell O O
proliferation O O
following O O
cortisol O O
depletion O O
by O O
MET O O
may O O
be O O
seen O O
in O O
connection O O
with O O
impaired O O
glucocorticoid O O
- O O
mediated O O
induction O O
of O O
interleukin O O
- O O
1 O O
receptor O O
synthesis O O
. O O

Transcription O O
specific O O
differences O O
visualized O O
by O O
fluorescence O O
in O O
situ O O
hybridization O O
pattern O O
on O O
interphase O O
nuclei O O
of O O
different O O
cell O O
types O O
. O O

Application O O
of O O
a O O
" O O
formamide O O
free O O
" O O
and O O
thus O O
" O O
material O O
preserving O O
" O O
in O O
situ O O
hybridization O O
technique O O
using O O
the O O
cDNA B-DNA B-DNA
of O O
the O O
myf3 B-DNA B-DNA
gene I-DNA I-DNA
revealed O O
the O O
following O O
results O O
: O O
Human O O
rhabdomyosarcoma O O
cells O O
, O O
characterized O O
by O O
a O O
high O O
expression O O
of O O
myf3 B-DNA O
show O O
intensive O O
hybridization O O
signals O O
in O O
their O O
interphase O O
. O O

RNase O O
treatment O O
prior O O
to O O
hybridization O O
considerably O O
reduces O O
the O O
size O O
of O O
this O O
signals O O
. O O

In O O
comparison O O
, O O
isolated O O
nuclei O O
of O O
human O O
lymphocytes O O
in O O
which O O
no O O
need O O
for O O
the O O
expression O O
of O O
this O O
gene O O
exists O O
, O O
show O O
barely O O
hybridization O O
signals O O
. O O

Correspondingly O O
, O O
RNase O O
treatment O O
had O O
no O O
effect O O
on O O
hybridization O O
pattern O O
at O O
all O O
. O O

In O O
conclusion O O
an O O
increased O O
transcription O O
efficiency O O
of O O
a O O
cell O B-DNA
type O I-DNA
specific O I-DNA
gene O I-DNA
is O O
accompanied O O
by O O
a O O
higher O O
hybridization O O
accessibility O O
in O O
the O O
corresponding O O
cell O O
nuclei O O
. O O

Oncogenicity O O
of O O
human O O
papillomavirus O O
- O O
or O O
adenovirus O O
- O O
transformed O O
cells O O
correlates O O
with O O
resistance O O
to O O
lysis O O
by O O
natural O O
killer O O
cells O O
. O O

The O O
reasons O O
for O O
the O O
dissimilar O O
oncogenicities O O
of O O
human O O
adenoviruses O O
and O O
human O O
papillomaviruses O O
( O O
HPV O O
) O O
in O O
humans O O
are O O
unknown O O
but O O
may O O
relate O O
to O O
differences O O
in O O
the O O
capacities O O
of O O
the O O
E1A O O
and O O
E7 O O
proteins O O
to O O
target O O
cells O O
for O O
rejection O O
by O O
the O O
host O O
natural O O
killer O O
( O O
NK O O
) O O
cell O O
response O O
. O O

As O O
one O O
test O O
of O O
this O O
hypothesis O O
, O O
we O O
compared O O
the O O
abilities O O
of O O
E1A O O
- O O
and O O
E7 O O
- O O
expressing O O
human O O
fibroblastic O O
or O O
keratinocyte O O
- O O
derived O O
human O O
cells O O
to O O
be O O
selectively O O
killed O O
by O O
either O O
unstimulated O O
or O O
interferon O O
( O O
IFN O O
) O O
- O O
activated O O
NK O O
cells O O
. O O

Cells O O
expressing O O
the O O
E1A O O
oncoprotein O O
were O O
selectively O O
killed O O
by O O
unstimulated O O
NK O O
cells O O
, O O
while O O
the O O
same O O
parental O O
cells O O
but O O
expressing O O
the O O
HPV O O
type O O
16 O O
( O O
HPV O O
- O O
16 O O
) O O
or O O
HPV O O
- O O
18 O O
E7 O O
oncoprotein O O
were O O
resistant O O
to O O
NK O O
cell O O
lysis O O
. O O

The O O
ability O O
of O O
IFN O O
- O O
activated O O
NK O O
cells O O
to O O
selectively O O
kill O O
virally O O
transformed O O
cells O O
depends O O
on O O
IFN O O
' O O
s O O
ability O O
to O O
induce O O
resistance O O
to O O
NK O O
cell O O
lysis O O
in O O
normal O O
( O O
i O O
. O O
e O O
. O O
, O O
non O O
- O O
viral O O
oncogene O O
- O O
expressing O O
) O O
but O O
not O O
virally O O
transformed O O
cells O O
. O O

E1A O O
blocked O O
IFN O O
' O O
s O O
induction O O
of O O
cytolytic O O
resistance O O
, O O
resulting O O
in O O
the O O
selective O O
lysis O O
of O O
adenovirus O O
- O O
transformed O O
cells O O
by O O
IFN O O
- O O
activated O O
NK O O
cells O O
. O O

The O O
extent O O
of O O
IFN O O
- O O
induced O O
NK O O
cell O O
killing O O
of O O
E1A O O
- O O
expressing O O
cells O O
was O O
proportional O O
to O O
the O O
level O O
of O O
E1A O O
expression O O
and O O
correlated O O
with O O
the O O
ability O O
of O O
E1A O O
to O O
block O O
IFN O O
- O O
stimulated O O
gene O O
expression O O
in O O
target O O
cells O O
. O O

In O O
contrast O O
, O O
E7 O O
blocked O O
neither O O
IFN O O
- O O
stimulated O O
gene O O
expression O O
nor O O
IFN O O
' O O
s O O
induction O O
of O O
cytolytic O O
resistance O O
, O O
thereby O O
precluding O O
the O O
selective O O
lysis O O
of O O
HPV O O
- O O
transformed O O
cells O O
by O O
IFN O O
- O O
activated O O
NK O O
cells O O
. O O

In O O
conclusion O O
, O O
E1A O O
expression O O
marks O O
cells O O
for O O
destruction O O
by O O
the O O
host O O
NK O O
cell O O
response O O
, O O
whereas O O
the O O
E7 O O
oncoprotein O O
lacks O O
this O O
activity O O
. O O

Regulation O O
of O O
IkB O O
alpha O O
phosphorylation O O
by O O
PKC O O
- O O
and O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
signal O O
transduction O O
pathways O O
. O O

The O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
phosphatase O O
calcineurin O O
, O O
a O O
target O O
of O O
FK506 O O
and O O
CsA O O
, O O
synergizes O O
with O O
PKC O O
- O O
induced O O
activation O O
of O O
nuclear O O
factor O O
( O O
NF O O
) O O
- O O
kappa O O
B O O
in O O
T O O
cell O O
lines O O
. O O

We O O
have O O
investigated O O
whether O O
this O O
synergy O O
is O O
present O O
in O O
other O O
cell O O
types O O
and O O
the O O
mechanism O O
( O O
s O O
) O O
by O O
which O O
these O O
two O O
pathways O O
lead O O
to O O
NF O O
- O O
kappa O O
B O O
activation O O
. O O

While O O
this O O
synergy O O
is O O
present O O
in O O
other O O
cell O O
types O O
, O O
in O O
the O O
monocytic O O
cell O O
line O O
U937 O O
calcineurin O O
is O O
also O O
sufficient O O
to O O
activate O O
NF O O
- O O
kappa O O
B O O
. O O

Having O O
previously O O
shown O O
that O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
and O O
PKC O O
- O O
dependent O O
pathways O O
synergize O O
by O O
accelerating O O
the O O
degradation O O
of O O
IkB O O
alpha O O
, O O
we O O
focused O O
on O O
the O O
regulation O O
of O O
IkB O O
alpha O O
phosphorylation O O
. O O

While O O
PKC O O
- O O
dependent O O
pathways O O
sequentially O O
result O O
in O O
the O O
phosphorylation O O
and O O
in O O
an O O
incomplete O O
degradation O O
of O O
IkB O O
alpha O O
in O O
T O O
cell O O
lines O O
, O O
co O O
- O O
activation O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
pathways O O
accelerates O O
the O O
rate O O
of O O
IkB O O
alpha O O
phosphorylation O O
and O O
results O O
in O O
its O O
complete O O
degradation O O
. O O

Activation O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
pathways O O
alone O O
do O O
not O O
result O O
in O O
the O O
phosphorylation O O
and O O
/ O O
or O O
degradation O O
of O O
IkB O O
alpha O O
in O O
Jurkat O O
T O O
or O O
in O O
U937 O O
cells O O
. O O

Treatment O O
of O O
T O O
cells O O
with O O
the O O
selective O O
PKC O O
inhibitor O O
GF109203X O O
abrogates O O
the O O
PMA O O
- O O
induced O O
IkB O O
alpha O O
phosphorylation O O
/ O O
degradation O O
irrespective O O
of O O
activation O O
of O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
pathways O O
, O O
but O O
not O O
the O O
phosphorylation O O
and O O
degradation O O
of O O
IkB O O
alpha O O
induced O O
by O O
TNF O O
- O O
alpha O O
, O O
a O O
PKC O O
- O O
independent O O
stimulus O O
. O O

Contrary O O
to O O
the O O
interaction O O
with O O
PKC O O
, O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
pathways O O
synergize O O
with O O
TNF O O
- O O
alpha O O
not O O
at O O
the O O
level O O
of O O
IkB O O
alpha O O
phosphorylation O O
, O O
but O O
at O O
the O O
level O O
of O O
its O O
degradation O O
. O O

These O O
results O O
indicate O O
that O O
Ca O O
( O O
2 O O
+ O O
) O O
- O O
dependent O O
pathways O O
, O O
including O O
the O O
phosphatase O O
calcineurin O O
, O O
participate O O
in O O
the O O
regulation O O
of O O
NF O O
- O O
kappa O O
B O O
in O O
a O O
cell O O
specific O O
fashion O O
and O O
synergize O O
with O O
PKC O O
- O O
dependent O O
and O O
- O O
independent O O
pathways O O
at O O
the O O
level O O
of O O
IkB O O
alpha O O
phosphorylation O O
and O O
degradation O O
. O O

Vitamin O O
E O O
therapy O O
of O O
acute O O
CCl4 O O
- O O
induced O O
hepatic O O
injury O O
in O O
mice O O
is O O
associated O O
with O O
inhibition O O
of O O
nuclear O O
factor O O
kappa O O
B O O
binding O O
. O O

Oxidative O O
stress O O
, O O
with O O
reactive O O
oxygen O O
intermediate O O
formation O O
, O O
may O O
represent O O
a O O
common O O
mechanism O O
by O O
which O O
liver O O
injury O O
is O O
induced O O
by O O
diverse O O
etiologies O O
. O O

Oxidative O O
stress O O
enhances O O
nuclear O O
factor O O
kappa O O
B O O
( O O
NF O O
- O O
kappa O O
B O O
) O O
activity O O
, O O
and O O
NF O O
- O O
kappa O O
B O O
activity O O
has O O
been O O
shown O O
to O O
enhance O O
the O O
expression O O
of O O
cytotoxic O O
cytokines O O
. O O

Acute O O
hepatic O O
injury O O
caused O O
by O O
reactive O O
oxygen O O
intermediate O O
production O O
was O O
induced O O
by O O
an O O
intraperitoneal O O
injection O O
of O O
CCl4 O O
in O O
mice O O
. O O

This O O
injury O O
was O O
significantly O O
inhibited O O
by O O
intravenous O O
pretreatment O O
of O O
the O O
mice O O
with O O
a O O
water O O
- O O
soluble O O
emulsion O O
of O O
alpha O O
- O O
tocopherol O O
. O O

Alpha O O
- O O
tocopherol O O
treatment O O
of O O
the O O
mice O O
given O O
the O O
CCl4 O O
also O O
reduced O O
the O O
NF O O
- O O
kappa O O
B O O
binding O O
to O O
levels O O
approaching O O
those O O
found O O
in O O
normal O O
mice O O
. O O

In O O
vitro O O
treatment O O
of O O
a O O
monocyte O O
/ O O
macrophage O O
cell O O
line O O
with O O
CCl4 O O
led O O
to O O
enhanced O O
NF O O
- O O
kappa O O
B O O
binding O O
and O O
an O O
increase O O
in O O
tumor O O
necrosis O O
factor O O
- O O
alpha O O
( O O
TNF O O
- O O
alpha O O
) O O
messenger O O
RNA O O
levels O O
. O O

Liver O O
specimens O O
taken O O
from O O
patients O O
with O O
acute O O
fulminant O O
hepatitis O O
had O O
markedly O O
increased O O
NF O O
- O O
kappa O O
B O O
binding O O
activity O O
in O O
comparison O O
with O O
the O O
binding O O
of O O
normal O O
livers O O
. O O

These O O
data O O
demonstrate O O
that O O
abolishing O O
acute O O
hepatic O O
injury O O
with O O
alpha O O
- O O
tocopherol O O
, O O
a O O
free O O
radical O O
scavenger O O
, O O
also O O
eliminated O O
increased O O
NF O O
- O O
kappa O O
B O O
binding O O
. O O

It O O
is O O
tempting O O
to O O
speculate O O
that O O
enhanced O O
NF O O
- O O
kappa O O
B O O
expression O O
caused O O
by O O
free O O
radical O O
production O O
/ O O
oxidative O O
stress O O
may O O
modulate O O
liver O O
injury O O
, O O
perhaps O O
through O O
an O O
effect O O
on O O
cytotoxic O O
cytokine O O
synthesis O O
. O O

Immunosuppression O O
by O O
glucocorticoids O O
: O O
inhibition O O
of O O
NF O O
- O O
kappa O O
B O O
activity O O
through O O
induction O O
of O O
I O O
kappa O O
B O O
synthesis O O
[ O O
see O O
comments O O
] O O
. O O

Glucocorticoids O O
are O O
among O O
the O O
most O O
potent O O
anti O O
- O O
inflammatory O O
and O O
immunosuppressive O O
agents O O
. O O

They O O
inhibit O O
synthesis O O
of O O
almost O O
all O O
known O O
cytokines O O
and O O
of O O
several O O
cell O O
surface O O
molecules O O
required O O
for O O
immune O O
function O O
, O O
but O O
the O O
mechanism O O
underlying O O
this O O
activity O O
has O O
been O O
unclear O O
. O O
Here O O
it O O
is O O
shown O O
that O O
glucocorticoids O O
are O O
potent O O
inhibitors O O
of O O
nuclear O O
factor O O
kappa O O
B O O
( O O
NF O O
- O O
kappa O O
B O O
) O O
activation O O
in O O
mice O O
and O O
cultured O O
cells O O
. O O

This O O
inhibition O O
is O O
mediated O O
by O O
induction O O
of O O
the O O
I O O
kappa O O
B O O
alpha O O
inhibitory O O
protein O O
, O O
which O O
traps O O
activated O O
NF O O
- O O
kappa O O
B O O
in O O
inactive O O
cytoplasmic O O
complexes O O
. O O

Because O O
NF O O
- O O
kappa O O
B O O
activates O O
many O O
immunoregulatory B-DNA B-DNA
genes I-DNA I-DNA
in O O
response O O
to O O
pro O O
- O O
inflammatory O O
stimuli O O
, O O
the O O
inhibition O O
of O O
its O O
activity O O
can O O
be O O
a O O
major O O
component O O
of O O
the O O
anti O O
- O O
inflammatory O O
activity O O
of O O
glucocorticoids O O
. O O

Transcriptional O O
repression O O
of O O
the O O
interleukin B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
gene I-DNA I-DNA
by O O
vitamin O O
D3 O O
: O O
direct O O
inhibition O O
of O O
NFATp O O
/ O O
AP O O
- O O
1 O O
complex O O
formation O O
by O O
a O O
nuclear O O
hormone O O
receptor O O
. O O

T O O
- O O
lymphocyte O O
proliferation O O
is O O
suppressed O O
by O O
1 O O
, O O
25 O O
- O O
dihydroxyvitamin O O
D3 O O
[ O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
] O O
, O O
the O O
active O O
metabolite O O
of O O
vitamin O O
D3 O O
, O O
and O O
is O O
associated O O
with O O
a O O
decrease O O
in O O
interleukin O O
2 O O
( O O
IL O O
- O O
2 O O
) O O
, O O
gamma O O
interferon O O
, O O
and O O
granulocyte O O
- O O
macrophage O O
colony O O
- O O
stimulating O O
factor O O
mRNA O O
levels O O
. O O

We O O
report O O
here O O
that O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
- O O
mediated O O
repression O O
in O O
Jurkat O O
cells O O
is O O
cycloheximide O O
resistant O O
, O O
suggesting O O
that O O
it O O
is O O
a O O
direct O O
transcriptional O O
repressive O O
effect O O
on O O
IL O O
- O O
2 O O
expression O O
by O O
the O O
vitamin O O
D3 O O
receptor O O
( O O
VDR O O
) O O
. O O

We O O
therefore O O
examined O O
vitamin O O
D3 O O
- O O
mediated O O
repression O O
of O O
activated O O
IL O O
- O O
2 O O
expression O O
by O O
cotransfecting O O
Jurkat O O
cells O O
with O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
promoter I-DNA I-DNA
/ I-DNA I-DNA
reporter I-DNA I-DNA
constructs I-DNA I-DNA
and O O
a O O
VDR B-DNA B-DNA
overexpression I-DNA I-DNA
vector I-DNA I-DNA
and O O
by O O
DNA O O
binding O O
. O O

We O O
delineated O O
an O O
element O O
conferring O O
both O O
DNA O O
binding O O
by O O
the O O
receptor O O
in O O
vitro O O
and O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
- O O
mediated O O
repression O O
in O O
vivo O O
to O O
a O O
short O B-DNA
40 B-DNA I-DNA
- I-DNA I-DNA
bp I-DNA I-DNA
region I-DNA I-DNA
encompassing O O
an O O
important O O
positive B-DNA B-DNA
regulatory I-DNA I-DNA
element I-DNA I-DNA
, O O
NF B-DNA B-DNA
- I-DNA I-DNA
AT I-DNA I-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
, O O
which O O
is O O
bound O O
by O O
a O O
T O O
- O O
cell O O
- O O
specific O O
transcription O O
factor O O
, O O
NFATp O O
, O O
as O O
well O O
as O O
by O O
AP O O
- O O
1 O O
. O O

VDR O O
DNA O O
- O O
binding O O
mutants O O
were O O
unable O O
to O O
either O O
bind O O
to O O
this O O
element O O
in O O
vitro O O
or O O
repress O O
in O O
vivo O O
; O O
the O O
VDR O B-DNA
DNA O I-DNA
- O I-DNA
binding O I-DNA
domain O I-DNA
alone O O
, O O
however O O
, O O
bound O O
the O O
element O O
but O O
also O O
could O O
not O O
repress O O
IL O O
- O O
2 O O
expression O O
. O O

These O O
results O O
indicate O O
that O O
DNA O O
binding O O
by O O
VDR O O
is O O
necessary O O
but O O
not O O
sufficient O O
to O O
mediate O O
IL O O
- O O
2 O O
repression O O
. O O

By O O
combining O O
partially O O
purified O O
proteins O O
in O O
vitro O O
, O O
we O O
observed O O
the O O
loss O O
of O O
the O O
bound O O
NFATp O O
/ O O
AP O O
- O O
1 O O
- O O
DNA O O
complex O O
upon O O
inclusion O O
of O O
VDR O O
or O O
VDR O O
- O O
retinoid O O
X O O
receptor O O
. O O

Order O O
of O O
addition O O
and O O
off O O
- O O
rate O O
experiments O O
indicate O O
that O O
the O O
VDR O O
- O O
retinoid O O
X O O
receptor O O
heterodimer O O
blocks O O
NFATp O O
/ O O
AP O O
- O O
1 O O
complex O O
formation O O
and O O
then O O
stably O O
associates O O
with O O
the O O
NF B-DNA B-DNA
- I-DNA I-DNA
AT I-DNA I-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
element I-DNA I-DNA
. O O

This O O
direct O O
inhibition O O
by O O
a O O
nuclear O O
hormone O O
receptor O O
of O O
transcriptional O O
activators O O
of O O
the O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
gene I-DNA I-DNA
may O O
provide O O
a O O
mechanistic O O
explanation O O
of O O
how O O
vitamin O O
derivatives O O
can O O
act O O
as O O
potent O O
immunosuppressive O O
agents O O
. O O

Tissue O O
- O O
specific O O
regulation O O
of O O
the O O
rabbit B-DNA B-DNA
15 I-DNA I-DNA
- I-DNA I-DNA
lipoxygenase I-DNA I-DNA
gene I-DNA I-DNA
in O O
erythroid O O
cells O O
by O O
a O O
transcriptional B-DNA B-DNA
silencer I-DNA I-DNA
. O O

The O O
15 B-DNA B-DNA
- I-DNA I-DNA
lipoxygenase I-DNA I-DNA
( I-DNA I-DNA
lox I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
is O O
expressed O O
in O O
a O O
tissue O O
- O O
specific O O
manner O O
, O O
predominantly O O
in O O
erythroid O O
cells O O
but O O
also O O
in O O
airway O O
epithelial O O
cells O O
and O O
eosinophils O O
. O O

We O O
demonstrate O O
in O O
this O O
report O O
that O O
the O O
5 B-DNA B-DNA
' I-DNA I-DNA
flanking I-DNA I-DNA
DNA I-DNA I-DNA
of O O
the O O
15 B-DNA B-DNA
- I-DNA I-DNA
lox I-DNA I-DNA
gene I-DNA I-DNA
contains O O
sequences O O
which O O
down O O
- O O
regulate O O
its O O
activity O O
in O O
a O O
variety O O
of O O
non O O
- O O
erythroid O O
cell O O
lines O O
but O O
not O O
in O O
two O O
erythroid O O
cell O O
lines O O
. O O

The O O
element O O
has O O
characteristics O O
of O O
a O O
transcriptional B-DNA B-DNA
' I-DNA I-DNA
silencer I-DNA I-DNA
' I-DNA O
since O O
it O O
functions O O
in O O
both O O
orientations O O
. O O

The O O
main O O
activity O O
of O O
the O O
silencer B-DNA B-DNA
has O O
been O O
mapped O O
to O O
the O O
first O O
900 O O
bp O O
of O O
5 B-DNA B-DNA
' I-DNA I-DNA
flanking I-DNA I-DNA
DNA I-DNA I-DNA
, O O
which O O
contains O O
nine O O
binding O B-DNA
sites O I-DNA
for O O
a O O
nuclear O O
factor O O
present O O
in O O
non O O
- O O
erythroid O O
cells O O
but O O
not O O
in O O
erythroid O O
cells O O
. O O

These O O
binding O B-DNA
sites O I-DNA
have O O
similar O O
sequences O O
and O O
multiple O O
copies O O
of O O
the O O
binding B-DNA B-DNA
sites I-DNA I-DNA
confer O O
tissue O O
- O O
specific O O
down O O
- O O
regulation O O
when O O
attached O O
to O O
a O O
minimal B-DNA B-DNA
lox I-DNA I-DNA
promoter I-DNA I-DNA
fragment I-DNA I-DNA
. O O

The O O
5 B-DNA B-DNA
' I-DNA I-DNA
flanking I-DNA I-DNA
DNA I-DNA I-DNA
also O O
contains O O
a O O
cluster O O
of O O
three O O
binding B-DNA B-DNA
sites I-DNA I-DNA
for O O
the O O
GATA O O
family O O
of O O
transcription O O
factors O O
. O O

Phosphorylation O O
of O O
the O O
transcription O O
factor O O
NFATp O O
inhibits O O
its O O
DNA O O
binding O O
activity O O
in O O
cyclosporin O O
A O O
- O O
treated O O
human O O
B O O
and O O
T O O
cells O O
. O O

Cyclosporin O O
A O O
( O O
CsA O O
) O O
exerts O O
its O O
immunosuppressive O O
effect O O
by O O
inhibiting O O
the O O
activity O O
of O O
nuclear O O
factor O O
of O O
activated O O
T O O
cells O O
( O O
NFAT O O
) O O
, O O
thus O O
preventing O O
transcriptional O O
induction O O
of O O
several O O
cytokine O B-DNA
genes O I-DNA
. O O

This O O
effect O O
is O O
thought O O
to O O
be O O
largely O O
mediated O O
through O O
inactivation O O
of O O
the O O
phosphatase O O
calcineurin O O
, O O
which O O
in O O
turn O O
inhibits O O
translocation O O
of O O
an O O
NFAT O O
component O O
to O O
the O O
nucleus O O
. O O

Here O O
we O O
report O O
that O O
CsA O O
treatment O O
of O O
Raji O O
B O O
and O O
Jurkat O O
T O O
cell O O
lines O O
yields O O
a O O
phosphorylated O O
form O O
of O O
NFATp O O
that O O
is O O
inhibited O O
in O O
DNA O O
- O O
binding O O
and O O
in O O
its O O
ability O O
to O O
form O O
an O O
NFAT O O
complex O O
with O O
Fos O O
and O O
Jun O O
. O O

Immunoblot O O
analyses O O
and O O
metabolic O O
labeling O O
with O O
[ O O
32P O O
] O O
orthophosphate O O
show O O
that O O
CsA O O
alters O O
NFATp O O
migration O O
on O O
SDS O O
- O O
polyacrylamide O O
gel O O
electrophoresis O O
by O O
increasing O O
its O O
phosphorylation O O
level O O
without O O
affecting O O
subcellular O O
distribution O O
. O O

Dephosphorylation O O
by O O
in O O
vitro O O
treatment O O
with O O
calcineurin O O
or O O
alkaline O O
phosphatase O O
restores O O
NFATp O O
DNA O O
binding O O
activity O O
and O O
its O O
ability O O
to O O
reconstitute O O
an O O
NFAT O O
complex O O
with O O
Fos O O
and O O
Jun O O
proteins O O
. O O

These O O
data O O
point O O
to O O
a O O
new O O
mechanism O O
for O O
CsA O O
- O O
sensitive O O
regulation O O
of O O
NFATp O O
in O O
which O O
dephosphorylation O O
is O O
critical O O
for O O
DNA O O
binding O O
. O O

Transcription O O
factors O O
as O O
targets O O
for O O
oxidative O O
signalling O O
during O O
lymphocyte O O
activation O O
. O O

We O O
previously O O
have O O
demonstrated O O
a O O
requirement O O
for O O
oxidative O O
events O O
during O O
cell O O
cycle O O
entry O O
in O O
T O O
lymphocytes O O
and O O
have O O
hypothesised O O
that O O
reactive O O
oxygen O O
species O O
may O O
act O O
as O O
intracellular O O
signalling O O
agents O O
during O O
lymphocyte O O
activation O O
. O O

In O O
the O O
current O O
study O O
, O O
cysteamine O O
, O O
an O O
aminothiol O O
compound O O
with O O
antioxidant O O
activity O O
, O O
has O O
been O O
used O O
to O O
further O O
investigate O O
the O O
role O O
of O O
oxidative O O
signalling O O
during O O
lymphocyte O O
activation O O
. O O

Treatment O O
of O O
normal O O
human O O
peripheral O O
blood O O
lymphocytes O O
with O O
cysteamine O O
in O O
vitro O O
was O O
found O O
to O O
inhibit O O
proliferation O O
in O O
a O O
dose O O
- O O
dependent O O
manner O O
, O O
with O O
essentially O O
complete O O
inhibition O O
occurring O O
at O O
a O O
dose O O
of O O
400 O O
microM O O
. O O

This O O
inhibitory O O
effect O O
was O O
limited O O
to O O
the O O
first O O
2 O O
h O O
after O O
mitogenic O O
activation O O
, O O
localizing O O
the O O
time O O
- O O
frame O O
of O O
action O O
of O O
cysteamine O O
to O O
within O O
the O O
commitment O O
period O O
. O O

It O O
therefore O O
was O O
of O O
interest O O
to O O
establish O O
which O O
, O O
if O O
any O O
, O O
commitment O O
events O O
were O O
affected O O
by O O
oxidative O O
signalling O O
during O O
cell O O
cycle O O
entry O O
. O O

Taking O O
the O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
gene I-DNA I-DNA
as O O
a O O
candidate O O
, O O
we O O
examined O O
the O O
effect O O
of O O
cysteamine O O
treatment O O
on O O
early B-DNA O
gene I-DNA O
expression O O
during O O
lymphocyte O O
activation O O
, O O
and O O
on O O
the O O
activity O O
of O O
transcription O O
factors O O
AP O O
- O O
1 O O
, O O
NF O O
- O O
kappa O O
B O O
, O O
NF O O
- O O
AT O O
and O O
Oct1 O O
, O O
whose O O
functions O O
are O O
required O O
for O O
expression O O
of O O
the O O
IL O O
- O O
2 O O
mRNA O O
. O O

Cysteamine O O
treatment O O
inhibited O O
both O O
expression O O
of O O
the O O
IL O O
- O O
2 O O
mRNA O O
and O O
secretion O O
of O O
IL O O
- O O
2 O O
into O O
the O O
culture O O
medium O O
. O O

The O O
inhibitory O O
effect O O
of O O
cysteamine O O
may O O
be O O
mediated O O
at O O
least O O
in O O
part O O
by O O
an O O
effect O O
on O O
transcription O O
factor O O
function O O
, O O
as O O
the O O
DNA O O
binding O O
activities O O
of O O
AP O O
- O O
1 O O
and O O
NF O O
- O O
kappa O O
B O O
extracted O O
from O O
mitogen O O
- O O
stimulated O O
cells O O
were O O
significantly O O
inhibited O O
by O O
cysteamine O O
treatment O O
. O O

Interestingly O O
, O O
Oct1 O O
and O O
NF O O
- O O
AT O O
DNA O O
binding O O
activity O O
were O O
not O O
affected O O
by O O
cysteamine O O
treatment O O
, O O
suggesting O O
that O O
oxidative O O
signalling O O
processes O O
operate O O
in O O
a O O
selective O O
manner O O
. O O

The O O
identification O O
of O O
regulatory O O
proteins O O
, O O
such O O
as O O
transcription O O
factors O O
, O O
as O O
molecular O O
targets O O
for O O
oxidative O O
signalling O O
provides O O
further O O
evidence O O
to O O
implicate O O
oxidative O O
signalling O O
as O O
being O O
intimately O O
involved O O
in O O
the O O
G0 O O
to O O
G1 O O
phase O O
transition O O
in O O
T O O
lymphocytes O O
. O O

Sex O O
and O O
age O O
distribution O O
of O O
1 O O
, O O
25 O O
( O O
OH O O
) O O
2D3 O O
receptors O O
in O O
peripheral O O
blood O O
mononuclear O O
cells O O
from O O
normal O O
human O O
subjects O O
. O O

Specific O O
receptors O O
for O O
1 O O
, O O
25 O O
Dihydroxyvitamin O O
D3 O O
have O O
been O O
described O O
in O O
human O O
peripheral O O
blood O O
mononuclear O O
cells O O
( O O
PBMC O O
) O O
. O O

We O O
have O O
tried O O
to O O
find O O
out O O
whether O O
these O O
receptors O O
could O O
show O O
any O O
difference O O
in O O
sex O O
or O O
age O O
distribution O O
. O O

Twenty O O
two O O
healthy O O
men O O
aged O O
21 O O
- O O
66 O O
yr O O
( O O
mean O O
+ O O
/ O O
- O O
SD O O
41 O O
. O O
0 O O
+ O O
/ O O
- O O
13 O O
. O O
6 O O
) O O
and O O
nineteen O O
healthy O O
women O O
aged O O
22 O O
- O O
60 O O
yr O O
( O O
38 O O
. O O
9 O O
+ O O
/ O O
- O O
13 O O
. O O
9 O O
) O O
have O O
been O O
studied O O
. O O

The O O
mean O O
dissociation O O
constant O O
( O O
Kd O O
) O O
was O O
similar O O
in O O
both O O
sexes O O
( O O
1 O O
. O O
35 O O
+ O O
/ O O
- O O
0 O O
. O O
70 O O
x O O
10 O O
( O O
- O O
10 O O
) O O
M O O
in O O
males O O
, O O
1 O O
. O O
13 O O
+ O O
/ O O
- O O
0 O O
. O O
66 O O
x O O
10 O O
( O O
- O O
10 O O
) O O
M O O
in O O
females O O
) O O
, O O
but O O
the O O
concentration O O
of O O
binding O O
sites O O
( O O
Nmax O O
) O O
was O O
significantly O O
lower O O
in O O
females O O
( O O
2 O O
. O O
32 O O
+ O O
/ O O
- O O
0 O O
. O O
92 O O
fmol O O
/ O O
10 O O
( O O
7 O O
) O O
PBMC O O
vs O O
4 O O
. O O
43 O O
+ O O
/ O O
- O O
1 O O
. O O
38 O O
fmol O O
/ O O
10 O O
( O O
7 O O
) O O
PBMC O O
in O O
males O O
; O O
p O O
= O O
0 O O
. O O
0001 O O
) O O
. O O

Neither O O
Kd O O
nor O O
Nmax O O
were O O
significantly O O
correlated O O
with O O
age O O
. O O

No O O
difference O O
was O O
found O O
between O O
pre O O
and O O
postmenopausal O O
women O O
. O O

Further O O
studies O O
are O O
needed O O
to O O
elucidate O O
if O O
this O O
sex O O
difference O O
in O O
PBMC O O
receptors O O
for O O
1 O O
. O O
25 O O
Dihydroxyvitamin O O
D3 O O
is O O
of O O
any O O
pathophysiological O O
relevance O O
. O O

Expression O O
of O O
Id2 O O
and O O
Id3 O O
mRNA O O
in O O
human O O
lymphocytes O O
. O O

Helix O O
- O O
loop O O
- O O
helix O O
( O O
HLH O O
) O O
transcription O O
factors O O
are O O
involved O O
in O O
cellular O O
growth O O
and O O
differentiation O O
. O O

The O O
Id O O
( O O
inhibitor O O
of O O
DNA O O
binding O O
and O O
differentiation O O
) O O
HLH O O
proteins O O
, O O
in O O
a O O
dominantly O O
negative O O
fashion O O
, O O
regulate O O
transcriptional O O
activities O O
of O O
basic O O
HLH O O
proteins O O
. O O

We O O
examined O O
by O O
northern O O
hybridization O O
the O O
expression O O
of O O
Id2 O O
and O O
Id3 O O
mRNA O O
in O O
human O O
leukemia O O
/ O O
lymphoma O O
lines O O
and O O
patient O O
samples O O
, O O
as O O
well O O
as O O
resting O O
and O O
activated O O
normal O O
human O O
lymphocytes O O
from O O
peripheral O O
blood O O
( O O
PBL O O
) O O
. O O

The O O
Id2 O O
mRNA O O
was O O
abundantly O O
expressed O O
in O O
5 O O
/ O O
12 O O
T O O
- O O
cell O O
and O O
3 O O
/ O O
4 O O
B O O
- O O
cell O O
lines O O
, O O
and O O
Id3 O O
mRNA O O
was O O
detected O O
in O O
4 O O
/ O O
12 O O
T O O
- O O
cell O O
and O O
3 O O
/ O O
4 O O
B O O
- O O
cell O O
lines O O
. O O

Interestingly O O
, O O
Id2 O O
, O O
but O O
not O O
Id3 O O
, O O
mRNA O O
was O O
strongly O O
expressed O O
in O O
4 O O
/ O O
5 O O
T O O
- O O
cell O O
lines O O
infected O O
with O O
human O O
T O O
- O O
cell O O
leukemia O O
virus O O
type O O
I O O
( O O
HTLV O O
- O O
I O O
) O O
( O O
ATL O O
- O O
1k O O
, O O
MT O O
- O O
2 O O
, O O
S O O
- O O
LB1 O O
) O O
and O O
type O O
II O O
( O O
Mo O O
) O O
. O O

Another O O
unexpected O O
finding O O
was O O
that O O
T O O
- O O
cell O O
leukemias O O
and O O
T O O
- O O
cell O O
lines O O
often O O
expressed O O
either O O
Id2 O O
or O O
Id3 O O
mRNA O O
. O O

In O O
addition O O
, O O
resting O O
PBL O O
constitutively O O
expressed O O
prominent O O
levels O O
of O O
Id2 O O
mRNA O O
, O O
but O O
not O O
Id3 O O
mRNA O O
. O O

Upon O O
PHA O O
- O O
stimulation O O
, O O
Id2 O O
expression O O
decreased O O
and O O
Id3 O O
levels O O
increased O O
with O O
biphasic O O
kinetics O O
. O O

Taken O O
together O O
, O O
our O O
studies O O
revealed O O
three O O
unexpected O O
findings O O
which O O
require O O
further O O
analysis O O
: O O
( O O
1 O O
) O O
expression O O
of O O
Id2 O O
mRNA O O
is O O
often O O
associated O O
with O O
lymphocytic O O
transformation O O
by O O
HTLV O O
- O O
I O O
or O O
- O O
II O O
; O O
( O O
2 O O
) O O
T O O
- O O
cells O O
usually O O
express O O
either O O
Id2 O O
or O O
Id3 O O
mRNA O O
, O O
but O O
B O O
- O O
cells O O
often O O
express O O
both O O
simultaneously O O
; O O
( O O
3 O O
) O O
non O O
- O O
dividing O O
, O O
normal O O
PBL O O
express O O
high O O
levels O O
of O O
Id2 O O
and O O
no O O
Id3 O O
mRNA O O
; O O
and O O
with O O
the O O
onset O O
of O O
cellular O O
proliferation O O
, O O
levels O O
of O O
Id2 O O
mRNA O O
decrease O O
while O O
levels O O
of O O
Id3 O O
mRNA O O
increase O O
, O O
suggesting O O
that O O
regulation O O
of O O
expression O O
of O O
these O O
closely O O
related O O
genes B-DNA O
is O O
disparate O O
. O O

Salicylates O O
inhibit O O
lipopolysaccharide O O
- O O
induced O O
transcriptional O O
activation O O
of O O
the O O
tissue O B-DNA
factor O I-DNA
gene O I-DNA
in O O
human O O
monocytic O O
cells O O
. O O

Binding O O
of O O
plasma O O
Factor O O
VII O O
/ O O
VIIa O O
to O O
the O O
tissue O O
factor O O
( O O
TF O O
) O O
receptor O O
initiates O O
the O O
coagulation O O
protease O O
cascades O O
. O O

TF O O
expression O O
by O O
circulating O O
monocytes O O
is O O
associated O O
with O O
thrombotic O O
and O O
inflammatory O O
complications O O
in O O
a O O
variety O O
of O O
diseases O O
. O O

Transcriptional O O
activation O O
of O O
the O O
human B-DNA B-DNA
TF I-DNA I-DNA
gene I-DNA I-DNA
in O O
monocytic O O
cells O O
exposed O O
to O O
bacterial O O
lipopolysaccharide O O
( O O
LPS O O
) O O
is O O
mediated O O
by O O
binding O O
of O O
c O O
- O O
Rel O O
/ O O
p65 O O
heterodimers O O
to O O
a O O
kappa B-DNA B-DNA
B I-DNA I-DNA
site I-DNA I-DNA
in O O
the O O
TF B-DNA B-DNA
promoter I-DNA I-DNA
. O O

Here O O
, O O
we O O
report O O
that O O
a O O
family O O
of O O
anti O O
- O O
inflammatory O O
agents O O
, O O
known O O
as O O
the O O
salicylates O O
, O O
inhibited O O
LPS O O
induction O O
of O O
TF O O
activity O O
and O O
TF B-DNA B-DNA
gene I-DNA I-DNA
transcription O O
in O O
human O O
monocytes O O
and O O
monocytic O O
THP O O
- O O
1 O O
cells O O
at O O
clinically O O
relevant O O
doses O O
. O O

Furthermore O O
, O O
sodium O O
salicylate O O
blocked O O
the O O
LPS O O
- O O
induced O O
proteolytic O O
degradation O O
of O O
I O O
kappa O O
B O O
alpha O O
, O O
which O O
prevented O O
the O O
nuclear O O
translocation O O
of O O
c O O
- O O
Rel O O
/ O O
p65 O O
heterodimers O O
. O O

In O O
contrast O O
, O O
two O O
other O O
nonsteroidal O O
anti O O
- O O
inflammatory O O
drugs O O
, O O
ibuprofen O O
and O O
indomethacin O O
, O O
did O O
not O O
inhibit O O
LPS O O
induction O O
of O O
the O O
TF B-DNA B-DNA
gene I-DNA I-DNA
. O O

These O O
results O O
indicated O O
that O O
salicylates O O
inhibited O O
LPS O O
induction O O
of O O
TF B-DNA B-DNA
gene I-DNA I-DNA
transcription O O
in O O
monocytic O O
cells O O
by O O
preventing O O
nuclear O O
translocation O O
of O O
c O O
- O O
Rel O O
/ O O
p65 O O
heterodimers O O
. O O

The O O
clinical O O
benefits O O
of O O
salicylates O O
in O O
the O O
treatment O O
of O O
several O O
diseases O O
, O O
including O O
atherosclerosis O O
and O O
rheumatoid O O
arthritis O O
, O O
may O O
be O O
related O O
to O O
their O O
ability O O
to O O
reduce O O
monocyte O O
gene O O
expression O O
. O O

Activation O O
of O O
the O O
signal O O
transducer O O
and O O
transcription O O
( O O
STAT O O
) O O
signaling O O
pathway O O
in O O
a O O
primary O O
T O O
cell O O
response O O
. O O

Critical O O
role O O
for O O
IL O O
- O O
6 O O
. O O

The O O
T O O
cell O O
activation O O
is O O
initiated O O
by O O
interaction O O
of O O
specific O O
Ags O O
with O O
TCR O O
, O O
followed O O
by O O
activation O O
of O O
intracellular O O
biochemical O O
events O O
leading O O
to O O
activation O O
of O O
several O O
genes O O
. O O

The O O
activation O O
of O O
signal O O
transducer O O
and O O
activator O O
of O O
transcription O O
( O O
STAT O O
) O O
proteins O O
in O O
a O O
primary O O
TCR O O
- O O
mediated O O
activation O O
of O O
T O O
cells O O
have O O
been O O
explored O O
. O O

In O O
purified O O
human O O
peripheral O O
blood O O
T O O
cells O O
, O O
nuclear O O
STAT O O
proteins O O
were O O
activated O O
approximately O O
3 O O
h O O
after O O
activation O O
by O O
cross O O
- O O
linked O O
anti O O
- O O
CD3 O O
Abs O O
. O O

These O O
STAT O O
proteins O O
were O O
detected O O
by O O
using O O
the O O
IFN B-DNA B-DNA
- I-DNA I-DNA
gamma I-DNA I-DNA
- I-DNA I-DNA
activated I-DNA I-DNA
sequence I-DNA I-DNA
( O O
GAS B-DNA B-DNA
) O O
and O O
related O O
oligonucleotides O O
as O O
probes O O
in O O
electrophoretic O O
mobility O O
shift O O
assay O O
. O O

Analysis O O
of O O
the O O
nuclear O O
extracts O O
with O O
anti O O
- O O
STAT O O
Abs O O
indicated O O
that O O
they O O
contained O O
STAT O O
- O O
3 O O
and O O
additional O O
proteins O O
crossreactive O O
with O O
the O O
STAT O O
family O O
. O O

The O O
induction O O
of O O
STAT O O
activity O O
was O O
inhibited O O
completely O O
by O O
pretreatment O O
with O O
either O O
cycloheximide O O
or O O
cyclosporin O O
A O O
, O O
thus O O
indicating O O
that O O
the O O
induction O O
was O O
due O O
to O O
a O O
secondary O O
factor O O
produced O O
by O O
the O O
activated O O
T O O
cells O O
. O O

As O O
neutralizing O O
anti O O
- O O
IL O O
- O O
6 O O
Abs O O
effectively O O
down O O
- O O
regulated O O
the O O
early O O
induction O O
of O O
STAT O O
proteins O O
and O O
as O O
exogenously O O
added O O
IL O O
- O O
6 O O
rapidly O O
activated O O
DNA O O
binding O O
similar O O
to O O
TCR O O
- O O
mediated O O
bindings O O
, O O
it O O
can O O
be O O
concluded O O
that O O
IL O O
- O O
6 O O
is O O
the O O
factor O O
responsible O O
for O O
the O O
activation O O
of O O
STAT O O
proteins O O
in O O
a O O
primary O O
T O O
cell O O
response O O
. O O

The O O
normal O O
cell O O
cycle O O
activation O O
program O O
is O O
exploited O O
during O O
the O O
infection O O
of O O
quiescent O O
B O O
lymphocytes O O
by O O
Epstein O O
- O O
Barr O O
virus O O
. O O

B O O
lymphocytes O O
in O O
the O O
peripheral O O
circulation O O
are O O
maintained O O
in O O
a O O
non O O
- O O
proliferative O O
state O O
. O O

Antigen O O
recognition O O
stimulates O O
limited O O
proliferation O O
, O O
whereas O O
infection O O
with O O
Epstein O O
- O O
Barr O O
virus O O
( O O
EBV O O
) O O
results O O
in O O
continual O O
proliferation O O
and O O
the O O
outgrowth O O
of O O
immortal O O
cell O O
lines O O
. O O

Because O O
it O O
is O O
not O O
clear O O
at O O
which O O
point O O
in O O
cell O O
cycle O O
the O O
peripheral O O
B O O
lymphocytes O O
are O O
arrested O O
, O O
we O O
characterized O O
the O O
expression O O
of O O
several O O
cell B-DNA B-DNA
cycle I-DNA I-DNA
- I-DNA I-DNA
associated I-DNA I-DNA
genes I-DNA I-DNA
in O O
quiescent O O
and O O
stimulated O O
cells O O
. O O

We O O
show O O
that O O
the O O
expression O O
of O O
four O O
cell B-DNA B-DNA
genes I-DNA I-DNA
, O O
cdc B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
, O O
cyclin B-DNA B-DNA
E I-DNA I-DNA
, O O
CD23 B-DNA B-DNA
, O O
and O O
cyclin B-DNA B-DNA
D2 I-DNA I-DNA
, O O
are O O
up O O
- O O
regulated O O
approximately O O
100 O O
- O O
fold O O
as O O
a O O
result O O
of O O
EBV O O
- O O
mediated O O
immortalization O O
. O O

Because O O
these O O
genes O O
play O O
a O O
positive O O
role O O
in O O
cell O O
proliferation O O
, O O
we O O
suggest O O
that O O
this O O
regulatory O O
switch O O
contributes O O
to O O
controlling O O
entry O O
into O O
the O O
cell O O
cycle O O
. O O

Transient O O
stimulation O O
of O O
quiescent O O
B O O
lymphocytes O O
with O O
either O O
a O O
cocktail O O
of O O
anti O O
- O O
CD40 O O
, O O
anti O O
- O O
IgM O O
, O O
and O O
IL4 O O
, O O
or O O
EBV O O
results O O
in O O
the O O
rapid O O
expression O O
of O O
the O O
same O O
four O O
genes O O
, O O
suggesting O O
that O O
, O O
after O O
infection O O
, O O
EBV O O
exploits O O
the O O
normal O O
program O O
of O O
B O O
- O O
lymphocyte O O
cell O O
cycle O O
activation O O
. O O

Expression O O
of O O
the O O
chemokine O O
receptor O O
BLR2 O O
/ O O
EBI1 O O
is O O
specifically O O
transactivated O O
by O O
Epstein O O
- O O
Barr O O
virus O O
nuclear O O
antigen O O
2 O O
. O O

In O O
our O O
attempt O O
to O O
identify O O
chemokine O O
receptors O O
that O O
are O O
related O O
to O O
Burkitt O O
' O O
s O O
lymphoma O O
receptor O O
1 O O
( O O
BLR1 O O
) O O
and O O
are O O
expressed O O
in O O
activated O O
lymphocytes O O
we O O
used O O
RT O O
- O O
PCR O O
resulting O O
in O O
the O O
isolation O O
of O O
a O O
cDNA O B-DNA
encoding O O
a O O
seven O O
transmembrane O O
receptor O O
termed O O
BLR2 O O
. O O

The O O
protein O O
shows O O
significant O O
sequence O O
similarities O O
to O O
the O O
family O O
of O O
G O O
- O O
protein O O
coupled O O
chemokine O O
receptors O O
and O O
turned O O
out O O
to O O
be O O
identical O O
to O O
the O O
recently O O
described O O
receptor O O
EBI1 O O
. O O

Northern O O
blot O O
analysis O O
revealed O O
that O O
BLR2 O O
mRNA O O
could O O
be O O
highly O O
stimulated O O
in O O
mitogen O O
- O O
and O O
anti O O
- O O
CD3 O O
- O O
treated O O
peripheral O O
blood O O
lymphocytes O O
. O O

BLR2 O O
- O O
specific O O
mRNA O O
could O O
be O O
detected O O
in O O
all O O
Epstein O O
- O O
Barr O O
virus O O
positive O O
B O O
cell O O
lines O O
. O O

We O O
show O O
that O O
transcription O O
of O O
the O O
BLR2 B-DNA B-DNA
gene I-DNA I-DNA
could O O
be O O
specifically O O
induced O O
in O O
Epstein O O
- O O
Barr O O
virus O O
negative O O
BL O O
41 O O
cells O O
via O O
estrogen O O
- O O
mediated O O
activation O O
of O O
Epstein O O
- O O
Barr O O
virus O O
nuclear O O
antigen O O
2 O O
, O O
a O O
key O O
regulator O O
of O O
viral B-DNA O
and O O
cellular B-DNA O
genes I-DNA O
in O O
immortalized O O
B O O
cells O O
. O O

Our O O
data O O
suggest O O
an O O
involvement O O
of O O
BLR2 O O
in O O
the O O
regulation O O
of O O
migration O O
in O O
activated O O
lymphocytes O O
and O O
in O O
viral O O
pathogenesis O O
. O O

A O O
central O O
role O O
for O O
a O O
single B-DNA O
c I-DNA B-DNA
- I-DNA I-DNA
Myb I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
in O O
a O O
thymic B-DNA B-DNA
locus I-DNA I-DNA
control I-DNA I-DNA
region I-DNA I-DNA
. O O

Locus B-DNA B-DNA
control I-DNA I-DNA
regions I-DNA I-DNA
( O O
LCRs B-DNA B-DNA
) O O
are O O
powerful O O
assemblies O O
of O O
cis B-DNA B-DNA
elements I-DNA I-DNA
that O O
organize O O
the O O
actions O O
of O O
cell O O
- O O
type O O
- O O
specific O O
trans O O
- O O
acting O O
factors O O
. O O

A O O
2 O B-DNA
. O I-DNA
3 O I-DNA
- O I-DNA
kb O I-DNA
LCR O I-DNA
in O O
the O O
human B-DNA B-DNA
adenosine I-DNA I-DNA
deaminase I-DNA I-DNA
( I-DNA I-DNA
ADA I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
first I-DNA I-DNA
intron I-DNA I-DNA
, O O
which O O
controls O O
expression O O
in O O
thymocytes O O
, O O
is O O
composed O O
of O O
a O O
200 B-DNA B-DNA
- I-DNA I-DNA
bp I-DNA I-DNA
enhancer I-DNA I-DNA
domain I-DNA I-DNA
and O O
extended O B-DNA
flanking O I-DNA
sequences O I-DNA
that O O
facilitate O O
activation O O
from O O
within O O
chromatin B-DNA B-DNA
. O O

Prior O O
analyses O O
have O O
demonstrated O O
that O O
the O O
enhancer B-DNA B-DNA
contains O O
a O O
28 B-DNA B-DNA
- I-DNA I-DNA
bp I-DNA I-DNA
core I-DNA I-DNA
region I-DNA I-DNA
and O O
local O O
adjacent O B-DNA
augmentative O I-DNA
cis B-DNA I-DNA
elements I-DNA I-DNA
. O O

We O O
now O O
show O O
that O O
the O O
core O O
contains O O
a O O
single O O
critical O O
c B-DNA B-DNA
- I-DNA I-DNA
Myb I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
. O O

In O O
both O O
transiently O O
cotransfected O O
human O O
cells O O
and O O
stable O O
chromatin O O
- O O
integrated O O
yeast O O
cells O O
, O O
c O B-DNA
- O I-DNA
Myb O I-DNA
strongly O I-DNA
transactivated B-DNA I-DNA
reporter I-DNA I-DNA
constructs I-DNA I-DNA
that O O
contained O O
polymerized B-DNA B-DNA
core I-DNA I-DNA
sequences I-DNA I-DNA
. O O

c O O
- O O
Myb O O
protein O O
was O O
strongly O O
evident O O
in O O
T O O
lymphoblasts O O
in O O
which O O
the O O
enhancer B-DNA O
was O O
active O O
and O O
was O O
localized O O
within O O
discrete O O
nuclear O O
structures O O
. O O

Fetal O O
murine O O
thymus O O
exhibited O O
a O O
striking O O
concordance O O
of O O
endogenous O O
c B-DNA B-DNA
- I-DNA I-DNA
myb I-DNA I-DNA
expression O O
with O O
that O O
of O O
mouse B-DNA O
ADA I-DNA O
and O O
human B-DNA O
ADA I-DNA O
LCR I-DNA O
- O O
directed O O
transgene O O
expression O O
. O O

Point O O
mutation O O
of O O
the O O
c B-DNA B-DNA
- I-DNA I-DNA
Myb I-DNA I-DNA
site I-DNA I-DNA
within O O
the O O
intact O O
2 O B-DNA
. O I-DNA
3 O I-DNA
- O I-DNA
kb O I-DNA
LCR O I-DNA
severely O O
attenuated O O
enhancer O O
activity O O
in O O
transfections O O
and O O
LCR B-DNA B-DNA
activity O O
in O O
transgenic O O
thymocytes O O
. O O

Within O O
the O O
context O O
of O O
a O O
complex B-DNA B-DNA
enhancer I-DNA I-DNA
and O O
LCR B-DNA B-DNA
, O O
c O B-DNA
- O I-DNA
Myb O I-DNA
can O O
act O O
as O O
an O O
organizer O O
of O O
thymocyte B-DNA B-DNA
- I-DNA I-DNA
specific I-DNA I-DNA
gene I-DNA I-DNA
expression O O
via O O
a O O
single O O
binding O B-DNA
site O I-DNA
. O O

A O O
regulatory B-DNA B-DNA
element I-DNA I-DNA
in O O
the O O
human B-DNA B-DNA
interleukin I-DNA I-DNA
2 I-DNA I-DNA
gene I-DNA I-DNA
promoter I-DNA I-DNA
is O O
a O O
binding B-DNA B-DNA
site I-DNA I-DNA
for O O
the O O
zinc O O
finger O O
proteins O O
Sp1 O O
and O O
EGR O O
- O O
1 O O
. O O

Activation O O
of O O
the O O
interleukin B-DNA B-DNA
2 I-DNA I-DNA
( I-DNA I-DNA
IL I-DNA I-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
) I-DNA I-DNA
gene I-DNA I-DNA
after O O
antigen O O
recognition O O
is O O
a O O
critical O O
event O O
for O O
T O O
cell O O
proliferation O O
and O O
effector O O
function O O
. O O

Prior O O
studies O O
have O O
identified O O
several O O
transcription O O
factors O O
that O O
contribute O O
to O O
the O O
activity O O
of O O
the O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
promoter I-DNA I-DNA
in O O
stimulated O O
T O O
lymphocytes O O
. O O

Here O O
we O O
describe O O
a O O
novel O O
regulatory B-DNA B-DNA
element I-DNA I-DNA
within O O
the O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
promoter I-DNA I-DNA
located O O
immediately O O
upstream O O
of O O
the O O
nuclear B-DNA B-DNA
factor I-DNA I-DNA
of I-DNA I-DNA
activated I-DNA I-DNA
T I-DNA I-DNA
cell I-DNA I-DNA
( I-DNA I-DNA
NFAT I-DNA I-DNA
) I-DNA I-DNA
domain I-DNA I-DNA
. O O

This O O
region O O
( O O
termed O O
the O O
zinc B-DNA B-DNA
finger I-DNA I-DNA
protein I-DNA I-DNA
binding I-DNA I-DNA
region I-DNA I-DNA
( O O
ZIP B-DNA B-DNA
) O O
) O O
serves O O
as O O
binding O O
site O O
for O O
two O O
differently O O
regulated O O
zinc O O
finger O O
proteins O O
: O O
the O O
constitutively O O
expressed O O
transcription O O
factor O O
Sp1 O O
and O O
the O O
inducible O O
early O O
growth O O
response O O
protein O O
EGR O O
- O O
1 O O
. O O

In O O
unstimulated O O
cells O O
which O O
do O O
not O O
secrete O O
IL O O
- O O
2 O O
, O O
only O O
Sp1 O O
binds O O
to O O
this O O
region O O
, O O
while O O
in O O
stimulated O O
IL O O
- O O
2 O O
secreting O O
cells O O
the O O
inducible O O
EGR O B-DNA
- O I-DNA
1 O I-DNA
protein O O
recognizes O O
this O O
element O O
. O O

In O O
Jurkat O O
T O O
cells O O
, O O
the O O
ZIP B-DNA B-DNA
site I-DNA I-DNA
serves O O
as O O
an O O
activator O O
for O O
IL O B-DNA
- O I-DNA
2 O I-DNA
gene O I-DNA
expression O O
, O O
and O O
a O O
combination O O
of O O
ZIP B-DNA O
and O O
NFAT B-DNA O
binding I-DNA O
sites I-DNA O
is O O
required O O
for O O
maximal O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
promoter I-DNA I-DNA
activity O O
. O O

These O O
results O O
suggest O O
a O O
critical O O
role O O
of O O
the O O
ZIP B-DNA B-DNA
site I-DNA I-DNA
for O O
IL B-DNA B-DNA
- I-DNA I-DNA
2 I-DNA I-DNA
promoter I-DNA I-DNA
activity O O
. O O

Activation O O
of O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
enhancer I-DNA I-DNA
by O O
the O O
LEF O O
- O O
1 O O
HMG O O
protein O O
on O O
nucleosome B-DNA B-DNA
- I-DNA I-DNA
assembled I-DNA I-DNA
DNA I-DNA I-DNA
in O O
vitro O O
. O O

Lymphoid O O
enhancer O O
- O O
binding O O
factor O O
1 O O
( O O
LEF O O
- O O
1 O O
) O O
is O O
a O O
regulatory O O
high O O
mobility O O
group O O
( O O
HMG O O
) O O
protein O O
that O O
activates O O
the O O
T B-DNA B-DNA
cell I-DNA I-DNA
receptor I-DNA I-DNA
alpha I-DNA I-DNA
( I-DNA I-DNA
TCR I-DNA I-DNA
alpha I-DNA I-DNA
) I-DNA I-DNA
enhancer I-DNA I-DNA
in O O
a O O
context O O
- O O
restricted O O
manner O O
in O O
T O O
cells O O
. O O

In O O
this O O
paper O O
we O O
demonstrate O O
that O O
the O O
distal O O
region O O
of O O
the O O
human B-DNA B-DNA
immunodeficiency I-DNA I-DNA
virus I-DNA I-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
( I-DNA I-DNA
HIV I-DNA I-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
) I-DNA I-DNA
enhancer I-DNA I-DNA
, O O
which O O
contains O O
DNA B-DNA B-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
sites I-DNA I-DNA
for O O
LEF O O
- O O
1 O O
and O O
Ets O O
- O O
1 O O
, O O
also O O
provides O O
a O O
functional O O
context O O
for O O
activation O O
by O O
LEF O O
- O O
1 O O
. O O

First O O
, O O
we O O
show O O
that O O
mutations O O
in O O
the O O
LEF B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
- I-DNA I-DNA
binding I-DNA I-DNA
site I-DNA I-DNA
inhibit O O
the O O
activity O O
of O O
multimerized B-DNA O
copies I-DNA O
of O O
the O O
HIV B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
enhancer I-DNA I-DNA
in O O
Jurkat O O
T O O
cells O O
, O O
and O O
that O O
LEF O O
- O O
1 O O
/ O O
GAL4 O O
can O O
activate O O
a O O
GAL4 B-DNA O
- I-DNA O
substituted I-DNA O
HIV I-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
enhancer I-DNA I-DNA
80 O O
- O O
to O O
100 O O
- O O
fold O O
in O O
vivo O O
. O O

Second O O
, O O
recombinant O O
LEF O O
- O O
1 O O
is O O
shown O O
to O O
activate O O
HIV O O
- O O
1 O O
transcription O O
on O O
chromatin B-DNA B-DNA
- I-DNA I-DNA
assembled I-DNA I-DNA
DNA I-DNA I-DNA
in O O
vitro O O
. O O

By O O
using O O
a O O
nucleosome O O
- O O
assembly O O
system O O
derived O O
from O O
Drosophila O O
embryos O O
, O O
we O O
find O O
that O O
the O O
packaging O O
of O O
DNA O O
into O O
chromatin B-DNA B-DNA
in O O
vitro O O
strongly O O
represses O O
HIV O O
- O O
1 O O
transcription O O
and O O
that O O
repression O O
can O O
be O O
counteracted O O
efficiently O O
by O O
preincubation O O
of O O
the O O
DNA O O
with O O
LEF O O
- O O
1 O O
( O O
or O O
LEF O O
- O O
1 O O
and O O
Ets O O
- O O
1 O O
) O O
supplemented O O
with O O
fractions O O
containing O O
the O O
promoter O O
- O O
binding O O
protein O O
, O O
Sp1 O O
. O O

Addition O O
of O O
TFE O O
- O O
3 O O
, O O
which O O
binds O O
to O O
an O O
E B-DNA B-DNA
- I-DNA I-DNA
box I-DNA I-DNA
motif I-DNA I-DNA
upstream O O
of O O
the O O
LEF O O
- O O
1 O O
and O O
Ets O O
- O O
1 O O
sites O O
, O O
further O O
augments O O
transcription O O
in O O
this O O
system O O
. O O

Individually O O
or O O
collectively O O
, O O
none O O
of O O
the O O
three O O
enhancer O O
- O O
binding O O
proteins O O
( O O
LEF O O
- O O
1 O O
, O O
Ets O O
- O O
1 O O
, O O
and O O
TFE O O
- O O
3 O O
) O O
could O O
activate O O
transcription O O
in O O
the O O
absence O O
of O O
Sp1 O O
. O O

A O O
truncation O O
mutant O O
of O O
LEF O O
- O O
1 O O
( O O
HMG O O
- O O
88 O O
) O O
, O O
which O O
contains O O
the O O
HMG O O
box O O
but O O
lacks O O
the O O
trans O O
- O O
activation O O
domain O O
, O O
did O O
not O O
activate O O
transcription O O
from O O
nucleosomal B-DNA B-DNA
DNA I-DNA I-DNA
, O O
indicating O O
that O O
bending O O
of O O
DNA O O
by O O
the O O
HMG O O
domain O O
is O O
not O O
sufficient O O
to O O
activate O O
transcription O O
in O O
vitro O O
. O O

We O O
conclude O O
that O O
transcription O O
activation O O
by O O
LEF O O
- O O
1 O O
in O O
vitro O O
is O O
a O O
chromatin B-DNA B-DNA
- O O
dependent O O
process O O
that O O
requires O O
a O O
functional O O
trans O O
- O O
activation O O
domain O O
in O O
addition O O
to O O
the O O
HMG O O
domain O O
. O O

HIV O O
- O O
1 O O
envelope O O
glycoproteins O O
induce O O
activation O O
of O O
activated O O
protein O O
- O O
1 O O
in O O
CD4 O O
+ O O
T O O
cells O O
[ O O
published O O
erratum O O
appears O O
in O O
J O O
Biol O O
Chem O O
1995 O O
Dec O O
1 O O
; O O
270 O O
( O O
48 O O
) O O
: O O
29038 O O
] O O
. O O

Activation O O
of O O
CD4 O O
positive O O
T O O
cells O O
is O O
a O O
primary O O
requirement O O
for O O
human O O
immunodeficiency O O
virus O O
( O O
HIV O O
) O O
entry O O
, O O
efficient O O
HIV O O
replication O O
, O O
and O O
progression O O
to O O
AIDS O O
, O O
Utilizing O O
CD4 O O
positive O O
T O O
cell O O
lines O O
and O O
purified O O
T O O
cells O O
from O O
normal O O
individuals O O
, O O
we O O
have O O
demonstrated O O
that O O
native O O
envelope O O
glycoproteins O O
of O O
HIV O O
, O O
gp O O
160 O O
, O O
can O O
induce O O
activation O O
of O O
transcription O O
factor O O
, O O
activated O O
protein O O
- O O
1 O O
( O O
AP O O
- O O
1 O O
) O O
. O O

The O O
stimulatory O O
effects O O
of O O
gp160 O O
are O O
mediated O O
through O O
the O O
CD4 O O
molecule O O
, O O
since O O
treatment O O
of O O
gp160 O O
with O O
soluble O O
CD4 O O
- O O
IgG O O
abrogates O O
its O O
activity O O
, O O
and O O
CD4 O O
negative O O
T O O
cell O O
lines O O
fail O O
to O O
be O O
stimulated O O
with O O
gp160 O O
. O O

Immunoprecipitation O O
of O O
the O O
gp O O
160 O O
- O O
induced O O
nuclear O O
extracts O O
with O O
polyclonal O O
antibodies O O
to O O
Fos O O
and O O
Jun O O
proteins O O
indicates O O
that O O
AP O O
- O O
1 O O
complex O O
is O O
comprised O O
of O O
members O O
of O O
these O O
family O O
of O O
proteins O O
. O O

The O O
gp160 O O
- O O
induced O O
AP O O
- O O
1 O O
complex O O
is O O
dependent O O
upon O O
protein O O
tyrosine O O
phosphorylation O O
and O O
is O O
protein O O
synthesis O O
- O O
independent O O
. O O

This O O
stimulation O O
can O O
also O O
be O O
abolished O O
by O O
inhibitors O O
of O O
protein O O
kinase O O
C O O
, O O
but O O
it O O
is O O
unaffected O O
by O O
calcium O O
channel O O
blocker O O
or O O
cyclosporine O O
A O O
. O O

This O O
gp160 O O
treatment O O
adversely O O
affects O O
the O O
functional O O
capabilities O O
of O O
T O O
cells O O
: O O
pre O O
- O O
treatment O O
of O O
CD4 O O
+ O O
T O O
cells O O
with O O
gp160 O O
for O O
4 O O
h O O
at O O
37 O O
degrees O O
C O O
inhibited O O
anti O O
- O O
CD3 O O
- O O
induced O O
interleukin O O
- O O
2 O O
secretion O O
. O O

Effects O O
similar O O
to O O
gp160 O O
were O O
seen O O
with O O
anti O O
- O O
CD4 O O
mAb O O
. O O

The O O
aberrant O O
activation O O
of O O
AP O O
- O O
1 O O
by O O
gp160 O O
in O O
CD4 O O
positive O O
T O O
cells O O
could O O
result O O
in O O
up O O
- O O
regulation O O
of O O
cytokines O O
containing O O
AP B-DNA B-DNA
- I-DNA I-DNA
1 I-DNA I-DNA
sites I-DNA I-DNA
, O O
e O O
. O O
g O O
. O O
interleukin O O
- O O
3 O O
and O O
granulocyte O O
macrophage O O
colony O O
- O O
stimulating O O
factor O O
, O O
and O O
concurrently O O
lead O O
to O O
T O O
cell O O
unresponsiveness O O
by O O
inhibiting O O
interleukin O O
- O O
2 O O
secretion O O
. O O

